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3	
ABSTRACT	
Nutrition	has	an	indirect	effect	on	the	gastrointestinal	function	of	the	host	and	thereby	
on	 health,	 mainly	 by	 influencing	 the	 composition	 and	 activity	 of	 the	 human	 gut	
microbiota.	 The	aim	of	 this	PhD	project	was	 to	 investigate	 the	effect	of	nutrition	as	a	
factor	 affecting	 the	 intestinal	microbiome-host	 relationship	 in	 critically	 ill	 children	and	
whether	it	has	an	impact	on	clinical	disease	severity.		
	
The	 balance	 between	 requirement	 and	 delivery	 of	 energy	 and	 macronutrients	 was	
assessed	 in	 a	 cohort	 of	 124	 critically	 ill	 children.	 Then	 an	 integrated	 approach	 of	
metataxonomics	 and	metabolomics	 analysis	 was	 undertaken	 to	 examine	 how	 feeding	
during	critical	 illness	affects	the	gut-host	relationship.	Collection	of	faecal	samples	was	
required	for	the	assessment	of	faecal	calprotectin,	gut	microbiota	and	their	metabolites	
while	 serum	 samples	 were	 used	 for	 the	 analysis	 of	 inflammatory	 cytokines,	 and	
intestinal	injury	biomarkers.	
	
Overall	 this	 project	 has	 recorded	 a	 cross-link	 between	 feed,	 gut	 homeostasis	 with	
systemic	inflammation	and	host	metabolism.	Within	the	feed	delivered,	fat	delivery	was	
often	 above	 requirements	 compared	 to	 protein	 and	 carbohydrate.	 In	 addition,	 both	
protein	deficit	and	higher	delivery	of	fat	were	associated	with	elevation	in	the	levels	of	
pro-inflammatory	 cytokines.	 The	 results	 also	 showed	 that	 abnormalities	 in	 gut	 health	
biomarkers	were	associated	with	elevation	in	inflammatory	cytokines.	Finally	this	study	
also	 recorded	 a	 profound	 loss	 of	 diversity	 in	 the	 faecal	 microbiome	 of	 critically	 ill	
children.	 This	 was	 associated	 with	 the	 loss	 of	 key	 commensal	 species	 and	 increased	
levels	of	opportunistic	pathogens.	Consequently	resulted	in	reduced	functionality	of	the	
gut	microbiome	manifested	by	 reduced	production	of	 SCFAs	and	abnormalities	 in	BAs	
metabolism.	 The	 current	 study	 showed	 for	 the	 first	 time	 that	 energy	 underfeeding	
appeared	to	influence	the	microbial	composition	of	critically	ill	children.		
	
In	conclusion	this	work	provided	an	insight	about	the	potential	contribution	of	nutrition	
as	a	factor	to	improve	the	disease	state	in	critically	ill	children,	if	targeted	to	modulate	
gut	microbiome	and	host	response	to	critical	illness.	
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1 Chapter	one:	Introduction	
	
Critical	illness	represents	the	most	complex	derangement	of	cellular	and	organ	function,	
and	 consumes	 a	 large	portion	of	 the	National	Health	 Service	 (NHS)	budget.	 There	 are	
over	 20,000	 admissions	 to	 Paediatric	 Intensive	 Care	 Units	 (PICUs)	 in	 the	 UK	 annually	
(Parslow	 &	 Draper	 2017).	 The	 care	 given	 in	 PICUs	 is	 costly	 and	 resources	 are	 often	
limited	(Turner	et	al.	2016).	The	majority	of	children	admitted	to	PICU	have	a	brief	stay	
and	 recover	well,	 but	 a	 significant	 proportion	may	 develop	 severe	multi-organ	 failure	
(MOF)	 and	 require	 prolonged	 hospitalisation	 (Villeneuve	 et	 al.	 2016;	 Hamshary	 et	 al.	
2017).	 MOF	 in	 critical	 illness	 imposes	 significant	 clinical	 challenges,	 often	 persisting	
beyond	the	period	of	acute	illness	(Taylor	et	al.	2003;		Typpo	et	al.	2009).	
	
The	human	intestine	is	host	to	a	large	and	complex	population	of	resident	microbes	(the	
gut	 microbiota).	 These	 bacteria	 (microbiota),	 and	 their	 metabolic	 products	 (together	
comprising	the	microbiome)	have	a	complex	synergistic	relationship	with	the	host	(Clark	
&	 Coopersmith	 2007).	 The	 intestinal	 microbiome	 contributes	 significantly	 to	 the	
nutritional,	 metabolic,	 endocrine	 and	 inflammatory	 activity	 of	 the	 host	 (Ramakrishna	
2013;	Krajmalnik-Brown	et	al.	2012;	Vinolo	et	al.	2011;	Byrne	et	al.	2015).	Because	of	its	
array	of	beneficial	 functions,	 the	microbiome	 is	 considered	an	organ	 that	 is	 important	
for	maintaining	the	health	and	wellbeing	of	the	host.	
	
Dysbiosis	 of	 the	 intestinal	 microbiome	 may	 have	 systemic	 consequences,	 due	 to	
extensive	 vascular,	 nerve	 and	 lymphatic	 connections	 between	 the	 intestinal	 tract	 and	
other	 distal	 organs	 (Petrova	 &	 Koh	 2018;	 Furness	 2008).	 Emerging	 evidence	 suggests	
that	the	intestinal	microbiome	may	interact	with	host	factors	during	critical	illness	to	
drive	 MOF	 and	 other	 adverse	 outcomes	 (Clark	 &	 Coopersmith	 2007;	 Mittal	 &	
Coopersmith	2014;	Dickson	2016;	Wolff	et	al.	2018).	There	are	many	examples	of	how	
the	composition	and	diversity	of	the	microbiome	is	associated	with	a	range	of	diseases	
in	both	children	and	adults,	 including	obesity,	heart	disease,	kidney	 injury	and	asthma	
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(Kasai	et	al.	2015;	Parekh	et	al.	2014;	Kelly	et	al.	2016;	Zhang	et	al.	2018;	Noval	Rivas	et	
al.	2016).	
	
A	 better	 understanding	 of	 the	 relationship	 between	 gut	 failure	 and	 multi-organ	
dysfunction	 in	 critical	 illness	 will	 allow	 us	 to	 define	 criteria	 for	 the	 therapeutic	
modulation	 of	 the	 intestinal	 environment.	 Whilst	 many	 of	 the	 triggers	 of	 intestinal	
dyshomeostasis	 may	 be	 unchangeable	 in	 critical	 illness,	 it	 seems	 a	 common-sense	
approach	to	support	the	intestinal	environment	in	patients	with	organ	failure.	Nutrition	
is	an	 important	 factor	determining	 intestinal	microbiota	composition.	 It	plays	a	critical	
role	in	the	colonisation,	maturation	and	stability	of	the	gut	residing	microbes	(Zhang	&	
Yang	2016).	Enteral	feeding	is	the	mainstay	of	nutrition	in	most	critically	ill	children,	with	
73%	 receiving	 enteral	 nutrition	 (EN),	 commenced	 and	 progressed	 where	 possible	
(Kerklaan	et	al.	2016).	Therapeutic	modulation	of	the	intestinal	environment	by	EN	could	
be	a	potential	effective	therapy	to	restore	homeostatic	state	in	affected	children.	
	
EN	modulation	of	the	body’s	response	has	been	tried	with	immune	nutrition	in	critically	
ill	 children	and	 it	has	been	associated	with	 lower	 infection	rates	and	 improvements	 in	
nutritional	indices	(Briassoulis	et	al.	2005;	Jacobs	et	al.	2013).	Nonetheless,	Carcillo	et	al.	
(2012)	showed	that	a	targeted	EN	intervention	was	not	associated	with	clinical	benefits	
and	 the	 assigned	 EN	 intervention	 made	 no	 difference	 in	 the	 overall	 population	 with	
respect	 to	 the	 onset	 of	 nosocomial	 infection	 or	 sepsis	 (Carcillo	 et	 al.	 2012).	 Targeted	
manipulation	 of	 the	 intestinal	 microbiome	 by	 EN	 has	 not	 been	 explored	 fully	 in	 this	
population.	Given	the	extensive	vascular	and	lymphatic	links	between	the	intestines	and	
other	 organs	 (Petrova	 &	 Koh	 2018),	 it	 is	 possible	 that	 enhancing	 the	 growth	 of	
commensal	bacteria	and	their	metabolites	by	EN	could	be	of	systemic	clinical	benefit.	
1.1 Critical	illness	
	
1.1.1 Pathophysiology	of	critical	illness	
The	acute	insult	of	critical	illness	is	characterised	by	disturbances	in	oxygen	supply	and	
consumption,	 resulting	 in	 reduced	 tissue	 oxygenation	 (Top	 et	 al.	 2011;	 Hayes	 et	 al.	
1994).	 The	 body	 adopts	 different	 mechanisms	 to	 maintain	 tissue	 oxygenation	 and	
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normal	 organ	 function	 (Mansjoer	 &	 George	 2008).	 This	 is	 characterised	 by	 dynamic	
changes	 in	 host	 physiology,	 including	 the	 induction	 of	 neuro-endocrine,	 immunologic	
and	metabolic	responses	(Joosten	et	al.	2016).	
	
The	stress	response	varies	according	to	the	phase	of	illness.	The	recent	European	Society	
for	 Paediatrics	 Gastroenterology,	 Hepatology	 and	 Nutrition	 (ESPGHAN)	 guidelines	 on	
paediatric	 parenteral	 nutrition	 (PN)	 proposed	 the	 following	 three	 phases	 of	 stress	
response	in	critically	ill	children	(Mesotten	et	al.	2018):	
	
• The	 acute	 phase:	 the	 resuscitation	 phase	 when	 the	 child	 requires	 vital	 organ	
support.	
	
• The	stable	phase:	characterised	by	stabilisation	and	weaning	from	vital	support.	
	
• The	 recovery	 phase:	 the	 mobilisation	 phase	 where	 the	 neuro-endocrine,	
immunologic	 and	 metabolic	 responses	 are	 resolved	 (Mesotten	 et	 al.	 2018;	
Joosten	et	al.	2016).	
	
The	acute	phase	of	stress	response	may	 last	 from	hours	up	to	days,	depending	on	the	
severity	of	 insult	 (Joosten	et	al.	2000).	 It	 is	 initiated	by	activation	of	 the	 inflammatory	
cytokine	 and	 the	 central	 nervous	 system	 to	 stimulate	 secretion	 of	 counter-regulatory	
hormones,	aimed	at	maintaining	tissue	perfusion	and	delivering	energy	substrate	to	the	
injured	organ	(Chwals	2014;	Joosten	et	al.	2016).	It	is	associated	with	hypovolemia	and	
hypoxia.	In	this	phase,	there	is	a	decrease	in	body	temperature,	cardiac	output,	oxygen	
consumption	 and	 energy	 expenditure	 (Stahel	 et	 al.	 2010;	 Chwals	 2014;	 Şimşek	 et	 al.	
2014;	Sobotka	et	al.	2009).	Abnormalities	of	the	endocrine	and	metabolic	responses	in	
critically	 ill	 children	were	recorded	 in	non-survivors	compared	to	survivors	 (Verhoeven	
et	al.	2011;	Joosten	et	al.	2000).	This	was	manifested	by	variation	 in	glycaemic	control	
and	 lipid	 profiles,	 as	 well	 as	 cortisol	 and	 adrenocorticotropic	 hormone	 responses	
(Verhoeven	et	al.	2011;	Joosten	et	al.	2000).	
	
The	stable	phase	of	critical	illness	is	characterised	by	a	reduction	in	serum	inflammatory	
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cytokines	and	suppression	of	catabolic	counter-regulatory	hormone	stimulation	(Preiser	
et	al.	2014).	The	duration	of	the	stable	phase	could	be	from	days	to	weeks	(Marcin	et	al.	
2001).	Lastly,	the	recovery	phase	is	the	mobilisation	and	anabolic	phase,	where	signs	of	
the	stress	response	are	resolved.	It	 is	also	associated	with	an	increased	rate	of	protein	
synthesis,	 tissue	 repair	 and	 restoration	of	mitochondrial	 function	 (Joosten	et	al.	 2016;	
Singer	2014).	
	
1.1.2 Inflammatory	response	in	critically	ill	children	
	
The	 acute	 phase	 stress	 response	 is	 characterised	 by	 the	 aggressive	 release	 of	
inflammatory	 mediators.	 These	 cytokines	 are	 the	 main	 regulators	 of	 the	 immune	
response	to	the	acute	insult;	they	can	either	have	a	protective	or	damaging	effect	(Brix-
Christensen	 2001).	 The	 acute	 pro-inflammatory	 response	 is	 typically	 followed	 by	 an	
induction	 of	 anti-inflammatory	 mediators	 (Oberholzer	 et	 al.	 2000).	 The	 interaction	
between	the	pro-inflammatory	and	anti-inflammatory	mediators	appears	to	determine	
the	 severity	 of	 outcome	 in	 critically	 ill	 patients	 (Oberholzer	 et	 al.	 2000;	 Wang	 &	 Ye	
2015).	
	
The	term	Systemic	Inflammatory	Response	Syndrome	(SIRS)	refers	to	the	widespread	of	
inflammation	in	areas	remote	form	the	primary	injured	site	(Ye-Ting	&	Dao-Ming	2018).	
The	dissemination	of	 inflammation	may	 result	 in	 the	 impaired	 function	of	other	distal	
organs,	 or	what	 is	 known	 as	MOF	 syndrome	 (Figure	 1.1).	 The	 clinical	 outcome	 of	 the	
inflammatory	response	depends	mainly	on	the	 intensity	and	concentration	of	released	
cytokines	and	the	type	of	cell	 they	are	acting	on,	as	well	as	 the	balance	between	pro-	
and	anti-inflammatory	responses	(Brix-Christensen	2001).	Uncontrolled	inflammation	is	
not	 only	 associated	 with	 adverse	 outcomes	 for	 tissue	 and	 organ	 function	 but	 it	 also	
affects	host	metabolism	(Wang	&	Ye	2015;	Chaudhry	et	al.	2013).	
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Figure	1.1	Development	of	SIRS	and	MOF	in	critical	illness	
Figure	1.1	shows	the	process	of	SIRS	and	MODS	development	in	critically	ill	patients.	Following	the	acute	
insult	 the	 immune	 cells,	 including	 monocytes,	 macrophages	 and	 lymphocytes,	 produce	 pro-	 and	 anti-
inflammatory	 mediators.	 The	 uncontrolled	 dissemination	 of	 inflammatory	 mediators	 to	 distal	 organs	
affects	 their	 function	 and	 results	 in	MOF.	 This	 generally	 begins	with	 lung	 failure	 followed	 by	 failure	 of	
other	organs.	
*	The	pictures	used	in	this	figure	have	been	obtained	from	MedScape.org	
	
1.1.3 Metabolic	derangement	in	paediatric	critical	illness	
	
Following	acute	 injury,	 the	 release	of	 inflammatory	 cytokines	 triggers	 the	 secretion	of	
counter-regulatory	 hormones.	 As	 a	 result,	 the	 body	 adopts	 a	 cascade	 of	 metabolic	
events.	This	includes	increased	glycogenolysis,	gluconeogenesis,	fatty	acid	oxidation	and	
ketogenesis	as	well	as	reduced	energy	expenditure	(Srinivasan	2012;	Caresta	et	al.	2007;	
Briassoulis	et	al.	2000;	Chwals	2014;		De	Cosmi	et	al.	2017)	(see	Figure	1.2).	
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1.1.3.1 Alteration	in	the	pattern	of	energy	expenditure	in	critically	ill	children	
	
The	typical	response	to	acute	injury	in	adults	is	a	reduction	in	energy	expenditure	during	
the	 ebb	phase	 followed	by	 an	 increase	 in	 energy	 expenditure	 after	 the	 restoration	of	
oxygen	transport,	where	the	body	enters	the	flow	phase.	However,	this	adaptive	pattern	
of	energy	expenditure	is	different	in	critically	ill	children;	the	dominant	hyper-metabolic	
response	seen	in	critically	ill	adults	is	not	evident	in	children’s	studies	(Briassoulis	et	al.	
2000;	Taylor	et	al.	2003;	Hardy	Framson	et	al.	2007).	 In	fact,	 these	studies	have	found	
that	 critically	 ill	 children	 have	 reduced	 energy	 expenditure	 during	 the	 acute	 phase	 of	
illness.	However,	energy	expenditure	may	be	increased	 transiently	 (4	 to	6	hours)	after	
acute	injury	(Pierro	2002).	Reduced	energy	expenditure	in	critically	ill	children	could	be	
due	 to	 lack	 of	 physical	 movement,	 decreased	 work	 of	 breathing,	 and	 maintaining	 a	
thermo-neutral	 environment	 in	 PICU	 settings	 (Briassoulis	 et	 al.	 2000).	 However,	 the	
most	 important	distinctive	physiological	 function	 in	children	 in	comparison	to	adults	 is	
somatic	growth.	During	critical	illness,	growth,	which	is	an	anabolic	process,	is	inhibited	
and	 restored	 again	 only	 after	 the	 acute	 metabolic	 stress	 has	 been	 resolved	 (Chwals	
2014).	Growth	accounts	for	30-35%	of	total	energy	expenditure	in	infants	(Verhoeven	et	
al.	 1998).	 Unlike	 adults,	 critically	 ill	 children	 have	 the	 ability	 to	 reduce	 their	 energy	
expenditure	through	re-channelling	the	spare	energy	used	for	growth	(Briassoulis	et	al.	
2000;	Vernon	&	Witte	2000).	However,	 this	may	not	be	 the	case	 for	older	 children	as	
energy	expenditure	used	for	growth	is	very	small	and	accounts	for	only	5%	of	the	total	
energy	expenditure	(Butte	et	al.	2000;	Hardy	Framson	et	al.	2007).	
	
The	pattern	of	energy	expenditure	is	variable	during	the	clinical	course	of	critical	illness.	
Energy	expenditure	is	 increased	by	1.3	times	in	the	stable	phase	and	by	2	times	in	the	
recovery	phase	as	the	body	shifts	from	catabolic	to	anabolic	state	(Joosten	et	al.	2016;	
Joosten	et	al.	2018).	
1.1.3.2 Shift	in	fuel	utilisation	
	
Critically	ill	children	utilise	fat	preferentially	as	a	substrate	for	their	energy	metabolism,	
thus	the	acute	metabolic	response	is	characterised	by	increased	lipolysis	and	fatty	acid	
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oxidation	relative	to	glucose	oxidation	(Coss-Bu	et	al.	2001;	Caresta	et	al.	2007).	Lipolysis	
is	 accelerated	 in	 the	 early	 phase	 of	 illness	 under	 the	 hormonal	 control	 of	
adrenocorticotropic	hormone,	 cortisol,	 catecholamine,	 glucagon,	 growth	hormone	and	
insulin	 resistance	 (Şimşek	 et	 al.	 2014).	 In	 addition,	 the	 release	 of	 pro-inflammatory	
cytokines	 affects	 fatty	 acid	 uptake	by	 adipose	 tissues	 and	muscles	 by	 suppressing	 the	
activity	of	lipoprotein	lipase	in	these	sites	(	Jan	&	Lowry	2010).	Muramoto	et	al.	(2016)	
reported	an	elevation	in	serum	triglycerides	levels	in	critically	ill	children	in	response	to	
an	 increase	 in	 inflammatory	 markers,	 which	 could	 be	 related	 to	 the	 effect	 of	
inflammatory	cytokines	on	suppressing	lipoprotein	lipase	activity.		
	
Loss	of	endogenous	protein	stores	is	another	feature	of	the	acute	metabolic	response	in	
children.	 Amino	 acids	 are	mobilised	 to	 the	 liver	where	 they	 provide	 substrate	 for	 the	
synthesis	of	acute	phase	proteins	and	glucose	(Şimşek	et	al.	2014;	Sobotka	et	al.	2009;		
De	Cosmi	et	al.	2017).	The	 risk	of	muscle	atrophy	 is	 substantially	 increased	during	 the	
stable	 phase	 of	 critical	 illness	where	 the	 anabolic	 process	 is	 initiated	 (De	Cosmi	 et	 al.	
2017;		Joosten	et	al.	2016;		Jotterand	Chaparro	et	al.	2016).	
	
Glucose	is	a	particularly	important	substrate	for	glycolytic	tissues	in	which	mitochondrial	
respiration	 is	 not	 possible,	 such	 as	 in	 leukocytes,	 erythrocytes,	macrophages	 and	 the	
renal	 medulla.	 Glycolysis	 in	 these	 tissues	 leads	 to	 the	 release	 of	 lactate,	 which	 is	
returned	to	the	liver	and	reconverted	into	glucose	by	the	lactic	acid	cycle	(Şimşek	et	al.	
2014;	Sobotka	et	al.	2009).	In	hypoxic	states,	mitochondrial	oxidative	phosphorylation	is	
limited,	 limiting	 pyruvate	 metabolism,	 which	 as	 a	 result	 is	 preferentially	 reduced	 to	
lactate,	resulting	in	increased	concentrations	of	arterial	lactate	(Fuller	&	Dellinger	2012).	
Lactate	 accumulation	 reflects	 the	 state	 of	 mitochondrial	 oxidative	 phosphorylation	 in	
cells.	 It	 serves	 as	 a	 biomarker	 of	 mitochondrial	 function	 and	 a	 predictor	 of	 disease	
severity	in	the	critically	ill	population	(Pang	et	al.	2014).	
1.1.3.3 Loss	of	glycaemic	control	in	critically	ill	children	
	
Loss	 of	 glycaemic	 control	 is	 frequently	 recorded	 in	 critically	 ill	 children	 due	 to	 the	
initiation	of	the	inflammatory	response,	the	dysregulation	of	endocrine	stimulation	and	
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substrate	metabolism,	as	well	as	peripheral	 insulin	resistance	(Faustino	&	Apkon	2005;		
Patki	&	Chougule	 2014;	 Srinivasan	2012).	Hyperglycaemia	 is	 a	 common	 feature	of	 the	
stress	response	in	critically	ill	children.	It	is	usually	induced	by	the	massive	induction	of	
counter-regulatory	hormones.	Increased	blood	glucose	levels	also	might	be	secondary	to	
the	state	of	 insulin	resistance	 (Patki	&	Chougule	2014).	Blood	glucose	 levels	appear	 to	
spontaneously	 normalise	 within	 48	 hours	 in	 septic	 children	 (Verhoeven	 et	 al.	 2011).	
Tight	glycaemic	control	has	been	shown	to	significantly	reduce	the	rate	of	infection	and	
length	of	 PICU	 stay	 in	 children	 (Vlasselaers	 et	 al.	 2009;	Day	et	 al.	 2008;	 Jeschke	et	 al.	
2010).	
	
1.1.3.4 Changes	in	gut	endocrine	function	during	critical	illness	
	
Glucagon-Like	Peptide-1	(GLP-1)	and	Peptide	YY	(PYY)	are	gut	hormones	secreted	from	
intestinal	L-cells	in	response	to	nutrient	stimulation.	They	play	an	important	role	in	the	
regulation	of	the	metabolism	by	controlling	the	appetite,	gastric	motility	and	to	a	lesser	
extend	energy	expenditure.	Generally	GLP-1	and	PYY	induce	a	state	of	negative	energy	
balance	 by	 suppressing	 appetite,	 inhibiting	 gastric	 emptying	 and	 increasing	 energy	
expenditure	(Vrieze	et	al.	2010;	Barrera	et	al.	2011;	Parekh	et	al.	2014).	
	
New	 emerging	 studies	 have	 recorded	 an	 alteration	 in	 gut	 hormone	 levels	 in	 both	
critically	 ill	 children	 and	 adults	 (Lebherz	 et	 al.	 2017;	Nematy	 et	 al.	 2006;	 Kahles	 et	 al.	
2014).	The	inflammatory	mediators	are	thought	to	contribute	to	the	induction	of	GLP-1	
and	 PYY	 secretion	 through	 stimulation	 of	 intestinal	 L-cells	 (Ellingsgaard	 et	 al.	 2011;	
Nguyen	 et	 al.	 2006).	 Studies	 also	 suggested	 that	 SCFAs	 produced	 from	 the	 bacterial	
fermentation	 of	 dietary	 carbohydrates	may	 stimulate	 the	 secretion	 of	 GLP-1	 and	 PYY	
through	the	activation	of	GPR41	and	GPR43	receptors	in	the	intestines	(Kim	et	al.	2014,	
Tolhurst	 et	 al.	 2012,	 Vrieze	 et	 al.	 2010),	 leading	 to	 up	 regulation	 of	 GLP1	 and	 PYY	
synthesis	by	intestinal	L	cells	(Kim	et	al.	2014,		Vrieze	et	al.	2010).	
	
Kahles	et	al.	(2014)	indicated	that	septic	adult	patients	had	statistically	higher	levels	of	
GLP-1	 compared	 to	 non-septic.	 GLP-1	 secretion	 also	 appeared	 to	 be	 increased	 in	
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response	to	endotoxin	stimulation	(Nguyen	et	al.	2014).	In	critically	ill	adults,	the	levels	
of	 GLP1	 were	 positively	 correlated	 with	 the	 severity	 of	 disease	 (Kahles	 et	 al.	 2014;	
Lebherz	 et	 al.	 2017).	 These	 aforementioned	 studies	 suggest	 a	 potential	 association	
between	gut	hormones	and	immune	system	activation.	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	1.2	Summary	of	the	metabolic	response	during	the	acute	phase	of	illness	
Figure	1.2	shows	the	adaptive	metabolic	cascade	in	response	to	acute	 illness.	The	metabolic	response	is	
initiated	 by	 the	 neurological	 stimulation	 of	 inflammatory	 cytokines	 and	 counter-regulatory	 hormone	
release,	resulting	in	metabolic	alteration	of	a	local	and	systemic	effect.	
*	The	pictures	used	in	this	figure	have	been	obtained	from	MedScape.org	
	
1.1.4 Key	difference	in	the	stress	response	between	children	and	adults	
	
The	 acute	 stress	 response	 is	 distinctive	between	adults	 and	 children	 in	many	 aspects.	
Therefore,	results	from	adult	studies	may	not	be	applicable	in	critically	ill	children.	The	
initial	stress	response	in	critically	ill	children	appears	to	be	different	from	that	of	adults	
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(Top	et	al.	2011).	Septic	shock	in	critically	ill	children	is	characterised	by	a	hypo-dynamic	
state,	 while	 in	 adults	 hyper-dynamic	 is	 the	 predominant	 pattern	 of	 hemodynamic	
instability	 (Mercier	 et	 al.	 1988;	 Top	 et	 al.	 2011).	 To	 compensate	 for	 hemodynamic	
instability,	adult	patients	increase	their	cardiac	output	through	ventricular	dilatation	and	
increased	 heart	 rate,	 while	 children	 lack	 this	 adaptive	 mechanism	 of	 ventricular	
dilatation	(Top	et	al.	2011).	Unlike	adults,	the	release	pattern	and	plasma	concentrations	
of	the	pro-inflammatory	response	in	children	are	characterised	by	a	large	variation	(Brix-
Christensen	2001;	Brix-Christensen	et	al.	1998;	Ozawa	et	al.	2000).	Critically	ill	children	
utilise	 fat	 preferentially	 as	 a	 substrate	 for	 their	 energy	 metabolism,	 thus	 the	 acute	
metabolic	 response	 is	 characterised	 by	 increased	 lipolysis	 and	 fatty	 acid	 oxidation	
relative	 to	 glucose	 oxidation	 (Coss-Bu	 et	 al.	 2001;	 Caresta	 et	 al.	 2007).	 In	 critically	 ill	
adults,	on	the	contrary,	the	rate	of	carbohydrates	oxidation	is	increased	more	than	lipid	
oxidation	 during	 the	 early	 phase	 of	 illness	 (Preiser	 et	 al.	 2014;	 Tappy	 et	 al.	 1998).	
Furthermore,	the	dominant	hyper-metabolic	response	in	critically	ill	adults	is	not	evident	
in	children	(Briassoulis	et	al.	2000;	Taylor	et	al.	2003;	Hardy	Framson	et	al.	2007).	Due	to	
variations	in	many	parameters	of	the	stress	response	between	adults	and	children,	the	
results	 derived	 from	 adult	 studies	 may	 not	 be	 relevant	 to	 the	 child	 population.	
Therefore,	 there	 is	 an	 urgent	 need	 for	 studies	 particularly	 performed	with	 critically	 ill	
children.	
 
1.2 Disruption	of	human	microbiome	in	critical	illness	
	
Changes	to	the	microbiome	 in	response	to	environmental	 influences	can	affect	overall	
health	 (Parekh	et	 al.	 2014;	Kelly	 et	 al.	 2016;	Noval	Rivas	et	 al.	 2016).	Critical	 illness	 is	
associated	 with	 pathophysiological	 effects	 that	 are	 damaging	 to	 the	 intestinal	
microbiome.	These	include	ischemia,	hypoxia	and	hypotension	along	with	the	iatrogenic	
effects	of	therapeutic	agents	and	the	lack	of	enteral	feeds	(Krezalek	et	al.	2016;	Ferrer	et	
al.	 2016;	 	 Maier	 et	 al.	 2018).	 As	 a	 result,	 of	 alteration	 to	 intestinal	 microbial	
composition,	 the	 integrity	 of	 the	 intestinal	 epithelial	 barrier	 and	 intestinal	 mucosa	
absorptive	function	are	compromised	(Lupp	et	al.	2007;	Kohler	et	al.	2005;	Morowitz	et	
al.	2011;	Lara	&	Jacobs	2016;	Btaiche	et	al.	2010).	
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Generally,	 the	 intestinal	microbiome	of	critically	 ill	children	and	adults	 is	characterised	
by	low	diversity	(Jacobs	et	al.	2017;	Rogers	et	al.	2016).	Critically	ill	children	and	adults	
appear	to	rapidly	colonised	with	opportunistic	pathogens	(Ojima	et	al.	2016;	Rogers	et	
al.	 2016).	 In	 addition,	 a	 loss	 of	 intestinal	 anaerobic	 bacteria	 has	 been	 frequently	
detected	 during	 the	 course	 of	 critical	 illness,	 and	 accordingly	 the	 colonic	 degradation	
capacity	of	undigested	carbohydrates	into	lactic	acid	and	short	chain	fatty	acids	(SCFAs)	
may	 be	 affected	 (Shimizu	 et	 al.	 2006;	 Iapichino	 et	 al.	 2008;	 Hayakawa	 et	 al.	 2011;		
Yamada	et	 al.	 2015).	 The	 interaction	between	 the	host	 and	 intestinal	microbiome	has	
been	 shown	 to	 be	 highly	 relevant	 to	 pathophysiology	 and	 outcomes	 in	 severe	 and	
critical	illness.	Damage	to	the	intestinal	mucosal	lining	in	severe	disease	may	lead	to	the	
translocation	 of	 bacteria	 or	 their	 fragments	 into	 the	 bloodstream	 and	 this	 may	
contribute	to	inflammation,	sepsis,	MOF	and	death	(Clark	&	Coopersmith	2007;	Pathan	
et	 al.	 2011;	 Deitch	 2012).	 Depletion	 of	 the	 normal	 gut	 microbial	 population	 and	
metabolites,	and	alterations	to	the	intraluminal	gut	environment	have	been	shown	to	be	
associated	with	adverse	outcomes	in	critically	ill	adults	(Reintam	et	al.	2009).	Indeed	the	
gut	is	seen	as	an	important	driver	of	organ	failure	in	critical	illness	(Mittal	&	Coopersmith	
2014),	(see	Figure	1.3).	
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The	changes	in	gut	micobiome	may	result	in	:	
•  Inflammation	
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•  Secondary	sepsis	
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Figure	1.3	How	critical	illness	affects	the	gut	microbiome	
Figure	1.3	summarises	the	changes	that	occur	in	the	gut	microbiome	during	critical	illness.	In	response	to	
acute	insult,	factors	such	as	reperfusion,	antibiotic	therapy	and	the	lack	of	enteral	feed	result	in	damage	
to	 the	 intestinal	 barrier	 and	 changes	 in	 microbial	 composition.	 Alterations	 to	 the	 gut	 microbiome	 are	
strongly	related	to	the	exacerbation	of	the	inflammatory	response,	metabolic	dysregulation	sepsis	and	the	
propagation	of	MOF.	
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1.2.1 Factors	affecting	intestinal	microbiome	
	
1.2.1.1 Disease	state	
	
The	 intestinal	 microbiome	 is	 altered	 in	 response	 to	 the	 pathophysiological	 effects	 of	
critical	illness.	The	pro-inflammatory	stimulation	appears	to	influence	the	tight	junctions	
between	enterocytes	and	results	 in	 increased	epithelial	permeability,	the	infiltration	of	
luminal	 antigens	 and	 the	 induction	 of	 intestinal	 inflammation	 (Clark	 &	 Coopersmith	
2007).	 Intestinal	 inflammation	 and	 hypoxia	 have	 significant	 impact	 on	modulating	 the	
gut	 microbiome	 and	 microbiota	 composition	 during	 critical	 illness	 (Lupp	 et	 al.	 2007;	
Kohler	et	al.	2005).	Both	promote	a	 shift	 from	commensal	anaerobes	 to	opportunistic	
pathogens	 (Lupp	et	al.	2007;	Kohler	et	al.	2005).	Furthermore,	 intestinal	 inflammation	
alters	 the	 responses	 of	 gut	 hormones	 and	 neurotransmitters	 and	 accordingly	 impacts	
gut	 motility	 (Btaiche	 et	 al.	 2010).	 It	 was	 speculated	 that	 inflammation	 supresses	 the	
expression	 of	 certain	 hormones	 such	 as	 PYY	 by	 mature	 endocrine	 cells,	 resulting	 in	
impaired	gut	motility	(El-Salhy	et	al.	2017).	The	activation	of	inflammatory	cytokines	and	
increased	levels	of	luminal	catecholamine	have	also	been	shown	to	promote	the	growth	
of	pathogenic	species	 (Dickson	2016;	Alverdy	et	al.	2000).	 Impaired	mucosal	 immunity	
and	 decreased	 IgA	 production	 are	 other	 features	 of	 acute	 illness,	 and	 are	 associated	
with	decreased	ability	to	eliminate	intestinal	pathogens	(Dickson	2016).	
	
1.2.1.2 Medication	
	
The	 pharmaceutical	 agents	 commonly	 used	 in	 ICU	 such	 as	 antibiotics,	 inotropic	 drugs	
and	vasopressors	are	known	to	impact	the	human	microbiota	(Lupp	et	al.	2007;	Kohler	
et	al.	2005;	Sandrini	et	al.	2015;	Freestone	et	al.	2008;	Maier	et	al.	2018).	
	
Critically	 ill	patients	are	 frequently	 treated	with	antibiotics.	 It	has	been	estimated	that	
the	 total	 antibiotic	 consumption	 in	 PICUs	 is	 nearly	 ten	 times	 greater	 than	 in	 general	
hospital	wards	(Malacarne	et	al.	2004).	Several	studies	have	recorded	profound	changes	
in	gut	microbial	communities	following	the	administration	of	antibiotic	treatment,	which	
can	subsequently	 result	 in	 important	 functional	alterations	of	 the	gut	microbiome	and	
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increase	 susceptibility	 to	 gastrointestinal	 infections	 (Palmer	 et	 al.	 2007;	 Preidis	 &	
Versalovic	2009).	 The	effect	of	 antibiotic	 exposure	on	gut	microbiota	has	been	widely	
investigated.	 The	 main	 phyla	 influenced	 by	 antibiotic	 treatment	 appear	 to	 be	
Actinobacteria,	Bacteroidetes,	Firmicutes,	and	Proteobacteria	(Theriot	et	al.	2014;	Panda	
et	 al.	 2014;	 Theriot	 et	 al.	 2016).	 In	 a	 study	 conducted	 on	 antibiotic-treated	 infants,	 a	
massive	 reduction	 in	 total	 bacterial	 densities	was	observed	 after	 antibiotic	 treatment,	
accompanied	 by	 delayed	 colonisation	 by	 beneficial	 species	 such	 as	Bifidobacteria	 and	
Lactobacilli,	 and	 induced	 colonisation	 by	 antibiotic-resistant	 strains	 (Schumann	 et	 al.	
2005).	The	findings	from	these	studies	could	explain	the	high	prevalence	of	nosocomial	
infections	with	 increased	 antibiotic	 consumption	 in	 critically	 ill	 patients	 (Weber	 et	 al.	
1999).	
The	alteration	in	the	balance	of	gut	microbiota	following	antibiotic	treatment	could	be	
short	 term	 or	 may	 last	 for	 a	 longer	 period.	 An	 example	 of	 the	 long-lasting	 effect	 of	
antibiotic	 use	 is	 reduced	 colonisation	 resistance	 against	 some	 pathogens	 such	 as	
Clostridium	 difficile	 (Theriot	 et	 al.	 2014).	 As	 this	 population	 often	 receives	 extensive	
antibiotic	 treatment,	 it	may,	 in	 addition	 to	 the	 functional	 loss	 of	 commensal	 species,	
affect	the	prevalence	of	antimicrobial-resistant	genes	within	the	intestinal	microbiome.	
Other	 therapeutic	 agents	 used	 in	 PICU	 are	 also	 known	 to	 impact	 the	 intestinal	
microbiome,	including	inotropic	drugs	that	promote	the	growth	of	pathogens	(Sandrini	
et	 al.	 2015;	 Freestone	 et	 al.	 2008).	 Vasopressors	 like	 calcium-channel	 blockers	 have	
recently	been	shown	to	inhibit	the	growth	of	commensal	bacteria,	however	the	exact	
mechanism	has	not	been	established	yet	(Maier	et	al.	2018).	
1.2.1.3 Nutrition	
	
Nutrition	has	an	indirect	effect	on	the	gastrointestinal	function	of	the	host	and	thereby	
on	 health,	 mainly	 by	 influencing	 the	 composition	 and	 activity	 of	 the	 human	 gut	
microbiota.	 It	 is	 considered	 one	 of	 the	major	 determinants	 of	 the	 intestinal	microbial	
composition.	The	route	of	feeding	greatly	affects	gut	microbial	population	(Hodin	et	al.	
2012;	 Shiga	 et	 al.	 2012).	 EN	 helps	 to	 maintain	 the	 immunological	 function	 of	 the	
gastrointestinal	 tract;	 it	 decreases	 bacterial	 translocation	 and	 accordingly	 blunts	 the	
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systemic	 inflammatory	 response	 (Heyland	 et	 al.	 1993;	 Yang	 et	 al.	 2009).	 In	 addition,	
early	compared	to	delayed	enteral	feeding	is	associated	with	less	bacterial	translocation	
and	better	mucosal	 integrity	 (Feng	 et	 al.	 2017;	 Kotani	 et	 al.	 1999).	 In	 contrast,	 bowel	
rest,	 as	 associated	 with	 total	 PN	 or	 delayed	 EN,	 results	 in	 gastrointestinal	 mucosal	
atrophy,	which	compromises	the	integrity	of	the	mucosal	barrier	and	enhances	exposure	
to	bacteria	and	endotoxins	(Deplancke	et	al.	2002;	Bjornvad	et	al.	2008;	Heyland	et	al.	
1993).	 The	 composition	 of	 EN	 is	 also	 known	 to	 greatly	 influence	 the	 colonisation,	
maturation	and	stability	of	the	intestinal	microbiota	(Zhang	&	Yang	2016).	The	effect	of	
the	 dietary	 component	 on	 intestinal	microbiota	 varies;	 it	may	promote	 the	 growth	of	
opportunistic	 microbes	 while	 other	 dietary	 factors	 could	 endorse	 beneficial	 microbes	
(Brown	et	al.	2012).		
	
Dietary	fibre	 is	the	primary	energy	source	for	most	commensal	species	and,	therefore,	
can	directly	 impact	 their	growth	(D.	Graf	et	al.	2015).	 	It	 is	also	the	main	substrate	 for	
the	 microbial	 production	 of	 important	 bacterial	 metabolites	 known	 to	 influence	 the	
host’s	 health	 (den	 Besten	 et	 al.	 2013a).	 The	 effect	 of	 fibre	 supplementation	 on	 gut	
microbiota	has	been	widely	investigated	in	healthy	subjects,	and	data	showed	that	the	
main	 species	 influenced	 were	 Bifidobacteria,	 Lactobacilli,	Faecalibacterium	 prausnitzii	
and	Roseburia	(Bouhnik	et	al.	1996;	Vulevic	et	al.	2008;	Ramirez-Farias	et	al.	2009;	Benus	
et	 al.	 2010;	 Sawicki	 et	 al.	 2017).	 The	 nutrition	 status	 is	 also	 an	 important	 factor	
determining	 the	 diversity	 of	 intestinal	 microbiome	 (Krajmalnik-Brown	 et	 al.	 2012).	
Therefore,	 the	 state	 of	 energy	 deficit,	 particularly	 during	 the	 acute	 phase	 of	 illness,	
might	have	a	profound	effect	on	the	gut	microbiota	and	environment.	
	
1.2.2 Contribution	of	intestinal	microbiota	to	the	host	health	
	
The	gut	microbiota	use	ingested	dietary	components	(carbohydrates	−	mainly	resistance	
starch,	 proteins,	 and	 lipids)	 to	 generate	 energy	 for	 cellular	 processes	 and	 for	 growth	
(Ramakrishna	 2013).	 During	 the	 process	 of	 utilising	 these	 substrates,	 the	 microbiota	
produce	 several	 metabolites	 that	 influence	 host	 health	 and	 metabolism	 (Krajmalnik-
Brown	et	al.	2012;	Ramakrishna	2013).	
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1.2.2.1 Macronutrient	metabolism	
	
Preclinical	 data	 and	 animal	 studies	 have	 suggested	 possible	 mechanisms	 of	 the	
contribution	of	intestinal	microbiota	to	the	regulation	of	macronutrient	metabolism.	
	
a.	Carbohydrates	
The	 fermentation	 of	 polysaccharides	 (fibre)	 by	 anaerobic	 bacteria	 leads	 to	 the	
production	of	SCFAs,	which	are	utilised	by	the	host.	Colonic	epithelial	cells	derive	up	to	
70%	of	their	energy	from	the	oxidation	of	butyrate	(Blaut	&	Clavel	2007).	The	microbial	
gluconeogenesis	 from	 propionate	 reduces	 hepatic	 gluconeogenesis	 and	 promotes	
energy	homeostasis	 (De	Vadder	 et	 al.	 2014;	 Rowland	et	 al.	 2018).	Gut	microbiota	 are	
also	 known	 to	 regulate	glucose	metabolism	 through	 the	 stimulation	of	GLP-1	and	PYY	
hormone	secretions	from	intestinal	L-cells	(Psichas	et	al.	2015;	Tolhurst	et	al.	2012).	
	
b.	Protein	
Gut	microbiota	contribute	to	host	nitrogen	balance	through	de	novo	synthesis	of	amino	
acids	 and	 intestinal	 urea	 recycling.	 Studies	with	 radiolabelled	 tracers	 suggest	 that	 gut	
microbes	 synthesise	 nearly	 20%	 of	 circulating	 threonine	 and	 lysine	 in	 healthy	 adult	
humans	 (Metges	 2000).	 The	 intestinal	 microbiota	 also	 contribute	 to	 host	 nitrogen	
balance	 by	 participating	 in	 urea	 nitrogen	 salvaging	 (Morowitz	 et	 al.	 2011).	 Elevated	
urease	expression	in	gut	microbes	results	in	the	metabolism	of	urea	in	the	GI	tract	into	
ammonia	 and	 carbon	dioxide.	 Some	of	 the	 ammonia	 can	be	utilised	 for	 the	microbial	
synthesis	of	amino	acids.	More	importantly,	the	nitrogen	generated	during	this	process	
can	 re-enter	 the	 host	 circulation	 and	 serve	 as	 a	 substrate	 for	 synthetic	 processes	
(Morowitz	et	al.	2011).	Reduced	urea	recycling	has	been	reported	in	germ-free	animals	
and	 in	 humans	 receiving	 antibiotic	 therapy	 (Levenson	 &	 Crowley	 1959;	 Walser	 &	
Bodenlos	1959).	Therefore,	the	state	of	negative	nitrogen	balance	frequently	observed	
during	critical	illness	could	be	partially	attributed	to	disturbances	in	the	gut	microbiome,	
which	impacts	the	intestinal	urea	recycling	process.	
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c.	Lipids	
The	 impact	of	dietary	 lipids	on	the	microbiota	 in	critically	 ill	 children	has	not	yet	been	
established.	 However,	 preclinical	 studies	 in	 animal	models	 indicate	 that	 the	 intestinal	
microbiota	regulate	fat	metabolism	by	suppressing	the	activity	of	a	circulating	inhibitor	
of	 lipoprotein	 lipase	 (LPL)	 (Bäckhed	 et	 al.	 2004).	 This	 results	 in	 increased	 levels	 of	
circulating	LPL,	which	stimulate	hepatic	triglyceride	production	and	promote	the	storage	
of	triglycerides	in	adipocyte	(Janssen	&	Kersten	2017;	Goldberg	et	al.	2009;	Bäckhed	et	
al.	 2004).	 Suppression	 of	 LPL	 inhibitors	 is	 promoted	 by	 intestinal	 microbiota	 through	
transcriptional	 suppression	of	 the	 intestinal	epithelial	 gene	encoding	 for	 LPL	 inhibitors	
(Bäckhed	et	al.	2004).	Abnormalities	in	lipid	metabolism	commonly	observed	during	the	
course	 of	 critical	 illness	 could	 be	 also	 related	 to	 the	 disturbance	 in	 the	 functional	
capacity	of	the	gut	microbiota.	
	
1.2.2.2 Short	chain	fatty	acids	(SCFAs)	
	
SCFAs	arising	from	the	anaerobic	bacterial	metabolism	of	indigestible	dietary	fibre	in	the	
colon	are	beneficial	to	the	host	health.	SCFAs	support	the	integrity	of	the	gut	barrier	by	
regulating	the	release	of	mucus	by	colonic	cells	and	acting	as	a	fuel	source	to	colon	cells.	
They	 also	 have	 immune	 modulating	 activity	 and	 are	 involved	 in	 the	 release	 of	 gut	
hormones	(Vinolo	et	al.	2011;	Byrne	et	al.	2015).	The	principal	SCFAs	seen	in	the	colon	
are	acetate,	propionate	and	butyrate.	SCFAs	have	been	shown	to	be	depleted	in	adults	
with	critical	illness,	often	due	to	the	effect	of	the	acute	insult	and	other	environmental	
factors	on	SCFAs-forming	species	(Shimizu	et	al.	2006;	Osuka	et	al.	2012;	Hayakawa	et	al.	
2011;		Yamada	et	al.	2015;	Vermeiren	et	al.	2012).	
	
a.	SCFAs	as	a	source	of	energy	
	
The	 bacterial	 formation	 of	 SCFAs	 enables	 the	 host	 to	 salvage	 some	 of	 the	 energy	
contained	in	dietary	fibre	that	would	otherwise	be	lost,	while	various	tissues	in	the	body	
are	 able	 to	 oxidise	 SCFAs	 for	 energy	 generation	 (Blaut	 &	 Clavel	 2007).	 SCFAs	 are	
absorbed	 by	 passive	 diffusion	 across	 the	 colonic	 epithelium,	 and	 utilised	 by	 different	
organs.	Colonic	epithelial	 cells	derive	up	 to	70%	of	 their	energy	 from	 the	oxidation	of	
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butyrate	 (den	 Besten	 et	 al.	 2013).	 Propionate	 serves	 as	 a	 substrate	 for	 microbial	
gluconeogenesis	(De	Vadder	et	al.	2014;	Rowland	et	al.	2018).	Acetate	is	used	by	skeletal	
and	cardiac	muscle	and	also	can	be	utilised	by	adipocytes	for	lipogenesis	(Hooper	et	al.	
2002).	Butyrate	is	metabolised	primarily	in	the	gut	epithelium	to	yield	ketone	bodies	or	
CO2	 and	 propionate	 is	 transported	 to	 the	 liver	 for	 gluconeogenesis	 (Morowitz	 et	 al.	
2011).	
	
b.	Physiological	functions	of	SCFAs	
Besides	being	used	as	fuel	by	different	organs,	SCFAs	have	other	physiological	functions	
(Topping	&	Clifton	2001;	Kasubuchi	et	al.	2015).	For	instance,	butyrate	appears	to	affect	
cell	 differentiation	 and	 protects	 cells	 from	 carcinogens,	 either	 by	 slowing	 growth	 and	
activating	apoptosis	 in	colon	cancer	cells	 (Scharlau	et	al.	2009),	or	by	upregulating	the	
detoxifying	enzymes,	such	as	glutathione-S-transferases	(Pool-Zobel	et	al.	2005).	SCFAs	
also	 impact	water	absorption,	 local	blood	flow,	and	epithelial	proliferation	 in	the	 large	
intestines	(Morowitz	et	al.	2011).	SCFAs	have	a	direct	protective	effect	on	strengthening	
the	 gut	 barrier	 in	 the	 normal	 colon	 by	 increasing	 the	 production	 of	 mucus	 by	
colonocytes	(Lewis	et	al.	2010).	Most	importantly,	SCFAs	are	involved	in	the	regulation	
of	inflammation.	Generally,	SCFAs	exert	their	physiological	functions	by	acting	as	signal	
molecules	that	activate	target	receptors	in	various	cells	and	organs.	
	
c.	SCFAs	as	signalling	molecules	
The	 physiological	 effects	 of	 SCFAs	 depend	 on	 the	 activation	 of	 G	 protein-coupled	
receptors	 (GPRs)	 (Vinolo	 et	 al.	 2011;	 Kim	et	 al.	 2014).	 In	 adipocytes,	 the	 activation	of	
GPR43	by	SCFAs	results	 in	the	suppression	of	 insulin	signalling	and	accordingly	 inhibits	
lipogenesis	 and	 enhances	 glucose	 and	 lipid	 utilisation	 by	 the	 muscles.	 On	 the	 other	
hand,	activated	G-protein-coupled	membrane	receptor	GPR41	enhances	the	production	
of	 leptin,	 and	 activated	 GPR109A	 suppresses	 lipolysis	 (Kim	 et	 al.	 2014;	 Kimura	 et	 al.	
2014).	 In	 addition,	 it	 has	 been	 suggested	 that	 the	 SCFAs	 activation	 of	 GPR41	 in	
adipocytes	 increases	 fatty	 acid	 oxidation	 and	 energy	 expenditure	 (den	 Besten	 et	 al.	
2013b).	 The	 expression	 of	 GPR41	 and	 GPR43	 by	 SCFA	 in	 the	 intestines	 promotes	 gut	
	
Chapter	One		
	
	 	
33	
hormone	secretion,	which	regulates	energy	homeostasis	(Psichas	et	al.	2015;	Tolhurst	et	
al.	2012)		(see	Figure	1.4).	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	1.4	SCFAs	as	signalling	molecules	activating	G-protein-coupled	receptors	
Figure	 1.4	 summaries	 the	 physiological	 function	 that	 SCFAs	 exert	 by	 activating	 G-protein-coupled	
receptors	in	different	target	organs	and	cells.	
*	The	pictures	used	in	this	figure	have	been	obtained	from	MedScape.org	
	
d.	SCFAs	and	inflammation	
	
An	 important	 driver	 of	 MOF	 in	 critical	 illness	 is	 the	 dysregulation	 of	 innate	 immune	
pathways	 and	 the	 loss	 of	 balance	 between	 pro-inflammatory	 and	 anti-inflammatory	
mechanisms	 (Cox	 2012).	 SCFAs	 appear	 to	 play	 a	 role	 in	modulating	 inflammatory	 and	
immune	 responses,	 since	 they	 modify	 the	 migration	 of	 leukocytes	 to	 the	 site	 of	
inflammation,	as	well	as	modifying	the	release	and	production	of	chemokine	(Vinolo	et	
al.	 2011).	 The	 activation	 of	 GPR43	 by	 SCFAs	 induces	 the	 chemotaxis	 and	 regulates	
degranulation	 of	 neutrophils	 (Kim	 et	 al.	 2014).	 The	 anti-inflammatory	 properties	 of	
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SCFAs	have	been	 investigated	 in	patients	with	 inflammatory	bowel	diseases	 (IBD).	 In	a	
previous	study	in	patients	with	IBD,	impaired	butyrate	metabolism	was	reported	(Canani	
et	al.	2011).	SCFAs,	in	particular	butyrate,	reduce	inflammatory	cytokine	production	and	
inflammation	 in	 the	 intestine	 through	 mechanisms	 including	 nuclear	 factor	 kappa	 B	
signalling	(Ramakrishna	2013;	Tedelind	et	al.	2007).	SCFAs	exert	an	inhibitory	effect	on	
both	 Tumour	 Necrosis	 Factor-alpha	 (TNF-α)	mediated	 activation	 of	 the	 nuclear	 factor	
kappa	B	pathway	and	 lipopolysaccharide-induced	TNF-α	release	 (Tedelind	et	al.	2007).	
On	 the	other	hand	 they	 increase	 the	secretion	of	anti-inflammatory	 Interleukin-10	 (IL-
10)	from	macrophages	(Kim	et	al.	2014).	
1.2.2.3 Regulation	of	bile	acid	metabolism	
Bile	 Acids	 (BAs)	 are	 synthesised	 in	 the	 liver	 from	 cholesterol	 and	 stored	 in	 the	 gall	
bladder.	They	are	released	into	the	small	 intestines	following	food	ingestion	to	aid	the	
digestion	 process	 by	 facilitating	 the	 emulsification	 of	 dietary	 fats.	 The	 physiological	
functions	of	BAs	in	the	human	body	are	not	only	restricted	to	facilitating	lipid	digestion	
and	 absorption;	 they	 appear	 to	 be	 also	 involved	 in	 the	 overall	 regulation	 of	 host	
metabolism	 (Ramírez-Pérez	 et	 al.	 2017).	 Recently,	 preclinical	 studies	 in	murine	 and	 in	
vitro	models	indicated	that	BAs	contribute	to	the	activation	of	farnesoid	X	receptor	(FXR)	
and	 the	 GPR5	 receptor.	 These	 receptors	 activate	 the	 expression	 of	 genes	 involved	 in	
BAs,	 lipids,	 and	 carbohydrates	 metabolism	 as	 well	 as	 energy	 expenditure	 regulation	
(Cariou	et	al.	2006;	Abdelkarim	et	al.	2010;	Watanabe	et	al.	2006).	
The	human	BA	pool	is	made	up	of	primary,	secondary	and	tertiary	BAs.	The	primary	BAs	
[Cholic	Acid	(CA)	and	Chenodeoxycholic	Acid	(CDCA)]	are	synthesised	in	the	liver,	while	
secondary	 BAs	 are	 produced	 in	 the	 gut	 via	 the	 modification	 of	 primary	 BAs	 through	
dehydroxylation,	epimerisation	and	oxidation.	The	tertiary	BAs	are	 formed	 in	both	the	
liver	 and	 gut	 microbiota	 via	 modification	 of	 secondary	 BAs	 through	 sulfation,	
glucuronidation,	 glucosidation	 and	 N-acetylglucosaminidation	 (Marschall	 et	 al.	 1992;			
Ridlon	et	al.	2006;	Wahlströ	et	al.	2016).	
	
Primary	BAs	synthesised	by	the	 liver	are	conjugated	with	taurine	or	glycine	and	during	
enterohepatic	 circulation,	 they	 are	 then	 deconjugated	 through	 gut	 microbial	 action	
	
Chapter	One		
	
	 	
35	
Cholesterol	
Primary	bile	acids		
						CA							CDCA		
Conjugated	bile	acids			
	+		
Liver		
Conjugated	bile	acids			
CA	
CDCA		
Secondary	bile	acids			
Bacteroides,	Clostridium,	
Lactobacillus,	Bifidobacterium	
Clostridium	
Eubacterium	
Gut			
(Ridlon	et	 al.	 2006).	 The	 resulting	 free	amino	acids	 are	 then	metabolised	by	 intestinal	
microbiota	(e.g.	Bifidobacterium)	for	energy	supply	(Tanaka	et	al.	2000).	
	
The	intestinal	microbiota	possess	enzymes	involved	in	the	regulation	of	the	BA	pool	such	
as	 bacterial	 bile	 salt	 hydrolases,	 bacterial	 hydroxysteroid	 dehydrogenases	 and	 7α/β-
dehydroxylase	(Ridlon	et	al.	2006).	The	majority	of	intestinal	microbial	species	facilitate	
deconjugation	and	dehydrogenation	of	bile	salts	through	expression	of	bacterial	bile	salt	
hydrolases	and	bacterial	hydroxysteroid	dehydrogenases.	Limited	intestinal	species	(e.g.	
Clostridium	clusters	 XI	 and	 XVIa,	 such	 as	C.	 sordellii,	C.	 sordelliifell,	 and	C.	 scindens)	
express	 7α/β-dehydroxylase	 enzymes	 that	 catalyse	 the	 dehydrogenation	 reaction	 of	
primary	BAs	(Ridlon	et	al.	2006;	Nie	et	al.	2015)	(see	Figure	1.5)	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	1.5	Regulation	of	bile	acid	metabolism	by	intestinal	microbiota	
Figure	 1.5	 illustrates	 the	 contribution	 of	 Bacteriodes	 Clostridium,	 Lactobacillus	 Bifidobacteria	 and	
Eubacterium	to	the	regulation	of	bile	acid	metabolism.	
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1.3 Nutrition	support	in	critically	ill	children	
	
Nutrition	 is	 an	 important	 component	 in	 the	management	 of	 critically	 ill	 children.	 The	
goals	of	nutrition	 support	 in	paediatric	 critical	 care	 is	 to	minimise	 catabolism,	 support	
basal	physiological	functions	and	aid	anabolism	during	the	recovery	phase	(Gurgueira	et	
al.	2005;	Meyer	and	Elwig	2007;	Joosten	et	al.	2016).	Under-	and	overfeeding	has	been	
shown	 to	 compromise	 this	 goal	 and	 to	 substantially	 complicate	 the	 stay	 in	 PICU	
(Mehta	et	al.	2012).	The	role	of	nutrition	in	shaping	gut	microbiome	has	been	recently	
highlighted	(Hodin	et	al.	2012;	Shiga	et	al.	2012;	Morowitz	et	al.	2011;	Krajmalnik-Brown	
et	al.	2012),	therefore	the	restoration	of	gut	homeostasis	should	be	one	of	the	goals	of	
nutrition	support	in	critically	ill	children.	
	
Achieving	 optimal	 nutrition	 prescription	 is	 challenging	 in	 critically	 ill	 children,	 as	 they	
undergo	different	phases	of	illness	and	accordingly	the	body	response	to	injury	vary	over	
time	(Wischmeyer	2013;	Joosten	et	al.	2016).	Understanding	energy	needs	during	the	
phases	 of	 illness	 is	 necessary	 to	 avoid	 imbalances	 between	 energy	 intake	 and	
requirements	 (Joosten	et	al.	2016).	To	maintain	energy	balance,	energy	 intake	should	
ideally	be	equivalent	to	energy	expenditure.	As	energy	expenditure	is	changeable	during	
the	 phases	 of	 illness,	 the	 nutritional	 requirements	 should	 be	 adjusted	 accordingly	
(Joosten	et	al.	2016).	Macronutrients,	carbohydrates,	fat	and	protein	are	the	main	fuel	
used	 for	 the	generation	of	energy	 to	maintain	normal	body	 function	and	 they	are	 the	
main	 substrate	 of	 intestinal	 microbiota.	 Therefore,	 substrate	 metabolism	 (i.e.	
carbohydrate,	 protein,	 fat	 sources)	 should	 also	 be	 considered	when	 choosing	 feeds	
for	these	children.	
	
1.3.1 Assessment	of	energy	and	macronutrient	requirements	in	critically	ill	children	
	
To	 ensure	 adequate	 nutrition	 delivery,	 a	 proper	 assessment	 of	 energy	 and	
macronutrient	requirements	should	be	undertaken.	Energy	requirements	for	critically	ill	
children	 ideally	should	be	measured	by	 indirect	calorimetry	 (IC).	However,	generally	 in	
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clinical	 practice,	 energy	needs	are	often	estimated	by	a	 range	of	prediction	equations	
due	to	the	limitation	of	using	IC	in	PICU	settings.	
1.3.1.1 Measurement	of	REE	by	IC	
	
IC	measures	energy	expenditure	by	determining	the	oxygen	consumption	and	carbon	
dioxide	 production	 of	 the	 body	 over	 a	 given	 period	 of	 time.	 The	 values	 of	 VO2	and	
VCO2	are	converted	to	energy	expenditure	via	a	metabolic	chart	using	the	Weir	equation	
(Weir	1949).	The	principle	of	IC	is	based	on	the	assumption	that	the	inspired	oxygen	is	
completely	utilised	to	oxidise	degradable	fuels,	and	during	this	process	carbon	dioxide	is	
generated	(Gupta	et	al.	2017).	 IC	 is	considered	the	gold	standard	to	determine	energy	
requirements	 in	 critically	 ill	 children	 (Mehta	 et	 al.	 2017).	 It	 ensures	 that	 the	 specific	
conditions	 of	 the	 critically	 ill	 patient	 are	 taken	 into	 account,	 thereby	 preventing	
potential	complications	from	over-	and	underfeeding	(Mehta	et	al.	2017).	IC	also	allows	
for	identification	of	energy	substrates	that	are	being	predominantly	metabolised	by	the	
body	during	 the	 course	of	 admission	 (Coss-Bu	et	 al.	 2001a).	A	number	of	 factors	may	
restrict	the	regular	use	of	IC	in	PICU	settings.	These	are	mainly	related	to	the	high	cost	of	
machines	and	a	lack	of	trained	clinical	staff	to	perform	IC	testing	(Mehta	et	al.,	2017).	In	
addition,	clinical	conditions	such	as	air	leak,	fraction	of	inspired	oxygen	(FiO2)	>60%,	and	
failure	 to	 achieve	 a	 steady	 state	 are	 known	 to	 compromise	 the	 accuracy	 of	 energy	
expenditure	 measurements	 by	 IC	 (Kyle	 et	 al.,	 2012).	 Measurements	 of	 energy	
expenditure	may	 also	 be	 limited	 in	 unstable	 children,	 where	medical	 care	 cannot	 be	
interrupted	for	such	measurements	(Framson	et	al.,	2007).	As	a	result,	the	feasibility	of	
IC	testing	in	intensive	care	settings	is	constrained,	in	a	worldwide	survey	of	156	PICUs,	IC	
was	used	in	only	14%	of	the	units	(Kerklaan	et	al.	2016).	
1.3.1.2 Prediction	equations	used	in	PICU	settings	to	estimate	energy	requirements	
	
In	 clinical	 practice,	 energy	 requirements	 are	 often	 estimated	 by	 prediction	 equations.	
The	 most	 commonly	 used	 prediction	 equations	 in	 PICU	 settings	 are:	 the	 Schofield	
equations,	 the	 World	 Health	 Organization	 (WHO)	 equations	 and	 the	 Harris-Benedict	
equations	 (Table	 1-1),	 (Schofield	 1985;	 Joint	 FAO/WHO/UNU	 Expert	 Consultation	 on	
Energy	 and	 Protein	 Requirements	 1981:	 Rome	 1985;	 Harris	 &	 Benedict	 1918).	 The	
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Recommended	Daily	Allowance	(RDA)	for	healthy	children	was	used	in	some	units	in	the	
past	to	guide	energy	prescription.	However,	it	is	no	longer	recommended	to	use	RDAs	in	
PICU	 settings	 as	 they	 integrate	 an	 activity	 factor	 resulting	 in	 the	 over-estimation	 of	
energy	 requirements	 (Mehta	 et	 al.	 2017).	 The	 Schofield	 and	 WHO	 equations	 are	
recommended	 by	 the	 recent	 American	 Society	 for	 Parenteral	 and	 Enteral	 Nutrition	
(ASPEN)	guidelines	to	estimate	energy	requirement	in	critically	ill	children	in	the	absence	
of	IC.	
	
The	use	of	predictive	equations	to	develop	nutrition	regimens	can	be	problematic	 in	
the	critical	care	setting,	as	the	effects	that	disease,	injury,	and	stress	have	on	energy	
expenditure	 are	 often	 varied	 and	 unpredictable	 (Joosten	 et	 al.	 2016;	 Coss-Bu	 et	 al.	
2001;	Briassoulis	et	al.	2000).	Multiple	studies	have	demonstrated	that	most	published	
predictive	 equations	 are	 inaccurate	 and	 lead	 to	 over-	 or	 underestimation	 of	 energy	
requirements	 (Table	1)	 (Christine	M.	Hardy	Framson	et	al.	2007;	 Jotterand	Chaparro	
et	 al.	 2017;	 Briassoulis	 et	 al.	 2000).	 As	 the	 feasibility	 of	 IC	measurements	 in	 PICU	 is	
limited	there	is	still	an	urgent	need	for	formulas	that	closely	estimate	the	energy	needs	
of	 critically	 ill	 children	 (Kyle,	 Arriaza,	 et	 al.	 2012).	 Efforts	 have	 been	 made	 to	 create	
predictive	equations	adapted	to	clinical	changes	during	critical	illness	(White	et	al.	2000;	
Meyer	et	al.	2012).	However,	still	 the	degree	of	agreement	between	measured	energy	
expenditure	 and	 estimated	 energy	 requirements	 by	 the	 available	 equations	 is	 not	
satisfactory.	
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Table	1-1:	Prediction	equations	commonly	used	in	PICU	settings	
Name	of	the	equation	 Equation	 Accuracy		
	
	
Schofield	Equation	
(weight	and	height)	
Male	
<	3	years:	(0.167	x	W)	+	(1517.4	x	H)	-	616.6	
3-10	years:	(19.59	x	W)	+	(130.3	x	H)	+	414.9	
10-18	years:	(16.25	x	W)	+	(137.2	x	H)	+	515.5	
Female	
<	3	years:	(16.252	x	W)	+	(1023.3	x	H)	-	413.5	
3-10	years:	(16.969	x	W)	+	(161.8	x	H)	+	371.2	
10-18	years:	(8.365	x	W)	+	(465	x	H)	+	200.0	
	
Recommended	 by	 ASPEN	
guidelines	 to	 estimate	 energy	
needs	in	critically	children	in	the	
absence	of	IC.	
	
Potential	 over-estimation	 of	
energy	 needs	 in	 critically	 ill	
children.	
	
	
	
WHO	Equation	
	
(only	weight)	
Male	
0-3	years:	(60.9	x	W)	-	54	
3-10	years:	(22.7	x	W)	-	495	
10-18	years:	(17.5	x	W)	+	651	
Female	
0-3	years:	(61	x	W)	-51	
3-10	years:	(22.5	x	W)	+	485.9	
10-18	years:	(17.686	x	W)	+	658.2	
Recommended	 by	 ASPEN	
guidelines	 to	 estimate	 energy	
needs	in	critically	children	in	the	
absence	of	IC.	
	
Potential	 over-estimation	 of	
energy	 needs	 in	 critically	 ill	
children.	
	
Does	not	 incorporate	the	height	
of	the	child	in	the	calculations	of	
energy	requirements.	
	
	
	
Harris-Benedict	Equation	
	
(weight	and	height)	
Male	
66.4730+	(5.0033	x	H)	+	(13.7516	x	W)	–	
(6.7550	x	age)	
Female	
655.0955	 +	 (18496	 x	 H)	 +	 (9.5634	 x	 W)	 –	
(4.6756	x	age)	
The	limits	of	agreement	between	
measured	energy	expenditure	
and	Harris-Benedict	equation	is	
poor.	
	
Not	recommended	to	estimate	
energy	requirements	in	PICU	
settings.	
	
1.3.1.3 Macronutrients	requirements	of	critically	ill	children	
	
Current	recommendations	for	macronutrient	requirements	in	this	population	are	based	
on	the	understanding	of	their	metabolism	and	their	handling	during	the	course	of	their	
illness	(Mehta	et	al.	2009;	Mehta	et	al.	2017).	The	ASPEN	guidelines	recommend	protein	
intakes	of	at	least	1.5	g/kg	(Mehta	et	al.	2017).	The	requirements	may	vary	by	age;	the	
recommendation	for	children	aged	0–2	years	is	2–3	g/kg/day;	for	2–13	years	it	is	1.5–2	
g/kg/day	 and	 for	 >13	 years	 it	 is	 1.5	 g/kg/day)	 (Mehta	 et	 al.	 2009).	 The	 available	
guidelines	regarding	carbohydrate	and	fat	requirements	are	based	on	maximal	doses	of	
parenteral	 glucose	 and	 fatty	 acids	 permitted	 (Mesotten	 et	 al.	 2018;	 Lapillonne	 et	 al.	
2018).	 There	 is	 a	 lack	 of	 published	 guidelines	 regarding	 enteral	 fat	 and	 carbohydrate	
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requirements	 for	 critically	 ill	 children.	 The	 new	 ESPGHAN	 guidelines	 for	 PN	 suggested	
that	energy	and	macronutrient	requirements	of	PN	are	close	to	those	of	EN	(Joosten	et	
al.	 2018;	 Mesotten	 et	 al.	 2018;	 Lapillonne	 et	 al.	 2018).	 Their	 argument	 is	 based	 on	
findings	 from	 20th-century	 experimental	 studies	 by	 Atwater	 where	 the	 metabolisable	
energy	of	IV	macronutrients	was	similar	to	that	provided	by	EN.	However,	their	findings	
remain	controversial	as	 there	are	key	differences	 in	the	metabolisms	of	enteral	versus	
parenteral	 carbohydrates,	 lipids	 and	 protein	 related	 to	 intestinal	 absorption	 of	
nutritional	 substrates,	 insulin	 and	 inflammatory	 stimulation	 and	 visceral	 protein	
synthesis	(Suchner	et	al.	1996).	
	
1.3.2 Nutrition	delivery	in	the	acute	phase	of	illness	
	
The	recent	ASPEN	guidelines	target	the	delivery	of	at	least	two-thirds	of	the	prescribed	
daily	energy	requirements	by	the	end	of	the	first	week	in	the	PICU,	to	avoid	undesired	
clinical	outcomes	associated	with	cumulative	nutrition	deprivation	(Mehta	et	al.	2017).	
Provision	of	protein	 in	 the	acute	phase	 is	 also	 recommended	 to	achieve	protein	goals	
and	promote	positive	nitrogen	balance	(Mehta	et	al.	2017).	
	
Early	 initiation	 of	 EN	 is	 recommended	 for	 critically	 ill	 children	 for	 several	 reasons,	 in	
particular	to	avoid	the	deleterious	effect	of	fasting.	In	addition,	EN	helps	to	maintain	the	
gut	function.	Lastly,	it	promotes	energy	metabolism	and	supports	the	functions	of	body	
organs	and	systems	(Meyer	and	Elwig	2007).	In	a	study	of	critically	ill	children,	the	early	
initiation	of	EN	within	48	hours	of	admission	was	associated	with	a	lower	mortality	rate	
(Mikhailov	 et	 al.	 2014).	 In	 addition,	 the	 implementation	 of	 an	 aggressive	 early	 EN	
protocol	was	significantly	effective	in	improving	nitrogen	balance	in	critically	ill	children	
(Briassoulis	et	al.	2002;	Botrán	et	al.	2011;	Briassoulis	et	al.	2005).	
	
Although	energy	requirements	are	reduced	during	the	acute	phase	of	critical	illness,	still	
the	nutritional	needs	are	often	not	fulfilled	via	the	enteral	route	due	to	poor	estimation	
of	energy	and	macronutrient	requirements,	lack	of	routine	nutritional	assessments,	fluid	
restrictions,	 feeding	 intolerance,	and	 frequent	 interruption	of	enteral	 feeding	 (Hulst	et	
al.	 2006;	Mehta	 et	 al.	 2012b).	Mehta	 et	 al.	 (2012)	 indicated	 that	 around	 60%	 of	 the	
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prescribed	 calories	 are	 not	 being	 delivered	 via	 the	 enteral	 route	 due	 to	 the	
aforementioned	 reasons.	 The	 development	 of	 PN	 substantially	 improved	 nutrient	
delivery	in	a	critically	ill	population,	however	the	early	use	of	PN	has	been	shown	to	be	
associated	 with	 numerous	 problems	 such	 as	 increased	 rate	 of	 infections,	 metabolic	
disturbances,	 and	 higher	 hospital	 costs	 (Cotogni	 2017;	 Netto	 et	 al.	 2017;	 Fivez	 et	 al.	
2016).	Early	initiation	of	PN	was	also	associated	with	prolonged	period	of	mechanical	
ventilation	 and	 PICU	 stay	 (Fivez	 et	 al.	 2016;	 van	 Puffelen	 et	 al.	 2018).	 The	 recent	
ESPGHAN	 guidelines	 for	 PN	 provision	 suggest	 that	 critically	 ill	 children	may	 benefit	
from	withholding	PN	while	providing	micronutrients	during	the	first	week	of	hospital	
admission	(Van	Goudoever	et	al.	2018).	There	is	evidence	that	withholding	PN	during	
the	acute	phase	of	illness	is	useful	for	enhancing	the	process	of	autophagy,	a	cellular	
survival	mechanism	that	involves	the	self-breakdown	of	damaged	components,	aimed	
at	recycling	intracellular	nutrients	and	generating	energy	during	starvation	(Levine	et	
al.	2011;	Vanhorebeek	et	al.	2017;		Joosten	et	al.	2016).	The	inhibition	of	autophagy	by	
forced	overfeeding	was	linked	to	an	increased	risk	of	organ	failure	and	cell	death,	and	is	
associated	with	adverse	clinical	outcomes	(Joosten	et	al.	2016).	
	
Although	the	majority	of	critically	ill	children	are	fed	via	the	enteral	route,	there	are	no	
clear	guidelines	on	the	optimal	amounts	for	enteral	carbohydrate	and	fat.	There	is	often	
a	clinical	focus	on	delivering	the	energy	and	protein	requirements	of	a	patient,	but	the	
balance	of	macronutrients	 is	often	neglected.	The	only	guidelines	available	 for	enteral	
nutritional	support	in	this	population	are	for	energy	and	protein.	
	
1.3.3 Nutrition	delivery	in	the	stable	and	recovery	phase	
	
The	 stable	 and	 recovery	 phases	 are	 characterised	 by	 early	 normalisation	 of	 counter-
regulatory	 hormones,	 accompanied	 by	 an	 increase	 in	 energy	 expenditure.	 Generally	
during	 this	 phase	 the	 nutritional	 requirements	 are	 increased.	 The	 goal	 of	 nutrition	
support	 at	 this	 point	 is	 to	 support	 the	 anabolic	 growth.	 Therefore,	 energy	 and	
macronutrient	 intake	 should	 gradually	 be	 increased	 to	 enable	 recovery,	 growth	 and	
catch-up	 growth	 (Joosten	 et	 al.	 2018;	Mesotten	 et	 al.	 2018;	Mehta	 et	 al.	 2017).	 The	
recent	ESPGHAN	guidelines	suggested	an	increase	by	1.3	times	of	energy	requirements	
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during	 the	 stable	 phase	 of	 critical	 illness	 and	 further	 increases	 in	 the	 recovery	 phase	
were	recommended	(Joosten	et	al.	2018).	
	
1.3.4 The	role	of	nutrition	in	contributing	to	clinical	outcomes	of	critically	ill	children	
	
The	role	of	nutrition	in	the	progression	of	adverse	clinical	outcome	has	been	highlighted	
in	 the	 recent	 ASPEN	 guidelines	 for	 nutrition	 support	 (Mehta	 et	 al.	 2017).	 Optimal	
nutrition	 support	 helps	 dramatically	 to	 improve	 the	 care	 and	 clinical	 outcomes	 of	
critically	 ill	 infants	 and	 children.	 Inadequate	 nutrition	 intake	 is	 associated	 with	 poor	
clinical	outcomes	such	as	decreased	muscle	function,	poor	wound	healing,	impaired	gut	
function	 and	 an	 increased	 risk	 of	 developing	 infections	 due	 to	 poor	 immune	 defence	
(Hulst	 et	 al.	 2006;	 Maslowski	 &	 Mackay	 2011).	 Under-nutrition,	 particularly	 protein	
energy	malnutrition,	also	has	been	strongly	linked	with	mortality,	prolonged	ventilation	
and	 hospital	 stay	 (Mehta	 et	 al.	 2012b;	 Correia	 2003;	 Hulst	 et	 al.	 2006;	 Maslowski	 &	
Mackay	2011).	
	
Overfeeding	critically	ill	children	may	lead	to	undesirable	outcomes	such	as	steatosis	and	
cholestasis,	 resulting	 in	 impaired	 liver	 function	 (Mehta	 et	 al.	 2009).	 In	 addition,	
hyperglycaemia	 associated	with	 overfeeding	 in	 parenterally	 fed	 children	 increases	 the	
risk	of	infection	and	has	been	linked	with	prolonged	ventilation	and	PICU	stay	(Alaedeen	
et	al.	2006;	Fivez	et	al.	2016).	Overfeeding	is	also	associated	with	an	increase	in	carbon	
dioxide	 production,	 which	 may	 be	 implicated	 in	 delayed	 weaning	 from	 mechanical	
ventilator	support	(Chwals	1994;	Meyer	and	Elwig	2007).	In	addition,	overfeeding	during	
the	acute	phase	was	linked	to	inhibition	of	autophagy	and	increased	risk	of	organ	failure	
and	cell	death	(Joosten	et	al.	2016).	
	
There	 is	a	growing	body	of	evidence	suggesting	 that	a	pattern	of	alteration	 in	 the	gut	
microbiome	 would	 be	 observed	 during	 a	 period	 of	 nutrient	 deprivation	 (Krajmalnik-
Brown	 et	 al.	 2012).	 Critically	 ill	 children	 are	 often	 underfed,	 and	 the	 state	 of	 energy	
deficit	might	have	a	profound	effect	on	the	gut	microbiota	and	environment.	Studies	are	
needed	to	define	the	role	of	starvation	or	underfeeding	during	critical	illness	on	the	gut	
microbes.	
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1.4 Targeted	modulation	of	intestinal	microbiome	to	improve	clinical	
outcomes	in	critically	ill	children	
	
	
Given	 the	 substantial	 clinical	 and	 experimental	 evidence	 supporting	 the	 gut-lymph	
hypothesis	 (Deitch	 et	 al.	 2006;	 Deitch	 2012),	 the	 targeted	 modulation	 of	 intestinal	
microbiome	 has	 been	 proposed	 as	 a	 therapy	 to	 support	 gut	 health	 in	 critically	 ill	
patients.	
	
The	suppression	of	pathogenic	gut	bacteria	was	the	first	therapeutic	line	of	microbiome	
modulation	 tried	 on	 critically	 ill	 patients.	 Selective	 decontamination	 of	 the	 digestive	
tract	(SDD)	was	first	introduced	in	the	1980s	(Unertl	et	al.	1987),	aimed	at	keeping	the	
overgrowth	 of	 potential	 pathogens	 in	 the	 gut	 to	 the	 minimum	 through	 the	
administration	of	 tailored	antibiotic	 treatment	 (Unertl	et	al.	1987;	Dickson	2016).	Ever	
since,	SDD	intervention	has	been	tested	in	many	clinical	trials	in	critically	ill	patients	(de	
Jonge	et	al.	2003;	de	Smet	et	al.	2009;	Daneman	et	al.	2013).	Although	proven	effective	
and	 shown	 to	 significantly	 reduce	 the	 rate	 of	 infections,	 the	 number	 of	 patients	with	
MOF	and	mortality	(Silvestri	et	al.	2012;	de	Jonge	et	al.	2003;	de	Smet	et	al.	2009),	there	
still	 remains	concern	about	 the	potential	 risk	of	antimicrobial	 resistance	 (Francis	et	al.	
2014;	 Cavalcanti	 et	 al.	 2017).	 All	 these	 data	 are	 derived	 from	 studies	 on	 critically	 ill	
adults,	and	there	is	an	absence	of	paediatric-specific	clinical	trials.	In	a	recent	survey	by	
Murthy	 et	 al.	 (2017)	 to	 determine	 the	 baseline	 knowledge	 of	 health	 care	 providers	
about	 SDD,	 they	 indicated	 that	 there	 is	 still	 uncertainty	 about	 implementing	 SDD	
protocols	in	PICU,	mainly	due	to	concerns	about	antimicrobial	resistance	(Murthy	et	al.	
2017).	
	
Given	 the	 extensive	 vascular	 and	 lymphatic	 links	 between	 the	 intestines	 and	 other	
organs,	 it	 is	 possible	 that	 enhancing	 the	 growth	 of	 commensal	 bacteria	 and	 their	
metabolites	 by	 EN	 could	 be	 of	 systemic	 clinical	 benefit.	 Certain	 nutrients	 have	 been	
verified	 for	 their	capacity	 to	modulate	 the	gut	bacterial	profile,	 such	as	glutamine	and	
prebiotics	(dietary	fibre	that	promotes	the	growth	of	beneficial	bacteria).	 In	a	previous	
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study	to	evaluate	the	effect	of	glutamine	supplementation	on	the	gut	microbial	content,	
they	 reported	 significant	 changes	 in	 the	 composition	 of	 the	 gut	 microbiota	 in	 obese	
subjects	 (de	 Souza	 et	 al.	 2015).	 As	 regards	 to	 prebiotics,	 lactulose	 added	 to	 infant	
formulas	 was	 used	 for	 long	 enough	 to	 increase	 the	 numbers	 of	 lactobacilli	 in	 infant	
intestines	 (Collins	 &	 Gibson	 1999).	 However,	 this	 practice	 has	 evolved	with	 extensive	
research	 on	 the	 role	 of	 prebiotics	 in	 enteral	 feeds.	 The	most	 common	 prebiotics	 are	
fructooligosaccharides	and	galactooligosaccharides;	they	have	been	added	to	a	number	
of	 infant	 formulas	 and	 they	 demonstrated	modulation	of	 the	 gut	 bacterial	 population	
(Vandenplas	 et	 al.	 2014;	 Fanaro	 et	 al.	 2005).	Using	 probiotics	 containing	 Lactobacillus	
and	 Bifidobacteria	 species	 has	 a	 beneficial	 effect	 on	 modulating	 the	 balance	 of	 the	
intestinal	 microbiota	 (Collins	 &	 Gibson	 1999).	 Furthermore,	 using	 probiotics	 in	
combination	with	antibiotic	therapy	has	proven	to	have	a	beneficial	effect,	as	probiotics	
not	 only	 suppress	 gastrointestinal	 pathogens	 but	 may	 potentiate	 the	 efficacy	 of	
antibiotics	 by	 producing	 antibacterial	 factors	 (Preidis	 &	 Versalovic	 2009).	 Generally,	
using	probiotics	 in	clinical	 settings	has	been	proven	to	be	safe,	however	 they	must	be	
used	 with	 caution	 in	 certain	 patient	 groups	 (Srinivasan	 et	 al.	 2006).	 A	 theoretical	
concern	 with	 the	 safety	 of	 using	 probiotics	 is	 that	 some	 of	 them	may	 adhere	 to	 the	
intestinal	mucosa	and	facilitate	bacterial	translocation	and	virulence	(Boyle	et	al.	2006).	
However,	 Srinivasan	 et	 al.	 (2006)	 showed	 that	 the	 supplementation	 of	 probiotics	 in	
enterally	 fed	 critically	 ill	 children	 is	 safe	 and	 is	 not	 associated	 with	 any	 clinical	
complications	(Srinivasan	et	al.	2006).	In	a	recent	study	of	critically	ill	adult	patients,	the	
administration	of	synbiotics,	a	combination	of	probiotics	and	prebiotics,	was	associated	
with	 a	 reduction	 in	 the	 rate	 of	 infections	 and	 an	 increase	 in	 the	 count	 of	 commensal	
bacteria,	 as	 well	 as	 SCFAs	 (Shimizu	 et	 al.	 2018).	 This	 suggests	 that	 nutritional	
intervention	 targeting	 the	 gut	 microbiota	 in	 critically	 ill	 patients	 has	 the	 potential	 to	
improve	clinical	outcomes	
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1.5 Key	identified	gaps	in	the	literature:	
	
Having	 reviewed	 the	 literature,	 gaps	 and	 unaddressed	 challenges	 in	 the	 field	 are	
identified	as	follows:	
	
• Studies	on	 the	effect	of	EN	on	clinical	outcomes	of	 critical	 illness	have	 focused	
mainly	 on	 energy	 and	 protein	 delivery.	 There	 is	 a	 critical	 lack	 of	 guidelines	 on	
carbohydrate	 and	 fat	 requirements	 for	 critically	 ill	 children.	 It	 is	 not	 surprising	
that	there	have	been	no	trials	of	enteral	macronutrient	targets	in	this	population.	
	
• There	 is	 a	 lack	 of	 studies	 investigating	 the	 effect	 of	macronutrient	 delivery	 on	
disease	features	such	as	inflammation	(systemic	and	intestinal).	
	
• All	 microbiome	 studies	 in	 critical	 care	 settings	 have	 arrived	 at	 a	 similar	
conclusion	 that	 commensal	 species	 are	 replaced	 by	 pathogens.	 None	 of	 them	
investigated	 the	 effect	 of	 environmental	 influences	 (e.g.	 nutrition,	 antibiotic	
treatment)	on	the	microbiome	of	critically	ill	patients.	
	
• No	 studies	 have	 investigated	 the	 specific	 influences	 of	 intestinal	 dysbiosis	 on	
host	metabolism	and	clinical	outcomes	in	this	setting.	
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2 Chapter	Two:	Methodology	
	
2.1 Main	aims	and	objectives	
	
The	main	aim	of	this	PhD	project	is	to	investigate	the	effect	of	nutrition	on	the	intestinal	
microbiome-host	 relationship	 in	 critically	 ill	 children	 and	whether	 it	 has	 an	 impact	 on	
clinical	disease	severity.	
	
Objectives	
	
• Describe	feeding	and	energy	metabolism	during	PICU	admission.	
• Identify	and	evaluate	relationships	between	nutritional	 intake	and	systemic	and	
intestinal	inflammation.	
• Describe	 changes	 in	 the	 gut	 microbiome	 and	 how	 it	 is	 influenced	 by	 current	
feeding	practice	in	the	PICU.	
• Establish	whether	changes	in	gut	homeostasis	and	the	relationship	between	gut	
and	host	have	clinical	significance	for	disease	progression	and	clinical	outcomes.	
2.2 Flow	of	the	study	
	
The	 research	 conducted	 for	 this	 thesis	 was	 undertaken	 using	 samples	 and	 clinical	
measurements	collected	from	the	Gut	Homeostasis	in	Critical	Illness	(GHICI)	study	taking	
place	at	Addenbrooke’s	Hospital	in	Cambridge,	UK	and	Hospices	Civils	de	Lyon	in	France.	
The	 Evelyn	 Trust	 funded	 the	 study,	 and	 ethical	 approval	was	 granted	 by	 the	 City	 and	
Hampstead	LREC	(Reference:	13/LO/0974).	Children	were	transferred	to	hospital	PICUs	
either	through	the	accident	and	emergency	(A&E)	department	or	from	regional	hospitals	
by	the	Children's	Acute	Transport	Service	(CATS).	
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2.3 Ethical	considerations	
	
Parents	were	 approached	 for	 consenting	 for	 their	 children	 to	 participate	 by	 the	 PICU	
research	nursing	team.	For	those	children	transported	to	Addenbrooke’s	Hospital	PICU	
from	regional	hospitals	by	the	CATS,	a	deferred	consent	process	was	implemented	and	
approved	by	the	local	research	ethical	committee,	and	samples	were	taken	on	retrieval.	
Where	consent	was	obtained	the	samples	were	processed	and	stored.	If	parents	refused	
consent	the	samples	were	destroyed	and	no	clinical	data	was	collected.	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	2.1	The	flow	of	this	study	
The	above	figure	shows	the	stages	of	the	recruitment	process	and	the	time	frame	of	samples	collection	
and	energy	expenditure	measurements.	
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2.4 Study	participants	
	
PICU	 research	 nurses	 at	 Addenbrooke’s	 Hospital	 performed	 the	 consent	 process	 for	
participation.	I	was	responsible	for	identifying	the	subjects	eligible	to	participate	in	the	
study.	Two	groups	of	children	were	recruited;	critically	ill	children	admitted	to	the	PICU	
alongside	 a	 cohort	of	 healthy	 children.	A	 subgroup	of	 critically	 ill	 and	 control	 children	
were	 recruited	 from	Hospices	Civils	 de	 Lyon	 in	 France.	Written	 informed	 consent	was	
obtained	 from	 the	 parents	 and	 ethical	 approval	 was	 granted	 by	 the	 hospital.	 Where	
comparison	is	made	between	the	two	groups	in	the	subsequent	chapters,	the	analysis	is	
restricted	to	the	age-matched	population.	
	
2.4.1 Critically	ill	children	
	
All	 children	 admitted	 to	 PICU	 and	 likely	 to	 remain	 ventilated	 for	more	 than	 24	 hours	
were	eligible	to	participate	in	the	study.	
Inclusion	criteria	
• One	or	more	organ	failures	requiring	intensive	care.	
• Mechanically	ventilated.	
• Age	0	month	to	16	years.	
Exclusion	criteria	
• Preterm	gestation	(birth	<	37	weeks).	
• Treatment	with	antibiotics	in	the	last	2	weeks	prior	to	admission.	
• Known	pre-existing	immune	paresis,	oncological	diagnosis	and	HIV.	
Further	 specific	 exclusion	 criteria	were	applied,	 and	will	 be	mentioned	 in	 the	 relevant	
chapters.	
	
2.4.2 Healthy	children	
	
Parents	of	children	undergoing	elective	surgeries	or	from	the	community	consented	for	
their	children’s	participation	and	were	asked	to	provide	samples	of	blood,	urine	and/or	
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faeces	where	possible.	Those	who	had	received	antibiotic	treatment	in	the	last	2	weeks	
prior	to	the	recruitment	process	were	excluded.	
	
2.4.3 Age	matching	patients	and	controls	
	
The	study	participants	were	categorised	into	three	age	groups:	0-6	months,	6-12	months	
and	>12	months	based	on	the	stages	of	diet	progression.	Critically	ill	children	were	age-
matched	with	healthy	children	to	allow	for	a	valid	comparison	between	the	groups.	
2.5 Biological	samples	
	
Samples	were	collected	from	both	critically	ill	patients	and	from	healthy	children.	Serum	
and	faecal	samples	were	collected	by	PICU	research	nurses	at	Addenbrooke’s	Hospital.	I	
was	responsible	for	the	processing	and	the	storage	of	the	biological	samples.	
	
2.5.1 Critically	ill	children	
Serial	 samples	 of	 serum	were	 collected	 at	 3	 time-points	 (TP),	 (see	 Figure	 2.1).	 Faecal	
samples	were	obtained	whenever	the	child	passed	a	stool.	
	
Blood:	2.5ml	of	blood	was	collected	if	there	was	an	indwelling	line	or	venepuncture	was	
taking	place	 already	 for	 clinical	 reasons.	A	 volume	of	 between	0.5-1	ml	 of	 serum	was	
obtained.	 The	 samples	 were	 centrifuged	 for	 10	 minutes	 at	 4000×	 g,	 4°C	 then	 the	
supernatant	 was	 removed	 and	 carefully	 transferred	 into	 micro-tubes	 and	 stored	 at	 -
80°C.	
Faeces:	 faecal	 samples	 of	 300	 mg	 were	 collected	 from	 the	 children’s	 nappies	 into	 a	
sterile	 container.	 Samples	 were	 refrigerated	 immediately	 after	 collection	 and	 then	
stored	at	-80°C	within	24	hours	of	collection	until	the	time	of	the	assay.	
	
2.5.2 Healthy	children	
A	single	sample	of	each	of	the	following	was	collected	from	each	child:	
Blood:	2.5ml	of	blood	was	obtained	if	venepuncture	was	taking	place	already	for	clinical	
reasons.	
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Faeces:	the	children	were	asked	to	defecate	into	a	clinically	clean	bedpan,	and	then	the	
specimen	was	collected	using	the	stool	pot.	
	
2.5.3 Samples	from	Hospices	Civils	de	Lyon	in	France	
	
Samples	 were	 processed	 immediately	 after	 collection	 then	 stored	 at	 -80°C	 until	 they	
were	 shipped	 for	 analysis	 at	 Addenbrooke’s	 Hospital	 laboratories.	 Serum	 and	 faecal	
samples	 were	 used	 for	 the	 assessment	 of	 Faecal	 Calprotectin	 (FC)	 and	 Cytokines	 in	
Chapter	7.	
2.6 Demographic	and	clinical	data	
	
Patients’	 data	 were	 obtained	 from	 the	 hospital	 electronic	 system	 (EPIC,	 Madison,	
Wisconsin,	 United	 States).	 The	 system	 went	 live	 on	 26	 October	 2014,	 therefore,	 the	
clinical	 information	 for	 the	 patients	 recruited	 before	 the	 initiation	 of	 the	 hospital’s	
electronic	system	were	not	obtainable	retrospectively.	
	
Demographic	and	anthropometric	data	 including	gender,	age,	weight,	and	height	were	
collected	 for	 each	 child.	 Patients’	 primary	 diagnosis	 necessitating	 PICU	 admission	was	
recorded	 and	 then	 categorised	 into	multi-organ	 system	 failure	 (MOF)	 or	 single	 organ	
failure	categories	as	described	in	Table	2-1	(Goldstein	et	al.	2005).	Information	related	to	
the	 presence	 of	 infection	 or	 signs	 of	 infections	 was	 also	 recorded	 from	 the	 patients’	
records.	 Sepsis	 was	 defined	 as	 ≥	 2	 abnormalities	 of	 body	 temperature,	 heart	 rate,	
respiratory	rate	or	abnormal	white	blood	cells	count	plus	suspected	or	proven	infection	
(Goldstein	et	al.	2005).	
	
The	 severity	 of	 disease	 and	morbidity	were	 assessed	by	 the	 paediatric	multiple	 organ	
dysfunction	 score	 (PMODS)	 (Graciano	 et	 al.	 2005),	 the	 paediatrics	 index	 mortality	 2	
(PIM2)	score	(Slater	et	al.	2003)	and	the	inotrope	score	(Gaies	et	al.	2010).	Data	on	the	
highest	blood	 lactate	and	highest	C	 reactive	protein	 (CRP)	 level	were	also	 recorded	as	
indicators	 of	 disease	 severity.	 Hours	 free	 of	 mechanical	 ventilation	 (ventilator-free	
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hours,	VFH)	at	30	days,	days	free	of	intensive	care	at	30	days,	hours	free	of	inotrope	and	
survival	status	were	recorded	and	used	as	clinical	outcome	measures.	
	
Table	2-1:	Primary	admission	diagnosis	categories:	
	
Diagnosis	 Diagnostic	Category	
• Cardiovascular	and	respiratory	dysfunction.	
• Neurological	and	haematological	abnormalities.	
• Renal	and	hepatic	dysfunction	
Examples	of	diagnoses	included	in	this	category:	
Meningococcal	Septicaemia	
Staphylococcus	Sepsis	
Cardiorespiratory	Arrest	
Diabetic	Ketoacidosis	leading	to	MOF	
Drug	Overdose	leading	to	MOF	
Any	other	condition	leading	to	MOF	
Multi-organ	failure	
Bronchiolitis	
Pneumonia	
Aspiration	Pneumonia	
Asthma	
Croup	
Acute	Respiratory	Distress	Syndrome	
Pleural	effusion	
Respiratory	Failure	
Supraventricular	Tachycardia	(SVT)	 Cardiac	Disorders	
Tracheal	repair	
Scoliosis	repair	
Appendectomy	
Laparotomy	
Splenectomy		
Surgical	Disorders	
Mallory	Weiss	tear	 Gastrointestinal	Disorders	
Meningoencephalitis	
Status	Epileptlicus	
Traumatic	Head	Injury	
Brain	Tumour	
Encephalitis	
Arteriovenous	Malformation	(AVM)	
Idiopathic	Intracranial	Hypertension	
Near	drowning	
Central	Nervous	System	(CNS)	Disorders	
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2.7 Assessment	of	nutritional	status	and	daily	dietary	intake	
	
The	nutritional	status	was	assessed	for	both	controls	and	critically	ill	children	using	z-
scores	 (weight	 for	 age,	 height	 for	 age	 and	 weight	 for	 height),	 which	 incorporate	
anthropometric	measurements	of	height/length	and	weight,	according	to	the	World	
Health	Organization	(WHO)	child	growth	standards	(Pichler	et	al.	2014).	The	z-scores	
were	 calculated	 using	 the	 WHO	 Anthro	 and	 AnthroPlus	 software	 (version	 3.2.2,	
January	 2011,	 Geneva)	 (Anon	 2017b).	 The	 definitions	 of	 the	 WHO	 were	 used	 to	
define	 under-nutrition:	 moderate	 under-nutrition	 was	 considered	 if	 z-scores	 were	
between	-2	and	-3	standard	deviation,	and	severe	under-nutrition	if	below	-3	z-scores	
(Anon	2010).	
The	 actual	 nutritional	 intake	was	prospectively	 recorded	 for	 critically	 ill	 children	using	
the	patient	clinical	daily	 record.	The	type	of	 feed	(EN/PN/IV	glucose)	and	total	volume	
delivered	was	 documented	 and	 from	 this	 the	 energy	 and	macronutrient	 delivery	was	
calculated	 for	each	patient.	Calculation	of	breast	milk	 composition	was	based	on	data	
from	a	previously	published	study	on	breast	milk	composition	(Ballard	&	Morrow	2013).	
	
To	evaluate	relationships	between	nutritional	intake	and	the	measured	biomarkers,	the	
amount	of	energy	and	macronutrients	delivered	were	calculated	for	the	24-hour	period	
prior	 to	 each	 sample	 collection.	 The	 cumulative	 intake	 of	 energy	 and	 macronutrient	
from	admission	was	also	calculated	to	assess	the	long-term	effect	of	feeding	on	disease	
state.	 Energy	 and	 macronutrient	 intake	 were	 expressed	 in	 percentages	 of	 calculated	
requirements.	
2.8 Standard	measurement	protocol	of	Indirect	Calorimetry	(IC)	
	
Resting	energy	expenditure	(REE)	was	measured	using	Ultima	CCM™®	IC.	This	metabolic	
cart	 employs	 a	 breath-by-breath	 gas	 analysis	 method.	 Gas	 sensors	 (pneumotach	flow	
meter)	measure	both	volume	of	oxygen	consumed	and	carbon	dioxide	produced,	which	
was	then	used	to	calculate	REE	automatically	using	the	Weir	equation:	
REE	=	[3.9	(VO2)	+	1.1	(VCO2)]	1.44	(WEIR	1949).	
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This	 indirect	 calorimeter	 has	 the	 capacity	 to	 measure	 REE	 in	 children	 over	 10	 Kg	
accurately.	
	
The	measurements	were	undertaken	when	the	child	was	 in	a	resting	state.	No	nursing	
care	or	physical	therapy	had	been	provided	for	at	least	1	hour	before	the	test,	to	ensure	
the	 volume	 of	 oxygen	 (VO2)	 and	 volume	 of	 carbon	 dioxide	 (VCO2)	 was	 as	 stable	 as	
possible.	IC	was	calibrated	to	reference	gases	prior	to	each	participant	according	to	the	
Manufacturer’s	Manual.	 The	 IC	was	 then	 attached	 to	 the	mechanical	 ventilator	 for	 at	
least	10	minutes	before	starting	the	test	to	ensure	patient	and	ventilator	stability	prior	
to	measuring	REE.	The	test	lasted	for	40	minutes	in	a	resting	state,	where	intra	variation	
between	VO2	and	VCO2	was	less	than	10%	(Frankenfield	et	al.	2004).	During	the	test,	if	
any	 medical	 intervention	 had	 to	 be	 provided,	 the	 test	 was	 stopped	 and	 the	
measurement	was	repeated	according	to	the	above	criteria,	to	ensure	the	continuity	of	
a	 resting	 state.	 Information	 including	 respiratory	quotient	 (RQ)	and	body	utilisation	of	
carbohydrate	and	fat	was	also	obtained	from	IC	and	will	be	described	in	Chapter	4.	
	
2.9 Faecal	Calprotectin	(FC)	assay:	
	
To	assess	the	intestinal	inflammation	the	levels	of	Calprotectin	were	measured	in	stool	
samples	using	IDK®	Calprotectin	ELISA	(Bensheim,	Germany),	the	lower	limit	of	detection	
was	1.023	ng/ml.	I	performed	the	FC	assays	at	the	Cambridge	University	Department	of	
Paediatrics	laboratories.	
Prior	 to	performing	 the	assay,	 the	 raw	 stool	 samples	were	 allowed	 to	 thaw	and	were	
then	mechanically	 homogenised.	 A	 volume	 of	 15	mg	 of	 faeces	 was	 required.	 FC	 was	
extracted	 from	 the	 stool	 samples	 using	 IDK®	 Calprotectin	 ELISA	 kit	 (Bensheim,	
Germany),	 then	 the	 ELISA	was	 performed	 according	 to	 the	manufacturer’s	 guidelines.	
The	plate	was	 read	 at	 an	 absorbance	of	 450nm	against	 620	nm.	 The	obtained	 results	
were	then	multiplied	by	the	dilution	factor	to	obtain	the	actual	FC	concentrations	in	the	
sample.	
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2.10 Collaboration	aspects:	
	
2.10.1 Cytokine	analysis	
	
This	assay	was	performed	at	the	Core	Biological	Assay	Laboratory	(CBAL)	in	collaboration	
with	Dr	Keith	Burling,	Director	of	CBAL.	 I	was	 responsible	 for	processing	and	 selecting	
the	samples	for	the	assay,	analysing	and	processing	the	data	and	securing	funds	for	the	
study.	
	
Cytokines	 were	 measured	 using	 an	 electrochemical	 luminescence	 immunoassay	 from	
MSD,	 Rockville,	 Maryland,	 USA.	 A	 customised	 version	 of	 MSD	 10-plex	 V-
PlexProinflammatory	 Cytokine	 panel	 was	 used	 for	 the	 assay	 of	 pro-	 and	 anti-	
inflammatory	cytokines.	The	lowest	levels	of	detection	are	shown	in	Table	2-2.	
	
Table	2-2:	The	lowest	level	of	detection	of	measured	inflammatory	cytokines:	
	
	
	
	
	
	
	
2.10.2 Metabolomics	work	
	
This	work	was	done	in	collaboration	with	Dr.	Anisha	Wijeyasekara,	Research	Manager	in	
the	Division	of	Computational	and	Systems	Medicine	at	 Imperial	College	and	Professor	
Elaine	 Holmes,	 the	 Head	 of	 the	Division	 of	 Computational	 and	 Systems	 Medicine	 at	
Imperial	College.	
	
Cytokine	 Lowest	level	of	detection	
Interleukin-6	(IL-6)	 0.01-0.11	pg/ml	
Tumour	necrosis	factor	alpha	(TNF-α)	 0.01-0.13	pg/ml	
Interleukin-10	(IL-10)	 0.01-0.15	pg/ml	
Interleukin-1	beta	(IL1-β)	 0.01-0.27	pg/ml	
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I	 was	 responsible	 for	 processing	 and	 selecting	 the	 samples	 for	 the	 assay,	 performing	
faecal	 water	 extraction	 and	 sample	 preparation	 procedure	 and	 I	 conducted	 the	
statistical	analysis.	
2.10.2.1 Faecal	water	extraction	sample	preparation	
Faecal	 samples	 were	 subjected	 to	 2	 x	 freeze-thaw	 cycles.	 When	 the	 samples	 were	
defrosted	they	were	mechanically	homogenised	using	an	inoculation	loop.	Roughly	100	
mg	 of	 defrosted	 faecal	 sample	 was	 weighed	 and	 placed	 in	 a	 microtube	 with	 added	
1.0mm	 Zirconia	 beads	 and	 250µl	 of	 acetonitrile:	 water	 (ACN:H2O)	 (1:3)	 (solvent).	 The	
tubes	were	 placed	 in	 the	 Biospec	 bead	 beater	 and	 beaten	 for	 1	 x	 10	 seconds.	 Other	
tubes	were	centrifuged	for	20	minutes	at	16,000	×	g	and	the	filter	was	washed	and	spun	
through	 3	 times	 with	 (ACN):H2O.	 Following	 this	 step,	 250µl	 of	 supernatant	 from	 the	
sample	was	removed	and	placed	into	spin	filter	tubes	and	centrifuged	for	30	minutes	at	
16,000	×	g.	The	samples	were	stored	at	-80°C	until	the	day	of	the	run.	
2.10.2.2 1H-NMR	spectroscopy	of	faecal	water	
	
Faecal	water	 samples	were	prepared	 for	 1H-NMR	 spectroscopy,	 for	 the	 assessment	of	
SCFAs,	according	to	published	protocols	(Gratton	et	al.	2016).	The	mixture	of	the	sample	
and	 the	 buffer	 solution	 was	 vortexed	 and	 centrifuged	 for	 10	 sec,	 and	 600	 μL	 of	 the	
mixture	was	pipetted	 into	NMR	tubes	with	an	outer	diameter	of	5	mm.	Samples	were	
analysed	in	a	randomised	order,	and	one-dimensional	spectroscopic	data	were	acquired	
according	to	established	metabolic	profiling	protocols	(Dona	et	al.	2014),	using	standard	
one-dimensional	NMR	pulse	sequence	with	water	pre-saturation.	
2.10.2.3 1H-NMR	spectral	pre-processing	and	faecal	water	metabolic	profile	data	
analysis	
Data	 was	 processed	 using	 the	 TopSpin	 3.1	 software	 package	 (Bruker	 Biospin,	
Rheinstetten,	 Germany)	 and	 SIMCA	 13.0	 software	 package	 (Umetrics	 AB,	 Umeå,	
Sweden)	 using	 unit	 variance	 (UV)	 scaling.	 Spectral	 peaks	 corresponding	 to	 the	 target	
compounds	were	 integrated	 using	 the	 TopSpin	 3.1	 software	 package	 (Bruker	 Biospin,	
Rheinstetten,	 Germany),	 and	 the	 spectral	 integrals	 exported	 into	 Excel	 for	 further	
statistical	analysis.	This	will	be	discussed	thoroughly	in	the	relevant	chapter.	
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2.10.2.4 Liquid	chromatography–mass	spectrometry	(LC/MS)	:	
Bile	 acid	data	were	acquired	by	 LC-MS	 in	profiling	mode	 (using	a	quadrupole	 time-of-
flight	(QToF)	instrument.	Data	were	acquired	using	protocols	described	by	Sarafian	et	al.	
(2015).	 The	 serum	 citrulline	 data	was	 also	 acquired	 using	 an	 LC-MS	 instrument	 but	 in	
targeted	mode	using	a	triple	quadrupole	(TQ)	instrument,	using	the	Absolute	IDQ®P	180	
kit	 (Biocrates	 Life	 Sciences,	 Innsbruck,	Austria)	which	 includes	 reference	 standards	 for	
targeted	detection	and	quantification.	Samples	were	prepared	for	analysis	according	to	
existing	protocols	(Sarafian	et	al.	2015).	The	identity	of	the	detected	compounds	in	the	
samples	was	confirmed	by	comparison	of	 their	 retention	times	and	their	mass	spectra	
with	those	of	authentic	standards	and	with	reference	spectra	database.	
2.10.3 Metataxonomic	work	
	
The	principle	of	this	work	relies	on	the	identification	bacterial	16S	ribosomal	RNA	(rRNA)	
gene	 in	 the	 faecal	 samples.	The	bacterial	16S	 rRNA	gene	has	conserved	 regions	which	
provide	good	PCR	targets	for	broad	range	amplification	and	nine	highly	variable	regions	
which	provide	good	resolution	of	bacteria	down	to	genus	level	and	in	many	cases	down	
to	 species	 level	 (Crawford	 et	 al.	 2009).	 In	 this	 study	 we	 sequenced	 the	 bacterial	 16S	
rRNA	 gene	 variable	 region	 one	 and	 two	 (V1-V2).	 The	 Illumina	 MiSeq	 600	 cycle	 kit	
enables	the	nearly	full-length	sequencing	of	the	approximately	350	bp	long	V1-V2	region	
from	 both	 ends.	 A	 full-length	 sequencing	 from	 both	 ends	 is	 important	 to	 keep	 the	
sequencing	error	as	low	as	possible.		
	
This	 work	 was	 done	 in	 collaboration	 with	 Mrs	 Sarah	 Thurston,	 research	 scientist,	
department	 of	 paediatrics	 at	 University	 of	 Cambridge,	 and	 Dr	 Josef	 Wagner,	 senior	
postdoctoral	 scientist	 at	 the	 Welcome	 Trust	 Sanger	 institute.	 I	 was	 responsible	 for	
processing	 the	 samples	 after	 collection,	 and	 perform	 the	 DNA	 extraction;	 I	 also	
performed	the	statistical	analysis.		
	
Faecal	 samples	were	 thawed	 before	 DNA	 extraction.	 Larger	 samples,	 especially	 those	
that	 came	 from	 healthy	 controls,	 were	 split	 for	 other	 analysis	 as	 well	 as	 for	 DNA	
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•  DNA	Extraction		
•  PCR	(Bacterial	DNA	amplification)	
•  MiSeq	gene	sequencing	
•  Clustering	and	identifying	sequenced	data	
•  Generating	OUT	table	
•  Performing	the	statistical	analysis	
extraction.	The	DNA	was	extracted	using	the	PowerFecal®	DNA	Isolation	kit,	MOBIO,	CA,	
USA,	 following	 manufacturer	 guidelines.	 PCR’s	 were	 then	 prepared	 to	 amplify	 the	
bacterial	16s	rRNA	gene	(Figure	2.3),	and	produce	libraries,	as	described	by	(Kozich	et	al.	
2013).	
	
PCR	product	was	then	cleaned	up	using	magnetic	bead	methodology.	Once	cleaned	the	
PCR	production	was	 quantified	using	 a	 high	 sensitivity	Qubit	 kit	 and	 fluorometer.	 The	
quantification	permits	the	construction	of	a	library	equimolar	mix	to	be	prepared,	which	
is	then	visualized	using	a	1%	agarose	gel	and	purified	by	using	the	Wizard®	SV	Gel	and	
PCR	Clean	up	system,	Promega,	WI,	USA,	following	the	manufacturers	guidelines.		
	
The	equimolar	library	was	then	sequenced	on	the	MiSeq	sequencing	platform	following	
validation	 and	 quality	 control	 procedures	 at	 the	 Welcome	 Sanger	 Institute.	 The	
sequencing	 data	was	 then	 quality	 filtered	 and	 analysed	 by	Mothur,	 software	 package	
according	 to	 the	 MOTHUR	 MiSeq	 SOP	 (MOTHUR	 wiki	 at	
http://www.mothur.org/wiki/MiSeq_SOP).	 		 Sequencing	 reads	 were	 binned	 into	
operational	 taxonomic	units	 (OTUs).	 The	generated	OTU	 tables	were	 then	used	 in	 the	
statistical	analysis	of	the	gut	microbial	profiles	of	critically	ill	and	healthy	children.	
	
	
	
	
	
	
	
	
	
	
	
Figure	2.2	The	process	of	sample	handling	and	data	analysis	of	the	metagenomic	work	
The	 above	 figure	 summarises	 the	 steps	 of	 gut	 microbial	 analysis,	 from	 the	 DNA	 extraction	 to	 the	
generation	of	OUT	tables	and	performing	the	statistical	plan	
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	 Components	 25	ul	Reaction	
	
MM	x	26	 Final	Concentration	
Nuclease	free	water	 	14.25	 µl	 370.5	 Make	up	to	25	µl	
5x	Q5	PCR	Buffer	 	5	 µl	 130	 1X	
10	mM	dNTPs	 	0.5	 µl	 13	 200	µM	
10	µM	forward	primers	
(500	number	primers)	 Add	individual	1.25		 µl	 32.5	 0.5	µM	
10	µM	reverse	primers	
(700	number	primers)	 	1.25	 µl	 32.5	 0.5	µM	
Q5	Taq	PCR	enzyme	 	0.25	 µl	 6.5	 0.02	U/µl	
Template	DNA	 	2.5	 µl	 65	 <	1000ng	
Total	volume	 	25	 µl	 650	
	Master	mix	volume	 	21.25	 µl	
	PCR	conditions:	
	 	98°C	 2	mins	
	
	
98°C	 30	secs	
20	cycles*	 	50°C	 30	secs	
72°C	 90	secs	
	
72°C	 5	mins	
	
		
4°C	 ∞	
	 		
Figure	2.3	PCR	mastermix	set-up	and	amplification	conditions	for	MiSeq	library	
preparation	
	
2.10.3.1 Contamination	detection	
	
By	using	various	guidelines	outlined	in	published	work	by	Salter	et	al.	(2014),	the	effects	
of	 exogenous	 kit-associated	 DNA	 contamination	was	mitigated.	 The	methods	 used	 to	
reduce	the	effects	of	contamination	included	using	and	sequencing	appropriate	controls	
including	 biological	 replicates,	 recording	 the	 kit	 from	 which	 samples	 were	 extracted,	
reducing	 contamination	 as	much	 as	 possible	 during	 collection	 and	 extraction	 by	 using	
sterile	 materials	 and	 applying	 general	 aseptic	 techniques,	 and	 randomising	 sample	
handling	 as	 much	 as	 logistically	 possible.	 Once	 the	 sequencing	 was	 performed,	
contaminant	 OTPs	 were	 identified	 using	 the	 negative	 controls,	 or	 association	 with	
extraction	 kit,	 batch	 or	 sequencing	 run.	 Many	 of	 these	 taxa	 were	 similar	 to	 those	
previously	identified	as	contaminants	(Salter	et	al.	2014).	
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2.11 Statistical	analysis	
	
2.11.1 Univariate	statistics	
	
The	statistical	package	used	for	this	analysis	were	 IBM	SPSS	v25	and	Microsoft®	Excel®	
2011.	The	statistical	tests	used	were	simple	descriptive	statistics	for	the	majority	of	the	
study	variables	to	show	the	counts	and	percentages	as	well	as	median	and	interquartile	
range	 (IQR).	 The	 Shapiro-Wilk	 Test	 was	 used	 to	 assess	 the	 normality	 of	 the	 data	
distribution	as	the	sample	size	was	not	large.	
For	 the	normally	distributed	variables	T-test	was	performed	 to	compare	 two	variables	
and	one-way	ANOVA	was	used	to	compare	repeated	measurement.	For	variables	with	
skewed	distribution,	Mann-	Witney-U	for	two	group	comparison	and	the	Kruskal-Wallis	
tests	 for	 three	 or	more	 group	 comparison	were	 applied.	 Spearman	 correlations	were	
performed	to	detect	the	statistical	association	between	variables.		
	
2.11.2 Multivariate	statistics	
	
Linear	and	logistic	regression	analysis	was	performed	to	assess	the	association	between	
multiple	 variables.	 Additional	 multivariate	 analysis	 was	 undertaken	 for	 the	
metataxonomics	 and	metabolomics	work	 (this	will	 be	 explained	 in	more	 detail	 in	 the	
relevant	 chapters).	 Multivariate	 analysis	 was	 necessary	 for	 these	 datasets	 as	 the	
generated	OTU	tables	contained	hundreds	of	bacterial	species.	In	addition,	the	digitised	
spectroscopic	 data	 also	 contained	 large	 number	 of	 variables	 from	 the	 same	 peak,	 or	
multiple	 peaks	 from	 the	 same	 metabolite.	 So	 multivariate	 analysis	 enables	 the	
assessment	 of	 these	 altogether,	 factoring	 in	 that	 there	 will	 be	 correlations	 between	
variables	from	the	same	class	(or	group).	Principal	component	analysis	 (PCA)	was	used	
to	 observe	 the	 overall	 pattern/trends	 and	 to	 detect	 outliers.	 A	 permutational	
multivariate	analysis	of	variance	(PERMANOVA)	test	was	used	to	assess	if	the	observed	
differences	 (in	 multivariate	 space)	 were	 statistically	 significant	 (Anderson	 &	 Walsh	
2013).	Partial	Least	Square	Discriminant	Analysis	(PLS-DA)	was	then	performed	to	reduce	
the	dimension,	maximise	the	separation	between	groups	and	view	important	microbial	
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characteristics	of	the	groups.	The	models	were	assessed	based	on	goodness-of-fit	(R2	Y)	
and	goodness-of-prediction	(Q2	Y)	metrics.	
	
2.11.3 Sample	size	calculation	
	
Sample	 size	 calculation	 was	 performed	 using	 the	 statistical	 power	 analysis	 program	
G*Power	3	(Faul	et	al.	2007).	Whilst	much	of	the	data	were	multiparametric,	the	level	
of	faecal	butyrate	was	selected	as	the	primary	outcome	for	this	project.	The	sample	size	
was	chosen	 to	detect	a	 clinically	 statistical	difference	 in	 total	 faecal	butyrate	between	
critically	ill	children	and	healthy	controls.	There	are	no	data	in	the	paediatric	population.	
Data	 from	 studies	 in	 critically	 ill	 adults	 demonstrates	 a	 rapid,	 sustained	 decrease	 in	
faecal	 butyrate	 compared	 to	 healthy	 adults.	 This	 assumption	 was	 based	 on	 work	 by	
Yamada	et	al.	(2015)	in	critically	ill	adults	where	a	difference	of	12	micromol/g	faeces	of	
butyrate	was	recorded	between	critically	ill	and	healthy	controls,	 it	was	estimated	that	
25	children	per	group	would	be	needed	to	detect	the	same	difference	between	critically	
ill	 and	 healthy	 children,	 assuming	 a	 5%	 significant	 level	 (2-sided)	 and	 90%	 power.	
Assuming	a	drop-out	rate	of	20%,	it	was	estimated	that	30	children	would	be	needed	in	
each	group.	
	
Many	other	studies	have	shown	a	rapid	and	dramatic	loss	total	SCFAs	in	the	critically	ill	
adults	 compared	 to	healthy	 subjects.	 In	 a	 study	by	 	 Shimizu	et	 al.	 (2006)	mean	 faecal	
butyrate	in	critically	ill	patients	was	0.9	micromol/g	faeces	compared	to	16	micromol/g	
faeces	 	 in	 healthy	 controls	 with	 recorded	 difference	 of	 15	micromol/g	 faeces.	 	While		
Hayakawa	 et	 al.	 (2011)	 recorded	 a	 difference	 of	 10	 micromol/g	 faeces	 of	 butyrate	
between	critically	ill	adults	and	healthy	controls.		
	
For	 the	 primary	 endpoint	 30	 children	were	 required,	 but	 as	 the	 secondary	 endpoints	
included:	 intestinal	 and	 systemic	 inflammation	 and	 stool	 microbial	 composition	 I	
performed	 sample	 calculation	 for	 each	 sub-analysis.	 Sample	 size	 calculation	 was	
performed	 considering	 the	 specification	 of	 the	research	question	 in	 each	 chapter	 to	
ensure	 that	 sufficient	 data	 was	 collected	 to	 show	 statistical	 significance.	
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3 Chapter	 Three:	 An	 Overview	 of	 the	 Population	
Characteristics,	Biological	samples	and	Assays	Undertaken	
	
3.1 Introduction	
Critical	 illness	 affects	 more	 than	 20,000	 children	 per	 year	 in	 the	 UK.	 It	 has	 been	
estimated	 that	 nearly	 2%	 of	 children	 admitted	 to	 PICUs	 are	 discharged	 and	 then	
readmitted	 as	 an	 emergency	 within	 48	 hours	 (Parslow	 &	 Draper	 2017).	 The	 recent	
Paediatric	Intensive	Care	Audit	Network	(PICANet)	report	indicated	that	the	majority	of	
admitted	children	were	under	one	year	of	age	(Parslow	&	Draper	2017).	There	are	many	
reasons	 for	 PICU	 admission;	 a	 national	 cohort	 study	 by	 Fraser	 &	 Parslow	 (2018)	
indicated	 that	 respiratory	 and	 cardiac	 diagnoses	 were	 the	most	 common	 reasons	 for	
PICU	 admission	 (Fraser	 &	 Parslow	 2018).	 The	 NHS	 national	 review	 showed	 that	 the	
mean	length	of	PICU	stay	for	children	who	survived	was	6	days	compared	to	17	days	for	
those	who	 died	 (Anon	 2017a).	 The	 PICANet	 report	 indicated	 that	 the	 crude	mortality	
rates	in	PICUs	is	4%	(Parslow	&	Draper	2017).	The	effect	of	acute	insult	may	extend	until	
after	discharge	from	PICU	and	compromise	the	functional	outcome	and	quality	of	life	in	
surviving	children	(Taylor	et	al.	2003;	Typpo	et	al.	2009).	Approximately	12%	of	children	
who	were	admitted	to	a	PICU	during	the	period	2002	–	2015	died	either	in	the	PICU	or	
following	discharge	(Parslow	&	Draper	2017).	
Growing	evidence	points	 to	 the	 role	of	gut	barrier	dysfunction	during	critical	 illness	 in	
the	pathophysiology	of	 inflammation	and	organ	dysfunction	(Pathan	et	al.	2011;	Mittal	
&	 Coopersmith	 2014).	 The	 main	 study	 of	 gut	 homeostasis	 (GHICI)	 was	 designed	 to	
examine	 the	 changes	 in	 gut-host	 relationship	 over	 a	 time-course	 from	 admission	 to	
discharge	in	critically	ill	children.	A	better	understanding	of	the	relationship	between	gut	
failure	and	multi-organ	dysfunction	 in	 critical	 illness	will	 allow	us	 to	define	 criteria	 for	
the	 therapeutic	 modulation	 of	 the	 intestinal	 environment	 using	 prebiotics	 and/or	
micronutrients.	This	PhD	focuses	particularly	on	examining	the	effect	of	nutrition	on	the	
		
Chapter	Three	
	
	 	
62	
intestinal	 microbiome-host	 relationship	 in	 critically	 ill	 children	 and	 whether	 it	 has	 an	
impact	on	clinical	disease	severity.	
The	 purposes	 of	 this	 chapter	 are	 to	 describe	 the	 subjects	 who	 were	 enrolled	 in	 the	
study,	 to	 present	 the	 number	 of	 samples	 collected	 from	 each	 study	 group	 and	 to	
highlight	the	assays	undertaken	in	this	PhD	project.	
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3.2 Results	
	
3.2.1 Population	
	
A	 total	of	186	critically	 ill	 children	and	70	healthy	children	were	recruited	 for	 this	PhD	
project.	 Critically	 ill	 children	 were	 recruited	 from	 paediatric	 intensive	 care	 at	
Addenbrooke’s	Hospital	in	the	UK	(N=166)	and	Hospices	Civils	de	Lyon	in	France	(N=20)	
between	 November	 2014	 and	 May	 2017.	 Healthy	 children	 were	 recruited	 from	
outpatient	clinics	and	from	the	community	in	the	Cambridge	area.	Due	to	the	limitation	
of	 obtaining	 blood	 samples	 from	 these	 children,	 another	 control	 group	 of	 children	
undergoing	elective	surgeries	was	recruited.	
	
The	demographic	characteristics	of	patients	and	controls	are	presented	in	Table	3-1.	The	
results	 showed	 that	 the	 control	 group	were	 significantly	 older	 and	 therefore	 also	 had	
higher	 growth	 parameters,	 than	 the	 patient	 group.	 There	 was	 no	 difference	 in	 the	
gender	 distribution	 of	 critically	 ill	 and	 healthy	 children.	 Eighty-five	 females	 and	 101	
males	 were	 recruited	 in	 the	 study	 group	 and	 38	 female	 and	 32	males	 in	 the	 control	
group.	All	patients	 received	at	 least	one	broad-spectrum	antibiotic	 therapy	and	61.8%	
(N=120)	of	them	received	more	than	one	type	of	antibiotics.	The	median	(IQR)	number	
of	antibiotic	classes	received	per	patients	was	2	(1-3).	
	
Among	the	study	group	the	majority	of	the	children	were	admitted	to	PICU	due	to	MOF,	
respiratory	 and	 CNS	 disorders	 diagnosis.	 The	 distribution	 of	 the	 categories	 of	 primary	
diagnosis	among	the	patient	group	is	shown	in	Table	3-2.	All	patients	received	invasive	
mechanical	ventilation.	The	PICU	mortality	among	the	study	group	was	5%	(N=10).	
	
The	majority	of	the	children	recruited	in	this	study	were	fed	via	enteral	route	(N=145),	
while	 8	 children	 received	parenteral	 nutrition	 (PN)	 and	3	 children	who	were	 enterally	
fed	had	also	supplementary	PN	(Table	3-3).	EN	was	commenced	at	a	median	(IQR)	time	
of	8	(5	-	12)	hours	following	PICU	admission.	Only	7	children	started	their	enteral	feeding	
>24	 hours	 after	 PICU	 admission.	 The	most	 common	 reasons	 for	 delaying	 enteral	 feed	
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were	 failed	 attempts	 of	 extubation	 (N=4),	 diagnostic	 tests	 (N=1),	 haemodynamic	
instability	(N=1)	and	planning	for	PN	(N=1).	
	
Table	3-1:	Anthropometric	and	clinical	characteristics	of	children	enrolled	in	the	study	
	
	
Population	characteristics	
All	patients	and	controls		
Patients	
(N=186)	
Control	
(N=70)	
P	value		
Age	(years)	 2.4				(		0.65		–				6				)		 4.8			(			2.9		–				6.6				)	 0.00**	
Weight	(Kg)	 13					(		7.8		–			20.1		)	 19.8		(						14		–				28		)	 0.00**	
Height	(cm)	 90					(		73				–		112			)	 110			(		92		–				123				)	 0.00**	
Weight	age	Z	score	 -0.33	(-1.56		–		0.54	)	 0.36	(	-0.07		–			0.72	)	 0.00**	
Height	for	age	Z	score	 -0.2		(		-1.9		–				0.97	)	 0.64		(		-0.27		–			1.1	)	 0.006**	
Weight	for	height	Z	score	 0.01		(-1.19		–				0.72)	 0.14		(	-0.44		–			0.81)	 0.056	
Disease	severity	variables	
PIM2	score		 3.7							(		1.2		–				7				)	 	
PMODS	 6										(					5		–				7					)	
Highest	Lactate	 1.9							(	1.4		–				3.3		)	
Highest	CRP	 74								(		35		–			198		)	
Inotrope	score		 0.0							(		0.0		–			17			)	
Duration	of	mechanical	ventilation		 93								(		61		–			168		)	
VFH	at	30	days		 625					(	545		–				657	)	
Hours	of	Inotrope	 0										(				0		–				28				)	
Hours	free	of	Inotrope	at	30	days		 720					(	683		–				720	)	
Length	of	PICU	stay			 7										(					5	–				11				)	
PICU	free	days	at	30	days		 23							(			18		–				25				)	
																																																					
																																																																					Data	are	presented	as	median	(IQR)	
**	P	value	is	significant	at	0.01	level																																											*	P	value	is	significant	at	0.05	level	
VFH	at	30	days:	ventilation-free	hours	at	30	days	
PICU	free	days	at	30	days:	days	free	of	paediatric	intensive	care	at	30	days	
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Table	3-2:	Patient’s	primary	admission	diagnostic	category	
	
Primary	admission	diagnosis		 N	(%)	
MOF		 56			(	30%	)	
Respiratory	Failure	 84			(	45%	)	
CNS	Disorders	 35			(	19%	)	
Surgical	Disorders	 8						(	4.3%)	
Cardiac	Disorders	 1						(0.5%	)	
Gastrointestinal	Disorders	 1						(0.5%	)	
	
	
Table	3-3:	Number	of	enterally	and	parenterally	fed	critically	ill	children	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Route	of	feeding	 N	(%)	
Oral	 3											(		1.6%	)	
Nasogastric	(NG)	 129							(	69.5%)	
Gastrostomy	 10									(		5.4%	)	
Jejunostomy	 2											(			1	%		)	
Orogastric	tube	(OGT)	 1											(	0.5%		)	
PN	 8											(		4.4%	)	
NG	with	supplementary	PN	 3											(		1.6%	)	
Unknown		 30									(		16%		)	
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3.2.2 Samples	
	
Serum	
A	total	of	204	serum	samples	were	collected	from	106	patients.	Of	those	194	were	serial	
samples	 collected	 from	 86	 patients	 (see	 Figure	 3.1).	 Seventeen	 serum	 samples	 were	
collected	from	the	control	group.	
	
Faecal	samples	
	
Eighty-nine	critically	ill	children	provided	119	faecal	samples.	Generally,	a	single	sample	
was	collected	from	each	child.	However,	in	a	number	of	critically	ill	children	more	than	
one	 faecal	 sample	 was	 available	 within	 the	 study	 period.	 A	 single	 faecal	 sample	 was	
collected	from	70	healthy	children.	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	3.1	The	number	of	longitudinal	serum	samples	collected	from	critically	ill	
children	
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3.2.3 Assays	and	measurements	undertaken	
	
Several	measurements	and	assays	were	undertaken;	these	included:	
• Collection	of	demographic,	anthropometry,	clinical	and	nutritional	data.	
• Measurements	of	energy	expenditure	by	IC.	
• Measurement	of	inflammatory	cytokines	and	citrulline	in	serum.	
• Measurement	of	faecal	calprotectin.	
• Faecal	metagenomic	and	metabolomic	analysis.	
The	numbers	of	patients	included	in	each	assay	are	presented	in	Figure	3.2.	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	 3.2	Patient	 and	 control	 enrolment	 algorithm	 showing	 the	number	of	 children	
included	in	each	study	of	this	PhD	project	
The	patients	and	controls	groups	recruited	 in	each	sub-study	were	sub	cohort	of	the	originally	recruited	
critically	 ill	 (N=186)	 and	 healthy	 children	 (N=70)	 groups,	 ie.	 For	 some	 patients	 multiple	 assays	 were	
preformed,	the	numbers	will	be	specified	in	the	relevant	chapters.	
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3.3 Discussion	
	
Studies	 investigating	 the	 changes	 in	 intestinal	 microbiome	 in	 critically	 ill	 children	 are	
limited.	The	majority	of	studies	have	been	performed	with	adult	populations	(Howard	et	
al.	2017;	Mcdonald	et	al.	2016;	Ojima	et	al.	2016;	Shimizu	et	al.	2011;	Hayakawa	et	al.	
2011;	 Shimizu	 et	 al.	 2006).	 Only	 one	 study	 by	 Rogers	 et	 al.	 (2016)	 investigated	 the	
microbiome	 of	 different	 body	 sites	 including	 the	 gut	 in	 critically	 ill	 children.	 They	
analysed	gut	microbial	data	in	37	critically	 ill	children	aged	between	1	and	9	years	old.	
This	PhD	project	aims	to	investigate	the	effect	of	nutrition	on	the	intestinal	microbiome-
host	 relationship	 in	 a	 larger	 cohort	 of	 critically	 children.	 This	 chapter	 describes	 the	
critically	ill	and	control	children	groups	recruited	in	the	study.	
	
The	median	age	of	the	patients	group	was	2.4	(0.65-6)	years	old,	which	is	similar	to	data	
from	population-based	studies	 in	PICU	settings	where	 the	majority	of	 the	children	are	
aged	between	1	and	4	years	(Ibiebele	et	al.	2018;	Fraser	&	Parslow	2018).	The	results	of	
this	chapter,	however,	showed	that	the	healthy	control	group	was	statistically	older	than	
the	 study	 group	with	 a	median	 age	 of	 4.8	 (2.9-6.6)	 years.	 This	 is	mainly	 because	 the	
majority	 of	 children	 admitted	 to	 PICU	 were	 under	 4	 years	 old,	 as	 was	 shown	 in	 the	
PICANet	 report	 and	 other	 national	 studies	 (Parslow	&	Draper	 2017;	 Fraser	&	 Parslow	
2018;	Ibiebele	et	al.	2018).	 In	addition,	the	control	group	included	children	undergoing	
elective	 surgeries	 and	 those	 are	 usually	 older	 than	 4	 years.	 Selvadurai	 et	 al.	 (2018)	
indicated	that	the	mean	age	of	patients	undergoing	elective	surgery	was	4.8	±2.0	years.	
Therefore,	 where	 comparison	 is	 made	 between	 patients	 and	 healthy	 children	 in	 the	
subsequent	chapters,	the	analysis	is	restricted	to	the	age-matched	cohort.	
	
The	most	 common	 diagnostic	 categories	 dictating	 PICU	 admission	 among	 the	 patient	
group	 were	 respiratory	 failure,	 MOF	 and	 CNS	 disorders.	 Other	 studies	 utilising	 data	
collected	from	the	PICANet	clinical	audit	database	have	also	shown	a	similar	distribution	
of	 patients’	 diagnosis	 (Ibiebele	 et	 al.	 2018;	Green	 et	 al.	 2016;	 Fraser	&	Parslow	2018;	
Morris	 et	 al.	 2017).	 Around	 45%	 of	 critically	 ill	 children	 included	 in	 this	 study	 were	
admitted	 due	 to	 respiratory	 conditions.	 PICU	 admissions	 for	 infants	with	 bronchiolitis	
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have	 increased	 in	recent	years	 in	the	UK	(Green	et	al.	2016).	This	 is	mainly	due	to	the	
increasing	 prevalence	 of	 maternal	 and	 perinatal	 factors	 that	 predispose	 to	 severe	
disease	 (Green	 et	 al.	 2016).	 	 The	 overall	 admission	 rates	 due	 to	 lower	 and	 upper	
respiratory	tract	infections	are	also	increasing	(Gill	et	al.	2013).	Many	children	admitted	
to	 PICU	 have	 a	 brief	 stay	 and	 recover	well,	 but	 a	 significant	 proportion	may	 develop	
MOF	(Hamshary	et	al.	2017).	Nearly	30%	of	the	patient	group	developed	MOF.	Watson	
et	al.	 (2017)	 indicated	that	MOF	 is	common	among	this	population,	occurring	 in	up	to	
57%	of	critically	ill	children.	CNS	disorders	were	also	frequent	among	the	current	cohort,	
occurring	in	19%	of	the	children.	Generally,	CNS	disorders	are	a	common	reason	for	PICU	
admission	 and	 they	 are	 usually	 associated	 with	 higher	 mortality,	 morbidity	 and	
prolonged	PICU	stay	(Aurangzeb	et	al.	2012).	
	
The	median	 (IQR)	 length	 of	 PICU	 stay	 among	 the	 study	 group	was	 7	 (5-11)	 days.	 This	
matched	the	national	data	where	a	median	of	6	days	stay	in	PICU	was	recorded	(Ibiebele	
et	al.	2018).	All	critically	ill	children	received	invasive	mechanical	ventilation	during	the	
first	day	of	PICU	admission	and	the	median	duration	of	invasive	mechanical	ventilation	
was	93	hours.	Based	on	PICANet	data,	67.5%	of	children	admitted	to	UK	PICUs	receive	
invasive	 mechanical	 ventilation	 compared	 to	 31.7%	 who	 receive	 non-invasive	
mechanical	 ventilation	 (Morris	 et	 al.	 2017).	 The	 duration	 of	 ventilation	 and	 length	 of	
PICU	 stay	were	also	presented	as	hours	 free	of	mechanical	 ventilation	at	30	days	and	
days	free	of	PICU	stay	at	30	days	to	correct	for	those	who	died.	
	
The	majority	of	the	children	included	in	the	current	study	were	fed	via	the	enteral	route.	
EN	was	 started	within	a	 few	hours	of	 admission	 (median	of	8	hours)	 according	 to	 the	
PICU’s	 enteral	 feeding	protocol.	 There	 is	 a	 strong	 consensus	 that	 the	 enteral	 route	of	
providing	 nutrition	 is	 preferred	 over	 the	 parenteral	 route	 (Seres	 et	 al.	 2013).	 Enteral	
feeding	 is	 a	mainstay	 of	 nutrition	 in	most	 critically	 ill	 children,	with	 73%	 receiving	 EN	
(Kerklaan	et	al.	2016).	The	current	practice	in	many	centres	is	the	early	initiation	of	EN	
within	24-72	hours	of	PICU	admission;	enteral	feeding	would	even	be	started	within	12	
hours	in	some	PICUs	(Kerklaan	et	al.	2016;	Mehta	et	al.	2009;	Mara	et	al.	2014).	Delayed	
initiation	of	enteral	nutrition	may	often	be	due	to	extubation,	 intubation,	feeding	tube	
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displacement,	 diagnostic	 procedures,	 gastrointestinal	 bleeding,	 decreased	 bowel	
motility,	abdominal	distention,	large	aspirates	and	hemodynamic	instability	(Keehn	et	al.	
2015;	 Lee	 et	 al.	 2013).	 In	 the	 current	 cohort,	 the	most	 common	 reasons	 for	 delaying	
enteral	 feed	 were	 failed	 attempts	 of	 extubation,	 diagnostic	 tests,	 haemodynamic	
instability	and	planning	for	PN.	Early	initiation	of	EN	is	associated	with	improvement	in	
the	 nutritional	 status	 and	 clinical	 outcomes	 in	 critically	 ill	 children	 (Briassoulis	 et	 al.	
2001;	Kaplan	&	Frangos	2005;	Mehta	et	al.	2012).	PN,	on	the	other	hand,	is	being	used	
to	supplement	or	 replace	EN	 in	some	cases	where	the	nutrition	goal	 is	not	met	by	EN	
alone	 (Mehta	 et	 al.	 2009).	 The	 results	 also	 suggested	 that	 our	 cohort	 is	 relatively	
normally	 nourished	 and	 representative	 of	 the	 general	 UK	 population	 (NatCen	 Social	
Research	2017).	
	
With	 regard	 to	 the	 primary	 objective	 of	 this	 study,	 an	 integrated	 approach	 of	
metataxonomics	 and	metabolomics	 analysis	was	 used	 to	 examine	how	 feeding	during	
critical	illness	affects	gut-host	relationship.	This	required	not	only	the	collection	of	faecal	
samples;	serum	samples	were	also	essential	 for	the	analysis	of	 inflammatory	cytokines	
and	 intestinal	 injury	 biomarkers.	 The	 results	 showed	 inconsistency	 in	 the	 number	 of	
serum	 serial	 samples	 collected	 at	 each	 time-point.	 Ideally	 all	 samples	 should	 be	
collected	 on	 the	 same	 day	 at	 the	 same	 time.	 This	was	 unlikely	 to	 happen	 due	 to	 the	
nature	of	PICU	settings,	so	the	samples	were	taken	when	permissible.	It	was	challenging	
to	 collect	 the	whole	 set	 of	 serum	 samples	 for	 a	 number	 of	 reasons.	 Firstly,	 for	 some	
children	it	was	not	possible	to	consent	the	parents	as	early	as	required	and	accordingly	
samples	 were	 not	 taken	 on	 the	 early	 days	 of	 admission.	 The	 majority	 of	 critically	
children	did	not	have	an	 indwelling	 line	until	day	7,	which	 limited	the	extent	 to	which	
time-course	analysis	is	possible.	Furthermore,	a	considerable	percentage	of	the	children	
were	extubated	 and	 the	 indwelling	 line	 for	 blood	 sampling	was	 removed.	All	 of	 these	
factors	accounted	for	the	inconsistency	in	the	number	of	samples	collected	at	each	time-
point.	Collecting	the	faecal	sample	was	also	challenging;	 it	 is	not	surprising	that	not	all	
the	enrolled	children	provided	a	faecal	sample	within	the	course	of	their	PICU	stay.	The	
sample	 volume	was	 also	 problematic;	 the	 small	 volumes	 of	 blood	 and	 faecal	 samples	
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obtained	from	children	required	the	prioritisation	of	assays.	 In	some	cases	the	volume	
was	only	enough	for	one	assay	and	not	the	other.	
	
A	 number	 of	 assays	 and	measures	were	 undertaken	 to	 achieve	 the	 objectives	 of	 this	
thesis.	As	not	all	the	sub-studies	of	this	PhD	project	included	the	same	cohort	of	critically	
ill	 and	 healthy	 children,	 I	 will	 present	 the	 population	 characteristics	 of	 the	 cohort	
included	in	each	study	in	the	relevant	chapter.	
3.4 Conclusion	
	
The	demographic	and	clinical	characteristics	of	the	critically	 ill	children	 included	 in	this	
study	match	the	national	reports	describing	PICU	population	in	the	UK.	The	age	variation	
between	patients	and	controls	might	affect	the	validity	of	the	comparison	between	the	
groups.	 Therefore,	 this	 should	 be	 taken	 into	 account	 when	 performing	 the	 statistical	
analysis	in	the	subsequent	chapters.	A	number	of	reason	accounted	for	inconsistency	in	
the	 number	 of	 serial	 biological	 samples,	 mostly	 related	 to	 limitations	 in	 the	 sample	
volumes	 and	 challenges	 in	 the	 sample	 collection	 process	 in	 this	 particular	 population	
and	setting.	
	
	
	
		
Chapter	Four	
	
	 	
72	
4 Chapter	 Four:	 Measuring	 Energy	 Expenditure	 in	 Critically	 Ill	
Children	
4.1 Introduction	
	
The	 nutritional	 needs	 for	 critically	 ill	 children	 are	 frequently	 not	 fulfilled	 in	 the	 acute	
phase	of	critical	 illness	due	to	several	 reasons:	 lack	of	routine	nutritional	assessments,	
fluid	restriction,	feed	intolerance,	and	frequent	interruption	of	enteral	feeding	(Hulst	et	
al.,	 2006;	 Mehta	 et	 al.,	 2012).	 Importantly,	 estimating	 energy	 and	 macronutrient	
requirements	 in	 this	 group	of	 patients	 remains	 a	 clinical	 challenge	 (Hulst	 et	 al.,	 2006;	
Mehta	et	al.,	2012).	
	
As	 critically	 ill	 children	 undergo	 different	 phases	 of	 illness,	 the	metabolic	 response	 to	
injury	varies	over	time	(Wischmeyer,	2013).	Studies	have	found	that	critically	ill	children	
have	 reduced	 energy	 expenditure	 during	 the	 acute	 phase	 of	 illness	 (Briassoulis	 et	 al.,	
2000;	 Taylor	 et	 al.,	 2003;	 Framson	 et	 al.,	 2007;	 Mehta	 et	 al.,	 2012).	 The	 increase	 in	
energy	expenditure	only	occurs	 in	the	 later	stable	and	recovery	phases	(Joosten	et	al.,	
2016).	 The	 variation	 in	 energy	 expenditure	 might	 be	 due	 to	 the	 different	 and	 often	
opposing	 effects	 of	 the	 neuro-endocrine,	 immunological	 and	 metabolic	 components	
(Joosten	et	al.,	2016).	As	it	is	extremely	challenging	to	estimate	requirements	during	the	
course	of	 illness,	 IC	has	been	recommended	as	the	gold	standard	to	determine	energy	
requirements	 in	 critically	 ill	 children	 (Mehta	 et	 al.,	 2017).	 During	 the	 oxidation	 of	
carbohydrates,	 proteins	 and	 fat,	 oxygen	 consumption	 and	 carbon	 dioxide	 production	
occur,	which	 is	measured	by	an	 IC	 to	enable	 the	automated	calculation	of	REE	 (Frayn,	
2003).	 The	 principle	 of	 IC	 is	 based	 on	 the	 assumption	 that	 the	 inspired	 oxygen	 is	
completely	utilised	to	oxidise	degradable	fuels,	and	during	this	process	carbon	dioxide	is	
generated	 (Gupta	et	al.,	2017).	Nearly	80%	of	REE	 is	due	 to	oxygen	consumption,	and	
the	remaining	20%	of	energy	expenditure	 is	due	to	carbon	dioxide	production.	Studies	
that	performed	serial	measurements	of	REE	recorded	a	minimal	intrapersonal	variation	
in	REE	of	<10%	during	the	first	week	of	PICU	stays	(De	Klerk	et	al.,	2001;	Framson	et	al.,	
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2007).	 These	 studies	 suggested	 that	 single	 measurement	 over	 the	 course	 of	 PICU	
admission	of	REE	would	provide	an	 insight	 regarding	 the	daily	energy	 requirements	of	
critically	 ill	 children.	 The	 ASPEN	 guidelines	 also	 recommend	 at	 least	 one	 REE	
measurement	 for	 children	 at	 high	 risk	 of	 metabolic	 alteration	 to	 guide	 energy	
administration	(Mehta	et	al.,	2017).	
	
A	number	of	factors	may	restrict	the	regular	use	of	IC	in	PICU	settings,	therefore,	there	is	
still	an	urgent	need	 for	 formulas	 that	closely	estimate	 the	energy	needs	of	critically	 ill	
children	 (Kyle	 et	 al.,	 2012).	 The	 aim	of	 this	 study	was	 to	 assess	 the	 energy	metabolic	
patterns	of	critically	ill	children	and	identify	an	equation	predicting	energy	requirements	
closest	to	measured	resting	energy	expenditure.	The	study	also	aimed	to	explore	factors	
that	might	affect	energy	expenditure,	such	as	disease	severity,	drugs,	body	temperature	
and	diagnosis.	
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4.2 Materials	and	Methods	
	
One	40-minute	measurement	of	REE	was	performed	for	critically	ill	children	admitted	to	
PICU	 between	 days	 1	 and	 6	 using	 Ultima	 CCM™®	 IC.	 The	 standard	 measurement	
protocol	of	IC	has	been	described	in	the	Method	Chapter	(Chapter	Two),	pages	52-53.	
	
Inclusion	criteria:	
• Mechanically	ventilated	children	for	more	than	24	hours.	
• Weight	>10	kg	(as	the	IC	is	not	accurate	in	children	with	a	weight	<	10	kg).	
Exclusion	criteria:	
• Fraction	of	inspired	oxygen	(FiO2)	>60%.	
• Endotracheal	tube	leak	>10%.	
• Chest	drain.	
• Peritoneal	dialysis.	
• Hemodialysis/hemofiltration.	
	
4.2.1 Respiratory	quotients	and	fuel	utilisation	
	
Information	including	respiratory	quotient	(RQ)	and	body	utilisation	of	carbohydrate	and	
fat	was	also	obtained	from	IC.	
RQ	was	automatically	calculated	by	the	IC	based	on	the	following	equation:	
	RQ	=	VCO2	/	VO2	
	
Table	4-1:	Interpretation	of	RQ	and	adequacy	of	intake	
	
RQ	 Feeding	status		
>1	 Overfeeding	with	lipogenesis	
0.85-0.95	 Mixed	substrate	utilisation	(adequate	intake)	
<0.82	 Underfeeding	
	
Values	are	adopted	from	The	Clinical	Dietitian's	Essential	Pocket	Guide	(Width	&	Reinhard,	2009).	
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The	percentage	of	 carbohydrate	and	 fat	utilised	was	obtained	 from	 IC	 automatically	
based	on	the	assumption	of	the	following	equations:	
	
Carbohydrate	grams	per	day	=	4.21*VO2	-	2.91*VCO2	(Ruppel,	1991).	
Percentage	of	carbohydrate	utilised	=	Carbohydrate	(kcal	per	day)	*100/REE	
	
Fat	grams	per	day	=1.69*VO2	-	1.69*VCO2	(Ruppel,	1991).	
Percentage	of	fat	utilised	=	Fat	(kcal	per	day)	*100/REE	
	
4.2.2 Estimation	of	energy	requirements	by	predictive	equations	
The	current	protocol	at	Addenbrooke’s	Hospital	 for	estimating	energy	requirements	 in	
critically	children	adopts	the	recommendations	of	the	Scientific	Advisory	Committee	on	
Nutrition	 (SACN)	 (Jackson,	 2011).	 The	 SACN	 established	 energy	 reference	 values	
predicted	 using	 healthy	 reference	 body	weights,	 corresponding	 to	 the	 50th	 centile	 of	
UK–WHO	growth	standards	for	infants	and	children	(Jackson,	2011).	For	the	purposes	of	
this	 study,	 energy	 requirements	 were	 also	 estimated	 by	 the	 Schofield	 equation	 and	
WHO	equation,	as	suggested	by	ASPEN	guidelines	and	other	studies,	in	the	absence	of	IC	
(Schofield,	 1985;	 Joint	 FAO/WHO/UNU	 Expert	 Consultation	 on	 Energy	 and	 Protein	
Requirements,	1981;	Rome,	1985;	Meyer	et	al.,	2012;	 Jotter	et	al.,	2017;	Mehta	et	al.,	
2017).	
	
4.2.3 Assessment	of	hypo-	and	hyper-metabolic	status	
In	 order	 to	 categorise	 the	 children’s	metabolic	 patterns	 into	 normal,	 hypo-	 or	 hyper-
metabolic	 states,	 measured	 energy	 expenditure	 (MEE)	 was	 compared	 with	 predicted	
norms	 that	 come	 from	 a	 set	 of	 predictive	 equations	 to	 determine	 predicted	 resting	
energy	expenditure	(PREE).	In	this	cohort,	PREE	calculations	were	based	on	the	Schofield	
and	WHO	equations,	 as	 these	are	 currently	 recommended	by	ASPEN	and	ESGPHAN	 in	
the	 absence	 of	 IC.	 The	 patient’s	 metabolic	 and	 energy	 expenditure	 pattern	 was	
determined	using	 the	previously	published	metabolic	 index	 (Briassoulis	et	al.,	2010)	of	
MEE/PREE	 previously	 used	 in	 studies:	 the	 indices	 of	 >1.1,	 0.9–1.1	 and	 <0.9	 were	
classified	 as	 hyper-metabolic,	 normo-metabolic	 and	 hypo-metabolic	 patterns,	
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respectively.	This	is	a	known	method	that	has	been	used	in	many	studies	to	assess	the	
energy	expenditure	patterns	of	critically	 ill	children	(Briassoulis	et	al.,	2010;	Coss-Bu	et	
al.,	2001;	Mehta	et	al.,	2017).	
	
4.2.4 Dietary	intake	
The	 actual	 nutritional	 intake	 over	 24	 hours	 prior	 to	 IC	 measurement	 was	 recorded	
retrospectively	 using	 patient	 clinical	 electronic	 records.	 The	 types	 of	 feed	 (enteral	 or	
parenteral,	 IV	 glucose)	 and	 total	 volume	delivered	were	 recorded	 for	each	patient	 for	
the	 calculations	 of	 energy	 and	macronutrient	 intake.	 Energy	 intake	was	 expressed	 as	
percentages	of	the	measured	requirements.	
	
4.2.5 Body	temperature	
Axillary	temperature	was	taken	hourly	by	the	nursing	team	and	logged	into	the	patient’s	
records.	 The	 value	 obtained	 for	 the	 analysis	 was	 taken	 within	 an	 hour	 of	 IC	
measurement.	
	
4.2.6 Medications	
	
Medications	 received	 within	 24	 hours	 of	 IC	 measurements	 were	 recorded	 and	
categorised	 into	 three	groups:	 sedatives,	 inotropic	agents	and	neuromuscular	blocking	
agents.	
	
Table	4-2:	Medication	categories	
	
Category		 Drugs		
Sedatives		 Midazolam,	Propofol,	Chloral	hydrate,	Fentanyl,	clonidine	
Inotropic	agents	 Adrenaline,	Noradrenaline,	Dopamine,	Milrinone	
Neuromuscular	blocking	agents	 Vecuronium,	Atracurium,	Suxamethonium	
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4.2.7 Sample	size	calculation	
	
As	this	study	was	observational	in	describing	the	energy	metabolic	pattern,	and	aimed	at	
just	 documenting	 differences	 between	 predictive	 equations	 and	 MEE,	 no	 power	
calculation	 was	 used.	 All	 children	 enrolled	 in	 the	 GHICI	 study	 and	 met	 the	 inclusion	
criteria	of	the	current	study	were	included.	
	
4.2.8 Statistical	analysis	
	
The	 statistical	 analysis	was	 conducted	using	 IBM	SPSS	v25	USA.	The	Shapiro-Wilk	Test	
was	 used	 to	 assess	 the	 normality	 of	 the	 data	 distribution.	Quantitative	 variables	with	
non-normal	distribution	were	expressed	as	a	median	with	interquartile	ranges	(IQR).	The	
Wilcoxon	signed	rank	test	was	used	to	compare	REE	measured	by	IC	and	estimated	by	
prediction	equations.	Bland-Altman	plots	were	used	to	evaluate	the	agreement	between	
measured	and	estimated	REE,	and	allow	for	the	identification	of	difference	between	the	
measurements.	These	plots	were	also	used	to	quantify	bias	and	the	range	of	agreement,	
within	95%	confidence	limits.	The	Mann-Witney	U	test	was	applied	to	assess	differences	
in	 fuel	 utilisation	 between	 groups.	 A	 chi-squared	 test	 was	 performed	 to	 assess	 the	
relationship	between	the	hyper-metabolic	response	and	the	diagnostic	categories.	
	
The	 Spearman	 correlation	 coefficient	 was	 used	 to	 establish	 the	 correlation	 between	
variables,	 which	was	 followed	 by	 stepwise	 linear	 regression	 analysis	 to	 assess	 factors	
that	 impact	 REE.	 A	 p-value	 of	 ≤	 0.05	 was	 considered	 statistically	 significant,	 and	 log	
transformation	 was	 applied	 on	 variables	 with	 skewed	 distribution	 prior	 to	 regression	
analysis.	
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4.3 Results	
	
IC	 measurements	 were	 performed	 on	 46	 critically	 ill	 children;	 four	 children	 were	
excluded	 due	 to	 the	 interruption	 of	 measurements	 by	 routine	medical	 care	 affecting	
VCO2/VO2,	 rendering	 measurements	 inaccurate.	 All	 measurements	 were	 performed	
between	days	1–6	post	admission,	with	a	median	(IQR)	3	(2–4)	days.	Forty-two	children	
[21	(50%)	males]	with	a	median	(IQR)	age	of	4	(2–10)	years	were	included	in	this	study.	
The	anthropometric	and	clinical	characteristics	of	 the	children	are	shown	 in	Table	4-3.	
Amongst	the	cohort,	hospital	mortality	was	5%	(n=2).	
Table	4-3:	Anthropometric	and	clinical	characteristics	of	children	enrolled	in	the	study	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Data	are	presented	as	median	(IQR).	
VFH	at	30	days:	ventilation	free	hours	at	30	days	
PICU	free	days	at	30	days:	days	free	of	paediatric	intensive	care	at	30	days	
Anthropometrics	N	(42)	 Median		
Age	(years)	 4									(				2			–			10							)	
Weight		(kg)	 17.8				(	13.8		–			25.8		)	
Height			(cm)	 101					(					87		–	117					)	
Weight	age	Z-	score	 0.43				(		-0.34		–		1.2			)	
Height	age	Z-	score	 -0.14			(		-1.2		–		1.12		)	
Disease	severity	variables	 Median		
PMODS	 6									(				5				–				7							)	
PIM2	score	 3.0					(			0.87			–			6.0		)	
Highest	lactate	(on	the	day	of	REE	measurement)		 1.1					(				0.7		–		1.7					)	
VFH	of	mechanical	ventilation	at	30	days	 628				(		544		–			649				)	
PICU	free	days	at	30	days	 22						(						19			–		24				)	
Primary	admission	diagnosis		 N	(%)	
MOF	 9			(22%)	
Respiratory	Failure	 16	(38%)	
CNS	Disorders	 14	(33%)	
Surgical	Disorders	 3			(	7%	)	
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values	are	presented	as	median	(IQR)	
P	>0.05	
P	>0.05	
P	<0.001**	
4.3.1 Comparison	between	measured	energy	expenditure	(MEE)	by	IC	and	the	
estimated	energy	requirements	with	predictive	equations	
	
The	 first	 step	 of	 the	 analysis	was	 to	 compare	MEE	 to	 estimated	 energy	 requirements	
with	 different	 predictive	 equations.	 The	 median	 (IQR)	 of	 MEE	 was	 922	 (679-1348)	
kcal/day	 [49	 (33-60)	 kcal/kg].	 No	 statistical	 difference	 between	 energy	 expenditure	
measured	by	IC	and	estimated	by	the	Schofield	equations	[median	(IQR)	899	(753-1001)	
kcal/day,	 46	 (38-52)	 kcal/kg],	 p	=	0.181	 and	 WHO	 equation	 [median	 (IQR)	 937	 (795-
1068)	 kcal/day,	 50	 (41-56)	 kcal/kg],	 p	=	0.431	 was	 recorded.	 Energy	 requirements	
estimated	by	SACN	 recommendation	were	 statistically	higher	 than	MEE	 [median	 (IQR)	
1378	(1092-1768)	kcal/day,	49	(33-60)	kcal/kg]	(p=0.431,	p=0.00)	(Figure	4.1).	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	4.1	Comparison	between	measured	energy	expenditure	and	estimated	energy	
with	different	predictive	equations	
Figure	4.1	 shows	 that	estimated	energy	 requirements,	according	 to	SACN	recommendations	 for	healthy	
children,	 were	 statistically	 higher	 than	 the	 measured	 requirements.	 On	 the	 other	 hand,	 there	 was	 no	
statistical	difference	between	measured	and	estimated	energy	with	the	Schofield	and	WHO	equations.	
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+1.96&SD&
)1.96&SD&
Mean&
The	Bland-Altman	method	was	also	used	to	assess	the	limits	of	agreement	between	MEE	
and	 estimated	 energy	 needs	 by	 Schofield	 equation,	 WHO	 equation	 and	 SACN	
recommendations	(Figures	4.2–4.4).	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	4.2	Bland-Altman	plot	comparing	means	of	energy	requirements	measured	by	
IC	and	estimated	by	Schofield	equation	
Figure	 4.2	 shows	 that	 the	 mean	 difference	 between	 the	 REE	 measured	 by	 IC	 and	 estimated	 by	 the	
Schofield	equation	was	77	kcal/day,	and	 the	SD	of	 the	differences	was	318	kcal/day.	The	 lower	 limit	of	
agreement	 for	REE	was	 -547	kcal/day	and	 the	upper	 limit	702	kcal/day,	with	a	wide	scatter	around	 the	
mean	and	three	outliers	outside	upper	and	lower	95%	CI.	
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Figure	4.3	Bland-Altman	plot	comparing	means	of	energy	requirements	measured	by	
IC	and	estimated	by	the	WHO	equation	
Figure	4.3	indicates	that	the	mean	difference	between	the	REE	measured	by	IC	and	estimated	by	the	WHO	
equation	was	40	kcal/day,	and	the	SD	of	the	differences	was	326	kcal/day.	The	lower	limit	of	agreement	
for	REE	was	-599	kcal/day	and	the	upper	limit	681	kcal/day,	with	a	wide	scatter	around	the	mean	and	two	
outliers	outside	upper	and	lower	95%	CI.	
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Figure	4.4	Bland-Altman	plot	comparing	means	of	energy	requirements	measured	by	
IC	and	estimated	by	SACN	recommendation		
Figure	4.4	shows	a	mean	difference	of	-488	kcal/day	(SD	467	kcal/day)	between	the	REE	measured	by	IC	
and	estimated	according	 to	SACN	 for	healthy	children.	The	 lower	 limit	of	agreement	 for	REE	was	 -1405	
kcal/day	and	the	upper	limit	427	kcal/day.	The	figure	also	shows	cluster	scores	where	the	mean	is	low	and	
the	difference	is	high.	
	
4.3.2 Energy	metabolic	pattern	in	critically	ill	children	
By	using	the	Schofield	equation	to	predict	the	normal	metabolic	response,	data	showed	
that	19	 children	exhibited	a	hyper-metabolic	pattern,	 13	were	hypo-metabolic	 and	10	
showed	normal	metabolic	response.	The	WHO	equation	predicted	slightly	higher	energy	
requirements,	and	therefore	only	16	showed	a	hyper-metabolic	pattern,	13	were	hypo-
metabolic	 and	 13	 showed	 normal	 metabolic	 response	 (Figure	 4.5).	 The	 age	 and	 the	
weight	 of	 children	 did	 not	 vary	 statistically	 between	 the	 groups	 (p	 value	 ≥	 0.05).	
However,	 a	 slight	 variation	 in	 gender	 distribution	 was	 recorded	 (Table	 4-4).	 The	 sex	
therefore	 was	 included	 in	 the	 regression	 model	 as	 it	 was	 thought	 be	 a	 confounding	
factor	affecting	the	metabolic	pattern.	
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N=13	
N=13	
N=16	
values	are	presented	as	median	(IQR)	
a)	
b)	
N=19	
N=13	
N=10	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	4.5	Metabolic	pattern	in	critically	ill	children	
Figure	4.5	shows	the	distribution	of	children	based	on	their	metabolic	response.	In	Figure	(a)	the	Schofield	
equation	was	used	to	predict	the	normal	energy	requirements,	and	the	WHO	equation	was	used	in	Figure	
(b).	The	median	MEE	for	children	who	exhibited	hyper-metabolic	and	normal	metabolic	pattern	was	lower	
in	(a)	compared	to	(b).	
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	Table	4-4:	anthropometric	characteristics	of	patients	based	on	their	metabolic	pattern		
	
4.3.3 Factors	affecting	MEE	in	critically	ill	children	
Stepwise	 linear	 regression	 analysis	 was	 performed	 using	 the	 metabolic	 index	 as	 the	
primary	 outcome	 variable,	 to	 determine	 clinical	 factors	 contributing	 independently	 to	
variation	in	the	metabolic	index	of	critically	ill	children.	The	Schofield	equation	was	used	
to	 predict	 REE	 to	 determine	 the	 clinical	 factors	 affecting	 the	metabolic	 index.	 Results	
indicated	 that	 the	 severity	 of	 organ	 failure	 assessed	 by	 PMOD	 score	 and	 body	
temperature	 statistically	 impacted	 the	 metabolic	 index	 in	 critically	 ill	 children.	 This	
regression	model	accounted	for	21%	of	the	variation	in	REE	(Table	4-5).	
	
Table	4-5:	Regression	model	to	determine	the	factors	affecting	the	metabolic	index	
Model	 R	 R	2	 Adjusted	R	2	 R	 P-value	
Metabolic	index	a	 0.461	 0.213	 0.175	 	
PMOD	score	b		 	 -0.362	 0.007*	
Body	temperature	b	 0.330	 0.013*	
Age	c	 -0.091	 0.277	
Sex	c	 -0.233	 0.11	
Weight	for	age	Z-score	c	 -0.009	 0.476	
Heart	rate	c	 0.136	 0.187	
PIM2	score	c	 -0.110	 0.497	
Highest	 lactate	 on	 the	 day	 of	
measurement	c	
-0.119	 0.218	
	
a. Dependent	variable	
b. Predictors:	(constant)	
c. Excluded	variables	
Metabolic	pattern	estimated	by	Schofield	equation	
	 Hyper-metabolic	 Normo-metabolic	 Hypo-metabolic	
Age	(Years)	 3.9	 5	 4	
Weight	(kg)	 17.4	 20	 18	
Ratio	of	Males	to	females		 9:10	 8:2	 2:11	
Metabolic	pattern	estimated	by	WHO	equation	
	 Hyper-metabolic	 Normo-metabolic	 Hypo-metabolic	
Age		(Years)	 3.9	 4.5	 4.9	
Weight	(kg)	 16.9	 17.8	 21	
Ratio	of	Males	to	females		 11:5	 8:5	 2:11	
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Twenty-six	 children	with	 infections	were	admitted,	 and	16	presented	with	no	 signs	of	
infections.	 A	 chi-squared	 test	was	 performed	 and	 no	 relationship	was	 found	between	
the	hyper-metabolic	 response	and	 the	presence	of	 infection	on	admission,	 0.278	 (N	=	
42),	 p	 =	 0.598.	 The	 chi-squared	 test	 was	 also	 performed	 to	 assess	 the	 relationship	
between	 the	 hyper-metabolic	 response	 observed	 in	 some	 children	 and	 the	 diagnostic	
categories.	No	 statistical	 association	was	 recorded	between	 the	hyper-metabolic	 state	
and	MOF	diagnosis	[1.6	(N	=	42),	p	=	0.19],	respiratory	diagnosis	[2.9	(N	=	42),	p	=	0.09]	
or	CNS	disorder	diagnosis	[0.76	(N	=	42),	p	=	0.300].	
	
The	effect	of	 inotropic	drugs	and	muscle	 relaxant	on	REE	status	was	also	evaluated.	A	
chi-squared	 test	 indicated	 no	 statistical	 relationship	 between	 the	 hyper-metabolic	
response	 and	 treatment	 with	 inotropic	 drugs,	 0.642	 (N	 =	 42),	 p	 =	 0.423.	 However,	 a	
statistical	relationship	was	recorded	between	the	provision	of	muscle	relaxant	drugs	and	
the	 hyper-metabolic	 response	 4.12	 (N	 =	 42),	 p	 =	 0.042.	 The	Mann-Whitney	 test	 was	
performed	 to	 compare	 the	 metabolic	 index	 between	 children	 who	 received	 muscle	
relaxant	within	24	hours	of	IC	measurement	and	those	who	did	not.	The	results	showed	
that	 children	 who	 received	 muscle	 relaxant	 medication	 had	 a	 statistically	 higher	
metabolic	index	(p=0.008).	To	further	investigate	the	effect	of	drugs	on	REE,	regression	
analysis	 was	 performed.	 The	 regression	 model	 indicated	 that	 muscle	 relaxant	 agents	
were	 the	 only	 therapeutic	 agents	 that	 statistically	 impacted	 REE.	 Those	who	 received	
muscle	relaxants	had	a	higher	metabolic	index	(Table	4-6).	
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Table	4-6:	Regression	model	to	determine	the	factors	affecting	metabolic	index	
	
a. Dependent	variable	
b. Predictors:	(constant)	
c. Excluded	variables	
	
4.3.4 Fuel	utilisation	in	critically	ill	children	
	
Correlation	analysis	was	performed	to	establish	the	relationship	between	energy	intake	
and	 substrate	 utilisation.	 The	 results	 indicated	 that	 energy	 intake	 was	 positively	
correlated	with	RQ	(r=0.550,	p=0.00),	the	percentage	of	carbohydrate	utilised	(r=0.583,	
p=0.00),	 and	 negatively	 correlated	 with	 the	 percentage	 fat	 utilised	 (r=-0.583,	 p=0.00)	
(Figure	 4.6).	 In	 addition,	 children	 who	 received	 less	 than	 50%	 of	 their	 energy	
requirements	utilised	more	fat	and	less	carbohydrate	compared	to	those	who	received	
more	 than	 50%	of	 their	 energy	 needs	 (p<0.001)	 (Figure	 4.7).	 The	 results	 also	 showed	
that	 hyper-metabolic	 children	 utilised	 more	 fat	 (64%)	 compared	 to	 children	 showing	
normal	 (45%)	 and	 hypo-metabolic	 patterns	 (52%).	 However	 the	 variation	 in	 fat	
utilisation	 between	 the	 two	 groups	 was	 not	 statistically	 significant	 (p>0.05).	 On	 the	
other	 hand,	 the	 percentage	 of	 carbohydrate	 utilisation	 was	 lower	 in	 hyper-metabolic	
children	(36%),	but	there	was	no	evidence	of	statistical	difference	between	the	groups	
(p>0.05)	(Figure	4.8).	
	
	
Model	 R	 R	2	 Adjusted	R	2	 R	 P-value	
Metabolic	index	a	 0.556	 0.309	 0.277	 	
PMOD	score	b		 	 -0.348	 0.009*	
Muscle	relaxants	b	 0.446	 0.001*	
Age	c	 -0.058	 0.350	
Morphine	c	 -0.022	 0.441	
Midazolam	c	 0.0.40	 0.396	
Inotropic	drugs	c	 0.032	 0.416	
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r=#0.550*#
r=#0.583*#
r=#*0.571*#
a)#
b)# c)#
r=#*0.583*#
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	4.6	Relationship	between	energy	intake	and	substrate	utilisation		
Figure	 4.6	 shows	 a	 positive	 correlation	 between	 energy	 intake	 with	 RQ	 (a)	 and	 the	 percentage	 of	
carbohydrate	utilised	(b),	while	a	negative	correlation	is	observed	with	the	percentage	of	fat	utilised	(c).	
Indicating	that	carbohydrate	is	the	primarily	fuel	utilised	with	sufficient	energy	intake	while	fat	oxidation	
is	 usually	 stimulated	 in	 response	 to	 under-delivery	 of	 energy.	 	 The	 percentage	of	 carbohydrate	 and	 fat	
utilisation	can	be	used	as	a	proxy	to	indicate	the	adequacy	of	the	energy	provided.	
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Figure	4.7	Comparison	between	the	percentage	of	fat	and	carbohydrate	utilisation	
based	on	the	amount	of	energy	received		
Figure	4.7	indicates	that	children	who	received	less	than	50%	of	their	energy	requirements	utilised	more	
fat	and	less	carbohydrate	compared	to	those	who	received	more	than	50%	of	their	energy	needs.	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	4.8	Comparison	between	the	percentage	of	fat	and	carbohydrate	utilisation	
based	on	the	metabolic	patter		
Figure	 4.8	 shows	 that	 hyper-metabolic	 children	 utilised	 more	 fat	 (64%)	 and	 less	 carbohydrate	 (36%),	
compared	 to	 children	 who	 exhibited	 normal	 and	 hypo-metabolic	 patterns;	 however,	 there	 was	 no	
evidence	of	statistical	difference	between	the	groups	(p>0.05).	
values	are	presented	as	median	with	95%	CI	
N=26	
N=16	
P<0.001*	
P<0.001*	
values	are	presented	as	median	with	95%	CI	
P>0.05	
P>0.05	
N=20	 N=10	 N=12	
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4.3.5 The	relationship	between	the	metabolic	index	and	clinical	outcomes	in	critically	
ill	children	
	
The	metabolic	index	and	its	association	with	clinical	outcomes	in	critically	ill	children	was	
also	 assessed.	 The	 data	 of	 42	 patients	 were	 included	 in	 this	 analysis.	 Two	 stepwise	
regression	models	were	performed;	in	these	regression	models,	PICU	free	days	and	VFH	
were	 the	 primary	 outcome	 variables.	 There	was	 no	 evidence	 of	 statistical	 association	
between	the	metabolic	index	and	clinical	outcomes	in	this	cohort.	The	severity	of	organ	
dysfunction	assessed	by	PMOD	score	was	the	only	variable	statistically	related	to	clinical	
outcomes	in	critically	ill	children	(Table	4-7).	
	
Table	4-7:	Regression	model	to	determine	the	factors	affecting	clinical	outcomes	in	
critically	ill	children	
Model	 R		 R	2		 Adjusted	R	2		 R	 P-value	
VFH	 0.560	 0.314	 0.295	 	
PMOD	score	b	 	 -0.560	 0.00*	
PIM2	score	c		 0.210	 0.213	
Age	c	 0.122	 0.473	
Weight	for	age	Z-score	c	 -0.059	 0.731	
Metabolic	index	c	 -0.191	 0.256	
PICU	free	days	 0.662	 0.439	 0.424	 	
PMOD	score	b	 	 0.662	 0.00*	
PIM2	score	c		 0.180	 0.273	
Age	c	 0.057	 0.732	
Weight	for	age	Z-score	c	 0.244	 0.134	
Metabolic	index	c	 -0.004	 0.864	
	
a. Dependent	variable	
b. Predictors:	(constant)	
c. Excluded	variables	
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4.4 Discussion	
In	this	study	it	was	found	that	the	median	(IQR)	of	MEE	was	922	(679-1348)	kcal/day	[49	
(33-60)	kcal/kg].	It	was	also	shown	that	the	Schofield	equation	and	WHO	equation	were	
associated	 with	 the	 smallest	 level	 of	 bias	 when	 compared	 to	 MEE,	 confirming	 the	
recommendation	 to	 use	 these	 formulas,	 in	 the	 absence	 of	 IC.	 The	 hyper-metabolic	
pattern	 was	 recorded	 in	 the	 majority	 of	 children,	 which	 is	 thought	 to	 be	 related	 to	
patient	 factors	 such	 as	 the	 severity	 of	 disease,	 body	 temperature	 and	 medications	
received.	
	
The	mean	difference	between	MEE	and	energy	expenditure	predicted	by	the	Schofield	
and	 WHO	 equations	 was	 84	 kcal	 and	 52	 kcal,	 respectively.	 These	 results	 are	 in	
agreement	with	other	authors’	findings,	where	they	evaluated	the	reproducibility	of	the	
Schofield	equation	in	estimating	energy	requirements	for	critically	ill	children,	and	found	
it	to	be	associated	with	the	smallest	level	of	bias	compared	to	other	available	equations	
(Meyer	 et	 al.,	 2012;	 Jotter	 and	 Chaparro	 et	 al.,	 2017).	 On	 the	 other	 hand,	 energy	
requirements	 estimated	 by	 SACN	 recommendations,	 according	 to	 hospital	 protocol,	
tend	 to	 over-estimate	 energy	 needs.	 This	 is	 because	 SACN	 recommendations	 are	
intended	 to	meet	 the	 needs	 of	 healthy	 children,	 and	 not	 critically	 ill	 children,	 as	 the	
recommendations	take	into	account	the	activity	factor.	The	motivation	for	using	SACN	to	
estimate	energy	requirements	in	Addenbook’s	Hospital	PICU	is	to	avoid	underfeeding,	as	
malnutrition	 is	 documented	 in	 20–30%	of	 critically	 ill	 children	 in	 developing	 countries	
(Skillman	 &	 Mehta,	 2012).	 EN	 is	 frequently	 interrupted	 in	 PICU,	 resulting	 in	 under-
delivery	of	energy;	 furthermore,	young	children	are	usually	 sensitive	 to	 fluid	overload,	
and	the	amount	of	fluid	permitted	to	feed	is	usually	limited	(Rogers	et	al.,	2003;	Kim	et	
al.,	2012).	Due	 to	 the	aforementioned	 factors,	 less	 than	65%	of	 the	prescribed	energy	
goal	(using	various	prediction	equations)	is	usually	delivered	to	patients	(Bockenkamp	et	
al.,	2009).	Therefore,	although	the	energy	goal	estimated	by	SACN	recommendations	is	
higher	 than	 the	 measured	 requirements,	 the	 actual	 intake	 still	 may	 not	 exceed	 the	
measured	 energy	 requirements	 by	 IC	 or	 estimated	 by	 the	 Schofield	 equation.	 This	
speculation	will	be	explored	in	more	detail	in	Chapter	Five.	
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In	the	current	study	a	significant	proportion	of	the	children	showed	a	hyper-metabolic	
response.	 Emerging	 evidence	 in	 the	 field	 of	 paediatric	 critical	 care	 nutrition	 suggests	
that	 during	 the	 acute	 phase	 critically	 ill	 children	 reduce	 their	 energy	 expenditure	
(Briassoulis	 et	 al.,	 2000;	 Taylor	 et	 al.,	 2003;	 Framson	 et	 al.,	 2007).	 Reduced	 REE	 in	
critically	 ill	 children	 could	 be	 due	 to	 lack	 of	 physical	 movement,	 decreased	 work	 of	
breathing,	and	maintaining	a	 thermo-neutral	environment	 in	PICU	settings	 (Briassoulis	
et	 al.,	 2000).	 Importantly,	 critically	 ill	 children	may	 have	 reduced	 energy	 expenditure	
during	 the	 critical	 phase	 of	 illness,	 because	 IGF-1	 and	 T3	 remain	 low,	 implying	 that	
growth	does	not	occur,	thereby	“sparing”	this	energy	(Briassoulis	et	al.,	2000;	Vernon	&	
Witte,	2000).	Although	the	expected	metabolic	response	in	children	involves	a	reduction	
of	REE,	a	hyper-metabolic	pattern	was	also	reported	in	other	studies,	which	is	thought	
to	 be	 due	 to	 the	 heterogeneity	 of	 the	 cohort	 in	 terms	 of	 disease	 type/severity,	
interventions,	comorbid	conditions	and	nutritional	status	(Coss-Bu	et	al.,	2001b;	Mehta	
et	al.,	2017).	
	
In	 this	 study	 the	 severity	 of	 organ	 failure	 assessed	 by	 PMOD	 score	 and	 body	
temperature	 both	 had	 a	 statistically	 significant	 impact	 on	 REE.	 An	 increase	 in	 PMOD	
score	was	 associated	with	 a	 reduction	 in	 the	metabolic	 index.	 These	 findings	 indicate	
that	children	with	multiple	organ	 failure	have	reduced	REE.	Similar	 findings	have	been	
documented	 by	 other	 authors	 using	 other	 markers	 of	 disease	 severity;	 Mehta	 et	 al.	
(2012)	 recorded	 higher	 intraoperative	 peak	 serum	 lactate	 in	 hypo-metabolic	 children	
undergoing	Fontan	surgery.	Lactate	levels	were	used	to	indicate	the	degree	of	severity	
of	 postoperative	 illness,	 and	 it	was	 correlated	with	morbidity	 after	 cardiac	 surgery.	 In	
addition,	Forsberg	et	al.	(1991)	indicated	that	hypo-metabolic	patterns	become	evident	
in	 adult	 patients	with	 fatal	 outcomes	 during	 intensive	 care	 stays;	 their	 findings	might	
explain	why	sicker	children	had	lower	REE.	However,	these	findings	are	contradictory	to	
previous	work	 (Briassoulis	et	al.,	2000;	Taylor	et	al.,	2003),	where	disease	 severity	did	
not	 statistically	 influence	 REE.	 The	 discrepancies	 could	 be	 explained	 by	 the	 fact	 that	
those	studies	used	paediatric	risk	of	mortality	(PRISM)	score,	which	is	mortality	risk	as	a	
marker	 of	 severity.	 The	 association	 between	 REE	 and	 body	 temperature	 has	 been	
established	 by	many	 previous	 studies.	 DuBois	 found	 that	 for	 each	 degree	 Celsius	 (ºC)	
		
Chapter	Four	
	
	 	
92	
rise	 in	 temperature,	 metabolism	 increases	 by	 13%	 (DuBois,	 1921).	 The	 recent	 ASPEN	
guidelines	 referred	 to	 body	 temperature	 as	 a	 potential	 factor	 in	 increasing	 energy	
expenditure,	 since	 increase	 in	 body	 temperature	may	 potentially	 lead	 to	 elevation	 in	
VO2	 and	 VCo2,	 and	 accordingly	 result	 in	 increased	 REE	 (Mehta	 et	 al.,	 2017).	
Furthermore,	an	increase	in	energy	expenditure	has	been	recorded	with	an	increase	in	
body	temperature	beyond	38°C	(Havalad	et	al.,	2006;	Meyer	and	Elwig,	2007).	Fever	in	
children	with	burn	injuries	was	also	associated	with	a	degree	of	hyper-metabolism	(Gore	
et	al.,	2003).	 In	a	 study	of	 critically	 ill	 adults,	 Frankenfield	et	al.	 (1997)	 suggested	 that	
fever,	 rather	 than	 severity	 of	 disease	or	 diagnosis,	was	 associated	with	 an	 increase	 in	
energy	expenditure.	Faisy	et	al.	 (2003)	affirmed	that	body	temperature	 impacts	REE	 in	
mechanically	 ventilated	 adults.	 In	 critically	 ill	 adults,	 targeted	 body	 temperature	
management	 at	 33°C	 after	 cardiac	 arrest	 reduced	 REE	 by	 20%	 compared	 to	 36°C	
(Holzinger	 et	 al.,	 2015).	With	 increasing	 evidence	 to	 support	 the	 implications	 of	 body	
temperature	 in	 changes	 in	 REE,	 a	 predictive	 equation	 utilised	 by	White	 et	 al.	 (2000),	
developed	for	estimating	REE	 in	critically	 ill	children,	 included	body	temperature	as	an	
independent	 variable.	 However,	 it	 is	 important	 to	 point	 out	 that	White’s	 formula	 has	
been	shown	to	be	inaccurate	and	impractical,	as	the	calculations	of	energy	requirements	
need	 to	 constantly	 change	 according	 to	 changes	 in	 body	 temperature.	 Mehta	 et	 al.	
(2011)	 failed	 to	detect	 a	 statistical	 association	between	REE	 and	body	 temperature	 in	
critically	ill	children;	additionally,	in	a	study	by	Briassoulis	et	al.	(2014),	REE	did	not	differ	
among	 children	 based	 on	 their	 body	 temperature.	 This	 could	 be	 due	 to	 the	
implementation	of	a	thermo-neutral	environment	in	PICU	to	maintain	body	temperature	
within	normal	ranges	–	accordingly,	it	is	difficult	to	detect	a	statistical	association	within	
the	minimum	rise	in	body	temperature.	
	
This	 study	 also	 evaluated	 the	 effect	 of	 inotropic	 drugs	 and	 muscle	 relaxant	 on	 REE.	
Surprisingly,	 children	 who	 received	muscle	 relaxant	medication	 within	 24	 hours	 of	 IC	
measurement	 had	 a	 statistically	 higher	 metabolic	 index.	 The	 regression	 analysis	 also	
showed	that	the	use	of	muscle	relaxant	agents	was	statistically	related	to	the	variation	
recorded	in	REE.	These	findings	are	contradictory	to	previously	published	studies,	where	
reduction	 in	REE	was	recorded	following	the	administration	of	neuromuscular	blocking	
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agents	(McCall	et	al.,	2003;	Vernon	&	Witte,	2000).	However,	these	studies	investigated	
the	immediate	action	of	those	drugs.	In	studies	of	oxygen	consumption	in	mechanically	
ventilated	 adults,	 an	 immediate	 reduction	 in	 oxygen	 consumption	was	 recorded	 after	
administration	 of	 neuromuscular	 blocking	 agents,	 whereas	 improvements	 in	
oxygenation	were	observed	24	hours	following	the	administration	of	the	drugs	(Price	et	
al.,	 2012;	 Gainnier	 et	 al.,	 2004;	 Forel	 et	 al.,	 2006).	 These	 researchers’	 findings	 could	
justify	 or	 provide	 a	 suitable	 clinical	 explanation	of	 the	 results	 from	 the	 current	 study.	
The	 findings	of	 the	current	study	may	also	be	explained	by	 the	 fact	 that	usually	 those	
who	are	sicker	(with	higher	PMOD	score)	are	more	likely	to	have	higher	doses	of	muscle	
relaxants.	
	
Studies	have	shown	that	critically	 ill	children	utilise	fat	preferentially	as	a	substrate	for	
their	 energy	metabolism,	 thus	 acute	metabolic	 response	 is	 characterised	by	 increased	
lipolysis	 and	 fatty	 acid	 oxidation	 relative	 to	 glucose	 oxidation	 (Coss-Bu	 et	 al.,	 2001;	
Caresta	et	al.,	2007).	 In	the	current	study,	energy	intake	was	positively	correlated	with	
RQ	 (r=0.550,	 p=0.00).	 RQ	 is	 known	 to	 be	 affected	 by	 body	 substrate	 utilisation,	 and	
therefore,	 it	 has	 been	 used	 before	 to	 identify	 the	 adequacy	 of	 nutritional	 intake	 in	
critically	 ill	 children	 (Liusuwan	 Manotok	 et	 al.,	 2008;	 Hulst	 et	 al.,	 2005).	 Hulst	 et	 al.	
(2005)	 similarly	 recorded	 a	 strong	 correlation	 between	 energy	 intake	 and	 RQ.	
Underfeeding	appears	to	stimulate	the	use	of	fat,	and	subsequently	causes	a	decrease	in	
the	RQ,	whereas	 overfeeding	 causes	 an	 increase	 in	 the	RQ	 (Liusuwan	Manotok	 et	 al.,	
2008).		
	
In	 the	 current	 study	 the	 amount	 of	 energy	 intake	 was	 positively	 correlated	 with	 the	
percentage	 of	 carbohydrate	 utilised	 (r=0.583,	 p=0.00),	 and	 negatively	 correlated	 with	
the	percentage	of	fat	utilised	(r=-0.571,	p=0.00).	This	is	because	fat	oxidation	is	usually	
stimulated	 in	 response	 to	 under-delivery	 of	 energy,	 while	 with	 adequate	 delivery	 of	
energy	carbohydrate	is	primarily	utilised	(Liusuwan	Manotok	et	al.,	2008;	Frayn,	2003).	
Studies	 have	 shown	 that	 critically	 ill	 children	 utilise	 fat	 preferentially,	 which	 may	 be	
related	to	their	feeding	status	(Coss-Bu	et	al.,	2001;	Caresta	et	al.,	2007).	The	results	of	
the	 current	 study	 also	 showed	 that	 hyper-metabolic	 children	 utilised	 more	 fat	 (64%)	
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compared	 to	 children	 exhibiting	 normal	 (45%)	 and	 hypo-metabolic	 patterns	 (52%),	
although	 the	 difference	 was	 not	 statistically	 significant	 (p>0.05).	 These	 findings	 are	
similar	to	previously	published	data,	where	Coss-Bu	et	al.	(2001)	reported	an	increased	
rate	of	 fat	oxidation	 in	hyper-metabolic	critically	 ill	children.	The	exact	mechanism	has	
not	 been	 fully	 explored	 in	 the	 critically	 ill	 population.	 Increasing	 the	 rate	 of	 lipid	
oxidation	could	be	an	adoptive	mechanism	to	provide	energy	substrate	and	compensate	
for	increased	requirements	in	hyper-metabolic	children.	
	
In	 this	 study,	 no	 evidence	 of	 statistical	 association	 was	 recorded	 between	 MEE	 and	
duration	of	ventilation	and	length	of	PICU	stay.	The	association	between	the	pattern	of	
MEE	and	clinical	outcomes	has	not	been	previously	investigated	in	children.	The	findings	
from	 adult	 studies	 are	 inconsistent;	 Forsberg	 et	 al.	 (1991)	 suggested	 that	 hyper-
metabolic	patterns	in	adult	patients	were	reduced	with	fatal	outcomes	during	intensive	
care	stays,	while	Rigaud	et	al.	(2000)	reported	an	increase	in	REE	in	dying	patients.	
4.5 Limitations	
	
The	study	was	 limited	by	the	 inability	to	measure	REE	 in	 infants,	as	the	 IC	used	 in	this	
study	did	not	accurately	measure	REE	in	children	under	10	kg.	
	
The	majority	of	 the	previously	published	studies	used	Deltatrac	 II®	 in	REE	assessment.	
Some	 other	 calorimeters	 such	 as	MGA	 1100®,	 Vmax	 Encore®	 and	 E-COVX®	were	 also	
introduced	(Coss-Bu	et	al.,	1998;	2001;	Mehta	et	al.,	2011;	2012;	Briassoulis	et	al.,	2014;	
Spanaki	et	al.,	2018).	The	IC	machine	used	in	this	study	was	different	to	the	Deltatrac	II®,	
as	 it	 utilises	 a	 breath-by-breath	 method,	 whereas	 the	 latter	 uses	 a	 mixed-method	
sampling	technique.	 In	addition,	this	metabolic	cart	has	not	been	validated	against	the	
Deltatrac	 II®.	 This	 may	 account	 for	 some	 of	 the	 discrepancies	 in	 the	 findings	 with	
previously	published	studies.		
	
As	 the	 Deltatrac	 is	 no	 longer	 available	 on	 the	 market,	 new	 IC	 machines	 should	 be	
validated	 in	 order	 to	 be	 used	 in	 clinical	 settings.	 A	 recent	 study	 by	 Graf	 et	 al.	 (2015)	
compared	the	efficacy	of	the	CCM	express®	and	Quark	RMR®	to	the	Deltatrac	II®.	Their	
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findings	 suggested	 that	 both	 machines	 suffered	 from	 inaccuracy	 in	 estimating	 REE	
compared	 to	 the	 Deltatrac	 II®.	 In	 another	 study,	 Cooper	 et	 al.	 (2009)	 assessed	 the	
validity	 of	 five	 gas	 analysis	 systems	 against	 the	 Deltatrac	 II®.	 The	 five	 validated	 IC	
systems	were	MedGraphics	CPX	Ultima®,	MedGem®,	Vmax	Encore	29	System®,	TrueOne	
2400®	and	Korr	ReeVue®.	The	results	were	not	satisfactory,	as	none	of	the	instruments	
were	within	person	reliability	of	the	Deltatrac	II®.	The	TrueOne	and	Vmax	were	the	most	
valid	instruments	for	REE	assessment	in	comparison	with	the	Deltatrac	II®.	
	
Future	studies	concerning	measuring	REE	in	intensive	care	settings	should	focus	on	the	
validation	 of	 the	 currently	 available	 IC	 machines	 against	 doubly	 labelled	 water	 or	
Douglas	 bags	 techniques,	 to	 further	 improve	 IC	machines	 before	 recommending	 their	
clinical	 use	 in	 intensive	 care	 settings	 (Cooper	 et	 al.,	 2009).	 Measuring	 energy	
expenditure	 in	healthy	children	and	compare	 it	against	 the	RDA	 for	energy	could	be	a	
convenient	 validation	 tool	 for	 the	 available	machine	 in	 the	market.	However,	 due	 the	
technical	difficulties	performing	energy	expenditure	measurement	and	achieving	steady	
state	in	healthy	children,	no	control	healthy	children	group	were	included	in	the	current	
study.	
4.6 Conclusion	
	
Energy	requirements	have	always	been	a	matter	of	debate	in	PICU	settings,	often	due	to	
the	unpredictability	of	the	metabolic	response	among	this	population.	The	variability	of	
metabolic	 state	 in	 critically	 ill	 children	 has	 been	 previously	 documented,	 and	 factors	
such	 as	 fever	 or	 type	 of	 illness	 have	 shown	 to	 influence	 REE.	 Understanding	 energy	
needs	during	 the	course	of	 illness	 is	necessary	 to	avoid	 imbalances	 in	energy	 intake	
and	 requirements.	 Inaccurate	 assessment	 of	 energy	 requirements	 results	 in	 both	
underfeeding	and	overfeeding	 in	critically	 ill	children.	IC	remains	the	gold	standard	in	
optimising	 nutritional	 support	 in	 PICU.	 Although	 several	 studies	 have	 concluded	 that	
predictive	equations	lack	precision,	the	Schofield	and	WHO	equations	have	shown	to	be	
the	best	available	equations	in	predicting	energy	needs	in	this	population.	
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5 Chapter	 Five:	 Prescribed	 versus	 delivered	 energy	 and	
macronutrients	and	their	impact	on	clinical	outcomes	
	
5.1 Introduction	
The	imbalance	between	nutritional	requirements	and	intake	may	predispose	critically	ill	
children	to	under-	or	overfeeding.	Previous	studies	of	critically	 ill	children	showed	that	
only	58–65%	of	the	prescribed	energy	goal	is	actually	delivered	to	patients	(Taylor	et	al.,	
2003;	Bockenkamp	et	al.,	2009).	Kyle	et	al.	(2012)	recorded	average	energy	and	protein	
intake	of	75%	and	40%,	respectively,	of	the	estimated	requirements	(Kyle	et	al.,	2012).	
Enteral	 feeding,	 the	 mainstay	 of	 nutrition	 in	 most	 critically	 ill	 children,	 is	 frequently	
interrupted	 in	 PICU,	 resulting	 in	 the	 under-delivery	 of	 energy	 and	 macronutrients	
(Rogers	et	al.,	2003;	Kerklaan	et	al.,	2016).	Furthermore,	critically	ill	children	are	usually	
sensitive	 to	 fluid	 overload,	 and	 consequently	 the	 amount	 of	 fluid	 permitted	 is	 usually	
limited	(Rogers	et	al.,	2003;	Kim	et	al.,	2012).	Patient	factors	such	as	age	and	nutritional	
status	 may	 also	 influence	 the	 delivery	 of	 energy	 in	 PICU	 settings.	 Younger	 children	
appear	to	accumulate	the	highest	energy	deficits,	while	the	delivery	of	energy	is	usually	
better	in	the	malnourished	population	(Hulst	et	al.,	2004;	Briassoulis	et	al.,	2001).	
Adequate	nutritional	delivery	 is	critical	 in	affecting	the	clinical	outcomes	of	critically	 ill	
children.	The	effects	of	under-	and	overfeeding	have	been	previously	investigated,	and	
both	 have	 been	 shown	 to	 be	 detrimental	 to	 critically	 ill	 children,	 in	 particular	 by	
extending	the	length	of	stay	on	the	intensive	care	unit	(Mehta	et	al.,	2009;	Hulst	et	al.,	
2006;	 Maslowski	 &	 Mackay,	 2011;	 Hulst	 et	 al.,	 2006;	 Maslowski	 &	 Mackay,	 2011).	
Therefore,	 optimal	 nutritional	 support,	 including	 accurate	 prescription	 and	 delivery	 of	
energy	and	macronutrients,	is	a	fundamental	element	in	improving	the	clinical	outcomes	
of	critically	ill	children	(Briassoulis	et	al.,	2001;	2002;	Gurgueira	et	al.,	2005;	Mehta	et	al.,	
2012).	The	main	focus	of	nutritional	balance	in	critically	ill	children	has	been	the	delivery	
of	energy	and	protein,	but	the	balance	of	other	macronutrients	is	often	neglected.	This	
is	 related	 to	 knowledge	 and	 guidelines	 focusing	 on	 energy	 and	 protein	 requirements	
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(Mehta	 et	 al.,	 2017),	 and	 the	 ideal	 balance	 of	macronutrients,	 carbohydrates,	 protein	
and	fats	has	not	yet	been	established.	
	
This	 study,	 therefore,	 sets	 out	 to	 assess	 the	 delivery	 of	 energy	 and	 macronutrients	
compared	to	the	estimated	requirements.	The	secondary	aim	of	the	study	is	to	identify	
factors	impacting	cumulative	energy	intake	in	this	population.	
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5.2 Material	and	Methods	
The	 delivery	 of	 energy	 and	 macronutrients	 (protein,	 carbohydrates	 and	 lipids)	 was	
prospectively	 evaluated	 in	 critically	 ill	 children	 from	November	 2014	 to	May	 2017,	 as	
part	of	a	study	assessing	gut	microbiome	in	critically	ill	children.	
Inclusion	criteria:	
• Aged	1	week	to	16	years.	
• Enterally	or	parenterally	fed	for	at	least	3	days.	
Exclusion	criteria:	
• Pre-term	gestation	(birth	<	37	weeks).	
• Known	pre-existing	immune	paresis,	oncological	diagnosis	and	HIV.	
• Children	who	require	feed	compositions	outside	of	the	norm,	such	as	ketogenic	
feeds.	
5.2.1 Nutrition	prescription	
5.2.1.1 EN	prescription	
	
For	the	purposes	of	this	study,	energy	requirements	were	estimated	using	the	Schofield	
equation	(Schofield,	1985),	in	line	with	findings	from	Chapter	Four,	where	the	Schofield	
equation	 showed	 the	 closest	 agreement	with	MEE,	 and	was	 suggested	 for	 use	by	 the	
current	 ASPEN	 guidelines	 in	 the	 absence	 of	 indirect	 calorimetry	 (Mehta	 et	 al.,	 2017).	
Protein	requirements	were	also	calculated	according	to	ASPEN	guidelines	for	critically	ill	
children	 (0–2	 years,	 2–3	 g/kg/day;	 2–13	 years,	 1.5–2	 g/kg/day;	 and	 >13	 years,	 1.5	
g/kg/day)	(Mehta	et	al.,	2009;	2017).	Due	to	the	lack	of	published	guidelines	regarding	
enteral	 CHO	 and	 fat	 requirements	 for	 critically	 ill	 children,	 the	 age-appropriate	 UK	
reference	nutrient	intake	(RNI)	for	healthy	children	was	used	as	a	guide	for	establishing	
CHO	 requirements	 as	 50%	 of	 the	 total	 energy	 requirements	 (Ashwell,	 1991).	 Fat	
requirements	of	40%	and	35%	of	the	total	energy	requirement	were	set	for	children	<1	
year	of	 age	and	>	1	 years,	 respectively,	 corresponding	 to	 ESPGHAN	 recommendations	
for	healthy	children	(Koletzko	et	al.,	2005;	Uauy	&	Dangour,	2009).	
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5.2.1.2 PN	prescription:	
	
The	unit	used	 individualised	PN;	 therefore,	energy,	 carbohydrates	 (glucose),	 lipids	and	
amino	acids	were	delivered	according	 to	 the	patient’s	 requirements	based	on	weight.	
The	 calculations	 of	 energy	 requirements	 were	 based	 on	 the	 Schofield	 equation	
(Schofield,	 1985;	 Joosten	 et	 al.,	 2018).	 Macronutrient	 requirements	 were	 calculated	
according	 to	 the	 recent	 ESPGHAN	 guidelines	 on	 paediatric	 parenteral	 nutrition	
(Mesotten	et	al.,	2018;	Van	Goudoever	et	al.,	2018;	Lapillonne	et	al.,	2018)	(Table	5-1).	
	
Table	 5-1:	 PN	 substrate	 requirements	 based	 on	 ESPGHAN/ESPEN	 practical	
recommendations	
	
	
	
	
	
	
	
	
	
	
	
5.2.2 Nutrition	delivery	
	
Actual	 intake	was	monitored	 for	 all	 recruited	 children	 for	 at	 least	 3	 days	 (1	 day	 =	 24	
completed	hours).	The	total	volume,	energy	and	macronutrient	composition	of	enteral	
feed	for	each	child	was	collected	using	the	patient’s	charts	and	nutritional	data	card	for	
each	 formula	 (Table	 5-2).	 The	 calculation	 of	 breast	 milk	 composition	 was	 based	 on	
previously	published	data	on	breast	milk	composition	(Ballard	&	Morrow,	2013).	
Weight	(kg)	 Carbohydrate	(glucose)	(g/kg/day)	
0-10	 2					–		4	
11-30	 1.5		–	2.5	
31-45	 1					–	1.5	
>	45	 0.5		–	1	
Age	group	 Lipid		(g/kg/day)	
Infants	 3			–		4	
Children	 2			–		3	
Age	group	 Protein	(amino	acids)		(g/kg/day)	
Pre-term	neonate	 1.5	–	3.5	
Term	neonates	 1.5	–	3	
2	months	to	3	years	 2.5	
>3	years	 2	
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Enteral	 formulas	were	 classified	 into	3	 types:	 the	energy-dense	 formula	 (1	 kcal/ml	 for	
infants	<	1	year	and	1.5	kcal/ml	feed	for	older	children),	standard	formulas	(0.67	kcal/ml	
for	 infants	<	1	year	and	1	kcal/ml	 feed	 for	older	children)	and	breast	milk.	Energy	and	
macronutrient	intake	were	expressed	in	percentages	of	calculated	requirements.		
	
Feed	selection:		
The	 hospital	 protocol	 adopts	 feed	 choice	 that	 is	 nutrient	 dense	 option	 of	 those	
prescribable	for	a	given	age	group.	For	infants	under	1	year	of	age	Infatrini	is	usually	the	
formula	of	choice.	Nutrini	Energy	was	routinely	prescribed	for	children	over	1	year	and	
Tenterini	Energy	for	children	aged	7-12	years	or	21-45	kg	in	body	weight.	If	an	infant	or	a	
child	 was	 admitted	 on	 a	 specialist	 formula	 for	 clinical	 reasons	 (e.g	 Peptijunior,	
Nutramigen,	Neocate	LCP,	Nutriprem	2	or	fiber	supplemented	feeds)	then	this	formula	
was	continued	and	did	not	changed	to	an	alternative	one.	
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Table	5-2:	Energy	and	macronutrient	composition	of	breast	milk	and	enteral	formulas	
given	during	the	course	of	study		
	
Formula	 Energy	
Kcal/	ml	
Carbohydrate	
	(g/ml)	
Carbohydrate	
(%	of	total	energy)	
Protein	
(g/ml)	
Protein	
(%	of	total	energy)	
Fat	
(g/ml)	
Fat		
(%	of	total	energy)	
Breast	milk	 0.68	 0.07	 41.18%	 0.01	 5.88%	 0.040	 53.00%	
Infatrini	Nutricia®	 1	 0.103	 41.20%	 0.026	 10.40%	 0.054	 48.60%	
Neocate	 (LCP	 0-12)	
Nutricia®	
0.67	 0.072	 42.99%	 0.018	 10.75%	 0.034	 45.67%	
Neocate	 advance	
Nutricia®	
1	 0.146	 58.40%	 0.025	 10.00%	 0.03	 27.00%	
SMA	althera	
Nestle®	
0.67	 0.073	 43.58%	 0.017	 10.15%	 0.034	 45.67%	
Cow&Gate®	 0.66	 0.073	 44.24%	 0.013	 7.88%	 0.034	 46.36%	
Similac	alimentum	
Abbott®	
0.68	 0.069	 40.59%	 0.0186	 10.94%	 0.037	 48.97%	
Nutriprem2	
Cow&Gate®	
0.75	 0.075	 40.00%	 0.02	 10.67%	 0.04	 48.00%	
Nutrini			
Nutricia®	
1	 0.123	 49.20%	 0.027	 10.80%	 0.044	 39.60%	
Nutrini	energy	
Nutricia®	
1.5	 0.185	 49.33%	 0.04	 10.67%	 0.067	 40.20%	
Nutrini	 energy	 multi-
fiber		
Nutricia®	
1.5	 0.185	 49.33%	 0.041	 10.93%	 0.067	 40.20%	
Nutrini	 peptisorb	
Nutricia®	
1	 0.137	 54.80%	 0.028	 11.20%	 0.039	 35.10%	
Tentrini		
Nutricia®	
1	 0.123	 49.20%	 0.033	 13.20%	 0.042	 37.80%	
Tentrini	energy	
Nutricia®	
1.5	 0.185	 49.33%	 0.048	 12.80%	 0.063	 37.80%	
Peptamen	 junior	
advance	
Abbott®	
1.5	 0.18	 48.00%	 0.045	 12.00%	 0.066	 39.60%	
Nutrison	soya	
Nutricia®	
1	 0.123	 49.20%	 0.04	 16.00%	 0.039	 35.10%	
Nutrison	 energy	
Nutricia®	
1.5	 0.183	 48.80%	 0.06	 16.00%	 0.058	 34.80%	
Frebini	energy	
Fresenius	Kabi®	
1.5	 0.187	 49.87%	 0.038	 10.13%	 0.067	 40.20%	
Elemental	028	Extra		
Nutricia®	
0.86	 0.11	 51.16%	 0.025	 11.62%	 0.035	 36.62%	
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5.2.3 Sample	size	calculation	
This	was	an	observational	study	to	monitor	nutritional	intake	in	critically	ill	children.	No	
specific	sample	size	calculation	was	performed	for	this	study,	as	all	children	enrolled	in	
the	 GHICI	 who	 met	 the	 inclusion	 and	 exclusion	 criteria	 of	 the	 current	 study	 were	
included.	
	
5.2.4 Statistical	analysis	
	
The	 statistical	 analysis	was	 conducted	using	 IBM	SPSS	v25	USA.	The	Shapiro-Wilk	Test	
was	 used	 to	 assess	 the	 normality	 of	 the	 data	 distribution.	Quantitative	 variables	with	
non-normal	distribution	were	expressed	as	a	median	with	interquartile	ranges	(IQR).	The	
Wilcoxon	 signed	 rank	 test	 was	 used	 to	 compare	 the	 difference	 in	 energy	 and	
macronutrient	delivery	between	day	1	and	day	3	of	admission,	whilst	the	Mann-Witney	
U	was	applied	to	assess	differences	in	disease	severity	variables	between	children.	The	
Spearman	 correlation	 coefficient	 was	 used	 to	 establish	 the	 correlation	 between	
variables,	 which	was	 followed	 by	 stepwise	 linear	 regression	 analysis	 to	 assess	 factors	
that	impact	on	cumulative	energy	intake	and	clinical	outcomes.	A	p-value	of	≤	0.05	was	
considered	statistically	significant.	
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Mechanically	ventilated	children	admitted	to	PICU	during	enrollment	period	
(N=639)	
	
Mechanically		ventilated	>3	
days	
	
EN	(N=120)	
	
	
	
	
Normal	feed		
(N=116)	
	
	
	
	
Yes	
(N=128)	
	
Consented	to	participate	in	Gut	microbiome	study	
(N=186)	
	
No	
(N=28)	
	
	
Excluded	
	PN	(N=8)	
	
	
	
	
Ketogenic	feed		
(N=4)	
Excluded	
	
	
	
	
	
Pre-EPIC		Patients	
(N=30)	
	
5.3 Results	
	
A	total	of	124	critically	ill	children	[70	(57%)	males],	with	a	median	(IQR)	age	of	1.9	(0.4	–	
4.9)	years,	were	enrolled	in	this	study.	The	anthropometric	and	clinical	characteristics	of	
the	children	are	shown	 in	Table	5-3.	Upon	admission	to	 the	PICU,	14%	of	 the	children	
had	moderate	 or	 severe	malnutrition	 as	 classified	 by	WHO	 criteria	 mentioned	 in	 the	
Method	Chapter,	page	52.	 Inpatient	mortality	was	4/124	patients	 (3%).	A	 summary	of	
the	recruitment	and	consenting	procedure	is	shown	in	Figure	5.1.	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	5.1	Summary	of	recruitment	procedure	
The	above	figure	shows	the	stages	of	patient	recruitment	and	consent.	
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Table	5-3:	Anthropometric	and	clinical	characteristics	of	children	enrolled	in	the	study	
Anthropometrics	 All	children	
(N=124)	
0-10	kg	
(N=	52)	
10-20	kg	
(N=41)	
>20kg	
(N=31)	
Age	(years)	 1.9			(			0.4	–	4.9		)	 0.4				(	0.1	–	0.8		)	 3.0			(			2.0	–	4.1					)	 11		(			7.9		–	13.4	)	
Weight		(kg)	 12.1	(		6.9	–	18				)	 5.3				(	3.5	–	8.4		)	 14.7	(		13.1	–	16.0	)	 35		(			25	–	43.8			)	
Height	(cm)	 89					(		69	–	111		)	 60.5	(			52	–	73			)	 96				(						87	–	101		)	 132	(		115	–	147		)	
Weight	for	age	Z-score	 -0.3		(	-1.4	–	0.58)	 -1.0	(	-2.2	–	-0.2	)	 0.24	(-0.377	–	0.88)	 0.35	(-0.89	–	1.12)	
%	 of	 children	 below	 <-2	 Z-
scoresz	scores	
14%	 21%	 7%	 9%	
Height	for	age	Z-score	 -0.15	(-1.9	–	1.09)	 -0.7		(	-3.9	–	0.8	)	 0.15		(		-0.43	–	1.3	)	 -0.19	(	-2.1	–	0.9		)	
%	 of	 children	 below	 <-2	 Z-
scoresz	scores	
15%	 15%	 12%	 19%	
Weight	height	Z-score	 0.07	(-1.15	–	0.81)	 -0.9	(-2.0	–	-0.08)	 0.26		(	-0.93	–	0.94)	 0.65	(	-0.22	–	2.03)	
%	 of	 children	 below	 <-2	 Z-
scoresz	scores	
6%	 8%	 9%	 0%	
Disease	severity		 	 	 	 	
PMODS	 6				(						5	–7										)	 6				(						5	–7										)	 5					(								4	–6										)	 6					(						5	–7									)	
PIM2	score	 3				(			0.93	–	6.1			)	 3.4	(		0.89	–	6.8		)	 2.6			(				0.97	–	5.6		)	 3.1		(			0.92	–	5.0	)	
Inotrope	score	 0				(		0	–	15.25					)	 0.0	(				0.0	–	15				)	 0.0			(		0.0	–	20.25		)	 0.0			(				0.0	–	27				)	
Highest	lactate	 1.9	(			1.3	–	3.22			)	 1.9	(				1.4	–	3.1			)	 1.2			(				1.7	–	2.8				)	 2.5		(				1.2		–	3.3		)	
Highest	CRP	 97		(				36	–	213				)	 52	(	22.7	–	117.5	)	 105		(			25	–	221					)	 139	(				44	–	269				)	
VFH	at	30	days	 627	(	549	–		653			)	 616	(		573	–	656		)	 635		(			562	–	652			)	 629	(				495	–	651		)	
PICU	-free	days	at	30	days	 22			(					18		–	24				)	 23		(			19	–	24						)	 22				(		20.0	–	24.0	)	 22			(					18	–	25					)	
Primary	 admission	
diagnosis	
N	(%)	
MOF	 40						(32%)	
Respiratory	Failure	 57						(46%)	
CNS	Disorders	 21						(	17%)	
Surgical	Disorder	 4								(		3%	)	
Gastrointestinal	Disorders	 1								(	1	%	)	
Cardiac	Disorders	 1								(	1%		)	
																																																																		Data	presented	as	median	(IQR)	
• VFH	at	30	days:	ventilation	-free	hours	at	30	days	
• PICU	-free	days	at	30	days:	days	free	of	paediatric	intensive	care	at	30	days	
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5.3.1 Feeding	in	PICU	
The	majority	of	 the	children	were	enterally	 fed	n=116	 (93%),	and	only	8	 (7%)	children	
received	 PN	 (see	 Figure	 5.1).	 Nutritional	 intake	 was	 analysed	 in	 both	 enterally	 and	
parenterally	fed	children.	
PN	fed	children:	
Eight	 children	 received	 PN,	 and	 6	 of	 them	were	 admitted	 due	 to	 gastrointestinal	 (GI)	
diagnoses	 including	 GI	 infections	 and	 surgery.	 PN	 was	 started	 within	 3	 days	 of	 PICU	
admission	 for	 4	 children,	 and	 the	 other	 4	 children	 started	 PN	 after	 day	 3.	 The	 daily	
intake	of	energy,	fat,	carbohydrate	and	protein	during	the	first	3	days	of	PICU	admission	
is	presented	in	Figure	5.2;	data	are	expressed	as	individual	data	points,	as	the	numbers	
were	small	to	show	median	(IQR).	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	5.2	Percentage	of	energy	and	macronutrients	delivered,	expressed	as	a	
percentage	of	the	calculated	requirement	
Figure	5.2	 shows	 the	daily	 intake	of	 energy,	 fat,	 carbohydrate	 and	protein	 expressed	as	 individual	 data	
points.	Each	line	represents	one	patient.	
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EN	fed	children:	
Data	 regarding	 the	 time	of	 commencing	EN	was	 recorded	 in	104	children:	 these	were	
started	at	a	median	 (IQR)	 time	of	8	 (5–13.75)	hours	 following	PICU	admission,	and	77	
(66%)	started	enteral	feeding	within	the	first	12	hours	of	admission.	EN	was	suspended	
for	a	median	(IQR)	duration	of	19	(	11–28)	hours	within	the	first	3	days	of	admission.	The	
most	 common	 reason	 for	 the	 cessation	of	 EN	among	 this	 cohort	was	 the	presence	of	
perceived	large	gastric	aspirates.	Failed	attempts	for	extubation	and	diagnostic	tests	also	
accounted	 for	withholding	EN.	Children	 commenced	EN	within	12	hours	of	 admission,	
had	 statistically	 lower	PIM2	 (p=0.04)	 and	 inotrope	 scores	 (p=0.02)	 compared	 to	 those	
who	 started	 EN	 ≥12	 hours	 of	 admission.	 Eighty-seven	 patients	 (75%)	 of	 the	 cohort	
received	 energy-dense	 formulas,	 9	 (8%)	 expressed	breast	milk,	 and	20	 (17%)	were	on	
standard	formulas	(Table	5-4).	
Table	5-4:	Number	of	patients	receiving	standard	and	ED	formulas	
	
	
	
	
	
	
	
Table	5-4	shows	the	number	of	children	receiving	standard	and	ED	formulas	among	each	weight	group.	
	
The	daily	 energy	 and	macronutrient	 intake	was	 calculated	 for	 the	 first	 3	days	of	 PICU	
admission	 (Figure	5.3).	The	enteral	 intake	of	energy	and	each	macronutrient	on	day	1	
and	 day	 2	 were	 lower	 than	 the	 calculated	 requirements.	 By	 day	 3,	 the	median	 (IQR)	
intake	of	 energy,	 fat,	 carbohydrate	and	protein	was	82%	 (53-108),	 90%	 (52-125),	 70%	
(47-101)	 and	 49%	 (28-66),	 respectively.	 Fat	 intake	 on	 day	 3	 exceeded	 100%	 of	 the	
requirements	 in	 53	 (45.7%)	 children.	 The	 delivery	 of	 energy	 and	macronutrients	 was	
statistically	improved	by	day	3	compared	to	day	1.	I	went	on	to	examine	how	the	daily	
	 All	children	
(N=116)	
0-10	kg	
(N=	51)	
10-20	kg	
(N=40)	
>20kg	
(N=25)	
Breast	milk		 9						(	8%	)	 9			(18%)	 0			(			0%	)	 0			(		0%	)	
Standard	infant	formula		 7						(	6%	)	 7			(14%)	 0			(		0%		)	 0			(		0%	)	
Standard	paediatric	feed	 13				(11%)	 0				(	0%	)	 7			(17.5%)	 6			(	24%)	
Energy	-dense	infant	formula		 31				(27%)	 28		(55%)	 3			(	7.5%	)	 0			(		0%	)	
Energy	-dense	paediatric	feed	 56				(48%)	 7				(13%)	 30	(	75%	)	 19	(76%)	
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Day	2	
Day	1	
Day	3	
a)	All	children	 b)	0-10	kg	
c)	10-20	kg	 d)	>	20	kg	
Values	are	presented	as	median	with	95%	CI	
P	<	0.00**	
P	<0.00**	P	<0.00**	
P	<	0.00**	
P	<	0.00**	
P	<0.00**	
P	<0.00**	
P	<	0.00**	
P	<	0.00**	
P	<0.00**	
P	<0.00**	
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intake	varied	among	different	weight	groups.	The	results	showed	that	the	children	with	
lower	weight	(0-10	kg)	received	higher	doses	of	energy	and	macronutrients.	The	average	
intake	 of	 energy	 and	 macronutrients	 from	 admission	 up	 to	 day	 3	 are	 presented	 in	
Table	5-5.	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	5.3	Percentage	of	enteral	energy	and	macronutrients	delivered	expressed	as	a	
percentage	of	the	calculated	requirements		
Figure	5.3.	a)	Shows	 the	daily	enteral	 intake	 (days	1-3)	of	energy	and	macronutrients	 in	116	critically	 ill	
children.		Figure	5.3.	b),	c)	and	d)	show	the	daily	enteral	intake	(days	1-3)	of	energy	and	macronutrients	in	
different	weight	groups.	The	above	figure	clearly	indicates	that	smaller	children	(0-10	kg)	received	higher	
doses	 of	 energy	 and	 macronutrients.	 The	 enteral	 intake	 of	 both	 energy	 and	 macronutrients	 has	
statistically	improved	on	day	3	compared	to	day	1	(p<0.001**).	
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Table	5-5:	Average	enteral	intake	of	energy	and	macronutrients	from	admission	up	to	
day	3	
Average	
intake	up	to	
day	3	
0-10	kg	
(N=	51)	
10-20	kg	
(N=40)	
>20kg	
(N=25)	
Crude	value		
kcal	or	g/kg/day	
%of	 reference	
intake	
Crude	value		
kcal	or	g/kg/day	
%of	 reference	
intake	
Crude	value	
kcal	or	g/kg/day	
%of	reference	
intake	
Energy	 37	(		31.0-49.0	)	 70	(			55-88		)	 38		(			26-44			)	 75	(		48-83		)	 13				(	6.3-25.9	)	 4			(			23-65		)	
Fat	 2			(			1.4	-2.6			)	 86	(		62-103	)	 1.6		(		0.9-1.9	)	 76	(		43	-93		)	 0.48	(0.18-1.07)	 37	(		18-67		)	
Carbohydrate	 4.6	(				3.8-4.6		)		 54	(			44-76			)	 4.9		(	3.5-5.6		)	 66		(		40-80		)	 1.8	(			1.2-3.3				)	 34	(		17-60		)	
Protein	 0.9	(			0.6-1.2			)	 40		(		24-51			)	 0.99	(0.56-1.1)	 45		(		32-63		)	 0.3	(	0.17-0.69	)	 21	(		9-42.7	)	
																																																							Data	presented	as	median	(IQR)					
The	above	table	shows	the	average	doses	of	enteral	energy	and	macronutrients	presented	as	crude	values	
and	as	a	percentage	of	reference	requirements.	
	
5.3.2 Factors	affecting	delivery	of	enteral	nutrition:	
	
Linear	 regression	 analysis	 was	 performed	 with	 three	 days	 cumulative	 enteral	 energy	
intake	 as	 an	 outcome	 to	 determine	 the	 factors	 affecting	 the	 delivery	 of	 energy.	 The	
regression	model	suggested	that	age,	weight	for	age	z-score	and	PIM2	score	statistically	
impacted	 the	 cumulative	 amount	 of	 energy	 delivered.	 This	 indicated	 that	 younger	
children	 and	 those	 who	 had	 lower	 weight	 for	 age	 z-score	 and	 PIM2	 score	 had	more	
cumulative	energy	 intake.	This	regression	model	accounted	for	30%	of	the	variation	 in	
cumulative	energy	intake	(Table	5-6).	
	
Table	5-6:	Regression	model	to	determine	the	factors	affecting	cumulative	energy	
intake	
Model	 R	 R	2	 Adjusted	R	2	 R	 P-value	
Cumulative	Energy	intake	a	 0.549	 0.302	 0.283	 	
Age	b		 	 -0.396	 0.00*	
Weight	for	age	z	–score	b	 -0.337	 0.00*	
PIM2	score	b	 -0.234	 0.013*	
	
a. Dependent	variable	
b. Predictors:	(constant)	
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5.3.3 Effect	of	enteral	feeding	on	clinical	outcomes	
	
In	 this	 section	 the	 association	 between	 clinical	 outcomes	 and	 the	 average	 intake	 of	
energy	 and	 macronutrients	 was	 investigated.	 Two	 stepwise	 regression	 models	 were	
performed;	 in	 these	 regression	 models	 PICU-free	 days	 and	 VFH	 were	 the	 outcome	
variables.	 There	 was	 no	 evidence	 of	 statistical	 association	 between	 the	 intake	 and	
clinical	outcomes	in	this	cohort	(Table	5-7).	
	
Table	5-7:	Regression	model	to	determine	the	effect	of	feeding	on	clinical	outcomes:		
	
Model	 R		 R	2		 Adjusted	R	2		 R	 P	value	
VFH	a		
PIM2	score	c	 	 0.039	 0.341	
Age	c	 -0.092	 0.165	
Average	energy	received	(3	days)	c	 -0.107	 0.13	
Average	carbohydrate	received	(3	days)	c	 -0.032	 0.367	
Average	protein	received	(3	days)	c		 -0.078	 0.206	
Average	fat	received	(3	days)	c	 -0.088	 0.177	
PICU	free	hours	at	30	days	
PIM2	score	c	 	 0.113	 0.115	
Age	c	 -0.115	 0.111	
Average	energy	received	(3	days)	c	 -0.024	 0.4	
Average	carbohydrate	received	(3	days)	c	 0.019	 0.419	
Average	protein	received	(3	days)	c		 0.007	 0.472	
Average	fat	received	(3	days)	c	 -0.011	 0.456	
	
a. Dependent	variable	
b. Predictors:	(constant)		
c. Excluded	variables	
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5.4 Discussion	
	
This	study	set	out	to	assess	the	difference	between	prescribed	and	delivered	energy	and	
macronutrients.	Previous	data	has	indicated	that	there	is	a	strong	association	between	
under-delivery	 of	 energy	 and	 protein	 with	 growth	 parameters	 and	 adverse	 clinical	
outcomes,	 including	 prolonged	 ventilation	 and	 hospital	 stays,	 multiple	 organ	
dysfunction	 and	mortality	 (Hulst	 et	 al.,	 2004;	Mehta	 et	 al.,	 2012;	 Bhutia	 et	 al.,	 2013;	
Correia,	 2003).	 Conversely,	 over-nutrition,	 particularly	 excessive	 glucose	 delivery,	 has	
also	 been	 linked	 to	 negative	 PICU	outcomes	 (Mehta	 et	 al.,	 2012;	 Bhutia	 et	 al.,	 2013).	
Therefore,	 it	 is	 crucial	 to	 take	 into	account	 the	proportion	of	macronutrients	 required	
and	not	only	aim	to	achieve	the	energy	goal.	
	
In	the	current	study	the	delivery	of	energy	increased	over	the	3	days	of	the	study	period.	
By	 day	 3,	 energy	 and	 carbohydrate	 intake	 reached	 82%	 and	 71%,	 respectively,	 of	 the	
estimated	requirements.	The	recent	ASPEN	guidelines	target	the	delivery	of	at	least	two-
thirds	 of	 the	 prescribed	 daily	 energy	 requirement	 by	 the	 end	 of	 the	 first	week	 in	 the	
PICU	 to	 avoid	 undesired	 clinical	 outcomes	 associated	 with	 cumulative	 nutrition	
deprivation	(Mehta	et	al.,	2017).	The	majority	of	the	children	achieved	this	energy	goal	
by	day	3,	which	was	 likely	to	occur,	as	EN	generally	commenced	within	a	few	hours	of	
admission	 (median	 of	 8	 hours),	 in	 accordance	with	 our	 unit	 enteral	 feeding	 protocol.	
However,	over	the	first	3	days,	protein	delivery	was	40%	of	the	calculated	requirements	
based	on	ASPEN	guidelines,	and	 reached	only	49%	of	 these	 requirements	by	day	3.	 In	
addition,	 our	 results	 showed	 that	 children	 >	 20	 kg	 were	 at	 the	 greatest	 risk	 of	 not	
fulfilling	 their	 protein	 requirements,	 only	 receiving	 an	 average	 of	 21%	 of	 the	
requirements	over	3	days.	Insufficient	delivery	of	protein	is	common,	particularly	in	the	
early	stages	of	admission.	These	findings	are	similar	to	previously	published	data	where	
under-delivery	of	protein	was	also	 reported	 (De	Neef	et	al.,	 2008;	Mehta	et	al.,	 2012;	
Brasil	de	Oliveira	 Iglesias	et	al.,	n.d.;	Kyle	et	al.,	2012).	On	 the	contrary,	on	day	3,	 the	
median	fat	intake	was	90%	and	exceeded	the	prescribed	requirements	in	almost	46%	of	
children.	
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To	the	knowledge	of	the	author,	this	is	the	first	study	to	assess	the	delivery	of	enteral	fat	
and	 carbohydrate	 in	 PICU	 settings.	 This	 study	 recorded	 discrepancies	 in	 energy,	
carbohydrate,	 protein	 and	 fat	 requirements	 and	 delivery,	 with	 the	 under-delivery	 of	
energy	and	protein	and	over-delivery	of	 fat.	This	 is	mainly	 related	 to	 two	aspects:	 the	
use	 of	 standardised,	 ready-to-feed	 energy-dense	 formulas	 in	 PICU,	 and	 the	 aim	
requirements	for	macronutrients	in	critically	ill	children.	The	only	guidelines	available	for	
enteral	nutritional	support	 in	this	population	are	 for	energy	and	protein	 (Mehta	et	al.,	
2009;	2017).	However,	none	have	been	established	 for	 fat	and	carbohydrate.	The	age	
specific	ESPGHAN	guidelines	 for	healthy	children	were	used	as	a	guide	 to	estimate	 fat	
requirements	 in	 a	 critically	 ill	 population,	 as	 younger	 children,	 particularly	 breast-fed	
infants,	 might	 have	 higher	 fat	 requirements.	 RNI	 for	 healthy	 children	 was	 used	 as	 a	
guide	for	establishing	carbohydrate	requirements.	 In	this	study	almost	80%	of	patients	
were	fed	energy-dense	feeds	to	help	meet	their	energy	needs,	and	to	compensate	for	
restrictions	 in	 fluid	 intake	 and	 the	 often	 frequent	 interruptions	 to	 EN	 (Rogers	 et	 al.,	
2003;	 Kim	 et	 al.,	 2012).	 These	 feeds	 have	 a	 higher	 energy	 density	 and	 provide,	 on	
average,	 50%	of	 energy	 from	 carbohydrate,	 10%	 from	protein	 and	 40%	 from	 fat.	 The	
macronutrient	composition	of	all	medical	formulas	in	Europe	is	guided	by	the	European	
Commission	of	Food	for	Special	Medical	Purposes	(FSMP)	guidelines.	Many	factors	need	
to	 be	 taken	 into	 account	 with	 the	 development	 of	 these	 enteral	 feeds,	 including	
macronutrient	 composition,	 osmolality,	 volume	 of	 feed	 for	 nutritional	 adequacy,	 and	
safety	 ranges	 for	 macro	 and	 micro	 nutrients	 for	 children,	 with	 a	 wide	 range	 of	
diagnoses.	 As	 energy	 requirements	 are	 lower	 and	 protein	 requirements	 are	 higher	 in	
critically	 ill	 children	 (Meyer	 et	 al.,	 2012;	 Jotter	&	 Chaparro	 et	 al.,	 2017;	Mehta	 et	 al.,	
2009;	2017),	the	distribution	of	macronutrients	in	standardised	feeds	may	not	match	the	
specific	requirements	of	critically	ill	children.	
	
The	results	showed	that	children	who	started	EN	within	12	hours	of	their	PICU	admission	
had	lower	inotrope	and	PIM2	scores.	This	indicates	that	less	sick	children	start	EN	earlier	
than	the	sicker	ones,	which	confirms	that	clinical	and	haemodynamic	instability	account	
for	 delaying	 EN	 (Lee	 et	 al.,	 2013).	 However,	 other	 studies	 showed	 that	 the	
implementation	 of	 aggressive	 early	 EN	 protocol	was	 safe	 and	 significantly	 effective	 in	
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improving	nitrogen	balance	in	critically	ill	children	(Briassoulis	et	al.,	2002;	2005;	Botrán	
et	al.,	2011).	
	
Factors	 that	 impacted	 the	 cumulative	 intake	of	 energy	have	also	been	 investigated.	 It	
was	 found	 that	 age	 and	 weight	 for	 age	 z-score	 were	 the	 strongest	 predictors	 of	
cumulative	energy	intake.	Younger	children	and	those	who	had	lower	weight	for	age	Z-
scores	and	PIM2	scores	had	more	cumulative	energy	intake.	The	findings	regarding	age	
are	similar	to	those	of	Mehta	et	al.	(2011),	but	contradictory	to	the	work	of	Hulst	et	al.	
(2004),	who	found	that	younger	children	accumulated	the	highest	energy	deficits.	This	
controversy	 could	 be	 explained	 by	 the	 fact	 that	 younger	 children	 had	 the	 highest	
percentage	 of	 malnutrition	 (21%),	 as	 assessed	 by	 weight	 for	 age	 Z-score.	 Due	 to	 the	
well-documented	 impact	 of	 early	 malnutrition	 (De	 Souza	 Menezes,	 et	 al.	 2012;	
Aurangzeb,	 et	 al.	 2012)(39,	 40),	 it	 is	 likely	 that	 the	 nutritional	 support	 team	 focused	
more	on	providing	 full	 nutritional	 requirements,	 particularly	 for	 smaller	 (lower	weight	
for	age	Z-scores)	children,	to	avoid	further	deterioration	of	their	nutritional	status	during	
PICU	stays.	Briassoulis	et	al.	 (2001)	have	similarly	shown	that	malnourished	critically	 ill	
children	have	better	energy	intake.	
	
In	 the	 absence	 of	 guidelines	 regarding	 enteral	 macronutrient	 requirements,	 it	 is	 not	
surprising	 that	 there	 have	 been	 no	 trials	 of	 enteral	 macronutrient	 targets	 outside	 of	
protein	in	critically	ill	children.	In	a	landmark	study	of	parenteral	nutrition	in	this	patient	
group	 (the	Paediatric	Early	versus	Late	Parenteral	Nutrition	 In	Critical	 Illness	(PEPaNIC)	
trial	by	Vanhorebeek	et	al.,	2017),	the	dose	of	amino	acids	delivered	was	associated	with	
an	increased	rate	of	infection	and	a	longer	ventilation	time.	The	authors	postulated	this	
to	 be	 due	 to	 the	 repression	 of	 autophagy	 by	 amino	 acids	 in	 critical	 illness.	 Another	
potential	 mechanism	 is	 the	 early	 induction	 of	 Resistin	 (a	 hormone	 derived	 from	
macrophages	in	humans),	 leading	to	repression	innate	immunity	and	changes	in	amino	
acids	 kinetics,	 including	 increased	 levels	 of	 phenylalanine	 and	 serine,	 and	 reduced	
glutamine	concentrations	(Spanaki	et	al.,	2018;	Tavladaki	et	al.,	2017).	The	PEPaNIC	trial	
indicated	 that	 parenteral	 delivery	 of	 glucose	 and	 lipids	 was	 associated	 with	 fewer	
infections	 and	 earlier	 PICU	 discharge,	 respectively.	 We	 did	 not	 observe	 such	 an	
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association	 between	 enteral	 nutritional	 intake	 and	 the	 duration	 of	 ventilation	 or	 the	
length	 of	 PICU	 stay.	 It	 is	 important	 to	 note	 that	 the	 route	 of	 delivering	 nutrition	was	
different	 from	 our	 study;	 also,	 a	 distinctive	 statistical	 plan	 was	 followed.	 Unlike	 the	
PEPaNIC	study,	we	monitored	the	intake	for	3	days,	which	may	be	insufficient	to	detect	
the	statistical	effect	of	nutritional	 intake	on	clinical	outcomes.	 Importantly,	our	cohort	
had	significantly	lower	protein	intake,	compared	to	requirements,	than	patients	enrolled	
in	 the	 PEPaNIC	 trial	 (40%	 vs	 80%)	 (Vanhorebeek	 et	 al.,	 2017).	 However,	 we	 only	
measured	 intake	 for	3	days,	compared	to	7	 in	 the	PEPaNIC	trial,	making	a	comparison	
between	data	from	the	two	studies	challenging.	
5.5 Limitations	
There	 is	 a	 lack	 of	 published	 guidelines	 regarding	 enteral	 fat	 and	 carbohydrate	
requirements	 for	 critically	 ill	 children.	 Although	 the	 PEPaNIC	 study	 contributes	
significantly	 to	 our	 knowledge	 of	 PN	 nutrient	 delivery	 in	 critically	 ill	 children,	 the	
requirements	 used	 for	 PN	 are	 not	 applicable	 for	 enteral	 nutrition.	 The	 new	ESPGHAN	
guidelines	 for	 PN	 suggested	 that	 energy	 and	 macronutrient	 requirements	 of	 PN	 are	
close	to	those	of	EN	(Joosten	et	al.,	2018;	Mesotten	et	al.,	2018;	Lapillonne	et	al.,	2018).	
This	argument	is	based	on	findings	from	20th-century	experimental	studies	by	Atwater,	
where	 the	metabolisable	 energy	of	 IV	macronutrients	was	 similar	 to	 that	 provided	by	
EN.	However,	there	are	key	differences	in	the	metabolisms	of	enteral	versus	parenteral;	
carbohydrates,	 lipids	 and	 protein	 are	 related	 to	 intestinal	 absorption	 of	 nutritional	
substrates,	insulin	and	inflammatory	stimulation	and	visceral	protein	synthesis	(Suchner	
et	 al.,	 1996).	 Therefore,	 guidelines	 from	 ESPGHAN	 for	 enteral	 fat	 and	 RNI	 for	
carbohydrate	 for	 healthy	 children	 were	 used,	 whilst	 utilising	 published	 guidance	 for	
recommended	 protein	 and	 energy	 intake	 in	 paediatric	 critical	 illness	 (Ashwell,	 1991;	
Koletzko	et	al.,	2005;	Uauy	&	Dangour,	2009;	Mehta	et	al.	2009;	2017).	
5.6 Conclusion	
The	 current	 data	 suggests	 that	 within	 the	 feed	 delivered,	 fat	 intake	 is	 often	 above	
requirements	 compared	 to	 protein	 and	 carbohydrate	 delivery.	 This	 imbalance	 of	
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nutrient	 provision	 may	 result	 from	 using	 the	 standard	 paediatric	 feeds	 that	 may	 not	
necessarily	 match	 the	 macronutrient	 requirements	 of	 critically	 ill	 children.	 To	 avoid	
imbalances	 of	macronutrients	 delivery	within	 the	 feed	 provided	we	 have	 to	 take	 into	
account	 the	 proportion	 of	 macronutrients	 required	 for	 a	 child,	 and	 not	 only	 aim	 to	
achieve	 the	 energy	 goal.	 These	 findings	 are	 based	 on	 generalised	 guidelines	 for	
macronutrient	 requirements	 in	 healthy	 children,	 and	 future	 work	 should	 examine	
whether	critically	ill	children	have	specific	macronutrient	needs.	
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6 Chapter	 Six:	 Association	 Between	 Enteral	 Macronutrient	
Delivery	and	Inflammatory	Response	In	Critically	Ill	Children	
6.1 Introduction	
	
Critical	illness	is	characterised	by	a	state	of	systemic	inflammation	accompanied	by	the	
release	of	 inflammatory	 cytokines	 (Joosten	et	 al.	 2016).	 These	 cytokines	 are	 the	main	
regulators	of	the	immune	response	to	the	acute	insult	(Jaffer	et	al.	2010).	The	acute	pro-
inflammatory	 response	 is	 typically	 followed	 by	 an	 induction	 of	 anti-inflammatory	
mediators	(Oberholzer	et	al.	2000).	The	interaction	between	the	pro-inflammatory	and	
anti-inflammatory	mediators	appears	to	determine	the	severity	of	outcome	in	critically	
ill	 patients	 (Oberholzer	 et	 al.	 2000;	Wang	&	 Ye	 2015).	 The	 balance	 between	pro-	 and	
anti-inflammatory	mediators	 needs	 to	 be	 achieved	 in	 order	 to	 restore	 a	 homeostatic	
state.	Excessive	production	of	 inflammatory	cytokines	can	cause	adverse	outcomes	on	
the	host	metabolism,	tissue	and	organ	function	(Wang	&	Ye	2015;	Chaudhry	et	al.	2013).	
	
Cytokines	 act	 systemically	 to	 regulate	 energy	metabolism.	 In	 the	 brain,	 inflammatory	
mediators	 inhibit	 energy	 intake	 through	 suppression	 of	 appetite.	 They	 also	 induce	
lipolysis	in	fat	tissue	and	protein	breakdown	in	muscles	(Wang	&	Ye	2015).	It	is	thought	
that	pro-inflammatory	cytokines	such	as	 IL-6,	 IL-1β	and	TNF-α	play	a	role	 in	 increasing	
energy	expenditure	in	critically	 ill	children	(Puigserver	et	al.	2001).	These	inflammatory	
cytokines	 act	 through	 cell	 membrane	 receptors	 in	 the	 brain	 or	 peripheral	 tissues	 to	
induce	energy	expenditure	(Wang	&	Ye	2015).	
	
There	is	a	growing	body	of	evidence	suggesting	that	there	is	interplay	between	nutrition	
and	 inflammation.	 Increased	 levels	 of	 inflammatory	 cytokines	 have	 been	 reported	
before	 in	 undernourished	 children	 with	 cirrhosis	 (Wilasco	 et	 al.	 2017).	 Studies	 also	
suggested	that	a	diet	high	 in	fat	might	 induce	systemic	 low-level	 inflammation	 in	adult	
populations	(Pendyala	et	al.	2012;	Parekh	et	al.	2014;	Sharman	&	Volek	2004).	
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The	aim	of	this	study	was	to	map	out	the	changes	occurring	in	TNFα,	IL-6,	IL-10	and	IL-1β	
during	 the	 course	 of	 PICU	 stay,	 and	 to	 investigate	 the	 effect	 of	 energy	 and	
macronutrients	intake	on	the	pattern	of	cytokine	release.	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
		
	
	
Chapter	Six	
	
	 	
117	
6.2 Materials	and	Methods	
	
This	study	included	only	enterally	fed	children,	where	the	daily	recording	of	intake	was	
accessible.	 Children	 who	 were	 on	 full/supplemental	 PN	 or	 a	 ketogenic	 diet	 were	
excluded.	
	
Measurements	 of	 circulating	 levels	 of	 key	 inflammatory	 mediators,	 including	 pro-	
inflammatory	(TNF-α,	IL-6,	IL-1β)	and	anti-inflammatory	response	pathways	(IL-10),	were	
undertaken	between	day	2	and	7.	The	detailed	methodology	of	the	cytokines	assay	was	
described	in	Chapter	Two,	page	54.	
	
To	 investigate	 the	association	between	enterally	delivered	energy	and	macronutrients	
and	cytokine	levels,	values	for	the	amount	delivered	were	calculated	from	the	24-hour	
period	prior	 to	each	sample	collection	 (1	day	=24	hours).	Cytokine	samples	were	 then	
categorised	into	early	samples,	measured	during	the	early	phase	of	illness	when	nutrient	
delivery	may	be	lower	(days	2-3)	and	a	later	sample	taken	4-7	days	after	admission.	As	
fat	 requirements	 varied	 between	 infants	 and	 older	 children,	 study	 participants	 were	
stratified	 into	 two	 age	 groups,	 >1	 year	 of	 age	 and	 <1	 year	 of	 age.	 The	 association	
between	 energy	 and	 macronutrient	 delivery	 with	 the	 inflammatory	 response	 was	
assessed	amongst	all	children	and	in	the	stratified	groups	by	age.	
	
6.2.1 Sample	size	calculation	
	
Sample	 size	 calculation	 was	 performed	 using	 the	 statistical	 power	 analysis	 program	
G*Power	3	(Faul	et	al.	2007).	The	sample	size	was	chosen	to	test	the	hypothesis	that	
higher	dietary	fat	is	associated	with	the	stimulation	of	inflammatory	cytokines.	Since	no	
studies	have	 investigated	 the	 impact	of	 feeding	on	 inflammation	 in	critical	 illness,	 this	
assumption	was	based	on	findings	from	studies	linking	inflammation	to	dietary	factors	in	
other	 populations,	 including	 obesity,	 heart	 disease	 and	 inflammatory	 bowel	 disease.	
Lennie	et	al.	(2005)	recorded	a	difference	of	3	pg/ml	of	TNFα	between	patients	having	
diets	 higher	 versus	 lower	 in	 saturated	 fat.	 The	 anti-inflammatory	 effect	 of	 caloric	
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restriction	on	plasma	 levels	of	TNFα	was	also	examined	 in	an	experimental	 rat	model;	
the	 mean	 TNFα	 in	 the	 calorie-restricted	 group	 was	 14	 pg/ml	 compared	 to	 38	 pg/ml	
(Ugochukwu	&	Figgers	2007)	.	For	an	effect	size	of	0.5	and	90%	power	it	was	estimated	
that	31	children	would	be	needed	to	detect	a	statistical	association	between	dietary	fat	
and	 inflammatory	 cytokines.	 Since	 those	 children	were	 part	 of	 the	main	 GHICI	 study,	
rather	than	reduce	the	sample	size	available,	all	children	who	met	the	inclusion	criteria	
were	included	in	the	study.	
	
6.2.2 Statistical	analysis	
	
The	 statistical	 analysis	was	 conducted	using	 IBM	SPSS	v25	USA.	The	Shapiro-Wilk	Test	
was	 used	 to	 assess	 the	 normality	 of	 the	 data	 distribution.	Quantitative	 variables	with	
non-normal	distribution	were	expressed	as	a	median	with	interquartile	ranges	(IQR).	The	
Mann-Witney	U	test	was	applied	to	assess	differences	in	cytokine	levels	between	day	1	
and	day	7.	 The	Spearman	correlation	 coefficient	was	used	 to	establish	 the	 correlation	
between	variables,	which	was	followed	by	stepwise	linear	regression	analysis	to	assess	
factors	that	impact	inflammatory	cytokines	(TNF-α,	IL-10,	IL-6	and	IL-1β).	A	p-value	of	≤	
0.05	was	considered	to	be	statistically	significant	and	log	transformation	was	performed	
on	cytokines	prior	to	regression	analysis.	
	
	
	
	
	
	
	
	
	
	
	
		
	
	
Chapter	Six	
	
	 	
119	
6.3 Results	
	
Cytokine	levels	were	measured	in	87	critically	ill	children	(51	males)	who	were	enterally	
fed.	Fifty-eight	 samples	were	collected	on	day	1,	50	 samples	on	day	2,	37	 samples	on	
day	 3	 and	 39	 samples	 between	 days	 4	 and	 7.	 The	 population	 characteristics	 of	 the	
children	recruited	in	this	study	are	shown	in	Table	6-1.	
	
Table	6-1:	Anthropometric	and	clinical	characteristics	of	children	enrolled	to	the	study	
Anthropometrics	 All	children		
(N=87)	
<1	year	of	age		
(N=	27)	
>	1	year	of	age		
(N=60)	
Age	(years)	 2					(				0.6	–	4.9				)	 0.25		(				0.1	–	52			)	 4							(						2	–	10						)	
Weight		(kg)	 14				(					8	–	21							)	 4.8			(				3.4	–	7.6			)	 16					(					13	–	28					)	
Height	(cm)	 95				(					74	–	112			)	 58				(					51	–	70				)	 102			(				88	–	122			)	
Weight	for	age	Z-score	 -0.1		(			-1.4	–	0.72	)	 -1.2		(	-2.5	–	-0.2			)	 0.2				(		-0.7	–	0.8				)	
Height	for	age	Z-score	 -0.15	(		-1.9	–	1.2		)	 -0.2		(		-1.9	–	1.7			)	 -0.03	(	-0.1	–	1.1				)	
Weight	height	Z-score	 0.05		(-1.1	–	0.81		)	 -0.5		(		-0.9	–	0.7			)	 0.20		(		-1.1	–	1.09	)	
Disease	severity		 	 	 	
PIM2	score	 3.2			(				0.9	–	6.2			)	 3.4		(				0.8	–	6.2				)	 3.1		(				1.1	–	6.8				)	
PMODS	 6						(				5			to			7						)	 6					(					5			to			7						)	 6					(					5			to			7						)	
Inotrope	score	 0						(							0	–	22						)	 2					(				0.0	–	17							)	 0.0			(			0.0	–	29						)	
Maximum	lactate	 1.9			(				1.3	–	3.3				)	 1.7		(				1.3	–	3.9					)	 1.9			(			1.3	–	3.1					)	
Maximum	CRP	 85			(					29	–	193					)	 60			(			32	–	165						)	 114		(		33	–	223						)	
VFH	at	30	days	 622	(		542	–		651				)	 609	(					547	–	648		)	 623		(		527	–	651				)	
PICU-	free	days	at	30	days	 23			(					19		–	24					)	 22			(					17–	25							)	 22			(					18	–	24						)	
Primary	admission	diagnosis	 N			(	%)	
MOF	 32				(37%)	
Respiratory	Failure	 33				(37%)	
CNS	Disorders	 19				(22	%)	
Cardiac	Disorders	 1						(	1		%	)		
Gastrointestinal	Disorders	 1						(	1		%	)	
Surgical	Disorders	 1						(	1		%	)	
																																																										Data	presented	as	median	(IQR)	
	
• VFH	at	30	days:	ventilation-free	hours	at	30	days	
• PICU-free	days	at	30	days:	days	free	of	paediatric	intensive	care	at	30	days	 	
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a)	 b)	
c)	 d)	
Values	are	presented	as	median	with	95%	CI	
P=	0.01*	 P=	0.00*	
P=	0.022	
P=	0.004*	
P=	0.00*	
N=58	
N=50	 N=37	 N=22	
N=58	
N=50	 N=37	 N=22	
N=58	
N=50	 N=37	 N=22	
N=58	
N=50	 N=37	 N=22	
6.3.1 The	inflammatory	response	in	critically	ill	children	
	
The	 levels	of	 IL-6,	 IL-10	and	 IL-1β	were	higher	 in	 the	early	days	of	admission	and	then	
they	 started	 to	 decline	 gradually.	 There	 was	 a	 statistical	 difference	 in	 their	 levels	
between	days	1	and	7,	p<0.05.	Whilst	TNFα	showed	a	fluctuating	pattern,	on	day	2	the	
level	 of	 TNF-α	 was	 the	 highest	 and	 it	 was	 lowest	 on	 day	 7,	 but	 remained	 relatively	
elevated	and	had	not	statistically	altered	between	admission	and	day	7	(see	Figure	6.	1).	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	6.1	Changes	in	the	levels	of	inflammatory	cytokines	following	PICU	admission	
The	above	figures	show	that	cytokines	levels	declined	gradually	over	the	course	of	PICU	stay,	except	TNFα,	
which	showed	a	fluctuating	pattern.	
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6.3.2 Feeding	and	inflammatory	response	
	
Serum	inflammatory	markers	were	measured	in	a	total	of	125	samples	collected	from	87	
children.	The	number	of	samples	collected	from	each	age	group	is	presented	in	Table	6-
2.	The	median	amount	of	energy	and	macronutrient	received	during	the	early	and	late	
phase	 are	presented	 in	 Figure	6.2.	 Prior	 to	performing	 regression	 analysis,	 correlation	
analysis	 was	 used	 to	 explore	 the	 association	 between	 macronutrient	 intake	 and	 the	
inflammatory	mediators.	
	
Table	6-2:	The	number	of	samples	collected	from	each	age	group	
All	children	
	
	
Early	 samples	 (Days	 2-
3)	
	
Number	of	samples	 Median	number	of	samples	per	patient	
87	 1	(1-1)	
TNFα	(pg/ml)	 1L-6	(pg/ml)	 IL-10	(pg/ml)	 IL1-β	(pg/ml)	
3.8	(2.3	–	7.5)	 6.5	(1.8	–	19)	 2.5	(0.9	–	7.8)	 0.2	(0.2	–	0.3)	
	
	
Late	samples	(Days	4-7)	
Number	of	samples	 Median	number	of	samples	per	patient	
39	 1	(1-2)	
TNFα	(pg/ml)	 1L-6(pg/ml)	 IL-10	(pg/ml)	 IL1-β	(pg/ml)	
3.7	(2.5	–	6.8)	 3.5	(1.5	–	8.6)	 1.6	(0.9	–	2.4)	 0.2	(0.1	–	0.2)	
<1	year	
	
Early	 samples	 (Days	 2-
3)	
Number	of	samples	 Median	number	of	samples	per	patient	
20	 1	(1-1)	
TNFα	(pg/ml)	 1L-6	(pg/ml)	 IL-10	(pg/ml)	 IL1-β	(pg/ml)	
5.8	(4.5	–	9.6)	 8.8	(2.8	–	14)	 4.3	(1.1	–	28)	 0.25	(0.2	–0.5)	
	
Late	samples	(Days	4-7)	
	
Number	of	samples	 Median	number	of	samples	per	patient	
15	 1	(1-2)	
TNFα	(pg/ml)	 1L-6	(pg/ml)	 IL-10	(pg/ml)	 IL1-β	(pg/ml)	
6.8	(4	–	7	)	 3	(1.5	–		5.9)	 1.8	(	0.9		–	3.1)	 0.2	(0.1	–	0.4)	
>1year	
	
Early	 samples	 (Days	 2-
3)	
	
Number	of	samples	 Median	number	of	samples	per	patient	
67	 1	(1-1)	
TNFα	(pg/ml)	 1L-6	(pg/ml)	 IL-10	(pg/ml)	 IL1-β	(pg/ml)	
3.2	(1.8	–	6.1)	 5.9	(1.7	–	20.2)	 2.2	(0.9	–	7)	 0.2	(0.2	–0.21)	
	
Late	samples	(Days	4-7)	
	
Number	of	samples	 Median	number	of	samples	per	patient	
24	 1	(1-2)	
TNFα	(pg/ml)	 1L-6	(pg/ml)	 IL-10	(pg/ml)	 IL1-β	(pg/ml)	
3.1	(2.2	–	4.3)	 3.6	(0.8	–	10.9)	 1.1	(0.7	–	2.3)	 0.2	(0.1	–	0.2)	
																																																									
																																																						Data	presented	as	median	(IQR)	
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Late	Phase	
Early	phase	
a)	All	children	
c)	>1	Year	b)	<1	year	
Values	are	presented	as	median	with	95%	CI	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	6.2	Average	enteral	energy	and	macronutrients	delivered	during	early	and	late	
phase	of	illness	
Figure	6.2	a)	shows	median	intake	of	energy	and	macronutrients	during	the	early	and	later	phase	of	illness	
in	 87	 critically	 ill	 children.	 The	 early	 phase	 covers	 day	 2-3,	 the	 later	 phase	 included	 days	 4-7	 post	
admission.	Day	1	was	 excluded	 from	 this	 analysis	 because	 it	was	not	 feasible	 to	 record	 the	 feeds	prior	
admission.	 Figures	 6.2	 b),	 c)	 and	 d)	 show	 the	 intake	 in	 different	 age	 groups.	 The	 above	 figure	 clearly	
indicates	that	younger	children	<1	year	of	received	higher	doses	of	enteral	fat.	
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a. Early	cytokines	(samples	obtained	on	day	2-3):	
	
There	was	no	correlation	between	macronutrients	and	early	 cytokines	except	 for	 IL-6,	
which	showed	a	weak	negative	correlation	with	energy	(r=	-0.22,	p=0.04)	and	protein	(r=	
-0.26,	p=0.01).	
Stepwise	linear	regression	analysis	was	performed,	with	IL-6	as	an	outcome	variable,	to	
determine	 whether	 feeding	 contributed	 to	 a	 change	 in	 IL-6	 independently	 from	 the	
severity	 of	 disease	 and	 age.	 The	 results	 indicated	 that	 both	 PIM2	 score	 and	 %	 of	
delivered	 protein	 were	 statistically	 related	 to	 IL6	 (p	 <	 0.01).	 This	 regression	 model	
accounted	for	20%	of	the	variation	in	IL-6	levels	(Table	6-3).	
In	children	<1	year	of	age,	a	lower	protein	intake	was	associated	with	an	increase	in	IL-6	
levels,	r=	-0.554,	p=	0.024,	whilst	in	older	children,	no	evidence	of	statistical	association	
was	recorded	between	the	percentage	of	protein	received	and	IL-6,	r=	-0.221,	p=	0.077	
(Table	6-3).	
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Table	6-3:	Factors	affecting	IL-6	during	the	period	of	nutrition	deprivation	
Model	 R		 R	2		 Adjusted	R	2		 R	 P-value	
IL-6	a	(all	children)	 0.457	 0.209	 0.189	 	
PIM2	score	b	 	 0.346	 0.001*	
%of	enteral	protein	received	b		 -0.295	 0.007*	
%	of	enteral	energy	received	c	 -0.053	 0.638	
%	of	enteral	carbohydrate	received	c	 0.104	 0.351	
%	of	enteral	fat	received	c	 0.077	 0.490	
Age	c	 0.213	 0.055	
IL-6	a	(children	<	1	year)	 0.544	 0.296	 0.249	 	
%of	enteral	protein	received	b	 	 -0.544	 0.024*	
%	of	enteral	energy	received	c	 -0.203	 0.450	
%	of	enteral	carbohydrate	received	c	 0.459	 0.074	
%	of	enteral	fat	received	c	 0.229	 0.394	
PIM2	score	c	 -0.074	 0.0784	
Age	c	 0.034	 0.90	
IL-6	a	(children	>	1	year)	 0.505	 0.255	 0.232	 	
PIM2	score	b	 	 0.429	 0.00*	
Age	b	 0.300	 0.014*	
%of	enteral	protein	received	c		 -0.221	 0.077	
%	of	enteral	energy	received	c	 -0.203	 0.105	
%	of	enteral	carbohydrate	received	c	 -0.156	 0.216	
%	of	enteral	fat	received	c	 -0.124	 0.326	
	
d. Dependent	variable	
e. Predictors:	(constant)	
f. Excluded	variables	
	
b. Late	cytokines	(samples	obtained	between	day	4-8):	
	
With	 the	 later	 samples,	 both	 TNF-α	 and	 IL-10	 were	 positively	 correlated	 with	 the	
delivery	 of	 energy,	 fat	 and	 carbohydrate,	whilst	 no	 evidence	 of	 statistically	 significant	
correlation	was	observed	with	protein	intake.	
Stepwise	 linear	 regression	 analysis	 was	 performed,	 with	 TNF-α	 as	 the	 outcome	 to	
determine	whether	energy	and	macronutrient	intake	contributed	to	an	increase	in	TNF-
α	 independently	 from	 the	 age	 and	 the	 severity	 of	 disease.	 The	 results	 indicated	 that	
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higher	delivery	of	fat	and	lower	delivery	of	protein	statistically	contributed	to	increases	
in	TNF-α,	p	<	0.01,	and	this	regression	model	accounted	for	31%	of	the	variation	in	TNF-
α	levels	(Table	6-4).	
I	further	investigated	the	effect	of	feeding	on	TNF-α,	between	different	age	groups.	The	
regression	models	suggested	that	the	percentage	of	enteral	 fat	delivered	was	the	only	
variable	 statistically	 related	 to	 the	 increase	 in	 TNF-α	 (r=0.440,	 p=0.032)	 in	 children	>1	
year	of	age.	This	was	not	replicated	in	the	younger	age	group	(r=0.387,	p=0.077)	(Table	
6-4).	
	
Table	6-4:	Factors	affecting	TNF-α	
	
Model	 R	 R	2	 Adjusted	R	2	 R	 P-value	
TNF-α	a	(all	children)		 0.561	 0.315	 0.277	 	
%	of	enteral	fat	received	b	 	 0.534	 0.001*	
%	of	enteral	protein	received	b		 -0.347	 0.033*	
%	of	enteral	energy	received	c	 -0.004	 0.983	
%	of	enteral	carbohydrate	received	c	 0.008	 0.963	
PIM2	score	c		 0.187	 0.269	
Age	c	 -0.191	 0.257	
TNF-α	a	(children	<	1	year)		 	 	
%	of	enteral	fat	received	c	 	 0.387	 0.077	
%	of	enteral	protein	received	c		 0.0.119	 0.377	
%	of	enteral	energy	received	c	 0.212	 0.224	
%	of	enteral	carbohydrate	received	c	 0.229	 0.206	
PIM2	score	c		 0.037	 0.448	
Age	c	 -0.202	 0.337	
TNF-α	a	(children	>	1	year)		 0.440	 0.193	 0.157	 	
%	of	enteral	fat	received	b	 	 0.440	 0.032*	
%	of	enteral	protein	received	c		 0.094	 0.669	
%	of	enteral	energy	received	c	 -0.094	 0.669	
%	of	enteral	carbohydrate	received	c	 -0.009	 0.969	
PIM2	score	c		 0.322	 0.134	
Age	c	 -0.010	 0.963	
	
a. Dependent	variable	
b. Predictors:	(constant)	
c. Excluded	variables	
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This	study	also	investigated	the	effect	of	energy	and	macronutrient	intake	in	a	stepwise	
linear	regression	analysis	where	IL-10	was	the	outcome	variable.	This	model	suggested	
that	both	energy	intake	and	PIM2	score	had	a	statistically	significant	effect	on	IL-10.	This	
regression	model	accounted	for	46%	of	the	variation	in	IL-10	(Table	6-5).	
In	 children	 <1	 year	 both	 the	 percentage	 of	 energy	 intake	 and	 PIM2	 score	 were	
statistically	 related	 to	 IL-10,	whilst	 in	 older	 children	 PIM2	 score	was	 the	 only	 variable	
statistically	related	to	an	increase	in	IL-10	(Table	6-5).	
	
Table	6-5:	Factors	affecting	IL-10	
	
Model	 R	 R	2	 Adjusted	R	2	 R	 P-value	
IL-10	a	(all	children)	 0.679	 0.461	 0.415	 	
%	of	enteral	energy	received	b	 	 0.575	 0.00*	
PIM2	score	b		 0.437	 0.004*	
%of	enteral	protein	received	b	 0.163	 0.018*	
%	of	enteral	carbohydrate	received	c	 0.082	 0.636	
%	of	enteral	fat	received	c	 -0.082	 0.636	
Age	c	 -0.188	 0.271	
IL-10a	(children	<	1	year)	 0.758	 0.575	 0.504	 	
%	of	enteral	energy	received	b	 	 0.698	 0.006*	
PIM2	score	b		 0.540	 0.046*	
%of	enteral	protein	received	c	 -0.357	 0.231	
%	of	enteral	carbohydrate	received	c	 0.257	 0.397	
%	of	enteral	fat	received	c	 -0.185	 0.546	
Age	c	 -0.143	 0.642	
IL-10a	(children	>	1	year)	 0.510	 0.260	 0.227	 	
PIM2	score	b	 	 0.510	 0.011*	
%	of	enteral	fat	received	c	 0.183	 0.403	
%	of	enteral	energy	received	c	 0.207	 0.344	
%of	enteral	protein	received	c	 0.146	 0.507	
%	of	enteral	carbohydrate	received	c	 0.177	 0.420	
Age	c	 -198	 0.365	
	
a. Dependent	variable	
b. Predictors:	(constant)	
c. Excluded	variables	
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6.4 Discussion	
	
The	initial	insult	in	critical	illness	is	usually	characterised	by	its	pro-inflammatory	nature	
(Hall	et	al.	2017).	In	the	current	study,	in	response	to	stress,	the	inflammatory	cytokines	
were	higher	in	the	early	course	of	critical	illness	and	then	declined	progressively,	except	
for	 TNFα,	 which	 showed	 a	 fluctuating	 pattern.	 These	 data	 are	 consistent	 with	 the	
expected	 course	 of	 the	 systemic	 inflammatory	 response	 in	 critical	 illness	 as	 shown	 in	
previously	published	studies	(Oberholzer	et	al.	2000;	Briassoulis	et	al.	2010;	Jaffer	et	al.	
2010;	Jawa	et	al.	2011).	 It	 is	known	that	the	degree	of	 inflammation	is	associated	with	
adverse	outcomes	(Hall	et	al.	2017);	this	study	investigated	the	effect	of	macronutrient	
delivery	on	the	cytokines’	response	in	critically	ill	children.	
	
It	was	 found	 that	both	protein	deficiency	and	a	higher	delivery	of	 fat	were	associated	
with	 elevated	 levels	 of	 inflammatory	 cytokines;	 in	 particular,	 the	 under-delivery	 of	
protein	 was	 associated	 with	 an	 increase	 in	 serum	 IL-6	 and	 TNF-α.	 The	 association	
between	dietary	protein	and	inflammatory	markers	has	not	been	previously	investigated	
in	 a	 critically	 ill	 population.	 However,	 increased	 levels	 of	 inflammatory	markers	 were	
recorded	 in	 malnutrition	 studies	 where	 presumably	 energy	 and	 protein	 intake	 were	
compromised.	An	increased	IL-6	level	was	reported	in	malnourished	critically	ill	children	
and	gastric	cancer	patients	(Delgado	et	al.	2008;	Correia	et	al.	2007).	Protein	intake	was	
not	assessed	in	neither	of	the	aforementioned	studies;	however,	low	protein	intake	has	
been	 shown	 to	 be	 associated	 with	 increased	 serum	 IL-6	 in	 a	 murine	 model	 of	
malnutrition	 (Ling	 et	 al.	 2004).	 In	 addition,	 IL-6	 and	 TNF-α	 have	 been	 proposed	 as	
possible	biomarkers	of	nutritional	deficits	(Wilasco	et	al.	2017;	Correia	et	al.	2007).	
	
Despite	 the	 current	 knowledge	 about	 the	 contribution	 of	 dietary	 fatty	 acids	 to	
modulating	 the	production	of	 lipid	mediators	and	signalling	molecules	 in	cells	 that	are	
involved	in	immune	regulation	and	inflammation	(Galli	&	Calder	2009),	to	the	knowledge	
of	 the	 author,	 no	 previous	 data	 have	 been	 published	 linking	 fat	 intake	with	 elevated	
levels	 of	 circulatory	 cytokines	 in	 critical	 illness.	 The	 current	 study	 recorded	 an	
association	between	enteral	fat	delivery	and	elevation	in	TNF-α,	particularly	in	children	
		
	
	
Chapter	Six	
	
	 	
128	
>1	 year	 of	 age.	 Although	 the	 younger	 group	 received	 higher	 doses	 of	 enteral	 fat	 and	
their	 median	 TNF-α	 was	 higher,	 there	 was	 no	 statistical	 association.	 This	 could	 be	
attributed	to	variations	 in	fat	requirements,	as	 in	young	children,	a	higher	fat	 intake	 is	
required	for	their	physiological	functions	(Koletzko	et	al.	2005;	Uauy	&	Dangour	2009).	
In	breast	milk	nearly	50%	of	energy	is	provided	from	fat	(Ballard	&	Morrow	2013).	There	
are	limited	data	describing	the	changes	in	 lipid	metabolism	in	relation	to	inflammation	
during	critical	illness.	In	septic	patients	the	changes	in	plasma	fatty	acid	profiles	appear	
to	be	related	to	the	intensity	of	the	inflammatory	response,	and	in	addition,	interleukins	
have	 been	 shown	 to	 be	 inversely	 related	 to	 low-LDL/low-HDL	 (Fitrolaki	 et	 al.	 2016;	
Novak	 et	 al.	 2017).	 In	 septic	 children,	 increased	 expression	 of	 Neutrophil	 CD64	 was	
associated	 with	 low	 HDL	 and	 LDL	 levels	 (Fitrolaki	 et	 al.	 2013).	 None	 of	 the	 above-
mentioned	 studies	 recorded	 the	 EN	 intake	or	 investigated	 the	 dietary	 factors.	 Studies	
linking	 inflammation	 to	dietary	 factors	do	exist	 in	other	populations	 including	patients	
with	 obesity,	 heart	 disease	 and	 inflammatory	 bowel	 disease.	 In	 patients	 with	 heart	
failure,	 TNF-α	 levels	were	elevated	with	a	higher	 intake	of	 saturated	 fat	 (Lennie	et	 al.	
2005).	In	an	obese	rat	model,	the	use	of	a	high-fat	diet	induced	the	expression	of	TNF-α,	
IL1β	and	IL-6	in	skeletal	muscle,	visceral	fat	and	blood	(Borst	&	Conover	2005;	Wu	et	al.	
2016;	 Shoelson	 et	 al.	 2006;	 Lee	 et	 al.	 2010).	 Studies	 also	 suggest	 that	 the	 high-fat	
western	diet	might	induce	systemic	low-level	inflammation	as	a	result	of	changes	in	gut	
microbiota	 (Pendyala	 et	 al.	 2012;	 Parekh	 et	 al.	 2014).	 In	 a	 study	 conducted	 on	 15	
overweight	men,	 a	 low-fat	 diet	 resulted	 in	 a	 statistically	 significant	 reduction	 in	 TNF-
α	(Sharman	&	Volek	 2004).	 However,	 it	 is	 important	 to	 point	 out	 that	 the	 type	 of	 fat	
delivered	 might	 also	 impact	 the	 inflammatory	 response.	 In	 an	 experimental	 induced	
colitis	 rat	 model,	 a	 medium-chain	 triglycerides	 (MCT)	 rich	 diet	 reduced	 IL-6	 and	 IL-8	
levels,	 indicating	 that	 MCT	 rich	 formulas	 exert	 an	 anti-inflammatory	 effect	 on	 colitis	
(Papada	et	al.	2014).	
	
Although	 the	 exact	 mechanism	 that	 links	 dietary	 fat	 to	 inflammation	 is	 not	 fully	
understood,	 several	 mechanisms	 have	 been	 proposed.	 It	 is	 thought	 that	 pro-
inflammatory	 fatty	 acids	 may	 act	 directly	 and	 activate	 receptors	 that	 signal	 an	
inflammatory	 response	 (Innes	 &	 Calder	 2018).	 It	 has	 also	 been	 suggested	 that	 the	
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infiltration	of	macrophages	associated	with	adiposity	accounts	for	the	increased	adipose	
expression	 of	 TNF-α	 (Borst	&	 Conover	 2005).	 However,	 one	 of	 the	 recently	 proposed	
mechanisms	that	 links	dietary	fat	to	 inflammation	 is	related	to	 its	effect	on	promoting	
the	 translocation	 of	 microbial	 products	 from	 the	 gut	 into	 the	 bloodstream	 (Fritsche	
2015).	The	well-documented	evidence	of	intestinal	dysbiosis	during	critical	illness	makes	
this	explanation	plausible	and	clinically	justifiable.	
	
In	the	current	study,	the	association	between	energy	intake	and	IL-10	could	be	related	
to	the	stimulation	of	insulin	secretion.	IL-10	signalling	has	been	proposed	as	a	potential	
mechanism	to	increase	energy	expenditure	and	improve	insulin	sensitivity	(Straczkowski	
et	al.	2005;	Ropelle	et	al.	2010).	
	
This	 study	 suggests	 that	 the	energy	and	macronutrient	delivery	 in	 the	 later	phase	are	
associated	with	alterations	 in	the	 inflammatory	response	when	data	was	analysed	 in	a	
single	 cohort.	 However,	 we	 recorded	 inconsistency	 in	 the	 findings	 with	 further	
stratification	 to	 different	 age	 groups,	 which	 could	 be	 related	 to	 the	 reduction	 in	 the	
sample	 size.	This	 could	also	be	attributed	 to	variations	 in	macronutrient	 requirements	
between	 infants	and	older	children.	 It	 is	worth	mentioning	 that	 the	changes	 in	clinical	
condition	could	be	contributory	or	indeed	driving	this	association	to	a	large	extent	and	
this	needs	to	be	explored	in	further	studies.	
	
6.5 Limitations	
	
This	study	has	several	 limitations	 including	the	small	 sample	size	and	heterogeneity	of	
the	patient	cohort.	 It	would	have	been	ideal	to	divide	the	children	into	more	than	two	
age	 groups	 and	 investigate	 the	relationship	 between	 macronutrient	 and	 cytokines	
within	 each	 age	 group.	As	 this	 study	 suggests	 that	 fat	 intake	 may	 drive	 a	 pro-
inflammatory	response,	it	seems	prudent	to	investigate	the	relationship	between	n3:n6	
in	this	study.	In	this	smaller	patient	cohort,	where	formula	delivery	was	protocolised	and	
most	children	received	a	similar	type	of	formula,	this	type	of	analysis	was	not	feasible.	
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Within	the	linear	regression	model,	there	were	some	variables	with	a	low	r-	value	that	
limit	 how	 well	 the	 changes	 in	 inflammatory	 cytokines	 can	 be	 attributed	 to	 them.	
However,	 the	 results	 of	 the	 analysis	 appear	 to	 be	 in	 agreement	 with	 reported	
associations	 between	 macronutrient	 intake	 and	 inflammation	 in	 other	 disease	 states	
(Borst	&	Conover	2005;	Wu	et	al.	2016;	Shoelson	et	al.	2006;	Lee	et	al.	2010;	Sharman	&	
Volek	 2004;	Delgado	 et	 al.	 2008;	 Correia	 et	 al.	 2007;	 Ling	 et	 al.	 2004).	 It	 is	 clear	 that	
further	work	is	needed	to	establish	appropriate	enteral	fat	intake	in	critically	ill	children,	
and	 also	 to	 examine	 the	 effect	 of	 specific	 fat	 sources	 such	 MCT	 and	 omega-3	 on	
inflammatory	response	and	other	clinical	outcomes.	
6.6 Conclusion	
	
The	 inflammatory	 response	 in	 critically	 ill	 children	 is	 complex	 and	mediated	 by	many	
factors.	The	current	study	suggests	that	the	amount	of	enteral	fat	and	protein	delivery	
may	influence	the	inflammatory	response	in	children	with	prolonged	PICU	stay.	In	other	
words,	macronutrients	 are	 rather	 a	 contributing	 factor	 that	might	worsen	 or	 improve	
the	 inflammatory	 condition.	 Finally,	 the	 findings	 of	 this	 chapter	 emphasize	 the	
importance	 of	 providing	 balanced	 macronutrients	 in	 the	 enteral	 feeds	 to	 avoid	
deleterious	effect	over	or	underfeeding	on	the	inflammatory	response.		
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7 Chapter	 Seven:	 Association	 between	 Intestinal	 Injury	 and	
Systemic	Inflammation	in	Critical	Illness	
7.1 Introduction	
	
The	intestinal	environment	is	very	disrupted	in	critically	ill	children	due	to	a	combination	
of	physiological	stresses,	pharmacological	effects	and	a	lack	of	EN	(Krezalek	et	al.,	2016;	
Ferrer	et	al.,	2016;	Maier	et	al.,	2018).	As	a	result,	 the	synergy	between	the	 intestinal	
microbiome	and	the	host	is	adversely	affected	(Krezalek	et	al.,	2016;	Ferrer	et	al.,	2016).	
As	an	organ	with	extensive	nutritional,	metabolic,	endocrine	and	inflammatory	activities,	
intestinal	 dyshomeostasis	 may	 have	 systemic	 consequences	 (Petrova	 &	 Koh,	 2018;	
Furness,	 2008).	 Previous	 studies	 have	 speculated	 that	 the	 gastrointestinal	 tract	might	
play	 a	 driving	 role	 in	 the	 development	 of	 sepsis,	 SIRS	 and	 MODS,	 due	 to	 impaired	
intestinal	barrier	function	caused	by	the	inflammation	(MacFie	et	al.,	1999;	Earley	et	al.,	
2015;	Clark	&	Coopersmith,	2007).	
	
Assessment	of	intestinal	integrity	in	clinical	practice	is	challenging,	due	to	difficulties	in	
evaluating	the	condition	of	the	gut	with	invasive	tests,	such	as	the	oral	administration	of	
polyethylene	 glycols	 or	 dual	 sugar	 (Van	 Wijck	 et	 al.,	 2012).	 However,	 a	 number	 of	
biomarkers	 have	 been	 recently	 suggested	 as	 alternative	 diagnostic	 tools	 to	 assess	
intestinal	permeability	and	inflammation	(Derikx	et	al.,	2010).	Circulating	or	urinary	fatty	
acid	binding	proteins	(FABP)	have	been	proposed	as	markers	of	mucosal	tissue	injury	in	
neonates	 with	 suspected	 necrotising	 enterocolitis	 (Kanda	 et	 al.,	 1996;	 Derikx	 et	 al.,	
2007;	Grootjans	et	al.,	2010).	Serum	zonulin	and	urinary	claudin-3	have	been	suggested	
as	 indicators	 of	 tight	 junction	 injury	 in	 septic	 and	 surgical	 patients	 (Klaus	 et	 al.,	 2013;	
Derikx	et	al.,	2008).	Serum	citrulline	appears	to	be	a	predictive	marker	of	enterocyte	loss	
and	villous	atrophy	(Crenn	et	al.,	2009).	Faecal	calprotectin	(FC)	has	been	widely	utilised	
in	 clinical	 practice	 as	 an	assessment	 tool	 of	mucosal	 inflammation	 (Costa	et	 al.,	 2003;	
Komraus	et	al.,	2012;	Moein	et	al.,	2017).	
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Citrulline	 is	an	amino	acid	produced	mainly	by	enterocytes	of	the	small	 intestines,	and	
has	been	well	correlated	with	the	functional	enterocyte	mass,	and	also	with	prognosis	in	
ICU	 patients	 (Crenn	 et	 al.,	 2008;	 2009;	 Hull	 et	 al.,	 2011;	 Piton	 et	 al.,	 2010).	 Evidence	
suggests	that	citrulline	can	be	used	as	a	predictive	marker	of	enterocyte	loss	and	villous	
atrophy	 in	 patients	 with	 HIV	 (Crenn	 et	 al.,	 2009).	 Reduced	 citrulline	 levels	 were	 also	
recorded	in	children	with	intestinal	failure	who	developed	catheter-related	bloodstream	
infections,	 suggesting	 a	 potential	 role	 of	 citrulline	 as	 a	 marker	 of	 impaired	 intestinal	
barrier	 integrity	 (Hull	 et	 al.,	 2011).	 In	 addition,	 citrulline	 concentration	 was	 inversely	
correlated	with	highest	endotoxin	 level	 in	post-cardiac	arrest	patients	 (Grimaldi	 et	 al.,	
2013).	Low	plasma	citrulline	has	shown	to	be	an	independent	factor	of	mortality,	and	a	
marker	of	acute	intestinal	failure	in	critically	ill	patients	(Piton	et	al.,	2010).	The	findings	
of	 these	 studies	 underpin	 the	 idea	 that	 citrulline	 production	 is	 linked	 to	 intestinal	
functional	mass,	 and	 therefore	 influenced	by	 diseases	 affecting	 the	 gut	 (Sertaridou	 et	
al.,	 2015).	 Historically,	 gut	 permeability	 was	 assessed	 using	 chromatographic	 urinary	
analysis	after	oral	administration	of	polyethylene	glycols	or	dual	sugars	(Van	Wijck	et	al.,	
2012).	These	pose	several	challenges	in	the	clinical	context	of	critical	illness.	Firstly,	the	
need	 for	 administering	 polyethylene	 glycols	 or	 dual	 sugars,	 and	 secondly,	 the	
measurement	requires	the	collection	of	urine	over	a	prolonged	period	(4-6	hours).	Spot	
measurement	 of	 serum	 citrulline	 is,	 therefore,	 a	 potentially	 attractive	 tool	 for	 the	
assessment	of	intestinal	mucosal	disease	(Hull	et	al.,	2011).	The	value	of	serum	citrulline	
was	utilised	as	a	marker	of	reduced	enterocyte	mass,	as	it	has	been	well	correlated	with	
the	 functional	 enterocyte	 mass,	 and	 also	 with	 prognosis	 in	 the	 critically	 ill	 adult	
population	(Poole	et	al.,	2015;	Piton	et	al.,	2010).	
	
Calprotectin	 is	 a	 calcium	 and	 zinc-binding	 protein	 belonging	 to	 the	 S100	 family;	 it	 is	
derived	mainly	 from	activated	neutrophils	present	 in	 the	 intestinal	mucosa	and	 lumen	
(Ho	et	al.,	2015).	It	is	largely	stored	in	neutrophil	granulocytes,	and	to	a	lesser	extent	in	
monocytes	and	activated	macrophages	(Benítez	&	García-Sánchez,	2015).	Calprotectin	is	
also	 known	 to	 have	 antibacterial	 activity	 and	 may	 play	 a	 role	 in	 the	 induction	 of	
apoptosis	(Josefsson	et	al.,	2007).	Furthermore,	it	is	probably	involved	in	the	regulation	
of	 inflammatory	reactions	(Costa	et	al.,	2003).	A	faecal	Calprotectin	(FC)	concentration	
		
	
	
Chapter	Seven	
	
	 	
133	
of	 <50	 μg/g	 is	 considered	 the	 upper	 normal	 limit	 (Benítez	 &	 García-Sánchez,	 2015).	
During	bowel	inflammation,	raised	levels	of	calprotectin	are	detected	in	faeces.	Elevated	
levels	 of	 FC	 have	 been	 recorded	 in	 a	 number	 of	 gastrointestinal	 diseases,	 such	 as	
inflammatory	 bowel	 disease,	 colorectal	 cancer	 and	 Necrotizing	 Enterocolitis	 (NEC)	
(Costa	 et	 al.,	 2003;	 Komraus	 et	 al.,	 2012;	Moein	 et	 al.,	 2017).	 FC	 has	 been	previously	
used	in	the	diagnosis	and	monitoring	of	inflammatory	bowel	diseases	(Benítez	&	García-
Sánchez,	2015;	Ho	et	al.,	2015;	Moein	et	al.,	2017).	The	levels	of	FC	have	shown	a	good	
correlation	 with	 the	 degree	 of	 inflammatory	 activity	 in	 inflammatory	 bowel	 diseases	
(Benítez	 &	 García-Sánchez,	 2015).	 FC	 has	 also	 been	 investigated	 as	 a	 biomarker	 of	
mucosal	inflammation	in	NEC	and	intestinal	ischemia	reperfusion	(Ho	et	al.,	2015).	It	has	
been	 shown	 that	 FC	 level	 is	 a	 more	 specific	 marker	 of	 mucosal	 inflammation	 than	
circulating	CRP	(Benítez	&	García-Sánchez,	2015).	FC	provides	an	objective	evaluation	of	
the	gastrointestinal	tract	that	is	easy	to	use,	particularly	in	children,	for	many	reasons:	it	
is	easy	to	collect	stool	samples	from	children,	FC	is	stable	at	room	temperature	for	up	to	
one	week,	and	it	can	be	measured	easily	using	commercially	available	immunoassay	(Ho	
et	al.,	2015;	Andréasson	et	al.,	2011).	
	
The	previous	chapter	established	that	enteral	macronutrients	are	rather	a	contributing	
factor	that	might	worsen	or	 improve	the	inflammatory	condition.	The	main	aim	of	this	
study	 is	 to	 explore	 if	 critical	 illness	 is	 associated	 with	 abnormalities	 in	 gut	 health	
biomarkers	and	whether	this	is	associated	with	increase	in	inflammatory	cytokines.	The	
secondary	end	point	is	to	assess	the	effect	of	feeding	on	mucosal	integrity	during	critical	
illness.	
	
	
	
	
	
	
	
	
		
	
	
Chapter	Seven	
	
	 	
134	
7.2 Materials	and	Methods	
	
Both	healthy	and	critically	 ill	 children	were	 included	 in	 this	 study.	Where	comparisons	
were	 made	 between	 healthy	 and	 critically	 ill	 states,	 the	 analysis	 was	 restricted	 to	
samples	obtained	from	an	age-matched	cohort	of	critically	ill	and	healthy	children.	
	
Samples	collected:	
	
Faeces	
The	first	available	faecal	sample	was	collected	from	the	child’s	nappy	(around	300	mg)	in	
a	sterile	container.	A	volume	of	15	mg	was	required	for	the	analysis	of	FC.	
Serum	
Serial	blood	samples	were	collected	from	indwelling	vascular	catheters,	for	the	analysis	
of	serum	citrulline	and	 inflammatory	cytokines	 levels.	Samples	were	collected	at	day	1	
(TP1),	days	2-5	(TP2)	and	day	7	plus	(TP3)	following	PICU	admission.	Another	sample	was	
collected	for	cytokine	analysis,	to	match	the	time	of	the	faecal	sample	in	children	who	
had	indwelling	vascular	access	at	the	time	of	faecal	sampling.	
The	detailed	methodology	of	FC,	citrulline	and	inflammatory	cytokine	assays	is	described	
in	Chapter	Two,	pages	53-56.	
	
Nutritional	information:	
	
To	 investigate	 relationships	 between	 FC	 and	 citrulline	 with	 nutritional	 intake,	 the	
amount	of	energy	and	macronutrients	delivered	were	calculated	to	the	24-hour	period	
prior	to	each	sample	collection	(1	day	=24	hours).	The	cumulative	intake	of	energy	and	
macronutrients	 from	 admission	 was	 also	 calculated	 to	 assess	 the	 long-term	 effect	 of	
feeding.	
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7.2.1 Sample	size	calculation	
	
Sample	 size	 calculation	 was	 performed	 using	 the	 statistical	 power	 analysis	 program	
G*Power	3	(Faul	et	al.,	2007).	The	sample	size	was	chosen	to	test	the	hypothesis	that	
citrulline	 and	 FC	 levels	 are	 statistically	 increased	 during	 critical	 illness	 in	 response	 to	
intestinal	injury	and	inflammation,	respectively.	
Since	no	studies	in	critically	ill	children	have	investigated	citrulline	as	a	potential	marker	
of	intestinal	injury,	this	assumption	was	based	on	work	by	Poole	et	al.	(2015)	in	critically	
ill	adult	population.	The	mean	plasma	citrulline	level	was	15.2	μmol/L	in	the	critically	ill	
group,	 compared	 to	26.5	μmol/L	 in	healthy	 controls,	with	a	 recorded	difference	of	11	
μmol/L.	 It	 was	 estimated	 that	 16	 children	 per	 group	 would	 be	 needed	 to	 detect	 the	
same	difference	assuming	a	5%	significance	level	(2-sided)	and	90%	power.	
	
FC	 has	 also	 not	 been	 investigated	 before	 as	 a	 potential	 marker	 of	 intestinal	
inflammation	in	critically	ill	adults	or	children.	The	sample	size	calculation	was	based	on	
studies	of	inflammatory	bowel	diseases.	Many	studies	have	shown	a	marked	increase	in	
FC	 levels	 among	 patients	 with	 inflammatory	 bowel	 diseases	 compared	 to	 healthy	
subjects	 (Komraus	 et	 al.,	 2012;	 Chen	 et	 al.,	 2012;	Moein	 et	 al.,	 2017).	 These	 studies	
recorded	 a	 difference	 of	 (100-300)	 µg/g	 in	 FC	 levels	 between	 children	 with	 gastro-
inflammatory	 disorders	 and	 healthy	 children.	 Based	 on	 this	 assumption,	 it	 was	
estimated	 that	34	 children	per	group	would	be	needed	 to	detect	 the	 same	difference	
assuming	a	5%	significance	level	(2-sided)	and	90%	power.	
	
The	 second	 end	 point	 was	 the	 association	 between	 citrulline/FC	 and	 inflammatory	
cytokines.	 For	 an	 effect	 size	 of	 0.5	 and	90%	power,	 it	was	 estimated	 that	 31	 children	
would	 be	 needed	 to	 detect	 a	 statistical	 association	 between	 citrulline	 or	 FC	 and	
inflammatory	cytokines.	As	these	investigations	were	part	of	a	larger	study	assessing	gut	
homeostasis	 in	 critically	 ill	 children,	 rather	 than	 reducing	 the	 sample	 size,	 all	 children	
who	met	the	inclusion	criteria	of	the	current	study	were	included.	
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7.2.2 Statistical	analysis	
	
The	 statistical	 analysis	was	 conducted	using	 IBM	SPSS	v25	USA.	The	Shapiro-Wilk	Test	
was	 used	 to	 assess	 the	 normality	 of	 the	 data	 distribution.	Quantitative	 variables	with	
non-normal	 distribution	 were	 expressed	 as	 median	 with	 (25-75)	 interquartile	 ranges.	
Mann-Witney	U	was	used	to	compare	independent	groups	with	non-normal	distribution,	
such	 as	 differences	 in	 FC	 and	 citrulline	 between	 the	 patient	 and	 control	 groups.	 The	
Wilcoxon	 signed	 rank	 test	 was	 used	 to	 compare	 related	 samples	 with	 non-normal	
distribution,	 such	 as	 the	 difference	 in	 FC/citrulline	 levels	 in	 serial	 samples.	 Stepwise	
linear	 regression	 analysis	was	 applied	 to	 assess	 the	 relationship	 between	 FC/citrulline	
with	 inflammatory	 cytokines	 and	 clinical	 outcomes.	 A	 logistic	 regression	 was	 also	
performed	to	assess	the	effects	of	citrulline/FC	on	the	likelihood	that	critically	ill	children	
have	 sepsis.	 Log	 transformation	was	 performed	 on	 FC,	 citrulline,	 cytokines	 and	 other	
non-normally	distributed	variables	prior	to	regression	analysis.	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
		
	
	
Chapter	Seven	
	
	 	
137	
Patients	N=53	
Citrulline	
Controls	
N=17	
Serum	sample	
Patients	N=37	 Controls	N=17	
Faecal	sample	
Patients	
N=67	
FC	
Controls	
N=43	
Patients	
N=47	
Controls	
N=43	
TP1	
N=17	
TP2	
N=53	
TP1	
N=53	
TP3	
N=17	
TP1	
N=67	
TP2	
N=18	
TP1	
N=43	
TP1	
N=37	
TP1	
N=17	
TP1	
N=47	
TP1	
N=43	
Age	matched	
patients	and	controls		
Age	matched	
patients	and	controls		
7.3 Results	
	
The	data	used	in	this	chapter	was	derived	from	two	studies.	The	flow	of	each	study	and	
the	number	of	patients	and	healthy	controls	included	are	presented	in	Figure	7.1.	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	7.1	Study	participant	flow	diagram		
Figure	7.1	shows	the	number	of	study	participants	recruited	in	each	study,	as	well	as	the	number	of	age-
matched	healthy	children.	
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7.3.1 Assessment	of	intestinal	permeability	using	serum	citrulline	study	
	
Serum	samples	were	available	 from	53	 critically	 ill	 children	 (30	males)	 and	17	healthy	
children	(8	males).	Amongst	the	patient	cohort,	the	hospital	mortality	rate	was	5.6%	(3	
out	of	53	children).	The	demographics	of	patients	and	controls	are	shown	in	Table	7-1.		
The	results	showed	that	control	group	was	older	than	the	patients	group	even	after	the	
age	matching,	however,	the	difference	in	median	age	distribution	between	the	patients	
and	control	was	not	 statistically	 significant	 (p-value=	0.188).	 Since	 the	 serum	citrulline	
levels	are	known	to	be	affected	by	age,	 the	citrulline	was	plotted	against	age	for	both	
control	and	critically	 ill	to	see	if	there	were	differences	in	citrulline	at	each	age	(Figure	
7.2).	 	The	graph	showed	that	the	citrulline	varied	between	the	critically	 ill	and	healthy	
children	in	each	age,	indicating	a	good	age	matching.	
	
All	patients	received	at	least	one	broad-spectrum	antibiotic	therapy	and	75%	(N=40)	of	
them	received	more	than	one	type	of	antibiotics.	The	median	(IQR)	number	of	antibiotic	
classes	received	per	patients	was	2	(1-3).	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	7.2	Age	related	changes	of	citrulline	levels	in	critically	ill	children	and	their	age	
matched	controls		
The	 graph	 showed	 that	 the	 citrulline	 varied	 between	 the	 critically	 ill	 and	 healthy	 children	 in	 each	 age,	
indicating	 a	 good	 age	 matching.	 In	 critically	 ill	 children	 the	 citrulline	 levels	 increased	 with	 age,	 the	
citrulline	levels	remained	stable	in	controls.	
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Table	7-1:	Anthropometric	and	clinical	characteristics	of	children	enrolled	in	the	study	
	
	
Anthropometry	
All	patients	and	controls		 Age-matched	patients	and	controls	
Patients	
(N=53)	
Control	
(N=17)	
P-	value		 Patients	
(N=37)	
Control	
(N=17)	
P-	value		
Age	(Years)	 2.2	
(		0.9		–		4.4		)	
6.3	
(			2.3		–		7.2			)	
0.016**	 4.3	
(				2.1	–9.4			)	
7.4	
	(	2.7		–		13.7		)	
0.188	
Weight	(Kg)	 12	
(		8.5		–		17				)	
18	
(					3		–		25					)	
0.003**	 14.8		
(			11.9	to	24		)	
18.9	
(	13.5		–		7.3		)	
0.032*	
Height	(cm)	 88	
(				69	–	109				)	
112	
(			90	–	130					)	
0.00**	 100	
(				85	–	121			)	
115	
(				93	–	133				)	
0.010*	
Weight	age	Z-	
score	
-0.3	
(		-1		–		0.46			)	
0.45	
(-0.08		–		0.73)	
0.423*	 -0.33	
(	-1.41		–	0.54)	
0.3	
(		-0.1		–		0.67)	
0.678*	
Height	for	age	Z-	
score	
-0.3	
(		-1		–		1						)	
-0.12	
(-	0.65		–		0.6	)	
0.181	 0.07	
(		-1.1		–		1.3			)	
0.14	
		(		-0.5		–		0.7	)	
0.41	
Disease	severity	variables	
PMODS	 5	
(						4	–	6						)	
	 6	
(						4	–	6				)	
	
PIM2	score		
	
3.6	
(			1.1	–	6.4			)	
3.9	
(			0.96–	8.4	)	
Highest	Lactate	 1.8	
(		0.97	–	3.3		)	
2.1	
(		0.90	–	3.2		)	
Highest	CRP	 92	
(			39	–	257			)	
137	
(		34	–	262		)	
Inotrope	score		 0.0	
(					0	–	15					)	
0.0	
(				0	–	15				)	
VFH	at	30	days		 616	
(	541		–		648	)	
630	
(	501	–	653	)	
PICU-free	days	at	
30	days		
22	
(					17	–	24			)	
22	
(				16	–	24			)	
Inotrope-free	
hours	at	30	days	
710	
(	667		–		720	)	
715	
(		669–	720	)	
Primary	admission	
diagnosis	
N	(%)	
MOF	 19			(36%)	
Respiratory	failure	 20			(38%)	
CNS	Disorders	 11			(20%)	
Surgical	Disorders		 2					(	4%		)	
Cardiac	Disorders	 1					(		2%	)	
																																																														
																																																							Data	are	presented	as	median	(IQR)	
**	P-	value	is	significant	at	0.01	level																							*	P-	value	is	significant	at	0.05	level	
• PICU-free	days	at	30	days:	days	free	of	Paediatric	intensive	care	at	30	days	
• VFH	at	30	days:	ventilation-free	hours	at	30	days	
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7.3.1.1 Citrulline	in	critically	ill	and	healthy	states	
	
From	all	of	the	53	critically	ill	children,	TP1	and	TP2	samples	were	collected.	The	TP3	
sample	was	obtainable	only	from	17	critically	children.	
The	 results	 showed	 that	 critically	 ill	 children	 had	 statistically	 lower	 serum	 citrulline	
(measured	 in	admission	sample)	compared	to	age-matched	healthy	children	 (P	=	0.00)	
(Figure	7.3).	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	 7.3	 Differences	 in	 citrulline	 levels	 between	 patients	 and	 their	 age-matched	
healthy	controls	
Figure	7.3	shows	that	the	level	of	citrulline	measured	in	the	first	sample	obtained	from	the	patient	group	
was	statistically	lower	than	that	of	the	control	group	p-value		=	0.00**.	
	
	
values	are	presented	as	median	and	IQR	
P<0.001*	
N=37	
N=17	
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Median	 c i t ru l l ine	
l e v e l	 i n	 h e a l t h y	
controls	
values	are	presented	as	median	and	IQR	
N=53	
N=25	 N=13	
N=11	
N=12	
N=8	
A	time	course	analysis	of	serum	citrulline	was	undertaken	and	is	presented	in	Figure	7.4.	
The	 results	 showed	 that	 citrulline	 levels	 increased	 gradually	 over	 the	 course	 of	 PICU	
stays.	 However,	 the	 citrulline	 levels	were	 low	 in	 8	 patient	 samples	 obtained	 between	
days	8	and	10.	These	children	were	very	sick	upon	admission	to	PICU;	their	median	(IQR)	
PIM2	 score	 was	 5	 (1.7–7.2)	 and	 6	 of	 them	 had	 MOF.	 Their	 median	 (IQR)	 admission	
citrulline	 level	 was	 9.6	 (2.1–18.7)	 and	 remained	 low	 in	 the	 later	 sample	 obtained	
[median	(IQR)	9.7	(7.6	–	20.6)].	
	
The	 variation	 in	 citrulline	 levels	 was	 then	 assessed	 in	 the	 paired	 samples,	 where	 the	
analysis	was	restricted	to	children	who	had	samples	from	each	of	the	time	points	being	
compared.	 No	 statistical	 difference	 in	 citrulline	 concentration	 was	 recorded	 between	
TP1	and	TP2	samples	(p=0.17).	In	a	subset	of	17	patients	who	had	a	PICU	stay	of	at	least	
7	 days,	 there	 was	 no	 evidence	 of	 statistical	 difference	 in	 citrulline	 concentration	
between	TP1	and	TP3	samples	(p=0.30)	(Figure	7.5).	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	7.4	Changes	in	the	levels	of	serum	citrulline	in	different	stages	following	PICU	
admission	
The	above	figure	shows	that	citrulline	levels	increased	gradually	over	the	course	of	PICU	stays.	However,	
the	citrulline	levels	were	low	in	the	samples	obtained	between	days	8	and	10.	
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values'are'presented'as'median'and'IQR'
P>0.05&
N=17&
N=17&
a)	
b)	
values	are	presented	as	median	and	IQR	
P>0.05	
N=53	
N=53	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	7.5	Comparing	the	levels	of	serum	citrulline	in	the	paired	samples	
	
Figure	 7.5	 a)	 shows	 the	 difference	 in	 citrulline	 levels	 between	 TP1	 and	 TP2	 samples	 in	 all	 recruited	
children.	Figure	7.4	b)	shows	the	difference	in	citrulline	levels	between	TP1	and	TP3	samples	in	a	subset	of	
children	who	stayed	for	a	longer	period.	The	above	figure	shows	that	the	level	of	citrulline	measured	on	
admission	was	lower	than	in	the	other	consecutive	samples,	though	no	evidence	of	statistical	difference	
was	recorded,	p-value	>0.05.	
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7.3.1.2 The	effect	of	disease	severity	and	medications	on	citrulline	levels	
	
This	 section	of	 the	analysis	aims	 to	explore	whether	disease	 severity,	 inotropic	agents	
and	duration	of	antibiotic	therapy	influenced	intestinal	permeability.	Since	TP1	samples	
were	collected	on	day	1,	it	was	not	possible	to	investigate	the	effect	of	medications	on	
citrulline	concentration	in	those	samples.	Therefore,	only	TP2	and	TP3	were	included	in	
this	analysis.	The	regression	analysis	indicated	that	inotrope	score	was	the	only	variable	
statistically	related	to	citrulline	(r=	-0.279,	p-value=0.013)	(Table	7-2).	
	
Table	7-2:	Association	between	citrulline,	medications	and	clinical	variables	
 
Model	 R	2	 Adjusted	R	2	 R	 P-value	
Citrullinea	 0.279	 0.078	 0.066	 	
Inotrope	score	b	 	 -0.279	 0.013*	
Age	c	 -0.043	 0.710	
PIM2	score	c	 -0.018	 0.897	
Days	of	antibiotic	exposure	c	 0.188	 0.099	
	
a. Dependent	variable	
b. Predictors:	(constant)	
c. Excluded	variables	
	
7.3.1.3 The	effect	of	feeding	on	citrulline	concentrations	
	
This	section	of	the	analysis	aims	to	explore	whether	feeding	in	PICU	influenced	intestinal	
permeability	during	PICU	stays,	 independently	from	age	disease	severity.	Data	from	17	
children	 were	 included	 in	 the	 regression	 models.	 To	 investigate	 the	 effect	 of	 the	
cumulative	nutritional	intake	on	citrulline	concentration,	only	citrulline	measured	in	the	
later	 stages	 of	 illness	 (TP3	 sample	 obtained	 from	 day	 7	 onward)	 was	 used	 for	 this	
analysis	 (N=17).	 The	 results	 showed	 that	 there	was	 no	 statistical	 association	 between	
citrulline	and	the	amount	energy	and	macronutrients	received	during	the	24hours	prior	
the	 collection	 of	 serum	 samples.	 	 However,	 the	 regression	 analysis	 indicated	 that	 the	
cumulative	intake	of	enteral	fat	was	statistically	related	to	citrulline,	(r=0.540,	p=0.017),	
(Table	7-3).	
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Table	7-3:	Association	between	citrulline	and	the	amount	of	nutrition	received	in	PICU	
	
a. Dependent	variable	
b. Predictors:	(constant)	
c. Excluded	variables	
	
	
7.3.1.4 Association	between	intestinal	injury	and	systemic	inflammation	
	
The	relationship	between	intestinal	injury	and	systemic	inflammation	was	explored	in	53	
children	where	serum	samples	were	collected	on	admission	for	the	analysis	of	citrulline	
and	 the	 inflammatory	 cytokines.	 Stepwise	 linear	 regression	analysis	was	performed	 to	
determine	 whether	 intestinal	 injury/permeability	 assessed	 by	 Serum	 citrulline	
independently	 influenced	 systemic	 inflammation.	 The	 regression	models	 that	 included	
inflammatory	 cytokines	 as	 the	 outcome	 variables	 suggested	 that	 citrulline	 statistically	
related	to	IL-6,	TNF-α,	IL-1β	and	IL-10	(Table	7-4).	
	
	
	
	
	
Model	 R	2	 Adjusted	R	2	 R	 P-value	
Citrulline	a	 0.290	 0.243	 	
Age	b	 	 -0.539	 0.009*	
PIM2	score	c	 0.174	 0.238	
%	of	energy	received	c		 0.185	 0.	225	
%	of	carbohydrate	received	c	 0.344	 0.075	
%	of	protein	received	c	 0.183	 0.225	
%	of	fat	received	c	 0.401	 0.044	
Citrulline	a	 0.291	 0.250	 	
Cumulative	fat	received	b	 	 0.540	 0.009*	
Age	c	 -0.539	 0.009	
PIM2	score	c	 0.174	 0.238	
Cumulative	energy	received	c		 0.357	 0.067	
Cumulative	carbohydrate	received	c	 0.502	 0.014	
Cumulative	protein	received	c	 0.419	 0.037	
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Table	7-4:	Association	between	citrulline	and	inflammatory	cytokines	
	
Model	 R	2	 Adjusted	R	2	 R	 P-value	
IL-6	a		 0.366	 0.336	 	
Citrulline	b		 	 -0.407	 0.002*	
PIM2	score	b	 	 0.436	 0.001*	
Age	c	 -0.093	 0.269	
TNFα	a		 0.501	 0.466	 	
Citrulline	b	 	 -0.315	 0.037*	
PIM2	score	b	 -0.521	 0.002*	
Age	b	 -0.469	 0.007*	
IL-1β	a		 0.202	 0.165	 	
Citrulline	b	 	
	
	
-0.342	 0.010*	
PIM2	score	b	 0.284	 0.028*	
Age	c	 -0.111	 0.224	
IL-10	a	 0.261	 0.226	 	
Citrulline	b	 	
	
	
-0.344	 0.010*	
PIM2	score	b	 0.369	 0.006*	
Age	c	 -0.152	 0.157	
	
a. Dependent	variable	
b. Predictors:	(constant)	
c. Excluded	variables	
	
7.3.1.5 Association	between	serum	citrulline	and	sepsis	in	critically	ill	children	
	
Sepsis	was	diagnosed	according	to	the	criteria	described	in	the	method	chapter	(Chapter	
Two).	 Sepsis	 diagnosis	 was	 documented	 in	 32	 out	 of	 53	 children.	 In	 15	 children	 the	
primary	site	of	infection	was	the	respiratory	system,	8	children	in	CNS,	and	8	children	in	
blood	(see	Table	7-5).	
	
Table	7-5:	Citrulline	levels	in	three	groups	of	patients	with	sepsis	
	 Primary	site	of	infection	
Respiratory	
N=16	
CNS	
N=8	
Blood	
N=8	
Citrulline		 12.2	(6.7–20.9)	 20.9	(6.7–23)	 8	(6.7–	17	)	
Day	of	sample	collection	 1	 1	 1	
Days	of	antibiotic	exposure		 1	 1	 1	
	
																																																																Data	are	presented	as	median	(IQR)	
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The	first	step	of	the	analysis	was	comparing	the	levels	of	admission	citrulline	in	children	
who	 developed	 sepsis	 and	 those	who	 did	 not.	No	 evidence	 of	 statistical	 difference	 in	
serum	 citrulline	 was	 recorded	 between	 septic	 children	 and	 non-septic	 children	 (p	 =	
0.729).	 A	 logistic	 regression	 was	 also	 performed	 to	 assess	 the	 relationship	 between	
serum	citrulline	measured	 in	 the	admission	 sample	and	sepsis	 (Table	7-5).	The	 logistic	
regression	model	was	 not	 statistically	 significant,	 χ2	 (6)	 =	 9.3,	 p	 =	 0.155.	None	of	 the	
included	variables	were	statistically	related	to	the	incidence	of	sepsis	(Table	7-6).	
	
Table	7-6:	Regression	model	to	assess	the	relationship	between	serum	citrulline	and	
sepsis	
	
a. Dependent	variable	
b. Predictors	
c. Insignificant	variables	
	
7.3.1.6 Association	between	citrulline	and	clinical	outcomes	in	critically	ill	children	
	
I	also	investigated	the	effect	of	intestinal	injury	assessed	by	serum	citrulline	measured	in	
the	 admission	 sample	 on	 clinical	 outcomes.	 No	 statistical	 association	 was	 recorded	
between	 citrulline	 and	 length	of	 ventilation,	 duration	of	 PICU	 stay,	 or	 the	duration	of	
inotrope	 treatment	 (Table	 7-7).	 In	 addition,	 no	 evidence	 of	 statistical	 difference	 was	
recorded	 between	 children	 treated	 with	 inotrope	 and	 those	 who	 did	 not	 receive	
inotrope	treatment	(p=0.231).	
	
	
Model	 Model	statistics	χ2	 	
B	
	
	
Exp	(B)	
	
Significance	
Sepsis	a	 χ2	(6)	=	9.6,	p-value=	0.155	 	
Citrulline	c	 	 0.239	 1.27	 0.485	
Age	c	 0.37	 1.447	 0.566	
PIM2	score	c	 0.432	 1.54	 0.598	
Highest	TNFα	c	 1.926	 6.861	 0.253	
Highest	IL-6	c	 1.026	 2.789	 0.164	
Highest	IL-1	β	c	 -1.797	 0.166	 0.105	
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Table	7-7:	Association	between	citrulline	and	clinical	outcomes	
	
	
a. Dependent	variable	
b. Predictors:	(constant)	
c. Excluded	variables	
	
	
7.3.2 Assessment	of	intestinal	inflammation	using	FC	study	
	
FC	 was	 measured	 in	 67	 critically	 ill	 children	 (33	 males)	 and	 43	 healthy	 children	 (21	
males).	Amongst	 the	patient	cohort,	 the	hospital	mortality	 rate	was	5.9%	 (4	out	of	67	
children).	The	demographics	of	patients	and	controls	are	shown	in	(Table	7-8).		
All	patients	received	at	least	one	broad-spectrum	antibiotic	therapy	and	63%	(N=42)	of	
them	received	more	than	one	type	of	antibiotics.	The	median	(IQR)	number	of	antibiotic	
classes	received	per	patients	was	2	(1-3).	
	
	
	
	
	
	
Model	 R	2	 Adjusted	R	2	 R	 P-value	
VFH	at	30	days	a	(N=53)	
Citrulline	c		 	 -0.193	 0.096	
Age	c	 -0.257	 0.040	
PIM2	score	c	 -0.159	 0.143	
PICU-free	days	at	30	days	a	(N=53)	
Citrulline	c		 	 -0.245	 0.048	
Age	c	 -0.203	 0.085	
PIM2	score	c	 -0.158	 0.144	
Hours	free	of	Inotrope	at	30	days	a	(N=20)	
Citrulline	c	 	 -0.153	 0.260	
Age	c	 0.244	 0.150	
PIM2	score	c	 0.009	 0.486	
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Table	7-8:	Anthropometric	and	clinical	characteristics	of	children	enrolled	in	the	study	
	
	
Anthropometry	
All	patients	and	controls		 Age-matched	patients	and	controls	
Patients	
(N=67)	
Control	
(N=43)	
P-	value		 Patients	
(N=47)	
Control	
(N=43)	
P-value	
value		
Age	 2.1	
(		0.9		–	4.4		)	
4.5	
(	2.3		–		7.2			)	
0.001**	 3.25	
(					2	–6.1						)	
4.5	
(			2.3		–		7.2	)	
0.13	
Weight	(Kg)	 12	
(		8.5		–		17		)	
18	
(			3		–		25						)	
0.00**	 14.8		
(		11.9		–		24		)	
18	
(					3		–	25					)	
0.04*	
Height	(cm)	 88	
(				69	–	109	)	
114	
(91.0	–	130.0	)	
0.00**	 100	
(				85	–	121			)	
114	
(91.0	–	130.0)	
0.010*	
Weight	age	Z	-
score	
-0.3	
(	-1		–		0.46	)	
0.45	
(-0.08		–		0.73)	
0.01*	 -0.33	
(	-1.41		–	0.54)	
0.45	
(-0.08		–		0.73)	
0.04*	
Height	for	age	Z	-
score	
-0.3	
(		-1		–		1						)	
-0.12	
(-	0.65		–		0.6	)	
0.18	 0.07	
(	-1.1		–		1.3				)	
-0.12	
(-	0.65		–		0.6	)	
0.50	
Disease	severity	variables	
PMODS	 5	
(						4	–	6						)	
	 6	
(						4	–	6				)	
	
PIM2	score		
	
3.8	
(				1.2	–	9.8		)	
3.9	
(			1.8	–	9.7	)	
Highest	Lactate	 1.9	
(			1.9	–	3.3			)	
1.9	
(		1.2	–	3.3		)	
Highest	CRP	 105	
(				42	–	210		)	
136	
(		35	–	260		)	
Inotrope	score		 0.0	
(					0	–	20					)	
0.0	
(				0	–	26				)	
VFH	at	30	days		 627	
(	549	to	669	)	
628	
(	524	–	669	)	
PICU-free	days	at	
30	days		
22	
(				18	–	25				)	
22	
(				17	–	25			)	
Inotrope-	free	
hours	at	30	days	
720	
(682	to	720	)	
712	
(		669–	720	)	
Primary	admission	
diagnosis	
N	(%)	
MOF	 26			(39%)	
Respiratory	failure	 24			(34%)	
CNS	Disorders	 14			(21%)	
Surgical	Disorders		 4					(	6%		)	
																																																				
																																													Data	are	presented	as	median	(IQR)	
**	P-	value	is	significant	at	0.01	level																							*	P-	value	is	significant	at	0.05	level	
• VFH	at	30	days:	ventilation-free	hours	at	30	days	
• PICU-free	days	at	30	days:	days	free	of	Paediatric	intensive	care	at	30	days	
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values	are	presented	as	median	and	IQR	
P<0.05*	
N=47	
N=43	
FC
	(μ
g/
g)
	
7.3.2.1 FC	in	critically	ill	and	healthy	states	
	
Eighty-five	 samples	 were	 obtained	 from	 the	 patient	 group	 and	 43	 from	 the	 healthy	
control	group.	In	most	children,	a	single	faecal	sample	was	collected.	Eighteen	children	
had	a	second	sample	collected	during	their	PICU	stay.	The	age-matched	population	was	
represented	 by	 47	 critically	 ill	 children	 and	 43	 controls.	 Critically	 ill	 children	 had	
statistically	 higher	 levels	 of	 FC	 measured	 in	 the	 first	 sample	 obtained	 compared	 to	
healthy	 children	 (P	 =	 0.02)	 (Figure	 7.6).	 Among	 healthy	 children,	 FC	 was	 negatively	
correlated	with	age	(p=0.01)	and	weight	(p=	0.02),	 indicating	that	younger	and	smaller	
children	had	higher	FC	levels.	However,	no	such	correlation	was	recorded	in	critically	ill	
children	(Figure	7.7).	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	7.6	Differences	in	FC	levels	between	patients	and	age-matched	healthy	controls		
Figure	 7.6	 shows	 that	 the	 levels	 of	 FC	measured	 in	 the	 samples	 obtained	 from	 the	patient	 group	were	
statistically	higher	than	in	those	of	the	control	group	p-value	=	0.031*.	
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Figure	 7.7	 Age	 related	 changes	 of	 FC	 levels	 in	 critically	 ill	 children	 and	 their	 age	
matched	controls		
Figure	 7.7	 shows	 that	 FC	 in	 the	 healthy	 children	 is	 negatively	 correlated	 with	 age	 (p=0.01).	 No	 such	
correlation	was	recorded	in	critically	ill	children	no	particular	pattern	of	FC	was	recorded	with	age.	
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The	differences	in	FC	levels	between	the	first	sample	and	second	sample	were	compared	
in	 18	 critically	 ill	 children,	where	 two	 faecal	 samples	were	 available.	 The	 levels	 of	 FC	
appear	 to	be	 reduced	 in	 the	 later	 stages	of	disease	compared	 to	 the	early	 stages	 (P	=	
0.02)	(Figure	7.8).	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	7.8	Changes	in	FC	level	during	the	course	of	illness	
Figure	7.8	 shows	 the	differences	 in	 FC	 levels	 between	 sample	1	 and	 sample	2	obtained	 from	 the	 same	
patients.	Clearly	FC	levels	were	higher	in	the	first	sample,	then	gradually	decrease	over	the	PICU	stay	p=	
0.021*.	
In	 graph	 a)	 data	 are	 presented	 as	 median	 values,	 and	 graph	 b)	 is	 a	 graphic	 illustration	 of	 the	 data	
expressed	as	individual	data	points.	
P<0.05*'
N=18'
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7.3.2.2 The	effect	of	disease	severity	and	medications	on	FC	levels	
	
This	 section	of	 the	analysis	aims	 to	explore	whether	disease	 severity,	 inotropic	agents	
and	the	duration	of	antibiotic	therapy	influenced	intestinal	 inflammation.	The	FC	value	
measured	in	the	first	sample	obtained	from	each	child	(between	days	3-5)	was	included	
in	 the	 analysis.	 The	 regression	 analysis	 indicated	 that	 inotrope	 score	 was	 the	 only	
variable	statistically	related	to	FC	(r=	0.293,	p-value=0.018),	(Table	7-9).	
	
Table	7-9:	Association	between	FC,	medications	and	clinical	variables	
 
Model	 R	2	 Adjusted	R	2	 R	 P	value	
FC	a	 0.293	 0.086	 0.071	 	
	Inotrope	score	b	 	 0.293	 0.0.018*	
Age	c	 -0.031	 0.679	
PIM2	score	c	 -0.061	 0.634	
Days	of	antibiotic	exposure	c	 -0.128	 0.314	
 
 
a. Dependent	variable	
b. Predictors:	(constant)		
c. Excluded	variables	
	
7.3.2.3 The	effect	of	feeding	on	FC	levels	
	
This	section	of	the	analysis	aims	to	explore	whether	feeding	in	PICU	influenced	intestinal	
inflammation	 during	 PICU	 stays	 independently	 from	 age	 and	 disease	 severity.	 The	 FC	
value	measured	 in	 the	 first	 sample	 obtained	 from	 each	 child	 (between	 days	 3-5)	was	
included	in	the	analysis.	
	
No	 evidence	 of	 statistical	 association	 was	 recorded	 between	 FC	 and	 the	 amount	 of	
energy	and	macronutrients	received	during	the	24-hour	period	prior	to	the	collection	of	
faecal	samples.	In	addition,	the	cumulative	amount	of	nutrition	received	from	admission	
to	the	time	of	the	sample	collection	was	not	statistically	associated	with	any	variation	in	
FC	concentration	(Table	7-10).	
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Table	7-10:	Association	between	FC	and	the	amount	of	nutrition	received	in	PICU	
Model	 R	2	 Adjusted	R	2	 R	 P-value	
FC	a	
Age	c	 	 0.035	 0.399	
PIM2	score	c	 -0.031	 0.412	
%	of	energy	received	c		 0.091	 0.256	
%	of	carbohydrate	received	c	 -0.062	 0.328	
%	of	protein	received	c	 -0.037	 0.391	
%	of	fat	received	c	 -0.104	 0.227	
FC	a	
Age	c	 	 0.035	 0.399	
PIM2	score	c	 -0.021	 0.440	
Cumulative	energy	received	c		 -0.101	 0.232	
Cumulative	carbohydrate	received	c	 -0.185	 0.088	
Cumulative	protein	received	c	 -0.184	 0.089	
Cumulative	fat	received	c	 -0.199	 0.073	
	
a. Dependent	variable	
b. Predictors:	(constant)	
c. Excluded	variables	
	
7.3.2.4 Association	between	intestinal	and	systemic	inflammation	
	
The	 relationship	 between	 intestinal	 and	 systemic	 inflammation	 was	 explored	 in	 32	
children,	 where	 serum	 samples	 were	 collected	 at	 the	 time	 of	 obtaining	 the	 faecal	
sample.	 Stepwise	 lineal	 regression	 analysis	 was	 performed	 to	 determine	 whether	
intestinal	inflammation	assessed	by	FC	influenced	systemic	inflammation	independently	
from	age	and	disease	severity.	The	regression	models	that	included	IL6	and	TNFα	as	the	
outcome	variables	suggested	that	FC	is	statistically	related	to	both	IL6	and	TNFα,	but	no	
evidence	of	statistical	association	was	observed	between	FC	and	IL1β	and	IL-10	(Table	7-
11).	
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Table	7-11:	Association	between	FC	and	inflammatory	cytokines	
Model	 R	2	 Adjusted	R	2	 R	 P-value	
IL-6	a		 0.366	 0.345	 	
FC	b		 	 0.605	 0.00*	
Age	c	 -0.008	 0.483	
PIM2	score	c	 -0.132	 0.235	
TNFα	a		 0.143	 0.115	 	
FC	b		 	 0.379	 0.016*	
Age	c	 -0.315	 0.040	
PIM2	score	c	 -0.001	 0.997	
IL-1β	a		
FC	c		 	 0.324	 0.035	
Age	c	 0.156	 0.197	
PIM2	score	c	 -0.048	 0.397	
IL-10	a	 	
FCc		 	 0.210	 0.125	
Age	c	 -0.014	 0.947	
PIM2	score	c	 -0.104	 0.286	
a. Dependent	variable	
b. Predictors:	(constant)	
c. Excluded	variables	
	
7.3.2.5 Association	between	FC	and	the	incidence	of	sepsis	in	critically	ill	children	
	
Sepsis	was	diagnosed	according	to	the	criteria	described	in	the	method	chapter	(Chapter	
Two).	 Sepsis	 diagnosis	 was	 documented	 in	 25	 out	 of	 67	 children.	 In	 15	 children	 the	
primary	site	of	infection	was	the	respiratory	system,	for	5	children	in	CNS,	and	5	children	
in	blood	(see	Table	7-12).	
Table	7-12:	FC	levels	in	three	groups	of	patients	with	sepsis	
	 Primary	site	of	infection	
Respiratory		
N=15	
CNS	
N=5	
Blood		
N=5	
FC	 374	(181	–	633)	 361	(176	–	843)	 1860	(320	–	2148	)	
Day	of	sample	collection	 5						(				3	–		7				)	 3						(			1		–		7			)	 4								(			1			–		5					)	
Days	of	antibiotic	exposure		 5						(				3	–		7				)	 3						(			1		–		7			)	 4								(			1			–		5					)	
																																																										Data	are	presented	as	median	(IQR)	
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P<0.05*	
N=25	
N=42	
_	
			
			
			
			
FC
	(μ
g/
g)
	
values	are	presented	as	median	and	IQR	
Sepsis																																																													Non-sepsis	
The	 first	 step	of	 the	 analysis	was	 comparing	 FC	 levels	 in	 children	who	had	 sepsis	 and	
those	who	did	not.	The	results	 indicated	that	septic	children	had	statistically	higher	FC	
levels	compared	to	the	non-septic	group	(p=0.03)	(Figure	7.9).	A	logistic	regression	was	
then	 performed	 to	 assess	 the	 relationship	 between	 FC	 and	 sepsis	 (Table	 7-10).	 The	
logistic	regression	model	was	statistically	significant,	χ2	(6)	=	19.6,	p-value=	0.003.	The	
model	explained	41.3%	(Nagelkerke	R2)	of	the	variance	in	sepsis	and	correctly	classified	
81%	of	the	cases.	In	this	regression	model,	FC	was	the	only	variable	statistically	related	
to	the	incidence	of	sepsis.	Increasing	FC	was	associated	with	an	increased	likelihood	of	
having	sepsis.	(Table	7-13).	
	
	
	
	
	
	
	
	
	
	
Figure	7.9	Difference	in	FC	level	between	sepsis	and	non-sepsis	patients		
Figure	7.9	shows	that	septic	patients	had	significantly	higher	FC	levels	compared	to	the	non-septic	group\	
	
Table	7-13:	Regression	model	to	assess	the	relationship	between	FC	and	sepsis	
a. Dependent	variable	
b. Predictors	
c. Insignificant	variables	
Model	 Model	 statistics	
χ2	
Nagelkerke	
R2	
Classification	
accuracy	
	
B	
	
	
Exp	
(B)	
	
Significance	
Sepsis	a	 χ2	 (6)	 =	 19.6,	 p-
value	=	0.003	
0.413	 81%	 	 	 	
FC	b	 	 1.226	 3.407	 0.045*	
Highest	TNFα	c	 2.5	 12.18	 0.079	
Age	c	 0.037	 1.037	 0.947	
PIM2	score	c	 0.149	 1.161	 0.851	
Highest	IL-6	c	 1.037	 2.819	 0.105	
Days	of	antibiotic	exposure	c	 -0.057	 0.944	 0.701	
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7.3.2.6 Association	between	FC	and	clinical	outcomes	in	critically	ill	children	
	
The	effect	of	 intestinal	 inflammation	assessed	by	FC	 (measured	 in	 the	 first	sample)	on	
clinical	outcomes	was	also	investigated.	There	was	no	evidence	of	statistical	association	
between	 FC	 and	 length	 of	 ventilation;	 however,	 a	 weak	 negative	 association	 was	
recorded	between	FC	and	the	duration	of	a	PICU	stay	 (Table	7-14).	 In	children	treated	
with	 inotrope	 (n=32),	 FC	 was	 negatively	 correlated	 with	 the	 duration	 of	 inotrope	
treatment	 (r=-0.437,	 p=0.006).	 In	 the	 regression	model,	 FC	 accounted	 for	 19%	 of	 the	
variation	in	the	duration	of	inotrope	treatment	(Table	7-14).	
	
Table	7-14:	Association	between	FC	and	clinical	outcomes	
Model	 R	2	 Adjusted	R	2	 R	 P-value	
VFH	at	30	days	a	(N=67)	 	 	 	
FC	c		 	 -0.024	 0.423	
Age	c	 -0.235	 0.028	
PIM2	score	c	 0.070	 0.286	
PICU-free	days	at	30	days	a	(N=67)	 0.95	 0.54	 	 	
FC	b	 	 -0.243	 0.045*	
Age	c	 -0.132	 0.291	
PIM2	score	c	 	0.097	 0.438	
Hours	free	of	Inotrope	at	30	days	a	(N=32)	 0.191	 0.164	 	
FC	b	 	 -0.437	 0.006*	
Age	c	 -0.234	 0.099	
PIM2	score	c	 0.176	 0.168	
	
a. Dependent	variable	
b. Predictors:	(constant)	
c. Excluded	variables	
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7.3.3 Relationship	between	serum	citrulline	and	FC	in	critically	ill	children	
	
In	 a	 subset	 of	 20	 children,	 the	 association	 between	 serum	 citrulline	 and	 FC	 was	
investigated	where	 concomitant	 blood	 and	 faecal	 samples	 were	 available.	 The	 serum	
levels	 of	 citrulline	 and	 cytokines	were	 paired	 to	 levels	 of	 FC	measured	 in	 the	 nearest	
faecal	sample	obtained.	The	faecal	samples	were	collected	within	a	median	of	3	days	of	
the	 blood	 sampling.	 In	 this	 small	 cohort	 no	 evidence	 of	 statistical	 association	 was	
recorded	between	FC	and	citrulline	(r=0.170,	p=0.500).	The	regression	analysis	indicated	
that	TNFα	and	IL-6	were	the	only	variables	statistically	related	to	citrulline	(Table	7-15).	
	
Table	7-15:	Association	between	FC	and	serum	citrulline	
Model	 R	2	 Adjusted	R	2	 R	 P-value	
Citrulline	a		 0.545	 0.492	 	
IL-6	b	 	 -0.592	 0.008*	
TNFα	b	 -0.548	 0.015*	
FC	c		 -0.170	 0.500	
Age	c	 0.170	 0.510	
PIM2	score	c	 -0.095	 0.706	
	
a. Dependent	variable	
b. Predictors:	(constant)	
c. Excluded	variables	
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7.4 Discussion	
	
This	 study	 showed	 that	 critically	 ill	 children	 had	 decreased	 levels	 of	 citrulline,	 and	
increased	 FC	 concentration,	 compared	 to	 age-matched	 healthy	 controls.	 In	 addition,	
decreased	 citrulline	 concentrations	 and	 increased	 FC	 levels	 were	 associated	 with	
elevation	in	pro-inflammatory	cytokines	levels	and	longer	of	PICU	stay.	In	a	small	cohort	
of	20	critically	ill	children,	where	both	FC	and	citrulline	were	measured,	no	evidence	of	
statistical	correlation	was	recorded	between	the	two	biomarkers.	
	
The	 findings	 of	 this	 study	 regarding	 reduced	 levels	 of	 serum	 citrulline	 among	 the	
critically	 ill	group	are	consistent	with	previously	published	research	in	critically	 ill	adult	
population.	Piton	et	al.	(2010)	indicated	that,	in	critically	ill	adults,	low	plasma	citrulline	
at	 24	hours	of	 ICU	admission	was	 an	 independent	 factor	 of	mortality,	 and	 could	be	 a	
marker	of	 acute	 intestinal	 failure.	A	more	 recent	 study	by	Crenn	et	al.	 (2014)	 showed	
that	levels	of	plasma	citrulline	were	decreased	at	the	onset	of	septic	shock;	Crenn	et	al.	
suggested	that	this	was	related	to	early	acute	intestinal	dysfunction.	Citrulline	has	been	
previously	described	as	a	marker	of	gut	permeability	 in	other	disease	states	 (Crenn	et	
al.,	 2008;	 2009;	 Hull	 et	 al.,	 2011).	 Evidence	 suggests	 that	 citrulline	 can	 be	 used	 as	 a	
predictive	marker	of	enterocyte	 loss	and	villous	atrophy	 in	patients	with	HIV	(Crenn	et	
al.,	2009).	Reduced	citrulline	levels	were	also	recorded	in	children	with	intestinal	failure	
who	developed	catheter-related	bloodstream	 infections	 (Hull	et	al.,	2011).	 In	addition,	
citrulline	 concentration	was	 inversely	 correlated	with	 highest	 endotoxin	 level	 in	 post-
cardiac	arrest	patients	(Grimaldi	et	al.,	2013).	These	findings	suggest	a	potential	role	of	
citrulline	as	a	marker	of	impaired	intestinal	barrier	integrity.	It	is	important	to	point	out	
that	citrulline	levels	should	be	interpreted	carefully,	as	they	might	be	affected	by	factors	
other	than	compromised	gut	integrity.	The	deterioration	of	renal	function,	for	instance,	
can	 potentially	 increase	 levels	 of	 circulating	 citrulline,	 since	 it	 is	 metabolised	 into	
arginine	in	the	proximal	convoluted	tubule	(Van	de	Poll	et	al.,	2004;	Crenn	et	al.,	2008).	
However,	in	the	current	study,	none	of	the	study	participants	had	any	renal	problems.	
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In	 this	 study,	 a	 gradual	 increase	 in	 serum	 citrulline	 was	 recorded	 in	 the	 time	 course	
analysis.	Increasing	serum	citrulline	could	be	a	sign	of	recovery.	However,	the	citrulline	
levels	were	low	in	8	patient	samples	obtained	between	days	8	and	10.	Six	out	of	these	8	
patients	 had	MOF,	 and	 their	median	 (IQR)	 PIM2	 score	was	 5	 (1.7-7.2),	 indicating	 that	
sicker	patients	who	were	in	PICU	for	prolonged	period	had	lower	serum	citrulline	levels.	
However,	these	patients	also	had	low	admission	citrulline,	and	it	remained	low	through	
the	period	of	their	PICU	stay.	
	
This	 study	 also	 recorded	 an	 increase	 in	 FC	 concentration	 among	 critically	 ill	 children	
compared	to	age-matched	healthy	controls.	FC	has	been	assessed	before	in	paediatrics	
as	marker	of	intestinal	inflammation	in	necrotising	enterocolitis	and	inflammatory	bowel	
disease,	 and	 also	 to	 distinguish	 bacterial	 gastroenteritis	 from	 viral	 gastroenteritis	
(Josefsson	et	al.,	2007;	Kostakis	et	al.,	2013;	Duman	et	al.,	2015).	Therefore,	 increased	
levels	of	FC	 in	critically	 ill	 children	could	be	used	as	a	proxy	of	 intestinal	 inflammation	
and	 a	 marker	 of	 gut	 homeostasis.	 The	 interaction	 between	 the	 host	 and	 intestinal	
microbiome	has	been	shown	to	be	highly	relevant	to	pathophysiology	and	outcomes	of	
severe	 and	 critical	 illness	 (Dethlefsen	 et	 al.,	 2007).	 Epithelial	 inflammation	 during	 the	
course	of	critical	illness	may	impact	the	integrity	of	the	intestinal	epithelial	barrier	(Lupp	
et	al.,	2007;	Kohler	et	al.,	2005;	Morowitz	et	al.,	2011).	Damage	to	the	intestinal	mucosal	
lining	in	severe	disease	may	lead	to	the	translocation	of	bacteria	or	their	fragments	into	
the	bloodstream,	and	may	contribute	to	systemic	inflammation,	sepsis	and	multi-organ	
failure	 (Clark	 &	 Coopersmith,	 2007;	 Deitch,	 2012).	 This	 could	 explain	 the	 recorded	
increase	in	FC	levels	among	the	septic	children	in	this	study.	
	
In	this	study,	decreased	levels	of	circulatory	citrulline	was	associated	with	elevation	in	all	
measured	inflammatory	mediators.	In	addition,	increased	FC	levels	were	associated	with	
increase	 in	 IL-6	 and	 TNF-α	 levels.	 Septic	 children	 appeared	 to	 have	 statistically	 higher	
levels	 of	 FC	 compared	 to	 the	 non-septic	 group.	 Furthermore,	 the	 regression	 analysis	
showed	 that	 FC	 was	 independently	 associated	 with	 the	 incidence	 of	 sepsis.	 There	 is	
much	 speculation	 of	 a	 cross-link	 between	 the	 disruption	 of	 gut	 homeostasis	 and	 the	
progression	 of	 systemic	 infection	 and	 inflammation.	 Given	 the	 extensive	 vascular	 and	
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lymphatic	 links	 between	 the	 intestines	 and	 other	 organs,	 it	 is	 possible	 that	 toxic	
mediators	released	from	the	intestine	are	transported	through	the	lymphatic	system	or	
intestinal	 lumen,	causing	systemic	damage	(Mittal	&	Coopersmith,	2014;	Latorre	et	al.,	
2015).	The	shift	of	intestinal	microbiota	to	pathogenic	species	has	been	recorded	before	
in	 systemic	 inflammatory	 response	 syndrome	 and	 septic	 neonates	 and	 infants;	 these	
findings	may	imply	that	systemic	infections	start	in	the	gut	(De	Jong	et	al.,	2016;	Madan	
et	 al.,	 2012;	 Pereira	 et	 al.,	 2013;	 Latorre	 et	 al.,	 2015).	 Increased	 FC	 levels	 in	 septic	
children	may	suggest	that	FC	is	influenced	by	bacterial	colonisation	of	the	gut.	Intestinal	
barrier	dysfunction	is	thought	to	contribute	to	the	pathophysiology	of	sepsis	(Yoseph	et	
al.,	2016);	this	study,	however,	did	not	record	an	association	between	the	level	of	serum	
citrulline	at	admission	and	sepsis	diagnosis	among	the	patient	group.	In	addition,	there	
was	 no	 statistical	 difference	 in	 serum	 citrulline	 between	 the	 septic	 and	 non-septic	
groups.	These	findings	are	contradictory	to	a	previously	published	pilot	study	of	critically	
ill	adults,	where	a	reduction	in	serum	citrulline	in	septic,	critically	ill	adults	was	observed	
(Crenn	et	al.,	2014).	However,	their	study	took	a	univariate	analytical	approach	and	did	
not	 adequately	 account	 for	 confounding	 influences,	 such	 as	 disease	 severity	 and	
antibiotic	therapy.	
	
The	current	study	also	recorded	a	variation	in	citrulline	and	FC	levels	 in	septic	patients	
based	 on	 the	 primary	 site	 of	 infection.	 Children	 who	 had	 sepsis	 as	 a	 result	 of	 blood	
infection	 appeared	 to	 have	 the	 lowest	 citrulline	 levels	 and	 highest	 FC	 concentration,	
compared	 to	 septic	 children	with	 primary	 respiratory	 and	 CNS	 infections.	 In	 addition,	
children	 with	 CNS	 infections	 had	 the	 highest	 citrulline	 and	 lowest	 FC	 levels.	 The	
association	between	gut	integrity	biomarkers	and	the	presence	of	bloodstream	infection	
has	been	investigated	in	children	and	adults.	Hull	et	al.	(2011)	have	shown	that	children	
who	 developed	 catheter-related	 bloodstream	 infections	 had	 reduced	 circulatory	
citrulline	 levels.	 In	 addition,	 in	 successfully	 resuscitated	patients,	markers	 of	 intestinal	
injury	such	as	urinary	FABP	and	circulatory	citrulline	were	associated	with	 incidence	of	
endotoxemia	 (Grimaldi	 et	 al.,	 2013).	 Plasma	 citrulline	 concentration	 was	 inversely	
correlated	 with	 highest	 endotoxin	 level,	 while	 urinary	 FABP	 was	 positively	 correlated	
with	 the	 levels	 of	 endotoxins	 (Grimaldi	 et	 al.,	 2013).	 However,	 no	 studies	 have	
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investigated	 the	 association	 between	 gut	 health	 biomarkers	 and	 sepsis	 diagnosis,	 and	
this	is	an	area	that	requires	further	investigation	in	a	larger	cohort	of	children.	
	
Nutritional	 intake	 did	 not	 appear	 to	 influence	 the	 marker	 of	 intestinal	 inflammation.	
However,	 in	 a	 small	 cohort,	 a	 statistical	 association	 was	 recorded	 between	 the	
cumulative	 amount	 of	 enteral	 fat	 received	 and	 citrulline	 levels.	 Previous	 studies	 have	
investigated	 the	 effect	 of	 feeding	 on	 FC	 levels	 in	 infants,	 and	 found	 that	 there	 is	 no	
difference	in	FC	levels	based	on	the	type	or	volume	of	EN	received	(Moussa	et	al.,	2016;	
Campeotto	et	al.,	2007;	Yang	et	al.,	2008).	Conversely,	Li	et	al.	(2014)	found	that	FC	was	
higher	 in	breast-fed	 infants	 than	 formula-fed	 infants.	The	association	between	 feeding	
and	gut	permeability	has	been	established	before.	It	has	been	indicated	that	breast-fed	
infants	have	statistically	lower	permeability	than	infants	receiving	minimal	or	no	human	
milk	(Taylor	et	al.,	2009).	In	addition,	in	a	study	of	critically	ill	adults,	the	late	initiation	of	
EN	was	associated	with	an	 increase	 in	 intestinal	permeability	 (Kompan	et	al.,	1999).	 In	
both	 studies,	 intestinal	 permeability	 was	 assessed	 by	 enteral	 lactulose	 and	 mannitol	
administration	and	urinary	measurement.	Although	it	has	been	suggested	that	citrulline	
concentration	may	reflect	the	small	intestinal	absorptive	function	in	various	conditions,	
the	relationship	between	macronutrient	absorption	and	citrulline	concentration	has	not	
been	 evaluated	 in	 critically	 ill	 children	 (Papadia	 et	 al.,	 2007;	 Van	 Vliet	 et	 al.,	 2009;	
Fragkos	 &	 Forbes,	 2018).	 Rhoads	 et	 al.	 (2005)	 have	 shown	 that	 serum	 citrulline	
correlates	linearly	with	the	percentage	of	enteral	calories	received	in	children	with	short	
bowel	syndrome.	They	suggested	that	higher	serum	citrulline	 is	associated	with	better	
tolerance	of	enteral	feeds	(Rhoads	et	al.,	2005).	The	findings	of	the	current	study	might	
similarly	indicate	that	improvement	in	gut	permeability,	as	assessed	by	citrulline	levels,	
leads	to	better	tolerance	of	enteral	feeds.	
	
In	 the	current	study,	negative	correlation	was	 recorded	between	FC	and	hours	 free	of	
inotrope	 (r=-0.437,	 p=0.006).	 Many	 studies	 speculated	 that	 disruption	 of	 gut	
homeostasis	 could	 drive	 multiple	 organ	 dysfunction	 syndrome	 (Clark	 &	 Coopersmith,	
2007;	De	Jong	et	al.,	2016;	Mittal	&	Coopersmith,	2014).	Gut	dyshomeostasis	could	be	
contributory	or	indeed	driving	cardiac	dysfunction	to	a	large	extent.	Typpo	et	al.	(2015)	
		
	
	
Chapter	Seven	
	
	 	
162	
have	recorded	abnormalities	in	the	intestinal	barrier	biomarker	(FABP	2)	in	children	with	
congenital	 heart	 diseases.	 In	 turn,	 impaired	 cardiac	 function	 may	 aggravate	 gut	
hypoperfusion	and	visceral	 ischemia,	resulting	 in	 initiation	of	an	immune-inflammatory	
event	 (De	 Jong	 et	 al.,	 2016).	 In	 this	 study,	 higher	 inotrope	 score	was	 associated	with	
increased	levels	of	FC	and	reduced	citrulline	concentration.	Inotropic	drugs,	particularly	
alpha	 vasoconstrictor,	 may	 reduce	 perfusion	 to	 the	 mesenteric	 vessel,	 which	 induce	
mucosal	inflammation	(Van	Haren	et	al.,	2003;	Sharma	et	al.,	2003).	Continuous	infusion	
of	 low-dose	 vasopressin	 resulted	 in	 gastrointestinal	 hypoperfusion	 in	 patients	 with	
septic	shock	(Van	Haren	et	al.,	2003).	However,	the	contribution	of	the	gut–heart	axis	in	
the	pathophysiology	of	organ	dysfunction	in	critically	ill	children	needs	to	be	explored	in	
further	studies.	
	
Generally	FC	is	affected	by	the	age	of	the	subject;	previous	studies	indicated	that	infants	
normally	 have	 higher	 FC	 compared	 to	 older	 children	 (Campeotto	 et	 al.,	 2004).	 In	 this	
study,	 among	 the	 healthy	 children	 group,	 FC	 was	 negatively	 correlated	 with	 age	 and	
weight,	 indicating	that	younger	and	smaller	children	had	higher	FC	levels.	However,	no	
such	correlation	was	recorded	in	critically	ill	children.	These	findings	suggest	that	during	
critical	illness	there	are	factors	stronger	than	age	influencing	FC	levels.	
7.5 Limitations	
	
The	data	in	this	chapter	were	derived	from	two	separate	studies.	Citrulline	and	FC	were	
both	measured	only	in	20	children,	but	the	two	biomarkers	were	not	matched	in	time,	
and	 no	 evidence	 of	 statistical	 correlation	 was	 recorded	 between	 them.	 Although	 the	
sample	 size	 in	 the	 current	 study	 was	 sufficient	 to	 demonstrate	 statistical	 differences	
between	critically	ill	and	healthy	children	with	regard	to	citrulline	and	FC	concentrations,	
it	may	have	been	underpowered	 to	detect	 a	 relationship	between	citrulline	and	FC	 in	
this	small	cohort.	Therefore,	a	further	in-depth	investigation	of	the	association	between	
FC	 and	 citrulline	 needs	 to	 be	 explored	 in	 a	 larger	 cohort,	where	 both	 biomarkers	 are	
measured	 at	 the	 same	 time.	 FC	 has	 been	widely	 used	 as	 a	 valid	marker	 of	 intestinal	
inflammation.	In	the	absence	of	synchronised	evaluation	of	intestinal	injury,	the	validity	
of	FC	as	a	marker	of	intestinal	inflammation	in	critical	illness	might	be	questioned.	This	is	
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particularly	important	to	differentiate	whether	FC	is	raised	due	to	the	generalised	state	
of	 inflammation,	 or	 as	 a	 result	 of	 intestinal	 injury.	 Finally,	 the	 limited	 size	 of	 the	
population	 included	 in	 the	 integrated	 analysis	 (N=20)	 precludes	 reliable	 analysis	 of	
clinical	 outcomes	 related	 to	 intestinal	 injury	 and	 mucosal	 inflammation.	 A	 larger	
prospective	observational	study	is	required	to	explore	these	concepts	further.	
7.6 Conclusion	
	
In	this	study,	nutritional	intake	did	not	appear	to	influence	markers	of	intestinal	injury	or	
inflammation.	However,	it	was	suggested	that	the	enhancement	of	gut	homeostasis	may	
lead	 to	 better	 tolerance	 of	 enteral	 feeds.	 Increased	 FC	 and	 reduced	 serum	 citrulline	
were	 associated	 with	 increased	 pro-inflammatory	 cytokine	 IL-6	 and	 TNF-α,	 which	
indicates	 that	 there	 is	 a	 cross-link	 between	 gut	 injury	 and	 systemic	 inflammatory	
response.	 This	 study	 has	 suggested	 that	 gut	 injury	 may	 amplify	 the	 systemic	
inflammatory	 response	 and	 contribute	 to	 MOF,	 and	 potentially	 death.	Future	 work	
should	focus	on	examining	the	possible	relationship	between	intestinal	failure	and	organ	
dysfunction	such	as	cardiac	dysfunction.	
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8 Chapter	 Eight:	 Clinical	 and	 Nutritional	 Factors	 Affecting	 the	
Composition	of	Intestinal	Microbiome	in	Critically	Ill	Children	
	
8.1 Introduction	
The	 previous	 chapters	 have	 shown	 that	 the	 ingested	 macronutrients	 influenced	 the	
inflammatory	 responses	 in	 critically	 ill	 children.	 In	 addition,	 the	 intensity	 of	
inflammatory	responses	was	closely	related	to	the	degree	of	intestinal	inflammation	and	
homeostasis.	
	
The	human	 intestines	host	a	 large	and	complex	population	of	 resident	microbes	–	 the	
microbiome,	also	referred	to	as	microbiota.	These	bacteria	and	their	metabolic	products	
have	 a	 complex	 synergistic	 relationship	 with	 the	 host	 (Clark	 &	 Coopersmith,	 2007).	
Changes	to	the	microbiome	 in	response	to	environmental	 influences	can	affect	overall	
health,	 and	 there	 are	 many	 examples	 of	 how	 the	 composition	 and	 diversity	 of	 the	
microbiome	 is	associated	with	predisposition	 to	a	 range	of	diseases,	 including	obesity,	
heart	disease,	renal	 injury	and	asthma	(Parekh	et	al.,	2014;	Kelly	et	al.,	2016;	Zhang	et	
al.,	2018;	Noval	Rivas	et	al.,	2016).	
	
The	physiological	effects	of	 critical	 illness	on	 the	 intestines	 include	 ischaemia,	hypoxia	
and	hypotension.	These,	along	with	 the	 iatrogenic	effects	of	 the	 lack	of	enteral	 feeds,	
and	the	use	of	antibiotics	and	other	drugs	such	as	vasopressors,	have	a	damaging	effect	
on	the	intestinal	microbiome	and	result	in	the	depletion	of	commensal	species	(Krezalek	
et	 al.,	 2016;	 Ferrer	 et	 al.,	 2016).	 Loss	 of	 commensal	 microbes	 and	 overgrowth	 of	
potentially	 pathogenic	 and	 inflammatory	 bacteria	 may	 contribute	 to	 metabolic	
dysregulation,	 hospital-acquired	 infections,	 sepsis,	 and	 multi-organ	 dysfunction	
syndrome	(Psichas	et	al.,	2015;	Tolhurst	et	al.,	2012;	Clark	&	Coopersmith,	2007;	Pathan	
et	al.,	2011;	Deitch,	2012).	It	is	most	likely	that	the	restoration	of	intestinal	homeostasis	
could	improve	recovery	from	critical	illness	and	reduce	morbidity,	particularly	in	children	
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with	severe	disease	(De	Jonge	et	al.,	2003;	De	Smet	et	al.,	2009;	Daneman	et	al.,	2013;	
Collins	&	Gibson,	1999;	De	Souza	et	al.,	2015).	
	
In	 health,	 nutrition	 is	 an	 important	 factor	 promoting	 colonisation,	 maturation	 and	
stability	of	 the	 intestinal	microbiota	 (Zhang	&	Yang,	2016).	 The	gut	microbiota	utilises	
ingested	 dietary	 components	 (carbohydrates,	 mainly	 resistance	 starch,	 proteins	 and	
lipids)	 and	 host-derived	 components	 including	 shed	 epithelial	 cells	 and	 mucus	
(Ramakrishna,	 2013).	 Dietary	 components	 may	 promote	 the	 growth	 of	 opportunistic	
microbes,	while	other	nutrients	could	endorse	beneficial	microbes	(Brown	et	al.,	2012).	
Dietary	fibre	 is	the	primary	energy	source	for	most	commensal	species	and,	therefore,	
can	 directly	 impact	 their	 growth	 (Graf	 et	 al.,	 2015).	 In	 addition,	 fibre	 is	 the	 main	
substrate	 for	 microbial	 production	 of	 SCFAs,	 a	 major	 bacterial	 metabolite	 known	 to	
influence	 the	 host’s	 health	 (Den	 Besten	 et	 al.,	 2013).	 The	 modulation	 of	 intestinal	
microbiota	by	fibres	has	received	interest	for	its	potential	impact	on	overall	health.	The	
effect	 of	 fibre	 supplementation	 on	 gut	microbiota	 has	 been	widely	 investigated,	with	
data	showing	that	the	main	genus	influenced	include	Bifidobacteria	and	Lactobacilli,	as	
well	 as	 the	Faecalibacterium	 prausnitzii	 and	 Roseburia	 species	 (Bouhnik	 et	 al.,	 1996;	
Vulevic	et	al.,	2008;	Ramirez-Farias	et	al.,	2009;	Benus	et	al.,	2010;	Sawicki	et	al.,	2017).	
It	is	clinically	accepted	that	antibiotics	are	the	main	adverse	exposure	on	gut	microbiota	
during	 critical	 illness.	 Data	 from	 adult	 studies	 have	 shown	 massive	 depletion	 of	
beneficial	Clostridium	 clusters	 (XIVa,	 IV)	 and	 increased	 pathogens	 associated	with	 the	
receipt	 of	 antibiotics	 (Iapichino	 et	 al.,	 2008;	 Livanos	 et	 al.,	 2018).	 However,	 lack	 of	
nutrient	availability	 in	the	colon	due	to	PN	or	EN	poor	 in	non-digestible	carbohydrates	
might	potentiate	the	effect	of	antimicrobial	drugs	and	intensify	the	 intestinal	dysbiosis	
(Schneider	et	al.,	2000).	A	state	of	energy	deficit	might	also	have	a	profound	effect	on	
the	gut	microbiota	and	environment	(Krajmalnik-Brown	et	al.,	2012).	
The	primary	aim	of	this	chapter	is	to	explore	the	changes	in	the	intestinal	microbiota	of	
critically	ill	children	compared	to	their	age-matched	healthy	controls.	The	secondary	aim	
is	 to	 investigate	 the	 effect	 of	 host	 factors	 on	 the	 microbial	 ecology	 of	 critically	 ill	
children;	these	include	age,	diagnosis,	antibiotics	and	feeds.	
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8.2 Materials	and	Methods	
The	 detailed	 methodology	 of	 samples	 handling,	 DNA	 extraction,	 bacterial	 16S	 rRNA	
gene	amplification	and	sequencing	were	described	in	Chapter	Two,	pages	56–58.	
	
For	the	purposes	of	this	study	the	patient	group	was	stratified	by	age	into	three	groups	
(based	on	the	stages	of	dietary	progression):	
• 0-6	months,	mainly	milk	fed,	
• 6-12	months,	weaning	diet,	
• >12	months,	mainly	solids	diet.	
Where	comparisons	were	made	between	healthy	and	critically	ill	states,	the	analysis	was	
restricted	to	samples	obtained	from	an	age-matched	cohort	of	critically	 ill	and	healthy	
children.	
Samples	collected:	
	
Faeces:	
The	 first	 available	 faecal	 sample	 from	 the	 child’s	 nappy	 was	 collected	 in	 a	 sterile	
container.	 A	 250	mg	 stool	 sample	 was	 used	 to	 perform	 the	 DNA	 extraction	 and	
sequencing	in	order	to	identify	intestinal	microbial	species.	
Serum:	
Serial	measurements	 of	 serum	 samples	were	 taken	between	days	 1–7	post-admission	
for	the	analysis	of	 inflammatory	cytokines.	The	maximum	values	were	used	to	indicate	
the	intensity	of	the	inflammatory	response	in	critically	ill	children.	
Nutritional	information:	
	
To	investigate	the	relationship	between	nutritional	intake	and	the	gut	microbiome,	the	
amount	of	energy	and	macronutrients	delivered	were	calculated	to	the	24-hour	period	
prior	 to	 each	 sample	 collection.	 The	 cumulative	 intake	 of	 energy	 and	macronutrients	
from	admission	was	also	calculated	to	assess	the	long-term	effect	of	feeding.	
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For	the	purposes	of	this	study,	the	cut-off	of	underfeeding	was	defined	as	less	than	65%	
of	the	calculated	requirements,	since	the	ASPEN	guidelines	target	the	delivery	of	at	least	
two-thirds	 (approximately	 65%)	 of	 the	 estimated	 requirements	 (Mehta	 et	 al.,	 2017).	
Overfeeding	was	considered	when	the	intake	exceeded	100%	of	the	calculated	needs.	
	
8.2.1 Sample	size	calculation	
	
Sample	 size	 calculation	 was	 performed	 using	 the	 statistical	 power	 analysis	 program	
G*Power	3	(Faul	et	al.,	2007).	The	sample	size	was	chosen	to	test	the	hypothesis	that	
critical	 illness	 is	 associated	 with	 change	 in	 microbiome	 composition.	 This	 assumption	
was	based	on	work	by	Rogers	et	al.	 (2016)	 involving	 the	 study	of	 critically	 ill	 children,	
where	 a	 significant	 reduction	 was	 detected	 in	 the	 intestinal	 microbial	 diversity	 of	
critically	ill	children	compared	to	controls.	The	mean	Shannon	index	of	Alpha	diversity	in	
critically	ill	children	was	3,	compared	to	6.5	in	controls.	It	was	estimated	that	39	children	
per	 group	 would	 be	 needed	 to	 detect	 the	 same	 difference	 between	 critically	 ill	 and	
healthy	children,	assuming	a	5%	significance	level	(2-sided)	and	85%	power.	
	
8.2.2 Statistical	analysis	
	
Following	the	DNA	extraction	and	amplification	of	bacterial	DNA,	the	sequencing	reads	
were	 binned	 into	 OTUs.	 OTUs	 is	 an	 operational	 definition	 used	 to	 classify	 groups	 of	
closely	 related	16s	 rDNA	marker	bacterial	gene	sequence.	 In	other	ward	 it	 is	a	way	of	
clustering	related	sequences	based	on	similarity	to	one	another.	The	generation	of	OTUs	
was	 done	 on	 collaboration	 with	 Dr.	 Joseph	 Wanger	 as	 mentioned	 previously	 in	 the	
method	chapter.	I	then	used	the	generated	OTU	tables	to	perform	the	statistical	analysis	
of	the	gut	microbial	profiles	of	critically	ill	and	healthy	children.	
	
The	 normalised	 read	 counts	 for	 OTUs	 and	 functional	 categories	 were	 used	 for	 all	
statistical	 tests	 by	 the	 METAGENassist	 (Arndt	 et	 al.,	 2012)	 and	 Microbiome	 Analyst	
(Dhariwal	et	al.,	2017)	web-based	programs.	PCA	is	un-supervised	method	of	analysis	it	
takes	 the	 multivariate	 data	 and	 creates	 a	 latent	 variables	 to	 show	 how	 similar	 the	
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obtained	 data	 are.	 The	 PCA	 plots	 were	 generated	 first	 to	 visualise	 the	 taxonomic	
differences	 between	 the	 groups.	 To	 maximise	 separation	 in	 order	 to	 view	 important	
microbial	 characteristics	 of	 groups,	 PLS-DA	 models	 were	 used.	 PLS-DA	 models	 were	
assessed	 based	 on	 goodness	 of	 fit	 (R2Y)	 and	 goodness	 of	 prediction	 (Q2Y)	metrics.	 In	
other	 ward	 Q2Y	 value	 indicate	 how	 well	 the	 model	 predicts	 if	 child	 is	 critically	
ill/underfed	or	not.	The	models	were	validated	with	permutation	multivariate	analysis	
of	 variance	 (PERMANOVA).	 The	 PERMANOVA	 test	 was	 used	 to	 assess	 whether	 the	
observed	 differences	 (in	 multivariate	 space)	 were	 statistically	 significant.	 The	
PERMANOVA	 is	 the	 most	 commonly	 applied	 distance-based	 method	 to	 test	 the	
association	of	microbial	composition	with	covariates	of	 interest	 (Tang	et	al.	2016).	The	
test	was	adjusted	for	participant	groups	(patients	and	controls),	age	groups,	number	of	
antibiotics,	diagnosis	and	feeding	status	(Anderson	&	Walsh,	2013).	
	
	T-test	was	 used	 to	 detect	whether	 species	 statistically	 varied	 between	 the	 compared	
groups,	 and	 a	 false	 Discovery	 Rate	 (FDR)	 value	 of	 <0.05	 was	 considered	 statistically	
significant.	 The	Alpha	 diversity	 (the	 diversity	 within	 sample)	 determined	what	 species	
and	 how	many	 different	 types	 of	 species	were	 present	within	 one	 the	 sample.	 Alpha	
diversity	was	assessed	in	both	patient	and	control	samples,	using	the	Shannon	index,	as	
it	was	shown	to	be	the	most	reliable	index	to	characterise	microbial	species	diversity	(He	
et	 al.,	 2013).	 T-test	 and	ANOVA	were	used	 to	 compare	diversity	 between	 the	 groups.	
Regression	 analysis	 was	 performed	 to	 assess	 the	 relationships	 between	 clinical	
outcomes	and	the	proportional	abundance	of	microbial	phyla.	
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8.3 Results	
	
A	 total	 of	 71	 critically	 ill	 children	 (41	males)	 and	 44	 healthy	 children	 (19	males)	were	
enrolled	in	this	study.	For	most	children,	a	single	faecal	sample	was	collected.	Nineteen	
children	had	a	second	sample	collected	during	their	PICU	stay.	The	number	of	samples	
collected	 from	 each	 age	 group	 is	 shown	 in	 Table	 8-1.	 Faecal	 samples	 were	 collected	
between	 day	 1	 and	 day	 9	 post-PICU	 admission.	 The	 demographics	 of	 patients	 and	
controls	 are	 shown	 in	 Table	 8-2,	 along	 with	 the	 distribution	 of	 categories	 of	 primary	
diagnosis	among	patients.	Amongst	the	patient	cohort,	 the	hospital	mortality	rate	was	
2.8%	(2	out	of	71	children).	
	
Table	8-1:	The	number	of	samples	collected	from	critically	ill	and	healthy	children	
	 Critically	ill	children		 Healthy	children		
N	 of	
samples	
Median	 number	 of	
samples	per	patient	
N	 of	
samples	
Median	 number	 of	
samples	per	patient	
All	children	 90	 1	(1-1)	 44	 1	(1-1)	
0-6	month	 29	 1	(1-2)	 0	 0	
6-12	months	 11	 1	(1-2)	 0	 0	
>	12	months	 50	 1	(1-1)	 44	 1	(1-1)	
	
																																									Data	presented	as	median	(IQR)	
	
	 	
		
	
	
Chapter	Eight	
	
	 	
170	
Table	8-2:	Anthropometric	and	clinical	characteristics	of	children	enrolled	in	the	study	
	
																																																															Data	presented	as	median	(IQR)	
*	Age-matched	population,	p>0.05	
• VFH	at	30	days:	ventilation-free	hours	at	30	days	
• PICU-free	days	at	30	days:	days	free	of	Paediatric	intensive	care	at	30	days	
	
Anthropometrics	
Critically	ill	children		 Healthy	children	
0-6	months	
(N=21)	
6-12	months	
(N=	8)	
>12	months	
(N=42)	
>	12	months	
(N=44)	
Age	(years)	 0.1						(					0.1	–	0.2				)	 0.7					(		0.6	–	0.9		)	 4.1			(				2.2–	8.3					)*	 4.8		(			3.3		–	6.2			)*	
Weight		(kg)	 3.4						(							3	–	4.7					)	 8.8					(			4.2	–	10		)	 15.5		(				12	–	24.5		)	 19.6	(				16		–		23			)	
Height	(cm)	 51							(			48	–	54.75		)	 73.5		(				66	–	78			)	 101			(			88.5	–	114	)	 110		(			98		–		117		)	
Weight	for	age	Z-score	 -0.1.8	(		-2.58	–	0.84	)	 -0.63	(-5.4	–	-0.29)	 -0.01	(		-1.1	–	0.79		)	 0.32	(-0.06		–		1.05)	
Height	for	age	Z-score	 -0.17		(		-2.76–	0.83		)	 -0.03	(			-1.2	–	1.8)	 -0.07	(	-2.43	–	0.76	)	 0.67	(-0.13		–		1.1		)	
Weight	height	Z-score	 -1.2				(				-1.9	–	0.31		)	 -0.77	(-2.8	–	-0.70)	 0.15		(-1.23	–	1.39		)	 0.65(	-0.22	–	2.03		)	
Disease	severity		 	 	 	 	
PIM2	score	 1.2				(				0.75	–	6.1				)	 3.6		(			3.1	–	8.9				)	 4.83		(			2.8	–	13.7			)	 	
Inotrope	score	 0							(								0	–	5										)	 0.0 (					0.0	–	0.0		)	 0.0			(			0.0	–	29.5				)	
Maximum	lactate	 1.9			(					1.47	–	2.6					)	 1.2			(			0.8	–	1.3			)	 2					(		0.975	–	3.3				)	
Maximum	CRP	 55.5		(		38.7	–	186.5		)	 66			(		29.5	–	106		)	 151	(		53.7	–	264					)	
VFH	at	30	days	 621			(			582	–		6536		)	 546	(			480	–	600	)	 628	(				532	–	657				)	
Inotrope	 free	 hours	 at	
30	days	
720			(			703		–	720				)	 720		(	540	–	720		)	 719		(				681	–	720			)	
PICU	 -free	 days	 at	 30	
days	
23					(							17		–	25					)	 19			(			19		–	23				)	 24					(				17		–	25						)	
Primary	 admission	
diagnosis	
N	(%)	
MOF	 22				(31%)	
Respiratory	Failure	 35				(49%)	
CNS	Disorders	 11				(16%)	
Surgical	Disorders	 3					(	4%		)	
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Patients	
Controls	
a)	PCA	 b)	PLS-DA	
[PERMANOVA]	F-value:	7.8227,	p-value	<	0.001	
8.3.1 Exploring	the	changes	in	the	intestinal	bacterial	profiles	of	critically	ill	children	
compared	to	healthy	controls	
	
8.3.1.1 The	global	intestinal	microbial	profiles	of	the	patients	and	control	samples	
	
The	first	step	of	 the	analysis	was	to	compare	the	global	gut	microbiome	profiles	of	an	
age-matched	 cohort	 of	 healthy	 and	 critically	 ill	 children.	 The	 PCA	 plot	 showed	 clear	
separation	 of	 samples	 obtained	 from	 critically	 ill	 and	 healthy	 children,	 reflecting	
systematic	differences	in	the	microbial	profile	between	the	two	groups,	[PERMANOVA]	
F-value:	 7.8227,	 p-value	 <	 0.001.	Model	 statistics	 for	 the	 supervised	 analysis	 (PLS-DA)	
were	R2Y	=	0.78	and	Q2Y	=	0.67.	The	samples	collected	from	healthy	children	were	more	
tightly	clustered	than	those	obtained	from	the	critically	ill	group	(Figure	8.1).	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	8.1	PCA	and	PLSDA	plots	to	compare	faecal	microbial	profiles	in	age-matched	
critically	ill	children	and	healthy	controls		
Figure	8.1	 shows	 clear	 separation	of	 samples	obtained	 from	critically	 ill	 and	healthy	 children,	 reflecting	
systematic	differences	in	the	intestinal	microbial	profile	between	the	two	groups.	
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8.3.1.2 Assessment	of	the	diversity	of	intestinal	ecology	in	patient	and	control	
samples	
	
The	 results	 showed	 that	 critically	 ill	 children	 had	 statistically	 reduced	microbial	 Alpha	
diversity	from	a	median	(IQR)	value	of	2.3	(2	–	2.5)	in	healthy	children	to	1.7	(1.2	–	2.2)	
in	the	critically	ill	group	(p	<0.00001)	(Figure	8.2).	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	8.2	Variation	in	Alpha	diversity	between	critically	ill	children	and	healthy	
controls	
Figure	 8.2	 shows	 that	 healthy	 children	had	 statistically	 higher	microbial	 diversity	 compared	 to	 the	 age-
matched	critically	ill	children	group.	
8.3.1.3 Comparing	the	microbial	ecology	of	patient	and	control	samples	
8.3.1.3.1 Phylum	level	
	
This	section	details	how	I	compared	the	gut	microbiome	at	the	phylum	level	in	critically	
ill	 children	 and	 healthy	 children,	 matching	 for	 age.	 The	 cluster	 analysis	 for	 the	 age-
matched	 patient	 and	 control	 sample	 cohort	 demonstrated	 separation	 of	 samples	 by	
patient-control	 group	 (Figure	 8.3).	 The	 absolute	 abundance	 of	 each	 phylum	 was	
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transferred	 to	proportional	abundance	across	 the	 sample.	Bacteroidetes,	 Firmicutes,	
Actinobacteria	 and	Proteobacteria	were	 the	dominant	 phyla	 in	 the	 faecal	 samples	 of	
the	two	groups.	An	expansion	in	proteobacteria	and	reduction	in	Firmicutes	abundance	
were	 recorded	 in	 critically	 ill	 children.	 The	 results	 also	 indicated	 that	 critically	 ill	
children	had	statistically	higher	relative	abundance	of	Proteobacteria,	Actinobacteria	
and	 lower	 relative	 abundance	 of	 Firmicutes	 compared	 to	 age-matched	 healthy	
children	(p	<0.001)	(Figure	8.4).	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	8.3	Hierarchical	clustering	with	heatmap	presentation	of	the	gut	microbiome	at	
Phyla	level	using	the	Bray	Curtis	matrix	and	Ward	method		
Figure	8.3	shows	a	separation	of	samples	obtained	from	the	patient	and	control	groups.	The	figure	also	
shows	that	proteobacteria	and	actinobacteria	phyla	dominated	in	the	patient	group.	
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Figure	8.4	Comparison	of	main	bacterial	phyla	in	critically	ill	children	and	age-
matched	healthy	controls	
Figure	8.4	shows	that	critically	ill	children	had	statistically	higher	relative	abundance	of	Proteobacteria	
and	 Actinobacteria,	 and	 lower	 relative	 abundance	 of	 Firmicutes	 compared	 to	 age-matched	 healthy	
children	(p	<0.001).	
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8.3.1.3.2 Species	level	
	
The	 cluster	 analysis	 for	 the	 age-matched	 patient	 and	 control	 sample	 cohort	
demonstrated	 a	 separation	 of	 samples	 by	 patient-control	 group	 at	 the	 species	 level	
(Figure	 8.5).	 A	 further	 in-depth	 analysis	 showed	 that	 there	 was	 a	 major	 shift	 in	 the	
abundances	of	bacterial	species	between	the	two	sample	groups.	T-test	analysis	showed	
that	 the	 patient	 group	 had	 statistically	 lower	 abundance	 of	 key	 known	 commensal	
species	and	an	increased	abundance	of	potential	pathogens	(Table	8-3)	(Figure	8.6	).	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	8.5	Hierarchical	clustering	and	heatmap	presentation	of	the	gut	microbiome	at	
the	species	level	using	Bray	Curtis	matrix	and	Ward	method	
Figure	8.5	shows	a	separation	of	samples	obtained	from	the	patient	and	control	groups.	The	figure	also	
shows	 that	 Escherichia	 coli	 dominated	 in	 the	 patient	 group,	 while	 the	 Eubacterium	 rectale	 and	
Faecalibacterium	prausnitzi	species	dominated	in	the	control	group.	
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Table	8-3:	Identified	microbial	species	distinguished	between	critically	ill	children	and	
their	age-matched	controls	
	
Microbial	species		 Mean	proportional	abundance	
(%)	
FDR	p-value	
Patients	 Controls	
Eubacterium	rectale	 0.08	 1.95	 1.35E-06	
Faecalibacterium	prausnitzii	 2.23	 8.53	 1.38E-05	
Clostridium	leptum	 0.09	 0.36	 0.023177	
Bacteroides	caccae	 0.27	 0.75	 0.003558	
Bacteroides	ovatus	 0.93	 2.82	 0.00049311	
Fusicatenibacter	
saccharivorans	 0.08	 0.51	 0.00019671	
Haemophilus	parainfluenzae	 0.09	 0.35	 0.040656	
Clostridium	celatum	 0.33	 1.63	 0.0011364	
Escherichia	coli	 10.47	 2.10	 3.34E-06	
Clostridium	clostridioforme		 1.84	 0.04	 3.02E-05	
Clostridium	hathewayi	 1.86	 0.03	 0.00029067	
Erysipelotrichaceae	
bacterium		 0.76	 0.05	 0.0060267	
Catabacter	hongkongensis	 1.49	 0.03	 0.010139	
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Figure	8.6	Key	identified	species	differed	between	critically	ill	children	and	age-
matched	controls		
Figure	 8.6	 indicates	 that	 critically	 ill	 children	 had	 statistically	 lower	 abundance	 of	 major	 commensal	
species	such	as	Eubacterium	rectale	and	Faecalibacterium	prausnitzi,	while	they	had	higher	abundance	of	
potentially	pathogenic	bacteria,	including	Escherichia	coli,	compared	to	healthy	children.	
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8.3.2 Investigating	the	effect	of	host	factors	on	the	microbial	ecology	of	critically	ill	
children	
	
For	the	investigation	of	the	effect	of	host	factors,	all	samples	collected	from	the	patient	
group	were	included	in	the	analysis.	
8.3.2.1 Age	
	
PCA	and	PLS-DA	plots	were	used	to	examine	the	distribution	of	microbial	profiles	by	age	
group	(Figure	8.7).	The	plots	showed	the	extent	of	separation	between	the	different	age	
groups.	 PERMANOVA	 analysis	 confirmed	 a	 statistically	 significant	 separation	 by	 age	
group	F-value:	2.0222,	p-value	<	0.006.	Model	statistics	for	the	supervised	analysis	(PLS-
DA)	were	R2Y	=	0.40	and	Q2Y	=	0.20.	
	
The	hierarchical	cluster	analysis	demonstrated	separation	of	samples	by	age	group.	As	
expected,	the	6-12	months	group	was	clustered	between	the	younger	and	older	groups.	
The	hierarchical	cluster	analysis	also	showed	that	Enterococcus	faecalis	and	Escherichia	
coli	 dominated	 in	 the	 younger	 group	 (Figure	 8.8).	 Furthermore,	 the	 patient’s	 age	
strongly	 influenced	 the	diversity	of	 the	 faecal	microbial	profile	 in	 this	 cohort.	 Younger	
children	 had	 statistically	 reduced	 microbial	 diversity	 compared	 to	 the	 older	 ones	 (p	
<0.001)	(Figure	8.9).	
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a)	PCA	 b)	PLS-DA	
>	12	months	
6-12	months	
0-6	months		
[PERMANOVA]	F-value:	2.0222,		p-value	<	0.006	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	8.7	PCA	and	PLS-DA	plots	to	compare	faecal	microbial	profiles	in	different	age	
groups	of	critically	ill	children	
Figure	 8.7	 shows	 the	 extent	 of	 separation	 between	 different	 age	 groups	 of	 critically	 ill	 children,	
particularly	in	children	below	6	months	of	age,	who	appear	to	have	a	distinctive	microbial	profile.	
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Figure	8.8	Hierarchical	clustering	and	heatmap	presentation	of	the	gut	microbiome	at	
the	species	level	based	on	age	using	Bray	Curtis	matrix	and	Ward	method	
Figure	 8.8	 shows	 a	 separation	 of	 samples	 obtained	 from	 patients	 >	1	 year	 and	 those	 obtained	 from	
children	 <	1	 year	 of	 age.	However,	 there	was	 an	overlap	between	 children	 aged	0-6	months	 and	 those	
aged	6-12	months.	The	figure	also	shows	that	Enterococcus	faecalis	and	Escherichia	coli	dominated	in	the	
younger	group.	
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Figure	8.9	Variation	in	Alpha	diversity	among	different	age	groups	of	critically	ill	
children		
Figure	8.9	shows	that	the	microbial	Alpha	diversity	varied	among	the	different	age	groups	of	critically	 ill	
children;	younger	children	had	the	lowest	microbial	diversity.	
8.3.2.2 Primary	diagnosis	
PCA	 and	 PLS-DA	 plots	 were	 used	 to	 examine	 the	 distribution	 of	microbial	 profiles	 by	
admission	diagnosis	(Figure	8.10).	The	faecal	microbial	profile	did	not	show	clustering	by	
admission	diagnosis	when	all	groups	were	compared;	hence	they	have	similar	bacterial	
profiles.	The	results	of	the	[PERMANOVA]	tests	were	not	statistically	significant,	F-value:	
1.0576,	 p-value	 <	 0.333.	 Cross-validation	 of	 the	 supervised	 analysis	 (PLS-DA)	 was	 not	
viable,	 as	 the	 minimum	 number	 of	 samples	 required	 per	 group	 is	 four.	 The	 faecal	
microbial	 profile	 also	 did	 not	 show	 clustering	by	 admission	diagnosis	when	examining	
specific	 diagnostic	 groups	 compared	 to	 the	 remaining	 patients,	 and	 the	 results	 of	 the	
[PERMANOVA]	 tests	were	not	 statistically	 significant	 (Figure	8.10).	Alpha	diversity	 also	
did	not	vary	between	patients	based	on	their	admission	diagnosis	when	all	groups	were	
compared,	p-value:	0.28823.	In	addition,	no	statistical	difference	was	recorded	in	Alpha	
diversity	 when	 specific	 diagnostic	 groups	 were	 compared	 to	 the	 remaining	 patients	
(MOF,	 p-value:	 0.2396),	 (Respiratory,	 p-value:	 0.076557),	 (CNS,	 p-value:	 0.20226),	
(Surgery,	p-value:	0.87481).	
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PCA	 PLS-DA	a)	Primary	diagnosis	
b)	MOF	
c)	Respiratory	failure	
d)	CNS	disorders	
e)	Surgery	
[PERMANOVA]	F-value:	1.0576,	p-value	<	0.333		
[PERMANOVA]	F-value:	0.71551,	p-value	<	0.787	
[PERMANOVA]	F-value:	1.4177,	p-value	<	0.132		
[PERMANOVA]	F-value:	1.5193,	p-value	<	0.08		
[PERMANOVA]	F-value:	0.69697,	p-value	<	0.867		
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	8.10	PCA	and	PLS-DA	plots	for	primary	admission	diagnosis		
Figure	8.10	does	not	 show	clustering	of	 the	patient’s	 samples	by	 admission	diagnosis,	 hence	 they	have	
similar	bacterial	profiles.	
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8.3.2.3 Antibiotic	treatment	
	
All	patients	received	at	least	one	broad-spectrum	antibiotic	therapy,	and	59%	(N=42)	of	
them	received	more	than	one	type	of	antibiotics	(Table	8-4).	The	median	(IQR)	number	
of	antibiotic	classes	received	per	patient	was	2	(1-3).	The	most	frequently	used	antibiotic	
classes	 among	 the	 current	 cohort	 were	 Cephalosporin	 (38%),	 Penicillin	 (22%),	
Macrolide	(16%)	and	Aminoglycoside	(12%).	As	the	neonatal	antibiotic	prescription	may	
differ	 due	 to	 birth-acquired	 infections,	 children	 were	 stratified	 by	 age	 to	 investigate	
whether	antibiotic	exposure	is	influenced	by	age	(Figure	8.11).	The	results	showed	that	
the	frequency	of	using	these	antibiotics	did	not	vary	statistically	between	the	different	
age	groups.	
	
PCA	and	PLS-DA	plots	were	used	to	examine	the	distribution	of	microbial	profiles	by	the	
number	of	antibiotic	classes	received	and	days	of	antibiotic	exposure	(Figures	8.12-8.13).	
The	faecal	microbial	profiles	of	this	cohort	did	not	show	clustering	based	on	the	number	
of	antimicrobial	classes	received,	[PERMANOVA]	F-value:	1.4058,	p-value	<	0.24,	nor	by	
the	 days	 of	 antibiotic	 exposure	 [PERMANOVA]	 F-value:	 1.1168,	 p-value	 <	 0.246.	 No	
significant	features	were	identified	in	the	supervised	analysis	(PLS-DA).	 In	addition,	the	
diversity	of	the	faecal	microbial	profile	was	not	influenced	by	the	number	of	antibiotics	
received,	p-value:	0.1582,	or	by	the	duration	of	antibiotic	exposure,	p-value:	0.48602.	
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N=3	 N=8	
c)			6-12	months		
Table	8-4:	Types	of	antibiotic	treatment	provided	to	the	patient	group	
Antibiotic	 Class	 N	of	patients	 (%)	
Ceftriaxone	 Cephalosporin	 36	 28.3	
Cefotaxime	 Cephalosporin 11	 8.7	
Gentamycin	 Aminoglycoside	 13	 10.2	
Tobramycin	 Aminoglycoside 1	 0.8	
Flucloxacillin	 Penicillin 4	 3.1	
Piperacillin	 Penicillin	 3	 2.4	
CoAmoxiclav	 Penicillin 8	 6.3	
Amoxicillin	 Penicillin 7	 5.5	
Benzylpenicillin	 Penicillin 6	 4.7	
Tazobactam	 Penicillin	 5	 3.9	
Clarithromycin	 Macrolide	 10	 7.9	
Erythromycin	 Macrolide		 4	 3.1	
Azithromycin	 Macrolide		 3	 2.4	
Ciprofloxacin	 Fluoroquinolone 2	 1.6	
Vancomycin	 Glycopeptide	 3	 2.4	
Clindamycin	 Lincosamide 8	 6.3	
Metronidazole	 Nitroimidazole 2	 1.6	
Trimethoprim	 Sulfonamides		 1	 0.8	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	8.11	The	frequency	of	using	the	major	antibiotic	classes	in	different	age	groups		
Figure	8.11	indicates	that	the	frequency	of	using	Cephalosporin,	Penicillin,	Macrolide	and	Aminoglycoside	
did	not	vary	statistically	between	different	age	groups.	
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a)	PCA	 b)	PLS-DA	
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[PERMANOVA]	F-value:	1.1168,	p-value	<	0.246.		
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	8.12	PCA	and	PLS-DA	plots	to	compare	faecal	microbial	profiles	of	critically	ill	
children	based	on	the	number	of	antibiotic	classes	received	at	the	time	of	sampling	
Figure	8.12	shows	an	overlap	of	patient	samples	based	on	the	number	of	antibiotics	received.	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	8.13	PCA	and	PLS-DA	plots	to	compare	faecal	microbial	profiles	of	critically	ill	
children	based	on	days	of	antibiotic	exposure		
Figure	8.13	shows	an	overlap	of	patient	samples	based	on	days	of	antibiotic	exposure.	
		
	
	
Chapter	Eight	
	
	 	
186	
a)	PCA	 b)	PLS-DA	
within	24	hours	
After	24	hours	
[PERMANOVA]	F-value:	0.75327,	p-value	<	0.791	
8.3.2.4 Nutrition	and	feeding	practice	in	PICU	
	
The	intestinal	microbial	profiles	were	compared	based	on	the	time	of	commencing	EN,	
dietary	 fibre	 received	 and	 feeding	 status.	 Dietary	 information	 was	 available	 for	 43	
children.	The	samples	in	each	comparison	group	were	age-matched.	
	
1. Time	of	commencing	EN:	
EN	was	started	at	a	median	time	of	9	hours	post-PICU	admission;	however,	10	children	
did	 not	 receive	 any	 EN	 in	 the	 first	 24	 hours.	 The	 PCA	 and	 PLS-DA	 plots	 showed	 an	
overlap	 between	 samples	 in	 each	 group,	 [PERMANOVA]	 F-value:	 0.75327,	 p-value	 <	
0.791	(Figure	8.14).	No	significant	feature	was	identified	in	the	supervised	analysis	(PLS-
DA).	 The	 Shannon	 index	 of	 Alpha	 diversity	 also	 did	 not	 vary	 significantly	 between	
patients	based	on	the	time	of	commencing	EN,	p-value:	0.78206.	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	8.14	Comparison	of	the	global	intestinal	microbial	profiles	based	on	the	time	of	
commencing	EN		
Figure	8.14	shows	an	overlap	between	samples	based	on	time	of	EN.	
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2. Fibre-supplemented	feeds:	
The	type	of	formulae	provided	was	protocolised	in	the	unit	based	on	age.	Most	children	
<	1	 year	 received	 fibre-supplemented	 formulae,	 and	 those	 >	1	 year	 received	 standard	
paediatric	formulae	(Table	8-5).	
	
Table	8-5:	Number	of	children	receiving	fibre-supplemented	formulae	in	each	age	
group	
	
Age	group	 N	of	children	receiving	fibre	feeds	 N	of	children	receiving	standard	feeds	
<	1	year	 12	 4	
>	1	year	 6	 21	
	
In	 both	 age	 groups,	 PCA	 and	 PLS-DA	 plots	 were	 used	 to	 examine	 the	 distribution	 of	
microbial	profiles	by	 the	 type	of	 feed	 received.	The	plots	 showed	an	overlap	between	
the	samples	based	on	the	type	of	formulae	received.	The	result	of	 the	[PERMANOVA]	
test	 was	 not	 statistically	 significant,	 and	 no	 significant	 feature	 was	 identified	 in	 the	
supervised	 analysis	 (PLS-DA)	 (Figure	 8.15).	 In	 addition,	 Alpha	 diversity	 did	 not	 vary	
statistically	between	patients	based	on	the	type	of	EN	formulae	received	in	children	<	1	
year	(p-value:	0.1033)	nor	in	children	>	1	year	(p-value:	0.4841).	
	
	
	
	
	
	
	
	
		
	
	
Chapter	Eight	
	
	 	
188	
Fibre	
No	Fibre	 PCA	 PLS-DA	
a)	Children	<1	year		
b)	Children	>1	year		
[PERMANOVA]	F-value:	0.75205,	p-value	<	0.703		
[PERMANOVA]	F-value:	1.018,	p-value	<	0.448	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	8.15	Comparison	of	global	intestinal	microbial	profiles	based	on	the	type	of	
formulae	received	
Figure	8.15	shows	an	overlap	between	samples	based	on	 the	 type	of	EN	 formulae	 received	 in	both	age	
groups.	
	
3. Feeding	status:	
Both	 the	 immediate	and	 cumulative	effect	of	 energy	and	macronutrient	 intake	during	
the	course	of	a	PICU	stay	were	investigated	in	this	cohort	of	critically	ill	children.	During	
the	24	hours	prior	to	sample	collection,	under-	and	overfeeding	were	recorded	among	
the	 patients.	 However,	 the	 cumulative	 amount	 of	 energy	 and	macronutrients	 did	 not	
exceed	 requirements	 in	 any	 of	 the	 children.	 The	 results	 indicated	 that	 energy	
underfeeding	 during	 the	 24	 hours	 prior	 to	 sample	 collection	 was	 the	 only	 factor	
influencing	the	microbial	composition	in	this	cohort,	[PERMANOVA]	F-value:	1.7007,	p-
value	<	0.041.	Model	statistics	for	the	supervised	analysis	(PLS-DA)	were	R2Y	=	0.57	and	
Q2Y	=	0.21.	However,	neither	the	amount	of	macronutrients	(carbohydrate,	protein,	fat)	
delivered	 in	 the	 24	 hours	 prior	 to	 sample	 collection	 nor	 the	 cumulative	 amounts	
affected	 the	 global	microbial	 profiles	 in	 critically	 ill	 children	 [PERMANOVA]	 p-value	 >	
0.05.	 In	 addition,	 no	 statistical	 difference	 in	 Alpha	 diversity	 measure	 was	 recorded	
between	groups	based	on	feeding	status,	p	>0.05	(Figures	8.16-	8.19).	
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Figure	8.16	Comparison	of	the	global	intestinal	microbial	profiles	and	diversity	based	
on	the	amount	of	enteral	energy	received	
The	above	figure	shows	that	energy	underfeeding	during	the	24	hours	prior	to	sample	collection	was	the	
only	factor	influencing	the	microbial	composition	in	this	cohort.	The	figure	also	indicates	that	Alpha	
diversity	was	not	affected	by	energy	feeding	state.	
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Figure	8.17	Comparison	of	global	intestinal	microbial	profiles	and	diversity	based	on	
the	amount	of	enteral	carbohydrate	received		
PCA	plots	show	an	overlap	between	the	samples	based	on	carbohydrate	feeding	status.	The	 figure	also	
indicates	that	Alpha	diversity	was	not	affected	by	carbohydrate	feeding	state.	
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Figure	8.18	Comparison	of	global	intestinal	microbial	profiles	and	diversity	based	on	
the	amount	of	enteral	protein	received	
PCA	 plots	 show	 an	 overlap	 between	 the	 samples	 based	 on	 protein	 feeding	 status.	 The	 figure	 also	
indicates	that	Alpha	diversity	was	not	affected	by	protein	feeding	state.	
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Figure	8.19	Comparison	of	global	intestinal	microbial	profiles	and	diversity	based	on	
the	amount	of	enteral	fat	received	
PCA	plots	 show	an	overlap	between	 the	 samples	based	on	 fat	 feeding	 status.	 The	 figure	also	 indicates	
that	Alpha	diversity	was	not	affected	by	fat	feeding	state.	
		
	
	
Chapter	Eight	
	
	 	
193	
Hypermetabolic	
Hypometabolic	
a)	PCA	 b)	PLS-DA	
[PERMANOVA]	F-value:	1.5402,	p-value	<	0.047	
4. Metabolic	pattern	
In	a	subgroup	of	10	children,	the	energy	expenditure	was	performed	by	IC.	Although	the	
number	is	very	small,	both	PCA	and	PLS-DA	score	plots	showed	a	cluster	of	patients	who	
exhibited	 a	 hypo-metabolic	 pattern,	 [PERMANOVA]	 F-value:	 1.5402,	 p-value	 <	 0.047	
(Figure	8.20).	Cross-validation	of	the	supervised	analysis	(PLS-DA)	was	not	viable,	as	the	
minimum	number	of	 samples	 required	per	 group	 is	 4.	As	 the	number	of	 samples	was	
very	small,	this	might	affect	the	validity	of	the	analysis.	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	8.20	Comparison	of	the	global	intestinal	microbial	profiles	based	on	the	
metabolic	pattern	
The	plots	show	a	good	separation	of	samples	obtained	from	children	exhibiting	hyper-metabolic	patterns	
and	those	who	did	not.	
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a.		 b.		
r=0.522	
	p=0.001*	
r=0.523	
	p=0.001*	
8.3.3 The	effect	of	intestinal	dysbiosis	during	critical	illness	on	disease	severity	and	
clinical	outcomes	
	
8.3.3.1 Systemic	inflammation	
	
Microbial	data	from	early	samples	obtained	between	days	1	and	4	were	included	in	this	
analysis.	 In	 the	 current	 study,	 positive	 correlation	 was	 recorded	 between	 the	
proportional	abundance	of	Proteobacteria	(%)	with	peak	TNF-α	(r=0.522,	p=0.001),	and	
IL1-β	 (r=0.523,	 p=0.001)	 (Figure	 8.21).	 No	 evidence	 of	 statistical	 correlation	 was	
recorded	 between	 the	 Shannon	 index	 of	 Alpha	 diversity	 and	 inflammatory	 cytokines.	
The	regression	model	indicated	that	the	association	between	Proteobacteria	(%)	and	the	
pro-inflammatory	mediators	was	influenced	by	age	and	disease	severity	(Table	8-6).	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	8.21	Association	between	and	the	proportional	abundance	of	Proteobacteria	
Figure	 8.21	 shows	 a	 positive	 correlation	 between	 the	 relative	 abundance	 of	 Proteobacteria	 and	 pro-
inflammatory	cytokines	TNF-α	and	IL1-β.	
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Table	8-6:	Regression	model	to	determine	the	association	between	Proteobacteria	(%)	
and	pro-inflammatory	mediators	
Model	 R	 R	2	 Adjusted	R	2	 R	 P-value	
TNF-α	a	 0.669	 0.448	 0.416	 	
Age	b		 	 -0.585	 0.006*	
PIM2	score	b	 0.076	 0.327*	
Proteobacteria	c	 0.406	 0.006	
IL1-β	a	 0.548	 0.301	 0.280	 	 	
Age	b		 	 -0.548	 0.00*	
PIM2	score	b	 -1.51	 0.327*	
Proteobacteria	c	 0.500	 0.001	
a. Dependent	variable	
b. Predictors:	(constant)	
c. Excluded	variable	
	
8.3.3.2 Clinical	outcomes	
The	 association	 between	 the	 intestinal	 microbial	 profiles	 and	 clinical	 outcomes	 was	
examined	using	hours	free	of	mechanical	ventilation	and	days	free	of	PICU	at	30	days	as	
the	outcome	measures.	The	results	did	not	show	any	statistical	correlation	between	the	
clinical	outcome	variables	and	Proteobacteria	(%)	or	the	Shannon	Alpha	diversity	index.	
In	the	regression	model	all	variables	were	excluded	(Table	8-7).	
	
Table	8-7:	Regression	model	to	determine	the	association	between	clinical	outcome	
variables	Proteobacteria	(%)	and	the	Shannon	Index	
Model	 R	 R	2	 Adjusted	R	2	 R	 P-value	
VFH	at	30	days	a	 	 	
Age	c	 	 -0.046	 0.368	
PIM2	score	c	 0.116	 0.197	
Proteobacteria	(%)	c	 -0.148	 0.137	
Shannon	index	c	 0.021	 0.438	
PICU-free	days	at	30	days	a	 	 	 	
Age	c	 	 -0.084	 0.269	
PIM2	score	c	 -0.034	 0.4	
Proteobacteria	(%)	c	 -0.13	 0.169	
Shannon	index	c	 0.111	 0.207	
a. Dependent	variable	
b. Predictors:	(constant)	
c. Excluded	variable	
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8.4 Discussion	
	
This	study	recorded	a	profound	loss	of	diversity	in	the	faecal	microbiome	of	critically	ill	
children.	 This	 was	 associated	 with	 the	 loss	 of	 key	 commensal	 species	 and	 increased	
levels	 of	 opportunistic	 pathogens	 such	 as	 Proteobacteria,	 Streptococcus	 and	
Enterococcus.	These	findings	are	in	agreement	with	previous	work	where	changes	in	the	
microbiome	composition	of	critically	 ill	 children	and	adults	were	 reported.	This	 shift	 is	
generally	 characterised	 by	 the	 increased	 abundance	 of	 opportunistic	 pathogens	 and	
reduced	beneficial	commensals	 (Shimizu	et	al.,	2011;	Rogers	et	al.,	2016;	Mcdonald	et	
al.,	2016;	Ojima	et	al.,	2016).	
	
In	 a	 healthy	 gut,	 the	 abundance	 of	 Proteobacteria	 is	 usually	 low;	 the	 expansion	 of	
Proteobacteria	 phyla	 is	 closely	 correlated	 with	 disease	 state	 (Shin	 et	 al.,	 2015).	 The	
current	 study	 showed	 that	 the	 proportional	 abundance	 of	 Proteobacteria	 was	 higher	
among	critically	ill	children	than	age-matched	healthy	children.	Furthermore,	the	patient	
group	 had	 statistically	 higher	 abundance	 of	 bacterial	 species	 linked	with	 diseases	 and	
infections	 such	 as	 Escherichia	 coli,	 Clostridium,	 Erysipelotrichaceae	 bacterium	 and	
Catabacter	 hongkongensis.	 Escherichia	 coli	 is	 responsible	 for	 up	 to	 30%	 of	 nosocomial	
infections	(Nagarjuna	 et	 al.,	 2015;	 Lodha	 et	 al.,	 2001).	 It	 is	 also	 the	 most	 common	
pathogen	causing	septicaemia	and	diarrhoea	in	critically	ill	children	(Puentes	&	Dunstan,	
2018).	 The	 Erysipelotrichaceae	 bacterium	 was	 found	 to	 be	 enriched	 in	 the	 patient	
group;	 this	 bacterial	 species	 has	 been	 implicated	 in	 inflammation-related	 disorders	 of	
the	 gastrointestinal	 tract	 (Kaakoush,	 2015),	 and	 it	 has	 been	 shown	 to	 be	 increased	 in	
patients	 with	 colorectal	 cancer	 (Chen	 et	 al.,	 2012).	 Catabacter	 hongkongensis	 was	
reported	in	many	cases	of	human	infection	and	was	associated	with	evidence	of	clinical	
sepsis,	gastrointestinal	diseases	and	prolonged	hospitalisation	(Elsendoorn	et	al.,	2011;	
Torri	et	al.,	2016;	Lau	et	al.,	2012).	
	
This	 study	 also	 recorded	 a	 striking	 loss	 of	 key	 SCFAs	 forming	 species	 in	 critically	 ill	
children.	These	 include	Eubacterium	rectale	and	Faecalibacterium	prausnitzii	(the	main	
butyrate	producers	of	Clostridium	clusters	XIVa	and	IV,	respectively),	which	are	usually	
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indicators	of	healthy	and	diverse	gut	microbiome	composition	(Antharam	et	al.,	2013).	
Faecalibacterium	 prausnitzii	 is	 also	 recognised	 as	 an	 anti-inflammatory	 commensal	
bacteria	(Sokol	et	al.,	2008).	
	
There	is	evidence	that	trauma	and	sepsis	cause	immediate	changes	to	the	microbiome	
and	intestinal	barrier.	It	is	not	quite	clear	whether	this	effect	is	solely	due	to	the	disease	
state	or	other	environmental	factors	such	as	nutrition,	or	microbiome-guided	therapies	
such	 as	 antibiotics	 are	 also	 involved.	 To	 the	 knowledge	 of	 the	 author,	 no	 previous	
studies	 have	 investigated	 how	 host	 factors,	 during	 critical	 illness,	 affect	 gut-residing	
microorganisms.	
	
Among	 the	 critically	 ill	 children	 group,	 age	 was	 a	 determinant	 factor	 influenced	 the	
microbial	profiles.	Stokholm	et	al.	(2018)	indicated	that	the	microbial	profile	during	the	
first	year	of	life	is	distinguished	from	later	stages,	as	the	composition	of	the	human	gut	
microbiome	is	still	developing.	In	this	study,	the	microbial	profiles	of	critically	ill	children	
did	not	appear	to	be	affected	by	the	category	of	admission	diagnosis.	Surprisingly,	 the	
number	 of	 antibiotic	 agents	 received	 and	 the	 duration	 of	 antibiotic	 exposure	 did	 not	
show	 clustering	 of	 the	 microbial	 profiles	 of	 critically	 ill	 children.	 Since	 samples	 were	
collected	after	day	2	of	PICU	admission,	where	antibiotic	treatment	was	already	initiated	
for	 all	 children,	 it	 was	 less	 likely	 to	 see	 massive	 differences	 in	 the	 microbial	 species	
across	the	patient	groups	based	on	antibiotic	therapy.	However,	as	this	population	often	
receives	extensive	antibiotic	treatment	(Malacarne	et	al.,	2004),	this	may,	in	addition	to	
the	 functional	 loss	 of	 commensal	 species,	 affect	 the	 prevalence	 of	 antimicrobial-
resistant	 genes	 within	 the	 intestinal	 microbiome.	 This	 may	 have	 a	 clinical	 impact	 on	
patients	 themselves	or	on	 the	ward	ecology	 (Palmer	et	al.,	2007;	Preidis	&	Versalovic,	
2009;	Theriot	et	al.,	2014).	
It	has	been	estimated	that	the	total	antibiotic	consumption	 in	 ICUs	 is	nearly	 ten	times	
greater	than	in	general	hospital	wards	(Malacarne	et	al.,	2004).	The	effect	of	antibiotic	
exposure	on	gut	microbiota	has	been	widely	 investigated,	with	data	 showing	 that	 the	
main	 phyla	 influenced	 by	 antibiotic	 treatment	 are	 Actinobacteria,	 Bacteroidetes,	
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Firmicutes	 and	Proteobacteria	 (Theriot	 et	 al.,	 2014;	 2016;	 Panda	 et	 al.,	 2014).	 Broad-
spectrum	antibiotics	in	particular	have	shown	to	affect	the	abundance	of	nearly	30%	of	
intestinal	 bacterial	 species	 (Dethlefsen	 et	 al.,	 2008).	 In	 a	 study	 of	 infants,	 a	 massive	
reduction	 in	 total	 bacterial	 densities	 was	 observed	 after	 antibiotic	 treatment,	
accompanied	 by	 delayed	 colonisation	 by	 beneficial	 species	 such	 as	Bifidobacteria	 and	
Lactobacilli,	 and	 induced	 colonisation	 by	 antibiotic-resistant	 strains	 (Schumann	 et	 al.,	
2005).	Data	from	adult	studies	have	shown	massive	depletion	of	beneficial	Clostridium	
clusters	 (XIVa,	 IV)	 and	 increased	 pathogens	 associated	 with	 the	 receipt	 of	 antibiotics	
(Iapichino	et	al.,	2008;	Livanos	et	al.,	2018).	Using	antibiotic	 therapy	can	subsequently	
result	 in	 important	 functional	 alterations	 in	 the	 gut	 microbiome	 and	 increased	
susceptibility	to	infections	(Palmer	et	al.,	2007;	Preidis	&	Versalovic,	2009).	In	fact,	in	the	
current	study	the	variation	seen	in	the	microbiome	of	critically	ill	children	compared	to	
healthy	 children	 group	may	 actually	 be	 related	 antibiotics	 exposure,	 since	 the	 control	
group	 did	 not	 receive	 any	 antimicrobial	 treatment	 for	 at	 least	 2	 week	 prior	 the	
recruitment.	 Suggesting	 that	 antibiotics	 are	 most	 likely	 the	 key	 driver	 of	 the	 shift	
observed	 in	 the	microbiome	of	 critically	 ill	 children	as	 compared	 to	 the	healthy	 state.	
The	 influence	 of	 antimicrobial	 agents	 on	 the	 gut	microbiome	 could	 be	 short-term,	 or	
may	last	for	a	longer	period	(Theriot	et	al.,	2014).	An	example	of	the	long-lasting	effect	
of	 antibiotic	 use	 is	 reduced	 colonisation	 resistance	 against	 some	 pathogens	 such	 as	
Clostridium	 difficile	 (Theriot	 et	 al.,	 2014).	 The	 effect	 of	 antibiotic	 exposure	 on	 the	
intestinal	 microbiome	 during	 critical	 illness	 needs	 to	 be	 examined	 in	 more	 detail	 in	
future	studies,	where	a	control	group	of	critically	ill	children	who	require	minimal	or	no	
antibiotic	therapy	should	be	recruited.	
In	the	current	study,	energy	underfeeding	during	the	24	hours	prior	to	sample	collection	
appeared	 to	 influence	 the	microbial	 composition	of	 critically	 ill	 children.	 The	effect	 of	
energy	balance	on	gut	microbiota	has	not	been	previously	investigated	in	the	critically	ill	
population.	However,	data	 from	obesity	 studies	has	 shown	a	noticeable	 shift	 in	major	
intestinal	bacterial	phyla	 in	 response	 to	 the	degree	of	under-	and	overfeeding	 (Cani	&	
Delzenne,	 2009;	 Jumpertz	 et	 al.,	 2011).	 Preclinical	 data	 in	 animal	models	 have	 shown	
starvation-induced	 reduction	 in	 commensal	 bacteria	 including	 Firmicutes	 Lactobacilli	
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(Crawford	et	al.,	2009;	Costello	et	al.,	2010).	As	critically	ill	children	are	often	underfed,	a	
pattern	of	alteration	in	the	gut	micobiome	would	be	observed	during	periods	of	energy	
deprivation	(Morowitz	et	al.,	2011;	Krajmalnik-Brown	et	al.,	2012).	
Outside	 of	 energy	 underfeeding,	 the	 effect	 of	 other	 nutritional	 factors	 on	 microbial	
composition	was	not	evident	in	the	current	study.	This	could	be	related	to	the	fact	that	
most	 samples	were	obtained	early	 after	 admission,	where	 the	ability	 to	modulate	 the	
intestinal	environment	by	feed	is	limited.	Furthermore,	during	the	acute	phase	of	illness,	
critically	 ill	 children	 are	 heavily	 treated	 with	 broad-spectrum	 antibiotics,	 which	 are	
thought	to	be	the	main	factor	driving	intestinal	dysbiosis	in	this	population	(Iapichino	et	
al.,	2008;	Livanos	et	al.,	2018).	Limitation	in	the	sample	size	could	also	be	a	factor	that	
compromised	the	reliability	of	the	analysis	in	the	current	study.	
The	 role	of	dietary	 fibres	 in	 stimulating	 the	growth	of	beneficial	 commensal	 species	 is	
well	 documented,	 yet	 only	 6	 children	 >	1	 year	 received	 fibre-supplemented	 feeds.	 EN	
practice	 in	 PICU	 adopting	 routine	 use	 of	 standard	 paediatric	 formulas	 lacking	 dietary	
fibre	 may	 potentiate	 the	 loss	 of	 beneficial	 species	 such	 as	 Bifidobacteria,	
Lactobacilli,	Faecalibacterium	prausnitzii	and	Roseburia	(Bouhnik	et	al.,	1996;	Vulevic	et	
al.,	2008;	Ramirez-Farias	et	al.,	2009;	Benus	et	al.,	2010;	Sawicki	et	al.,	2017).	
In	a	 small	number	of	 children,	 this	 study	 showed	 that	microbiome	composition	varied	
between	 children	 who	 exhibited	 hyper-metabolic	 response	 and	 those	 who	 did	 not.	
These	 findings	are	 in	 line	with	previously	published	work	on	10	healthy	men,	where	a	
correlation	 between	 changes	 in	microbiota	 composition	with	 host	 substrate	 oxidation	
rates	 and	 REE	 was	 recorded	 (Kelder	 et	 al.,	 2014).	 Several	 mechanisms	 have	 been	
proposed	 to	 link	 the	 composition	 of	 the	 gut	 microbial	 community	 and	 host	 energy	
homeostasis.	 Stappenbeck	 et	 al.	 (2002)	 suggested	 that	 the	 normal	 function	 of	 gut	
microbiota	 increases	the	capacity	of	capillaries	 in	 the	small	 intestinal	villus	epithelium,	
and	 accordingly	 helps	 in	 promoting	 the	 intestinal	 absorption	 of	 monosaccharide.	 In	
addition,	intestinal	microbial	fermentation	of	non-digestible	carbohydrates	is	associated	
with	 the	 secretion	 of	 enteroendocrine	 peptides,	 such	 as	 GLP-1	 produced	 by	 L-cells	
(Tolhurst	 et	 al.,	 2012).	 It	 has	 also	 been	 suggested	 that	 endotoxins	 such	 as	
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lipopolyscharide	 are	 associated	 with	 gut	 injury,	 stimulating	 the	 secretion	 of	 GLP-1	
(Lebrun	 et	 al.,	 2017;	Nguyen	 et	 al.,	 2014).	 These	mechanisms	may	 result	 in	 increased	
production	 of	 GLP-1,	 which	 appears	 to	 increase	 REE	 through	 stimulation	 of	 insulin	
secretion	or	 inducing	brown	adipose	tissues	thermogenesis	(Beiroa	et	al.,	2014;	Shalev	
et	al.,	1997).	In	addition,	the	depletion	of	some	microbial	species	has	been	shown	to	
promote	the	browning	of	white	adipose	tissue,	which	might	also	affect	REE	 (Suárez-
Zamorano	 et	 al.,	 2015).	 The	 association	 between	microbiota	 and	 REE	 signalling	 axis	
needs	to	be	explored	in	a	larger	cohort	in	order	to	draw	a	valid	statistical	conclusion.	
In	the	current	study,	the	expansion	of	proteobacteria	phylum	was	correlated	with	raised	
serum	TNF-α	and	IL1-β	in	patient	samples.	The	activation	of	pro-inflammatory	cytokines	
may	 influence	 the	 gut	 microbiome	 and	 promote	 the	 growth	 of	 pathogenic	 species	
(Dickson	2016;	Alverdy	et	 al.	 2000).	 It	 is	 also	possible	 that	 systemic	 inflammation	and	
tissue	 injury	 may	 actually	 be	 downstream	 consequences	 of	 disordered	 bacterial	
communities	in	the	gut	(	Dickson	2016,	Hakansson	&	Molin,	2011;	Maslowski	&	Mackay,	
2011;	Lobo	et	al.,	2016).		Hypoxia	in	the	colon	facilitates	the	loss	of	obligate	anaerobes	
and	allows	for	expansion	of	facultative	anaerobes	(Romick-Rosendale	et	al.	2018).	As	a	
result	 of	 bacterial	 translocation,	 the	 intestinal	 cells	 secrete	 innate	 immune	 effector	
molecules	such	as	TNF-α	when	exposed	to	bacteria	or	bacterial	antigens	(Schuijt	et	al.,	
2012).	Local	 inflammation	in	the	gut	may	further	aggravate	systemic	inflammation	and	
adverse	outcomes	among	this	patient	group	(Schuijt	et	al.	2012).	It	hard	to	postulate	if	
disordered	microbiome	 is	a	cause	or	effect	systemic	 inflammation.	An	anima	model	of	
faecal	 microbiota	 transplantation	 from	 septic	 to	 healthy	 animals	 could	 improve	 our	
understanding	about	the	potential	role	of	disordered	microbiome	on	the	progression	of	
systemic	inflammation.	This	must	be	explored	in	future	studies.		
	
Whilst	many	of	the	triggers	of	intestinal	dyshomeostasis	may	be	unchangeable	in	critical	
illness,	 it	 is	 logical	 that	 the	 intestinal	 environment	 should	 be	 supported	 actively	 in	
affected	 children.	 Given	 the	 extensive	 vascular	 and	 lymphatic	 links	 between	 the	
intestines	 and	 other	 organs,	 it	 is	 possible	 that	 targeted	manipulation	 of	 the	 intestinal	
microbiome	by	enteral	feeding	could	be	of	systemic	clinical	benefit	and	improve	clinical	
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outcomes	 in	 critically	 ill	 children.	 Although	 this	 has	 not	 been	 explored	 fully	 in	 this	
population,	 optimising	 the	 balance	 of	 gut	 ecology	 with	 pre-	 or	 probiotics	 could	 be	 a	
promising	 strategy	 to	 improve	 energy	 balance	 and	 clinical	 outcomes	 in	 critically	 ill	
children.	Prebiotics	such	as	Lactulose	fructooligosaccharides	and	galactooligosaccharides	
were	 used	 in	 infant	 formulas	 and	 demonstrated	 a	 significant	 modulation	 of	 the	 gut	
bacteria	 (Collins	&	Gibson,	 1999;	Vandenplas	 et	 al.,	 2014;	 Fanaro	 et	 al.,	 2005).	 Inulin-
type	 fructose	 prebiotics	 have	 been	 tested	 in	 a	 study	 of	 obese	 women,	 and	 showed	
selective	 changes	 in	 the	gut	microbiota	 composition	 (Dewulf	et	al.,	 2013).	 In	addition,	
probiotics	 containing	 Lactobacillus	 and	 Bifidobacteria	 species	 have	 shown	 beneficial	
effects	on	controlling	the	balance	of	the	intestinal	microbiome	(Collins	&	Gibson,	1999).	
Generally,	using	probiotics	in	clinical	settings	has	been	proven	to	be	safe;	however,	they	
must	be	used	with	caution	in	certain	patient	groups	(Srinivasan	et	al.,	2006).	
8.5 Limitations	
	
This	study	was	limited	by	the	relatively	small	number	of	children	included	in	the	analysis	
of	the	nutritional	factors.	The	study	was	originally	powered	to	detect	statistical	variation	
in	 the	 gut	 microbiome	 between	 critically	 ill	 children	 and	 healthy	 controls;	 the	
incorporation	of	the	nutrition	study	followed	the	completion	of	the	metagenomic	study.	
Dietary	information	was	collected	retrospectively	from	patients’	electronic	records.	The	
nutritional	data	was	not	obtainable	for	children	recruited	early	in	the	study,	due	to	the	
transition	 of	 the	 hospital	 recording	 system	 from	 paper	 files	 to	 an	 electronic	 system.	
Accordingly,	it	was	difficult	to	retrieve	the	data	documented	in	the	files	after	it	was	sent	
to	 the	hospital	archive.	Due	 to	 limitation	 in	 the	sample	size,	 it	was	difficult	 to	 identify	
statistical	 relationships	 from	 the	 data,	 as	 statistical	 tests	 normally	 require	 a	 larger	
sample	size	to	ensure	a	representative	distribution	of	the	population.	
8.6 Conclusion	
	
This	study	demonstrated	that	iatrogenic	factors	and	adverse	pathophysiology	appear	to	
decimate	 the	 healthy	 microbiome	 in	 critically	 ill	 children,	 resulting	 in	 the	 loss	 of	
commensal	bacteria.	The	nature	of	the	microbiome	in	critically	ill	children	is	shaped	by	
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many	 factors.	 Growing	 evidence	 suggests	 that	 the	 gut	 interacts	 with	 and	 influences	
other	 organ	 systems;	 therefore,	 supporting	 gut	 health	 should	 be	 integrated	 into	
management	 protocols	 for	 critically	 ill	 children.	 Since	 the	 insult	 of	 critical	 illness	 is	
inevitable,	 nutritional	 interventions	 to	 restore	normal	 gut-host	 relationships	may	be	 a	
potential	therapeutic	target.	It	 is	possible	that	personalised	nutritional	interventions	to	
encourage	the	restoration	of	commensal	species,	along	with	improved	rationalisation	of	
antibiotic	therapy,	could	support	longer-term	recovery	of	the	intestinal	mucosa	and	the	
resident	microbiome.	This	needs	to	be	examined	in	future	studies.	
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9 Chapter	 Nine:	 Metabolic	 Effects	 of	 Intestinal	 Dysbiosis	 in	
Critically	Ill	Children	
	
9.1 Introduction	
	
	
The	 interaction	 between	 gut	 microbiota,	 nutrition,	 and	 host	 metabolism	 has	
undoubtedly	drawn	attention	over	 the	past	 few	years	 (Morowitz	et	 al.	 2011).	 The	gut	
microbiota	uses	ingested	dietary	components	(carbohydrates	−	mainly	resistance	starch,	
proteins,	 and	 lipids)	 to	 generate	 energy	 for	 cellular	 processes	 and	 for	 growth	
(Ramakrishna	2013).	This	process	is	known	as	bacterial	fermentation.	The	fermentation	
process	is	crucially	important	for	maintaining	host	health	(Cheng	et	al.	2013).	During	the	
process	of	utilising	 these	substrates,	 the	microbiota	produces	several	metabolites	 that	
influence	 host	 health	 and	 metabolism	 (Krajmalnik-Brown	 et	 al.	 2012;	 Ramakrishna	
2013).The	shift	 in	gut	bacterial	population	during	critical	 illness	may	affect	 the	colonic	
degradation	capacity	(Iapichino	et	al.	2008).	
	
There	 are	 many	 bacterial	 metabolites	 derived	 from	 the	 fermentation	 of	 dietary	
components	known	to	 impact	 the	health	of	 the	host	 (Table	9-1).	These	 include	SCFAs,	
lactate,	ferulic	acid	and	other	organic	compounds	such	as	phenol,	para-cresol	and	indole	
(Russell	et	al.	2013;	Belenguer	et	al.	2011;	Westfall	&	Lomis	2016;	Russell	et	al.	2013).	
SCFAs	arising	from	anaerobic	bacterial	metabolism	of	polysaccharides	in	the	colon	have	
beneficial	effects	on	the	host	(Blaut	&	Clavel	2007;	Vinolo	et	al.	2011;	Byrne	et	al.	2015).	
SCFAs	have	been	shown	to	be	depleted	in	adults	with	critical	illness,	due	to	reduction	in	
SCFAs-forming	 species	 (Shimizu	 et	 al.	 2006;	Osuka	 et	 al.	 2012;	 Hayakawa	 et	 al.	 2011;	
Vermeiren	 et	 al.	 2012;	 Yamada	 et	 al.	 2015).	 Based	 on	 the	 results	 from	 the	 previous	
chapter,	 the	 paediatric	 faecal	 microbiomes	 appear	 to	 lose	 much	 of	 their	 commensal	
population	 such	 as	 Faecalibacterium	 prausnitzi	 and	 Eubacterium	 rectale	 species	 in	
critical	illness.		
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Table	9-1:	Common	bacterial	metabolites	linked	to	human	health	
	
Product	 of	 bacterial	
fermentation	
Intestinal	bacteria		 Reference	
SCFAs	
Butyrate	
Propionate	
Acetate	
	
Roseburia	
Eubacterium	rectale	
Eubacterium	hallii	
Faecalibacterium	
prausnitzii	
(Russell	et	al.	2013)	
(Benus	et	al.	2010)	
(Duncan	et	al.	2007)	
Lactate	
	
Bifidobacteria	
Lactobacillales	
Klebsiella	pneumoniae	
mutants	
(Belenguer	et	al.	2011)	
(X.	Feng	et	al.	2017)	
	
Ferulic	acid	 Lactobacillales	
Lactobacillus	
fermentum	
(Westfall	&	Lomis	2016)	
Phenol	
Para-cresol	
Indole	
B.	thetaiotaomicron	
Bacteroides	eggerthii	
Bacteroides	ovatus	
Bacteroides	fragilis	
Parabacteroides	
distasonis	
Clostridium	bartlettii	
Eubacterium	hallii	
(Wendy	R.	Russell	et	al.	2013)	
	
In	addition	to	producing	metabolites	that	contribute	to	host	health,	gut	microbiota	also	
serve	as	a	regulator	of	bile	acid	(BA)	metabolism	(Zhang	et	al.	2016).	The	human	BA	pool	
is	made	of	the	primary,	secondary	and	tertiary	BAs.	The	primary	BAs	(CA	and	CDCA)	are	
synthesised	in	the	liver,	while	secondary	BAs	are	produced	in	the	gut	via	modification	of	
primary	BAs	by	dehydroxylation,	epimerisation	and	oxidation	processes.	The	tertiary	BAs	
are	 formed	 in	both	 the	 liver	 and	by	 gut	microbiota	 via	modification	of	 secondary	BAs	
through	 sulfation,	 glucuronidation,	 glucosidation	 and	 N-acetylglucosaminidation	
(Marschall	et	al.	1992;	Ridlon	et	al.	2006;		Wahlströ	et	al.	2016).	Intestinal	microbiota	are	
known	 to	 regulate	 BAs	 synthesis,	 deconjugation	 and	metabolism	 (Zhang	 et	 al.	 2016).	
Secondary	BAs	produced	by	intestinal	microbiota	bind	to	and	activate	a	number	of	host	
nuclear	 receptors	 expressed	 in	 heart,	 adipose,	 liver	 and	 kidney	 tissues	 (Zhang	 et	 al.	
2016;	Ridlon	et	al.	2014).	
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The	 aim	 of	 this	 chapter	 is	 to	 assess	 the	 functional	 capacity	 of	 gut	 microbiota	 by	
comparing	the	levels	of	SCFAs	and	BA	pools	between	critically	ill	children	and	their	age-
matched	 healthy	 controls.	 SCFAs	 and	 BAs	 were	 chosen	 because	 they	 are	 easily	
measured	 in	 faecal	 water,	 which	 provides	 direct	 information	 about	 the	 interaction	
between	the	host	and	gut.	
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9.2 Materials	and	Methods	
	
The	detailed	methodology	of	 sample	handling,	 faecal	water	extraction,	SCFAs	and	BAs	
measurements	were	 described	 in	 Chapter	 Two	 page	 55-56.	Where	 a	 comparison	was	
made	 between	 healthy	 and	 critically	 ill	 states,	 the	 analysis	 was	 restricted	 to	 samples	
obtained	from	an	age-matched	cohort	of	critically	ill	and	healthy	children.	
Samples	collected:	
Faeces:	
Faecal	 samples	 were	 collected	 from	 the	 child’s	 nappy	 (around	 300	mg)	 into	 a	 sterile	
container.	 Around	 100	mg	 of	 stool	 sample	 was	 required	 to	 process	 the	 faecal	 water	
extraction	needed	for	the	quantification	of	SCFAs	and	BAs.	For	the	purpose	of	this	study	
samples	were	categorised	into	two	groups	early	samples	collected	between	days	1	and	
5,	the	late	samples	were	obtained	between	days	6	and	10.	
Serum	
Blood	 samples	 were	 drawn	 from	 indwelling	 vascular	 catheters	 at	 3	 time	 points.	 The	
maximum	values	were	 used	 to	 indicate	 the	 intensity	 of	 the	 inflammatory	 response	 in	
critically	ill	children.	
	
9.2.1 Sample	size	calculation:	
	
Sample	 size	 calculation	 was	 performed	 using	 the	 statistical	 power	 analysis	 program	
G*Power	3	(Faul	et	al.	2007).	The	level	of	faecal	butyrate	(one	of	the	key	SCFAs	involved	
in	intestinal	health)	was	selected	as	the	primary	outcome	in	this	study.	The	sample	size	
was	 chosen	 to	 detect	 a	 clinically	 statistical	 difference	 in	 faecal	 butyrate	 between	
patients	and	controls.	There	are	no	data	on	the	paediatric	population.	Data	from	studies	
on	 critically	 ill	 adults	 demonstrates	 a	 rapid,	 sustained	 decrease	 in	 faecal	 butyrate	
compared	to	healthy	adults.	This	assumption	was	based	on	work	by	Yamada	et	al.	(2015)	
with	 critically	 ill	 adults	 where	 a	 difference	 of	 12	 micromol/g	 faeces	 of	 butyrate	 was	
recorded	between	critically	ill	and	healthy	controls.	It	was	estimated	that	25	children	per	
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group	would	be	needed	to	detect	the	same	difference	between	critically	ill	and	healthy	
children,	assuming	a	5%	significant	level	(2-sided)	and	90%	power.	
	
9.2.2 Statistical	analysis:	
	
The	 statistical	 analysis	was	 conducted	using	 IBM	SPSS	v25	USA.	The	Shapiro-Wilk	Test	
was	 used	 to	 assess	 the	 normality	 of	 the	 data	 distribution.	Quantitative	 variables	with	
non-normal	 distribution	 were	 expressed	 as	 median	 with	 (25-75)	 interquartile	 ranges.	
The	Mann-Witney	U	test	was	used	to	compare	independent	variables	with	non-normal	
distribution	such	as	differences	 in	SCFAs	and	the	demographic	characteristics	between	
critically	 ill	 and	 healthy	 children.	 The	 BAs	 data	 was	 normalised	 and	 analysed	 using	
Metabo-Analyst,	 a	 web-based	 programme	 (Xia	 et	 al.	 2012).	 BAs	 profiles	 were	
investigated	using	a	 combination	of	univariate	 and	multivariate	 analysis.	 The	PCA-plot	
was	 generated	 first	 to	 visualise	 the	 BA	 patterns	 between	 critically	 ill	 and	 healthy	
children.	The	PERMANOVA	test	was	used	to	assess	whether	the	observed	differences	(in	
multivariate	space)	were	statistically	significant.		A	t-test	was	then	carried	out	to	identify	
how	BAs	varied	between	critically	ill	and	healthy	children;	a	false	Discovery	Rate	(FDR)	of	
<0.05	 was	 considered	 statistically	 significant.	 The	 regression	 analysis	 was	 conducted	
using	 IBM	SPSS	v25	USA.	Stepwise	 linear	 regression	analysis	was	applied	 to	assess	 the	
relationship	between	SCFAs/	BAs	with	 the	severity	of	disease,	 inflammatory	cytokines,	
clinical	 outcomes	 and	 the	 nutritional	 intake.	 Log	 transformation	 was	 performed	 on	
SCFAs	and	BAs	prior	to	regression	analysis.	
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9.3 Results	
A	 total	 of	 45	 critically	 ill	 children	 (21	males)	 and	 40	 healthy	 children	 (18	males)	were	
enrolled	in	this	study.	Fifty-four	samples	were	obtained	from	the	patient	group	and	40	
from	healthy	controls.	The	demographics	of	patients	and	controls	are	shown	in	Table	9-
2.	Amongst	the	patient	cohort,	hospital	mortality	was	3	out	of	45	children	(6.6%).	
	
Table	9-2:	Anthropometric	and	clinical	characteristics	of	children	enrolled	in	the	study	
																																				Data	are	presented	as	median	(IQR)	
**	P-value	is	significant	at	0.01	level																																*	P-value	is	significant	at	0.05	level	
• VFH	at	30	days:	ventilation-free	hours	at	30	days	
• PICU-free	days	at	30	days:	days	free	of	paediatric	intensive	care	at	30	days	
	
Anthropometry	
All	patients	and	controls		 Age-	matched	patients	and	controls	
Patients	
(N=45)	
Control	
(N=40)	
P-	value		 Patients	
(N=27)	
Control	
(N=40)	
P-	value		
Age	(Years)	 1.3	
(			0.3		–		3.9			)	
4.8	
(			3.3		–			6.2		)	
0.00**	 3	
(		1.5	–	6.9					)	
4.3	
(			3.3		–	6.2		)	
0.086	
Weight	(Kg)	 11	
(		4.8		–		15.9		)	
19.6	
(					16		–	23				)	
0.00**	 14.6	
(		12		–		24					)	
19.6	
(				16		–		23			)	
0.029*	
Height		(cm)	 75	
(			49.5		–		96		)	
110	
(			98		–		117			)	
0.00**	 90.0	
(		79		–		104			)	
110	
(			98		–		117		)	
0.001**	
Weight	age	Z-	score	 -0.5	
(		-1.8		–	0.42	)	
0.32	
(-0.06		–		1.05)	
0.00**	 -0.11	
(	-0.7		–		0.75	)	
0.32	
(-0.06		–		1.05)	
0.035	
Height	for	age	Z-	score	 0.00	
(			-1.7	–	0.52	)					
0.67	
(	-0.13		–		1.1	)	
0.02*	 -0.17	
(	-1.4		–		0.19	)	
0.67	
(	-0.13		–		1.1	)	
0.014*	
Disease	severity	variables	
PMOD	score	 5	
	(				4		–				6					)	
	
	
5	
	(				4		–				6					)	
	
PIM2	score		
	
3.6	
(		1.2		–		6.4			)	
4	
(		1.9		–		7.5			)	
Highest	Lactate	 1.6	
	(	1.0		–		2.2			)	
1.6	
(			0.9–		2.4				)	
Highest	CRP	 94	
(			34		–		222		)	
137	
(			34		–		245		)	
Inotrope	score		 0.0	
(			0		–		15							)	
0.0	
(			0		–		16							)	
VFH	at	30	days		 636	
(		584		–		667	)	
650	
(		571		–		681	)	
PICU-	free	days	at	30	days		 22	
(	18		–		24						)	
21	
(	17		–		25					)	
Inotrope-	free	hours	at	30	
days		
720	
(	676		–	720			)	
720	
(	657		–		720		)	
Primary	admission	diagnosis	 N	(%)	
MOF	 16	(36%)	
Respiratory	Failure	 19	(42%)	
CNS	Disorders	 7	(16%)	
Surgical	Disorders	 2	(	4%	)	
Gastrointestinal	Disorders	 1	(	2%	)	
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Faecal	samples	obtained	from	critically	children	were	collected	between	days	1	and	10	
post-PICU	admission.	A	total	of	30	samples	were	obtained	between	days	1	and	5	and	15	
samples	were	obtained	between	days	6	and	10.	The	numbers	of	samples	collected	on	
each	day	are	presented	in	Table	9-3.	
	
Table	9-3:	Number	of	samples	collected	post-PICU	admission	
	
	
9.3.1 Measurements	of	faecal	SCFAs	
	
To	allow	for	a	valid	comparison	between	critically	ill	and	healthy	children,	only	data	from	
the	age-matched	population	were	included	in	this	analysis.	The	results	indicated	that	the	
levels	 of	 the	 3	 measured	 key	 SCFAs	 are	 statistically	 lower	 among	 the	 patient	 group	
compared	to	age-matched	healthy	children	p≤0.05	(Figure	9.1).	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	9.1	Differences	in	faecal	SCFAs’	peak	integral	values	between	critically	ill	
children	and	their	age-matched	healthy	controls	
Figure	9.1	shows	that	critically	ill	children	had	statistically	lower	levels	of	acetate,	propionate	and	butyrate	
compared	to	healthy	children.	
Day	 ≤2	days	 Day	3-5	 Day	6-9	 ≥10	days	
Number	of	samples	 8	 22	 13	 2	
		
	
	
Chapter	Nine	
	
	 	
210	
9.3.2 Measurements	of	faecal	BAs	
To	allow	for	a	valid	comparison	between	critically	ill	and	healthy	children,	only	data	from	
the	age-matched	population	were	included	in	this	analysis.	
In	total,	18	BAs	were	detected	in	faecal	water	(Table	9-4).	The	PCA	plots	showed	a	clear	
separation	 of	 samples	 obtained	 from	 critically	 ill	 and	 healthy	 children,	 reflecting	
systematic	differences	in	the	BA	profiles	between	the	two	groups. PERMANOVA	analysis	
confirmed	a	statistically	significant	separation	between	the	groups’	F-values:	18.0222,	p-
value	<	0.001.	The	samples	collected	from	healthy	children	were	more	tightly	clustered	
than	 those	 obtained	 from	 the	 critically	 ill	 group	 (Figure	 9.2).	 Sixteen	 BAs	 compounds	
were	recognised	as	statistically	different	between	critically	ill	and	healthy	children	(FDR	
≤	0.05),	(Figure	9.3).	
	
Table	9-4:	List	of	18	Bile	acids	detected	in	the	faecal	water	of	critically	and	healthy	
children	
BA		marker	 Abbreviation		
Cholic	acid	 CA	
Chenodeoxycholic	Acid	 CDCA	
Lithocholic	acid	 LCA	
Deoxycholic	Acid	 DCA	
Taurohyocholic	Acid	 THCA	
Taurocholic	Acid	 TCA	
Glycochenodeoxycholic	Acid	 GCDCA	
Isolithocholic	Acid	 ILCA	
23-nor-5b-Cholanic	Acid-3a,	12a-diol	 23	nor	5ß-	CA-3α,	12a-diol	
5beta-Cholanic	Acid-3beta,	12a-diol	 5ß-	CA-3ß,	12a-diol	
3-Ketocholanic	Acid		 3KCA	
3a-Hydroxy-12	Ketolithocholic	Acid	 3a-H-12	KLCA	
3,12-Diketocholanic	Acid	 3,12-DKCA	
3a-Hydroxy-6,7-DiketoCholanic	Acid	 3aH-6,7-DCA	
	3	Dehydrocholic	Acid	 3DHCA	
12	Dehydrocholic	Acid		 12	DHCA	
Glycoursodeoxycholic	Acid	 GUDCA	
Ursodeoxycholic	acid	 UDCA	
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Figure	9.2	PCA	score	plots	obtained	from	critically	ill	and	age-matched	healthy	
children’s	faecal	water	showing	bile	acid	profiles		
Data	 was	 projected	 into	 2D	 and	 3D	 for	 a	 better	 visualisation	 of	 data.	 The	 PCA	 plots	 showed	 clear	
separation	of	samples	obtained	from	critically	ill	and	healthy	children,	reflecting	systematic	differences	in	
the	BA	profiles	between	the	two	groups.	
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Figure	9.3	Bile	acids	distinguished	between	critically	ill	children	and	healthy	children’s	
groups	
Figure	 9.3	 shows	 BAs	 that	 statistically	 differed	 between	 critically	 ill	 and	 healthy	 children,	 FDR	 ≤0.05.	
Critically	ill	children	had	higher	levels	of	primary	BAs	and	conjugated	bile	compared	to	their	age-matched	
healthy	controls.	Healthy	children	group	had	statistically	higher	 levels	of	secondary	BAs,	except	for	3aH-
6,7-DCA,	12	DHCA	and	3DHCA,	where	they	were	higher	among	the	critically	ill	children	cohort.	
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Critically	ill	children	
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9.3.3 Integrated	analysis	of	fecal	microbial	and	metabolic	changes	in	critically	ill	
children	compared	to	healthy	controls	
	
The	 microbiome	 and	 metabolic	 data	 were	 integrated	 to	 examine	 the	 association	
between	changes	in	microbial	composition	and	the	metabolic	environment.	A	PCA	of	the	
normalised	 metabolic	 and	 microbial	 data	 from	 critically	 and	 healthy	 children	 was	
performed.	 The	 PCA	 differentiates	 between	 the	 bacterial	 species	 and	 metabolites	
associated	with	healthy	and	critically	ill	profiles	(Figure	9.4).	The	critically	ill	profile	was	
associated	with	a	reduction	in	SCFAs-producing	species	(Faecalibacterium	prausnitzi	and	
Eubacterium	 rectale)	 and	 decreased	 levels	 of	 intraluminal	 SCFAs.	 Increased	 levels	 of	
primary	BAs	CA	and	CDCA	were	also	a	common	feature	of	 the	critically	 ill	 state.	There	
was	also	a	major	shift	in	Clostridium	and	Eubacterium	(the	main	genera	responsible	for	
metabolising	 primary	 BA	 into	 secondary	 bile)	 towards	 the	 healthy	 children’s	 profile.	
Secondary	BAs	LCA	and	DCA	are	also	clustered	towards	the	healthy	children’s	profile.	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	9.4	PCA	analysis	integrating	faecal	microbial	and	metabolic	changes	in	critically	
ill	children	compared	to	healthy	controls	
The	PCA	analysis	created	3	components	to	integrate	the	faecal	and	microbial	changes	in	critically	ill	state	
compared	to	healthy	state.	The	bacterial	species	and	metabolites	associated	with	healthy	and	critically	ill	
profiles	indicated	by	the	arrows.	 	
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9.3.4 The	effect	of	antibiotic	treatment	and	disease	severity	on	the	functional	
capacity	of	gut	microbiome	
	
Regression	 analysis	 was	 performed	 to	 further	 investigate	 the	 relationship	 between	
antibiotic	exposure,	key	commensals	and	SCFAs/BAs	production.	All	critically	ill	children	
were	treated	with	at	 least	one	broad-spectrum	antibiotic	agent	from	day	of	admission	
into	PICU.	The	median	(IQR)	period	of	antibiotic	exposure	was	4	(3-7)	days.	The	duration	
of	 antibiotic	 treatment	 did	 not	 appear	 to	 affect	 the	 levels	 of	 SCFAs	 or	 secondary	 BA	
production	in	this	cohort	(Table	9-5).	
	
The	 regression	 analysis	 suggested	 that	 increased	 proportional	 abundance	 of	
Faecalibacterium	prausnitzi	was	 statistically	associated	with	an	 increase	 in	SCFAs	peak	
integrals.	Increased	proportional	abundance	of	Eubacterium	was	statistically	associated	
with	increased	production	of	secondary	BAs	DCA	and	LCA	(Table	9-5).	
	
The	 results	also	 indicated	 that	children	with	higher	PIM2	scores	had	 reduced	 levels	of	
butyrate	 and	 propionate	 (Table	 9-5).	 Although	 the	 univariate	 analysis	 showed	 a	weak	
positive	correlation	between	PIM2	score	primary	BAs	 [CA	 (r=0.347,	p-value=0.03),	and	
CDCA	 (r=0.355,	 p-value=0.029)],	 in	 the	 regression	 analysis	 none	 of	 the	 variables	were	
statistically	related	to	the	levels	of	primary	BAs.	
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Table	9-5:	Association	between	faecal	SCFAs,	secondary	bile	acids	and	the	
proportional	abundance	of	key	commensals	
Model	 R		 R	2		 Adjusted	R	2		 R	 P-value	
Butyrate	a	(N=30)	 0.626	 0.391	 0.345	 	
Faecalibacterium	prausnitzi	(%)	b	 	 0.529	 0.004*	
PIM2	score	b	 -0.468	 0.012*	
Days	of	antibiotics	exposure	c	 0.265	 0.185	
Eubacterium	(%)	c	 0.161	 0.424	
Clostridium	(%)	c	 0.004	 0.982	
Age	c	 0.083	 0.697	
Propionate	a	(N=30)	 0.613	 0.379	 0.328	 	
Faecalibacterium	prausnitzi	(%)	b	 	
	
	
	
0.511	 0.005*	
PIM2	score	b	 -0.464	 0.013*	
Eubacterium	(%)	c	 0.208	 0.297	
Days	of	antibiotics	exposure	c	 0.178	 0.949	
Clostridium	(%)	c	 -0.07	 0.908	
Age	c	 -0.021	 0.916	
Acetate	a	(N=30)	 0.416	 0.173	 0.142	 	
Faecalibacterium	prausnitzi	(%)b	 	 0.416	 0.025*	
PIM2	score	c	 0.235	 0.228	
Clostridium(%)	c	 -0.050	 0.911	
Eubacterium	(%)	c	 0.178	 0.949	
Age	c	 -0.085	 0.668	
Days	of	antibiotics	exposure	c	 -0.067	 0.736	
DCA	a	(N=45)	 0.565	 0.319	 0.267	 	 	
Age	b	 	 0.505	 0.006*	
Eubacterium	(%)	b	 0.375	 0.049*	
Faecalibacterium	prausnitzi	(%)	c	 0.145	 0.472	
PIM2	score	c	 0.163	 0.416	
Days	of	antibiotics	exposure	c	 0.148	 0.461	
Clostridium	(%)	c	 -0.111	 0.560	
LCA	a	(N=45)	 0.774	 0.599	 0.568	 	 	
Age	b	 	 0.705	 0.00*	
Eubacterium	(%)	b	 0.622	 0.00*	
Faecalibacterium	prausnitzi	(%)	c	 -0.005	 0.981	
PIM2	score	c	 -0.01	 0.955	
Days	of	antibiotics	exposure	c	 0.161	 0.422	
Clostridium	(%)	c	 0.175	 0.384	
	
a. Dependent	variable	
b. Predictors:	(constant)	
c. Excluded	variables	
	
	
		
	
	
Chapter	Nine	
	
	 	
216	
9.3.5 The	association	between	faecal	SCFAs/bile	acids	and	inflammation	
	
	Inflammatory	 cytokines	 were	 measured	 in	 40	 children	 where	 serum	 samples	 were	
obtainable	and	FC	was	measured	 in	18	children.	A	correlation	analysis	was	performed	
first	 to	 establish	 the	 association	 between	 SCFAs/BAs	 and	 the	 inflammatory	 markers	
(Table	 9-6).	 The	 correlation	 table	 showed	 a	weak	 negative	 correlation	 between	 Peak-
TNF	α	with	propionate	(r=-0.389,	p-value=0.041)	and	acetate	(r=-0.354,	p-value=0.025).	
No	evidence	of	 statistical	 correlation	was	 recorded	between	 the	 levels	of	BAs	and	 the	
inflammatory	markers.	
	
Table	9-6:	Correlation	analysis	of	faecal	SCFAs/bile	acids	and	inflammatory	markers	
	
	
The	 regression	 analysis	was	 then	 performed	 to	 assess	 the	 association	 between	 SCFAs	
and	 TNFα.	 The	 results	 suggested	 that	 an	 increase	 in	 TNFα	was	 statistically	 associated	
with	 a	 reduction	 in	 the	 levels	 of	 acetate,	 independently	 from	 disease	 severity	 and	
antibiotic	 exposure.	 This	 model	 accounted	 for	 15%	 of	 the	 variation	 in	 acetate	 levels	
(Table	9-7).	
	
	
	 	
	Peak	IL-1	 Peak	IL-6	 Peak	IL-10	 Peak-TNF	α	 FC	
Butyrate	
R	 -0.273	 -0.275	 -0.271	 -0.31	 0.066	
P-value	 0.088	 0.086	 0.091	 0.052	 0.794	
Propionate	
R	 -0.196	 -0.184	 -0.182	 -0.389*	 -0.012	
P-value	 0.226	 0.256	 0.261	 0.013	 0.961	
Acetate	
R	 -0.287	 -0.19	 -0.258	 -0.354*	 -0.159	
P-value	 0.072	 0.24	 0.108	 0.025	 0.529	
CDCA	
R	 0.234	 0.016	 0.26	 0.041	 -0.046	
P-value	 0.147	 0.924	 0.106	 0.803	 0.855	
CA	
R	 0.225	 0.123	 0.243	 0.06	 -0.004	
P-value	 0.163	 0.45	 0.131	 0.714	 0.987	
LCA	
R	 0.158	 0.266	 0.071	 -0.219	 0.158	
P-value	 0.33	 0.097	 0.664	 0.174	 0.531	
DCA	
R	 0.164	 0.174	 0.123	 -0.103	 0.055	
P-value	 0.313	 0.284	 0.451	 0.528	 0.829	
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Table	9-7:	Association	between	inflammatory	cytokines	and	the	levels	of	faecal	SCFAs	
Model	 R		 R	2		 Adjusted	R	2		 R	 P-value	
Butyrate	a	(N=40)	 0.552	 0.346	 0.328	 	
Age	b	 	 0.588	 0.00*	
PIM2	score	c	 0.085	 0.611	
Peak	TNF-α	c	 -0.173	 0.298	
Days	of	antibiotics	exposure	c	 0.141	 0.399	
Propionate	a	(N=40)	 0.540	 0.291	 0.272	 	
Age	b	 	 0.540	 0.00*	
PIM2	score	c	 0.159	 0.341	
Peak	TNF-α	c	 -0.211	 0.211	
Days	of	antibiotics	exposure	c	 0.147	 0.378	
Acetate	a	(N=40)	 0.411	 0.169	 0.147	 	
Peak	TNF-α	b	 	 -0.411	 0.009*	
Age	c	 0.160	 0.309	
PIM2	score	c	 0.059	 0.724	
Days	of	antibiotics	exposure	c	 0.130	 0.436	
	
a. Dependent	variable	
b. Predictors:	(constant)	
c. Excluded	variables	
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9.3.6 Bacterial	metabolites	as	predictors	of	clinical	outcomes	in	critically	ill	children	
	
In	this	section,	SCFAs	and	BAs	were	tested	as	predictors	of	clinical	outcomes	in	critically	
ill	children.	VFH	at	30	days,	PICU-free	days	at	30	days	and	hours	free	of	inotrope	at	30	
days	 were	 used	 as	 the	 dependent	 variables	 in	 the	 regression	 models.	 This	 analysis	
included	only	the	SCFAs	and	BAs	measured	in	the	early	samples	obtained	between	day	1	
and	5;	samples	obtained	post-day	5	were	excluded.	
The	 regression	 models	 suggested	 that	 early	 butyrate,	 propionate	 and	 acetate	
statistically	predicted	the	duration	of	mechanical	ventilation,	length	of	PICU	stay	and	the	
duration	of	 inotrope	treatment	(see	Tables	9-8,	9-9,	9-10).	Unlike	SCFAs,	BAs	were	not	
statistically	 related	 to	 any	 of	 the	 chosen	 clinical	 outcome	measures	 independently	 of	
disease	severity	and	antibiotic	exposure.	
	
Table	9-8:	SCFAs	measured	in	early	samples	as	predictors	of	the	duration	of	
mechanical	ventilation	
Model	 R		 R	2		 Adjusted	R	2		 R	 P-value	
VFH	at	30	days	a	(N=30)	 0.397	 0.158	 0.127	 	
Butyrate	b	 	 0.397	 0.030*	
Age	c	 -0.05	 0.774	
PIM2	score	c	 0.04	 0.818	
Days	of	antibiotics	exposure	c	 0.26	 0.894	
VFH	at	30	days	a	(N=30)	 	 	
Propionate	c	 	
	
0.359	 0.026	
Age	c	 0.106	 0.288	
PIM2	score	c	 0.115	 0.272	
Days	of	antibiotics	exposure	c	 0.083	 0.332	
VFH	at	30	days	a	(N=30)	 	 	
Acetate	c	 	 0.304	 0.051	
Age	c	 0.106	 0.288	
PIM2	score	c	 0.115	 0.272	
Days	of	antibiotics	exposure	c	 0.083	 0.332	
	
a. Dependent	variable	
b. Predictors:	(constant)	
c. Excluded	variables	
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Table	9-9:	SCFAs	measured	in	early	samples	as	predictors	of	the	length	of	PICU	stay	
Model	 R		 R	2		 Adjusted	R	2		 R	 P-value	
PICU	free	days	a	(N=30)	 0.459	 0.210	 0.182	 	
Butyrate	b	 	 0.459	 0.011*	
Age	c	 0.154	 0.059	
PIM2	score	c	 0.174	 0.013	
Days	of	antibiotics	exposure	c	 -0.071	 0.716	
PICU	free	days	a	(N=30)	 0.434	 0.188	 0.159	 	
Propionate	b		 	
	
	
	
0.434	 0.017*	
Age	c	 0.150	 0.438	
PIM2	score	c	 0.144	 0.455	
Days	of	antibiotics	exposure	c	 -0.057	 0.759	
PICU	free	days	a	(N=30)	 0.435	 0.189	 0.155	 	
Acetate	c	 	 0.263	 0.080	
Age	c	 0.303	 0.052	
PIM2	score	c	 0.238	 0.102	
Days	of	antibiotics	exposure	c	 0.006	 0.487	
	
a. Dependent	variable	
b. Predictors:	(constant)	
c. Excluded	variables	
	
	
Table	9-10:	SCFAs	measured	in	early	samples	as	predictors	of	the	duration	of	inotrope	
treatment	
Model	 R		 R	2		 Adjusted	R	2		 R	 P-value	
Inotrope	free	hours	at	30	days	a	(N=30)	 0.584	 0.341	 0.290	 	
Butyrate	b	 	 0.425	 0.004*	
PIM2	score	b	 -0.305	 0.018*	
Age	c	 0.010	 0.959	
Days	of	antibiotics	exposure	c	 0.136	 0.497	
Inotrope	free	hours	at	30	days	a	(N=30)	 0.591	 0.349	 0.299	 	
Propionate	b	 	
	
	
	
0.531	 0.004*	
PIM2	score	b	 -0.473	 0.010*	
Age	c	 0.10	 0.960	
Days	of	antibiotics	exposure	c	 0.161	 0.422	
Inotrope	free	hours	at	30	days	a	(N=30)	 0.622	 0.387	 0.364	 	
Acetate	b	 	 0.622	 0.00*	
Age	c	 -0.353	 0.065	
PIM2	score	c	 -0.165	 0.400	
Days	of	antibiotics	exposure	c	 0.078	 0.693	
	
a. Dependent	variable	
b. Predictors:	(constant)	
c. Excluded	variables	
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9.4 Discussion	
	
The	results	of	this	chapter	indicate	that	critically	ill	children	had	a	reduced	concentration	
of	 faecal	 SCFAs	 and	 increased	 levels	 of	 the	 primary	 BAs	 compared	 to	 age-matched	
healthy	children.	
SCFAs	arise	from	the	anaerobic	bacterial	metabolism	of	polysaccharides	in	the	colon	and	
they	 have	many	 beneficial	 effects	 for	 the	 host.	 The	 reduction	 in	 SCFAs	 levels	 among	
critically	 ill	 children	 group	 may	 be	 related	 to	 the	 shift	 in	 gut	 bacterial	 population,	
resulting	 in	 a	 reduction	 of	 the	 degradation	 capacity	 of	 undigested	 carbohydrates	 into	
SCFAs	(Iapichino	et	al.	2008).	In	the	current	study,	increased	proportional	abundance	of	
Faecalibacterium	 prausnitzi	 was	 statistically	 associated	 with	 an	 increase	 in	 faecal	
butyrate,	 propionate	 and	 acetate.	 These	 findings	 are	 similar	 to	 previously	 published	
work	 in	 healthy	 subjects,	 where	 a	 strong	 correlation	 between	Faecalibacterium	
prausnitzi	and	the	production	of	butyrate	was	recorded	(Benus	et	al.	2010;	Duncan	et	al.	
2007).	SCFAs	have	been	shown	to	be	depleted	in	critically	ill	adult	patients,	often	due	to	
the	effect	of	antibiotic	therapy	on	SCFAs-forming	species	(Shimizu	et	al.	2006;	Osuka	et	
al.	2012;	Hayakawa	et	al.	2011;	Yamada	et	al.	2015;	Vermeiren	et	al.	2012).		
BA	pool	size	represents	the	function	of	the	microbial	metabolism	of	BAs	in	the	intestines	
(Ridlon	et	al.	2014).	 In	 the	current	 study,	 critically	 ill	 children	had	a	 statistically	higher	
concentration	 of	 primary	 and	 conjugated	 BAs	 compared	 to	 age-matched	 healthy	
children.	 Increased	 levels	of	CA,	CDCA	and	other	bile	conjugates	were	also	reported	 in	
previously	 published	 studies	 in	 critically	 ill	 patients	where	BA	was	measured	 in	 serum	
(Vanwijngaerden	et	al.	2011;	Horvatits	et	al.	2017).	CDCA	are	known	to	be	toxic	to	the	
gut	 bacteria	 as	 they	 are	 relatively	 hydrophobic,	 therefore	 under	 normal	 conditions,	
microbial	 epimerisation	 of	 the	 7α-hydroxy	 group	 is	 known	 to	 decrease	 the	 toxicity	 of	
CDCA	 (Ridlon	 et	 al.	 2016).	 The	 transformation	 of	 primary	 BA	 through	 the	 7α-
dehydroxylation	 enzymatic	 pathway	 is	 restricted	 to	 a	 group	 of	 commensal	 bacteria	
belonging	 to	 the	 Eubacterium	and	Clostridium	cluster	 XIV	 species	 (Studer	 et	 al.	 2016),	
which	 has	 shown	 to	 be	 diminished	 in	 critically	 ill	 children	 (see	 Chapter	 Eight).	 In	 the	
current	 study,	 an	 increased	 proportional	 abundance	 of	 Eubacterium	was	 statistically	
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associated	with	increases	in	faecal	DCA	and	LCA.	These	finding	may	imply	that	reduced	
concentrations	 of	 secondary	 BAs	 recorded	 in	 critically	 ill	 children	 group	 is	 actually	
related	 to	 reduced	 the	 abundance	 or	 the	 capacity	 of	 commensal	 species	 such	 as	
Eubacterium	 to	modifying	 primary	 BAs	 to	 secondary	 and	 tertiary	 bile	 (Wahlströ	 et	 al.	
2016).	 The	 secondary	 BAs	 are	 also	 known	 to	 have	 a	 protective	 effect	 against	 the	
intestinal	 colonisation	 of	 pathogens	 such	 as	Clostridium	 difficile	 (Studer	 et	 al.	 2016;	
Begley	 et	 al.	 2005).	 However,	 it	 is	 also	 important	 to	 note	 that	 increased	 BAs	
dehydroxylation	 by	 intestinal	 clostridia	 may	 result	 in	 increased	 production	 of	
hydrophobic	BAs,	which	could	be	problematic	(Wahlströ	et	al.	2016).	
The	integrated	analysis	of	metabolic	and	microbial	data	showed	that	a	critically	ill	profile	
was	 associated	 with	 a	 reduction	 in	 SCFAs-producing	 bacteria	 and	 decreased	 levels	 of	
intraluminal	SCFAs.	 Increased	levels	of	primary	BAs	CA	and	CDCA	were	also	a	common	
feature	 of	 the	 critically	 ill	 state.	 Previous	 studies	 recorded	 a	 strong	 correlation	
between	Faecalibacterium	 prausnitzii,	 Roseburia	 and	 the	 production	 of	 butyrate	 in	
healthy	 volunteers	 (Benus	 et	 al.	 2010;	Duncan	 et	 al.	 2007).	 Hence,	 reduced	 levels	 of	
SCFAs	 in	 a	 critically	 ill	 cohort	 could	 be	 related	 to	 reduced	 functional	 capacity	 of	 the	
microbiota	 to	 ferment	 dietary	 compounds,	 the	 substrate	 for	 SCFAs	 production	
(Morowitz	et	al.	2011).	 Similarly,	 an	 increase	 in	 the	concentration	of	primary	BAs	also	
reflects	the	diminished	capacity	of	the	intestinal	bacteria	to	metabolise	primary	BAs	into	
secondary	and	tertiary	compounds	(Marschall	et	al.	1992;		Ridlon	et	al.	2006;		Wahlströ	
et	al.	2016).	
The	 results	 also	 showed	 that	 among	 critically	 ill	 children,	 those	who	were	 sicker	with	
higher	PIM2	 score	had	 reduced	 levels	 of	 SCFAs.	 In	 addition,	 a	 reduction	 in	 SCFAs	was	
associated	with	longer	duration	of	mechanical	ventilation	and	length	of	PICU	stay.	TNF-α	
was	also	negatively	 associated	with	acetate	 levels.	An	 important	driver	of	multi-organ	
failure	 in	 critical	 illness	 is	 the	 dysregulation	 of	 innate	 immune	 pathways	 and	 loss	 of	
balance	 between	 pro-inflammatory	 and	 anti-inflammatory	 mechanisms	 (Cox	 2012).	
Decline	 in	 SCFAs	 generation	 by	 commensal	 bacteria	 may	 contribute	 to	 local	 and	
systemic	 inflammatory	 and	 metabolic	 dysregulation.	 SCFAs	 appear	 to	 play	 a	 role	 in	
modulating	 inflammatory	 and	 immune	 responses,	 since	 they	modify	 the	migration	 of	
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leukocytes	to	the	site	of	inflammation,	as	well	as	modifying	the	release	and	production	
of	chemokine	(Vinolo	et	al.	2011).	The	activation	of	GPR43	by	SCFAs	induces	chemotaxis	
and	 regulates	 the	 degranulation	 of	 neutrophils	 (Kim	 et	 al.	 2014).	 SCFAs,	 in	 particular	
butyrate,	 have	 been	 shown	 to	 reduce	 inflammatory	 cytokine	 production	 and	
inflammation	 in	 the	 intestine	 through	 mechanisms	 including	 nuclear	 factor	 kappa	 B	
signalling	(Ramakrishna	2013;	Tedelind	et	al.	2007).	In	addition,	they	exert	an	inhibitory	
effect	 on	 both	 TNFα-mediated	 activation	 of	 the	 nuclear	 factor	 kappa	 B	 pathway	 and	
lipopolysaccharide-induced	 TNFα	 release	 (Tedelind	 et	 al.	 2007).	 The	 findings	 of	 the	
current	 study	 suggest	 that	 SCFAs,	 particularly	 butyrate,	 could	be	used	 as	 a	prognostic	
biomarker	predicting	poor	clinical	outcomes	in	critically	ill	children.	Future	work	should	
focus	 on	 the	 longitudinal	 monitoring	 of	 key	 biomolecules	 such	 as	 SCFAs.	 The	
reappearance	of	faecal	SCFAs	later	in	the	PICU	stay	could	be	a	sign	of	recovery.	
In	the	current	study,	a	weak	correlation	was	recorded	between	both	CA	and	CDCA	and	
disease	 severity	 assessed	 by	 PIM2	 score.	 However,	 in	 the	 multivariate	 analysis	 this	
correlation	was	confounded	by	other	factors.	The	association	between	increased	levels	
of	primary	BAs	and	disease	severity	has	been	established	in	critically	ill	adults.	Horvatits	
et	 al.	 (2017)	 reported	 a	 positive	 correlation	 between	 conjugated	 BAs	 and	 disease	
severity	 assessed	 by	 simplified	 acute	 physiology	 score	 (SAPS2)	 and	 serum	 lactate	 in	
critically	ill	patients.	The	current	study	did	not	find	a	correlation	between	inflammatory	
markers	and	BAs.	BA	has	been	shown	to	play	an	important	role	in	the	regulation	of	the	
inflammatory	process.	It	has	previously	been	shown	that	serum	BAs	are	able	to	directly	
trigger	inflammatory	processes	via	cytokine	expression	(Allen	et	al.	2011).	Furthermore,	
BAs	may	also	exert	anti-inflammatory	and	immunosuppressive	effects	mediated	via	FXR	
and	TGR5	receptors	(Jia	et	al.	2018).	Previously	published	in	vitro	studies	indicated	that	
BAs	 such	as	deoxycholic	 acid	and	CDCA	acid	may	be	 implicated	 in	 intestinal	 injury,	by	
promoting	 apoptosis	 of	 colonocytes,	 enhancing	 mucosal	 permeability	 and	 promoting	
intestinal	 inflammation	(Barrasa	et	al.	2011;	Münch	et	al.	2007;	Raimondi	et	al.	2008).	
The	results	of	 this	study	showed	that	BAs	were	not	statistically	associated	with	any	of	
the	chosen	clinical	outcome	measures	independently	of	disease	severity.	However,	in	a	
previous	study	in	critically	ill	adults,	increased	levels	of	serum	BAs	were	associated	with	
		
	
	
Chapter	Nine	
	
	 	
223	
increased	28-day	mortality	and	it	was	proposed	as	an	early	risk	stratification	in	critically	
ill	patients	(Horvatits	et	al.	2017).	
	
9.5 Conclusion	
	
This	study	provides	evidence	that	SCFAs	and	BA	homeostasis	are	significantly	altered	in	
critically	ill	children.	Since	intestinal	microbiota	are	responsible	for	generating	SCFAs	and	
converting	primary	BAs	into	secondary	BAs,	 it	could	be	argued	that	abnormalities	seen	
in	 SCFAs	 and	 BAs	 profiles	 are	 actually	 related	 to	 the	 shift	 in	 gut	 bacteria	 population	
observed	 in	 critical	 illness.	 Reduction	 in	 SCFAs	 appears	 to	 be	 associated	 with	 a	 pro-
inflammatory	state	and	disease	severity.	Monitoring	early	metabolic	changes	in	critically	
ill	children	may	identify	key	biomolecules	that	might	be	able	to	independently	modulate	
the	 inflammatory	 and	 metabolic	 response	 and	 potentially	 affect	 clinical	 outcomes	
among	this	population.	These	findings	could	have	potential	clinical	implications	relating	
to	rapid	diagnostic	biomarkers	and	the	development	of	nutritional	interventions	aimed	
at	restoring	intestinal	bacterial	function.
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10 Chapter	Ten:	General	Discussion	and	Conclusion	
	
10.1 Key	findings	
	
The	main	aim	of	this	thesis	was	to	evaluate	the	adequacy	of	enteral	nutrition	delivery	in	
critically	 ill	 children	 in	 relation	 to	 the	gut	homeostasis	 and	disease	 state.	 First,	 energy	
and	macronutrient	 requirements	 for	 critically	 ill	 children	 needed	 to	 be	 established	 in	
order	 to	 assess	 the	 efficacy	 of	 the	 current	 feeding	 protocol.	 	 The	 balance	 between	
requirement	and	delivery	of	energy	and	macronutrients	was	then	evaluated	in	a	cohort	
of	 critically	 ill	 children.	 Finally,	 an	 integrated	 approach	 of	 metataxonomic	 and	
metabolomic	 analysis	 was	 undertaken	 to	 examine	 how	 critical	 illness	 and	 other	
iatrogenic	factors	 including	nutrition	affect	the	composition,	diversity	and	functionality	
of	the	intestinal	microbiome	in	critically	ill	children.	
	
Overall	this	project	has	recorded	a	cross	link	between	feed,	gut	homeostasis	in	terms	of	
mucosal	 integrity,	 and	 microbial	 composition	 with	 systemic	 inflammation	 and	 host	
metabolism	(Figure	10.1).	It	has	been	shown	that	within	the	feed	delivered,	fat	delivery	
was	often	above	requirements	compared	to	protein	and	carbohydrate.	In	addition,	both	
protein	deficit	and	higher	delivery	of	fat	were	associated	with	elevation	in	the	levels	of	
pro-inflammatory	cytokines.	In	particular	under-delivery	of	protein	was	associated	with	
an	increase	in	serum	levels	of	IL-6	and	TNF-α,	while	higher	delivery	of	fat	was	associated	
with	elevated	levels	of	TNF-α.	The	results	also	showed	that	abnormalities	in	gut	health	
biomarkers	were	associated	with	elevation	in	inflammatory	cytokines.	Finally,	this	study	
also	 recorded	 a	 profound	 loss	 of	 diversity	 in	 the	 faecal	 microbiome	 of	 critically	 ill	
children.	 This	 was	 associated	 with	 the	 loss	 of	 key	 commensal	 species	 and	 increased	
levels	 of	 opportunistic	 pathogens	 such	 as	 Proteobacteria,	 Streptococcus	 and	
Enterococcus.	Consequently,	resulted	in	reduced	the	functionality	of	the	gut	microbiome	
manifested	by	reduced	production	of	SCFAs	and	abnormalities	in	BAs	metabolism.	This	
project	 showed	 that	 SCFAs	 could	 be	 potential	 prognostic	 biomarkers	 predicting	 poor	
clinical	outcomes	in	critically	ill	children.	The	current	study	showed	for	the	first	time	that	
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energy	 underfeeding	 during	 the	 24	 hours	 prior	 the	 sample	 collection	 appeared	 to	
influence	the	microbial	composition	of	critically	ill	children.		
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	 10.1	 Summary	 of	 the	 interaction	 between	 gut	 microbiome,	 systemic	
inflammation	and	host	metabolism	during	 critical	 illness	based	on	 the	 findings	 from	
this	project	
	
It	 is	 crucial	 to	 understand	 the	 pathophysiological	basis	 of	 the	 acute	 insult	 in	 order	 to	
develop	new	novel	therapies	that	improve	clinical	outcomes	of	critically	ill	children.	The	
findings	of	this	thesis	point	to	the	role	of	gut	in	the	pathophysiology	of	inflammation	in	
critical	illness.	Therefore,	the	microbiome	should	be	considered	as	an	organ	that	can	fail	
in	 critically	 ill	 patients	 and	 can	 impact	 other	 organs.	 Based	 on	 the	 findings	 from	 this	
thesis	and	previous	work,	 it	become	obvious	 that	 critically	 ill	 children	may	actually	be	
stuck	in	a	vicious	cycle	of	systemic	inflammation	and	dysbiosis	of	gut	microbiome.	As	the	
findings	 of	 this	 thesis	 suggest	 that	 EN	 could	 impact	 the	 inflammatory	 state	 and	may	
potentially	modulate	the	intestinal	microbiome	and	the	residing	microbiota.	Nutritional	
intervention	 could	 be	 a	 potential	 therapy	 to	 alleviate	 the	 disease	 state	 and	 improve	
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clinical	outcome	in	this	population	by	breaking	this	cycle	and	restore	homeostatic	state	
of	the	intestinal	microbiome.		
	
Although,	 nutrition	 is	 considered	 an	 integral	 part	 of	 the	 treatment	 plan	of	 critically	 ill	
children,	 what	 is	 dismissed	 is	 whether	 the	 nutrients	 provided	 are	 adequate	 and	 how	
they	are	processed	and	utilised	by	the	host	and	the	microbiota.	As	the	results	suggest	
that	 aiming	 to	 achieve	 energy	 goal	 by	 using	 the	 standardised	 formulas	may	 result	 in	
higher	delivery	of	fat	and	compromise	protein	intake.	It	is	possible	that	the	distribution	
of	macronutrients	in	these	standardised	feeds	do	not	match	the	specific	requirements	of	
critically	 ill	 children.	 Therefore,	 there	 is	 an	urgent	need	 for	new	enteral	 formulas	 that	
closely	 meet	 the	 macronutrient	 needs	 of	 critically	 ill	 children	 while	 providing	 the	
optimum	substrate	necessary	for	the	maturation	and	growth	of	commensal	bacteria.		
	
The	 goal	 of	 nutrition	 therapy	 in	 critical	 illness	 should	 not	 only	 be	 limited	 to	 improve	
nitrogen	balance.	It	is	about	providing	a	good	quality	feeds	with	balance	macronutrient	
content	to	feed	up	the	entire	body	including	the	microbiota	and	host	cells.		Nutritional	
interventions	may	help	to	maintain	commensal	population	and	restore	normal	gut	host	
relationships.	 Yet	 no	 clinical	 trials	 in	 critically	 ill	 children	 have	 tried	 targeted	 gut	
modulation	by	nutritional	intervention.	Future	work	should	aim	at	personalising	the	care	
of	critically	 ill	 children,	and	suggest	ways	to	manipulate	the	body’s	 response	to	severe	
illness	in	order	to	restore	the	homeostatic	state.		
	
10.2 Strengths	and	weaknesses	
A	particular	strength	of	this	PhD	thesis	is	that	it	improved	our	understanding	about	the	
role	 of	 nutrition	 as	 a	 contributing	 factor	 affecting	 the	 disease	 state	 in	 critically	 ill	
children.	 In	 addition,	 it	 provided	 a	 guide	 for	 future	 studies	 aiming	 at	 targeted	 gut	
modulation	 by	 nutritional	 intervention	 to	 manipulate	 the	 body’s	 response	 to	 severe	
illness.	 The	 findings	 from	 this	 thesis	 also	 provided	 a	 plausible	 clinical	 connection	
between	 inflammation	 host	 metabolism	 and	 gut	 microbiome.	 This	 project	 also	
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highlighted	the	needs	for	establishing	macronutrient	requirements	that	specifically	meet	
the	needs	of	critically	ill	children.		
There	 are	 no	 previous	 studies	 investigated	 the	 effect	 of	 macronutrient	 delivery	 on	
disease	features	such	as	inflammation	(systemic	and	intestinal).	This	project	was	the	first	
to	show	that	macronutrient	delivery	may	 influence	the	systemic	 inflammatory	state	 in	
critically	ill	population	where	the	inflammatory	response	is	already	stimulated	by	injury.	
These	findings	are	of	clinical	significance	and	add	to	the	knowledge	of	the	field	of	critical	
care	nutrition	and	emphasize	the	need	to	develop	new	feed	that	particularly	meet	the	
macronutrient	requirements	of	critically	ill	children.	
All	 microbiome	 studies	 in	 critical	 settings	 have	 arrived	 at	 a	 similar	 conclusion	 that	
commensal	species	are	replaced	by	pathogens.	None	of	which	investigated	the	effect	of	
environmental	 influences	 (e.g.	 Nutrition,	 antibiotic	 treatment)	 on	 the	 microbiome	 of	
critically	ill	patients.	This	project	showed	that	patient’s	factors	such	as	age	and	feeding	
status	 are	 important	 factors	 influencing	 the	 intestinal	 microbiome	 of	 critically	 ill	
children.	 These	 factors	 may	 provide	 a	 tool	 to	 identify	 patients	 at	 risk	 of	 extreme	
intestinal	 dybiosis	 (infants	 as	 they	 low	 microbial	 diversity	 or	 underfed	 children)	 and	
implement	ways	to	support	the	gut	environment	in	this	group.	
This	work	also	showed	that	reduced	SCFAs	production	was	associated	with	 increase	 in	
pro-inflammatory	 cytokines	 and	 disease	 severity.	 These	 findings	 could	 have	 potential	
clinical	 implications	 relating	 to	 rapid	 diagnostic	 biomarkers	 and	 the	 development	 of	
nutritional	interventions	aimed	at	restoring	intestinal	bacterial	function.	
Unfortunately,	 this	 project	 also	 suffered	 from	 several	 weaknesses.	 Firstly,	 the	
heterogeneity	 of	 the	 cohort	 in	 terms	 of	 age/disease	 type/severity,	 interventions	 and	
nutritional	 status	 are	 a	 limiting	 factor	 in	 this	 project.	 However,	 this	 was	 taken	 into	
account	 when	 conducting	 the	 statistical	 analysis.	 For	 instance,	 all	 regression	 models	
were	adjusted	for	age	and	disease	severity.	In	addition,	where	necessary,	patients	were	
stratified	 by	 age	 groups	 or	 diagnosis.	 	 This	 resulted	 in	 reduced	 sample	 size	 for	 some	
aspects	of	the	work.	Therefore	it	was	difficult	to	find	significant	relationships	from	some	
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data,	as	statistical	tests	normally	require	a	larger	sample	size	to	ensure	a	representative	
distribution	of	the	population.		
Lack	 of	 published	 guidelines	 regarding	 enteral	 fat	 and	 carbohydrate	 requirements	 for	
critically	 ill	 children	 was	 also	 a	 limiting	 factor	 in	 this	 study.	 Therefore,	 the	
recommendation	for	healthy	children	was	used	as	a	guide	to	establish	carbohydrate	and	
fat	 goal	 for	 the	 purpose	 of	 this	 project.	 This	 provided	 an	 undisputed	 reference	 range	
universally	 accepted	 in	 general	 nutrition	 but	 it	 is	 still	 considered	 a	 weakness	 of	 this	
study.		
It	is	clinically	accepted	that	antibiotics	are	the	main	adverse	exposure	on	gut	microbiota			
during	 critical	 illness.	 However,	 the	 findings	 of	 this	 this	 thesis	 did	 not	 record	 an	
association	 between	 the	 type	 and	 duration	 of	 antibiotic	 treatment	 and	 intestinal	
dysbiosis.	This	could	be	because	all	 faecal	 samples	obtained	 for	 the	microbiome	study	
were	 collected	 after	 day	 2	 of	 PICU	 admission	 where	 broad-spectrum	 antibiotic	
treatment	 was	 already	 initiated	 for	 all	 children.	 This	 limited	 the	 extent	 of	 observing	
differences	 in	 the	 microbial	 species	 across	 the	 patient	 groups	 based	 on	 antibiotic	
therapy.	 The	 effect	 of	 antibiotic	 exposure	 on	 the	 intestinal	microbiome	during	 critical	
illness	needs	to	be	examined	in	more	details	in	future	studies	with	reference	to	the	type	
and	 dosing	 of	 antimicrobial	 agents	 as	 well	 as	 the	 time	 of	 exposure.	 However,	 since	
antibiotics	are	given	routinely,	often	for	 life-saving	purposes,	they	could	be	considered	
as	an	inevitable	component	in	the	combination	of	adverse	exposures	for	the	intestinal,	
and	other	microbiomes	in	the	critically	ill	child.	
	
10.3 Future	work	and	perspective		
	
This	 PhD	 project	 provided	 an	 insight	 about	 the	 role	 of	 host-gut	 interaction	 on	 host	
metabolism,	 disease	 severity	 and	 clinical	 outcomes	 in	 critically	 ill	 children.	 The	 next	
generation	 of	 microbiome	 studies	 in	 PICU	 settings	 should	 focus	 on	 distinguishing	
microbiome	changes	in	children	who	do	well	and	those	who	do	not.		In	addition	future	
work	should	try	to	develop	strategies	to	modulate	the	gut	environment	and	manipulate	
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the	body’s	response	to	severe	illness	in	order	to	restore	the	homeostatic	state.	This	may	
include	 the	 use	 of	 nutritional	 interventions	 (such	 as	 probiotics,	 prebiotics	 and	 short	
chain	fatty	acids	or	a	combination	of	these	agents)	to	promote	the	growth	of	commensal	
species	and	restore	the	normal	balance	of	the	gut	microbiota.		
	
The	findings	of	the	current	study	suggest	that	SCFAs	particularly	butyrate	could	be	used	
as	 a	 prognostic	 biomarker	 predicting	 poor	 clinical	 outcomes	 in	 critically	 ill	 children.	
Future	 work	 should	 aim	 at	 identifying	 key	 intermediates	 of	 host-gut	 microbiota	
interactions	to	develop	a	stratification	and	monitoring	tool	to	guide	implementation	and	
use	of	gut	protective	treatments	in	critically	children.	The	longitudinal	monitoring	of	key	
biomolecules	such	as	SCFAs	could	be	of	clinical	significance;	the	reappearance	of	these	
intermediates	later	in	the	PICU	stay	could	be	a	sign	of	recovery	from	illness.	
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Background and aims: An important goal of nutrition support in paediatric critical illness is minimising
catabolism. While focussing on providing full energy requirements, macronutrient balance is often
neglected. Studies suggest that there is interplay between nutrition and inﬂammation. We aimed to
assess the amount of enteral macronutrients delivered compared to estimated requirements, and the
association between delivered macronutrients and systemic inﬂammation in critically ill children.
Method: We prospectively evaluated energy and macronutrient intake in critically ill children who
required at least 72 h of mechanical ventilation. Data on enteral energy and macronutrient intake was
collected and expressed as a percentage of the estimated requirements. Circulating levels of inﬂam-
matory cytokines were measured by ELISA and association assessed with delivery of macronutrients
from the previous 24 h.
Results: A total of 87 children (0e16 years) were included in this study. By day 3 the median (IQR) intake
of energy, fat, carbohydrate (CHO) and protein were 75% (50e103), 85% (43e120), 63% (42e102) and 45%
(23e65) respectively. We have also shown that delivery of enteral fat and protein was associated with
elevation in the levels of tumour necrosis factor alpha (TNF-a) and interleukin-6 (IL-6).
Conclusion: The inﬂammatory response in critically ill children is inﬂuenced by the amount of enteral fat
and protein delivered. Our data suggests that within the feed delivered, fat is often higher than protein
and CHO. It is crucial to take into account the proportion of macronutrients required and not only aim to
achieve the energy goal.
Crown Copyright © 2018 Published by Elsevier Ltd. All rights reserved.
1. Introduction
An important goal of nutrition support in paediatric critical
illness is minimising catabolism and supporting basal physiological
function [1]. There is often a clinical focus on delivering the energy
and protein requirements of a patient, but the balance of macro-
nutrients is often neglected. Ready-to-feed energy-dense (ED)
formulae (1 kcal/ml below 1 year of age and 1.5 kcal/ml > 1 year of
age) are often used to achieve energy requirements in critically ill
children for a number of reasons. A higher prevalence of chronic
illness and co-morbidity means that critically ill children are more
likely to be malnourished on admission to the Paediatric Intensive
Care Unit (PICU) than healthy children [2,3]. It is important to
prevent further deterioration of their nutritional status. Further-
more, these feeds are used to compensate for restrictions in ﬂuid
intake and the often frequent interruptions to enteral feeding (EN)
[4,5]. However, it is also important to point out the potential risk of
overfeeding among this population particularly the malnourished
children, who exhibit a hypo-metabolic pattern [6].
The effect of under and over-feeding has been previously
investigated, and both have been shown to be detrimental in crit-
ically ill children [7e9,37,38]. Although more is known about en-
ergy balance and protein requirements [10], the ideal balance of
macronutrients, carbohydrates, protein and fats has not yet been* Corresponding author.
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established. Current recommendations for macronutrients re-
quirements in this population are based on the understanding of
their metabolism and handling during the course of their illness
[7,10]. Critical illness is characterized by impaired glucose meta-
bolism and increased protein catabolism [10e13]. Likewise the rate
of lipid turnover is generally accelerated, suggesting that critically
ill children utilise fat preferentially as a substrate for their energy
metabolism [7,14,15].
There is a growing body of evidence suggesting that there is
interplay between nutrition and inﬂammation. Increased levels of
inﬂammatory cytokines have been reported before in undernour-
ished childrenwith cirrhosis [16]. Studies also suggested that a diet
high in fat might induce systemic low-level inﬂammation in adult
population [17e19]. In this study, we aimed to assess the amount of
macronutrient delivered compared to estimated requirements and
investigate the association between delivered macronutrients and
systemic inﬂammation in a cohort of critically ill children.
2. Material and methods
We prospectively evaluated energy and macronutrients intake
in ventilated children admitted to PICU at Addenbrooke's Hospital
in Cambridge, between November 2014 and May 2017, as a part of
study looking at gut microbiome in critically ill children. Ethical
approval was authorized by City and Hampstead LREC (Reference:
13/LO/0974).
Inclusion criteria:
! Age 1 week to 16 years.
! Mechanically ventilated for >72 h.
! Enterally fed.
Exclusion criteria:
! Preterm gestation (birth < 37 weeks).
! Known pre-existing immune paresis, oncological diagnosis and
HIV.
! Children who were on full/supplemental parenteral nutrition
(PN) or ketogenic diet.
The actual nutritional intake was recorded daily using patient
clinical records until discharge from PICU. The type of enteral feed,
total volume delivered, energy and macronutrient delivered was
calculated for each patient from the nutrition data card of each
formulae (in the Supplementary Appendix). Calculation of breast
milk compositionwas based on data from previous published study
on breast milk composition [20].
Enteral formulae were classiﬁed into 3 types, energy dense
formula (1 kcal/ml for infant <1 year and 1.5 kcal/ml feed for older
children), standard formulae (0.67 kcal/ml for infant < 1 year and
1 kcal/ml feed for older children) and breast milk. Energy re-
quirements were estimated using the Schoﬁeld-equation [21] as
suggested by The American Society for Parenteral and Enteral
Nutrition (ASPEN) guidelines in absence of indirect calorimetry
[10,22,23]. Protein requirements were calculated according to
ASPEN guidelines for critically ill children (0e2 years, 2e3 g/kg/
day; 2e13 years, 1.5e2 g/kg/day; and >13 years, 1.5 g/kg/day) [7,10].
Due to lack of published guidelines regarding enteral CHO and fat
requirements for critically ill children, the age appropriate UK
reference nutrient intake (RNI) for healthy children was used as a
guide for establishing CHO requirements as 50% of the total energy
requirements [24]. Fat requirements of 40% for children <1 year and
35% for those >1 year were used, corresponding to European So-
ciety for Paediatric Gastroenterology, Hepatology and Nutrition
(ESPGHAN) recommendations (25, 26). Energy and macronutrient
intakewere transformed from crude values (kcal or grams/day) into
percentage of the reference requirements based on age and weight.
All anthropometry measurements were performed by PICU
nurses on admission, the information required for this study
including gender, age, weight, height and diagnosis were collected
for each patient from the hospital electronic system. Weight/height
for age z-scores were calculated based onWHO growth charts using
the WHO Anthro and Anthro Plus software (version 3.2.2, January
2011) [27]. Moderate under-nutrition was considered if weight/
height z-score was between"2 and -3 standard deviation (SD), and
severe under-nutrition if below "3 SD [28].In addition to patient
demographics, the Paediatrics Index of Mortality 2 (PIM2) scores
[29] and inotrope scores [30] were calculated. Clinical outcomes
such as hours free of mechanical ventilation (ventilator free hours,
VFH) at 30 days and days free of intensive care at 30 days were also
recorded.
Measurements of circulating levels of key inﬂammatory medi-
ators including pro-inﬂammatory TNF-a, IL-6, interleukin-1 beta
(IL-1b) and anti-inﬂammatory response pathways interleukin-10
(IL-10) were undertaken between Day 2 and 8. Serum levels of
these cytokines were measured by ELISA (MSD, Rockville, Mary-
land, USA). Cytokine levels were measured at an early (acute)
phase, during nutrition deprivation (day 2e3) and a later sample
taken between 4 and 8 days after admission. The lower limit of
detection for TNF-awas 0.01e0.13 pg/ml, IL-10 0.01e0.15 pg/ml, IL-
6 0.01e0.11 pg/ml and for IL-1bwas 0.01e0.27 pg/ml. Values for the
amount of energy and macronutrients delivered were calculated to
the 24-h period prior to each sample collection.
Statistical analysis
The statistical analysis was conducted using IBM SPSS v25 USA.
The ShapiroeWilk Test was used to assess the normality of the data
distribution. Quantitative variables with non-normal distribution
were expressed as a median with interquartile ranges (IQR). Wil-
coxon signed rank test, was used to compare the difference in en-
ergy and macronutrient delivery between day 1 and day 3 of
admission. Whilst the Mann- Witney U was applied to assess dif-
ferences in disease severity variables between children. The
Spearman correlation coefﬁcient was used to establish the corre-
lation between variables, which was followed by stepwise linear
regression analysis to assess factors that impact on cumulative
energy intake, inﬂammatory cytokines (TNF-a, IL-10, IL-6 and IL-
1b) and clinical outcomes. A p-value of #0.05 was considered sta-
tistically signiﬁcant and log transformation was performed on cy-
tokines prior to regression analysis.
3. Results
A total of 87 critically ill children [51 (58%) males] were enrolled
to the study. The summary of the recruitment and consenting
procedure is shown in (Fig. 1). Anthropometric and clinical char-
acteristics of the children are shown in Table 1. The admission
diagnosis for all study participants is presented (Fig. 2). Inpatient
mortality was 2/87 patients (2.3%).
3.1. Feeding in PICU
EN started at a median time of 8 h (IQR 5e14) following PICU
admission. Fifty-four children (62%) started their enteral feeding
within the ﬁrst 12 h of admission. EN was suspended for a median
duration of 19 (IQR 11e28) hours within the ﬁrst 3 days of
admission. The most common reason for holding EN among our
cohort was the presence of perceived large gastric aspirates.
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No statistical difference in PIM2 score and inotrope score was
recorded between children based on the time of commencing EN.
Seventy patients (80%) of the cohort received energy dense
formulae, 6 (7%) expressed breast milk and 11 (13%) were on
standard formulae (Table 2).
We calculated the daily energy andmacronutrient intake for the
ﬁrst 3 days of PICU admission (Fig. 3). The enteral intake of energy
and each macronutrient on day 1 and day 2 were lower than the
calculated requirements. By day 3 the median (IQR) intake of en-
ergy, fat, CHO and protein were 75% (50e103), 85% (43e120), 63%
(42e102) and 45% (23e65) respectively. Fat intake on day 3
exceeded 100% of the requirements in 35 (40%) children. The
delivery of energy and macronutrient was signiﬁcantly improved
by day 3 compared to day 1.
We went on to examine how the daily intake varied among
different weight groups. Our results showed that the children with
lower weight (0e10 kg) received higher doses of energy and
macronutrient. The average intake of energy and macronutrient
from admission up to day 3 are presented in Table 3.
Linear regression analysis was performed using the cumulative
energy intake at 3 days as outcome to determine the factors
affecting the delivery of energy. The regression model suggested
that age and weight for age z-score statistically impacted the cu-
mulative amount of energy delivered, this regression model
Fig. 1. Summary of recruitment procedure. The above ﬁgure shows the stages of patient recruitment and consent.
Table 1
Anthropometric and clinical characteristics of children enrolled to the study.
All children (n ¼ 87) 0e10 kg (n ¼ 33) 10e20 kg (n ¼ 31) >20 kg (n ¼ 23)
Anthropometrics
Age (years) 2 (0.6e4.9) 0.4 (0.1e1) 2.6 (1.8e3.5) 11 (8e13.4)
Weight (kg) 14 (8e21) 7.3 (3.6e8.6) 14.6 (12.3e16.0) 35 (25e45)
Height (cm) 95 (74e112) 68.5 (52e75) 97 (86e101) 132 (114e149)
Weight for age Z-score "0.1 ("1.4e0.72) "1.0 ("2.2e"0.05) 0.47 ("0.11e1.4) 0.35 ("0.87e1.1)
% of children below <-2 z scores 15% 30% 3% 9%
Height for age Z-score "0.15 ("1.9e1.2) "0.5 ("7e0.8) 0.45 ("0.21e2.04) "0.54 ("2.2e1.04)
% of children below <-2 z scores 17% 21% 9% 21%
Weight height Z-score 0.05 ("1.1e0.81) "0.8 ("1.8e"0.02) 0.36 ("1.1e1.07) 0.69 (0.01e2.1)
% of children below <-2 z scores 8% 12% 9% 0%
Disease severity
PIM2 score 3.2 (0.9e6.2) 4 (1.1e7.3) 2.4 (0.93e5.7) 2.9 (0.88e4.4)
Inotrope score 0 (0e22) 2 (0.0e20) 0.0 (0.0e22) 0.0 (0.0e28)
Maximum lactate 1.9 (1.3e3.3) 2.3 (1.5e3.9) 1.7 (1.2e2.5) 2.5 (1.3e3.3)
Maximum CRP 85 (29e193) 55 (18e142) 105 (25e223) 139 (34e285)
VFH at 30 days 622 (542e651) 601 (601e651) 636 (559e654) 609 (487e645)
PICU free days at 30 days 23 (19e24) 23 (18e24) 23 (20e24) 22 (18e24)
Data presented as median (IQR).
VFH at 30 days: ventilation free hours at 30 days.
PICU free days at 30 days: days free of Paediatric intensive care at 30 days.
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accounted for 16% of the variation in the cumulative energy intake
(Table 4).
3.2. Feeding and inﬂammatory response
Serum inﬂammatory markers were measured in a total of 125
samples collected from the 87 children enrolled to the study. The
number of samples collected from each age group are presented in
Table 5. All patients included in the study had an early sample, and
those for whom vascular access was available had a second (‘late’)
sample. Prior to performing regression analysis, correlation anal-
ysis was used to explore the association between macronutrient
intake and the inﬂammatory mediators.
3.2.1. Early cytokines (samples obtained on day 2e3)
There was no correlation between macronutrient intake and
early cytokine levels except for IL-6, which showed aweak negative
correlation with energy (r ¼ "0.22, p ¼ 0.04) and protein
(r ¼ "0.26, p ¼ 0.01).
Stepwise linear regression analysis was performed, with IL-6 as
an outcome variable to determinewhether feeding contributed to a
change in IL-6 independently from the severity of disease and age.
The results indicated that both PIM2 score and % of delivered
protein were statistically related to IL6 (p < 0.01). This regression
model accounted for 20% of the variation in IL-6 levels (Table 6).
In children <1 year of age low protein intake was associated
with increase in IL-6 levels, r ¼ "0.554, p ¼ 0.024. Whilst in older
children, no evidence of statistical association was recorded be-
tween the percentage of protein received and IL-6, r ¼ "0.221,
p ¼ 0.077 (Table 6).
3.2.2. Late cytokines (samples obtained between day 4e8)
With the later samples, both TNF-a and IL-10 were positively
correlated with the delivery of energy, fat and CHO whilst no evi-
dence of statistically signiﬁcant correlation was observed with
protein intake.
Stepwise linear regression analysis was performed, with TNF-a
as the outcome to determine whether energy and macronutrients
intake contributed to increase in TNF-a independently from the age
and severity of disease. Our results indicated that higher delivery of
fat and less delivery of protein statistically contributed to increase
in TNF-a, p < 0.01, this regression model accounted for 31% of the
variation in TNF-a levels (Table 7).
We further investigated the effect of feeding on TNF-a, between
different age groups. Our regression models suggested that the
percentage of enteral fat delivered was the only variable
Fig. 2. Distribution of patients based on their admission diagnostic categories. Each cluster of bars represent speciﬁc diagnostic category, individual bars represent the number of
patients admitted with infection, suspected infection and no infection.
Table 2
Number of patients receiving standard and ED formulae.
All children (n ¼ 87) 0e10 kg (n ¼ 33) 10e20 kg (n ¼ 31) >20 kg (n ¼ 23)
Breast milk 6 6 0 0
Standard infant formula 4 4 0 0
Standard paediatric formula 7 0 2 5
Energy dense infant formula 20 17 3 0
Energy dense paediatric formula 50 6 26 18
Table 2 indicates the number of children received, standard and ED formulae among each weight group.
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Fig. 3. Percentage of enteral energy and macronutrient delivered expressed as percentage of the calculated requirements. a) Shows the daily enteral intake (day 1e3) of energy and
macronutrient in 87 critically ill children. b), c) and d) Shows the daily enteral intake (day 1e3) of energy and macronutrient in different weight groups. The above ﬁgure clearly
indicated that smaller children (0e10 kg) received higher doses of energy and macronutrient. The enteral intake of both energy and macronutrient has statistically improved on day
3 compared to day 1 (p < 0.001**).
Table 3
Average enteral intake of energy and macronutrient from admission up to day 3.
Average intake up to day 3 0e10 kg (n ¼ 33) 10e20 kg (n ¼ 31) >20 kg (n ¼ 23)
Crude value
kcal or g/kg/day
%of reference intake Crude value
kcal or g/kg/day
%of reference intake Crude value kcal
or g/kg/day
%of reference intake
Energy 35 (27e48) 64 (52e86) 37 (25e44) 75 (48e83) 13 (6.3e25.9) 41 (21e68)
Fat 1.8 (1.2e2.3) 81 (58e100) 1.6 (0.8e1.9) 76 (42e94) 0.48 (0.18e1.07) 33 (17e72)
Carbohydrate 4.3 (3.7e5.6) 53 (39e71) 4.9 (3.5e5.6) 67 (40e81) 1.8 (1.2e3.3) 33 (15e65)
Protein 0.9 (0.6e1.1) 36 (22e45) 0.99 (0.56e1.1) 43 (31e64) 0.3 (0.17e0.69) 21 (9e43)
Data presented as median (IQR).
The above table shows the average doses of enteral energy and macronutrient presented as crude values and as a percentage of reference requirements.
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statistically related to the increase in TNF-a (r¼ 0.440, p¼ 0.032) in
children > 1 year of age. This was not replicated in the younger age
group (r ¼ 0.387, p ¼ 0.077) (Table 7).
We also investigated the effect of energy and macronutrient
intake in a stepwise linear regression analysis where IL-10 was the
outcome variable. This model suggested that both energy intake
and PIM2 score had a statistically signiﬁcant effect on IL-10. This
regression model accounted for 46% of the variation in IL-10
(Table 8). In children <1 year both the percentage of energy
intake and PIM2 score were statistically related to IL-10, whilst in
older children PIM2 score was the only variable statistically related
to increase in IL-10 (Table 8).
3.3. Effect of enteral feeding on clinical outcomes
We investigated the independent association of clinical out-
comes and the average intake of energy and macronutrient. Two
stepwise regression models were performed; in these regression
models PICU free days and VFH were the outcome variables. There
was no evidence of statistical association between energy or
macronutrient intake and clinical outcomes in this cohort
(Table 9).
4. Discussion
Protein energy malnutrition and abnormalities in glucose
metabolism have been strongly linked to prolonged ventilation and
hospital stay, multiple organ dysfunction and mortality [11,31,32].
Therefore it is crucial to take into account the proportion of mac-
ronutrients required and not only aim to achieve the energy goal. In
this study, there was no association between energy and macro-
nutrient intake and clinical outcomes. However, we recorded weak
association between the amount of energy and macronutrient
delivered with the inﬂammatory markers.
Table 4
Regression model to determine the factors affecting the cumulative energy intake.
Model R R2 Adjusted R2 R P value
Cumulative Energy Intakea 0.421 0.177 0.157
Age b "0.351 0.00*
Weight for age z escore b "0.326 0.001*
PIM2 score c "0.160 0.07
* A p-value of <0.05.
a Dependent variable.
b Predictors: (constant).
c Excluded variables.
Table 5
The number of samples collected from each age group.
All children
Early samples (Day 2e3) Number of samples Median number of samples per patient
87 1 (1e1)
TNFa (pg/ml) 1L-6 (pg/ml) IL-10 (pg/ml) IL1-b (pg/ml)
3.8 (2.3e7.5) 6.5 (1.8e19) 2.5 (0.9e7.8) 0.2 (0.2e0.3)
Late samples (Day 4e8) Number of samples Median number of samples per patient
39 1 (1e2)
TNFa (pg/ml) 1L-6(pg/ml) IL-10 (pg/ml) IL1-b (pg/ml)
3.7 (2.5e6.8) 3.5 (1.5e8.6) 1.6 (0.9e2.4) 0.2 (0.1e0.2)
<1 year
Early samples (Day 2e3) Number of samples Median number of samples per patient
20 1 (1e1)
TNFa (pg/ml) 1L-6 (pg/ml) IL-10 (pg/ml) IL1-b (pg/ml)
5.8 (4.5e9.6) 88 (2.8e14) 4.3 (1.1e28) 0.25 (0.2e0.5)
Late samples (Day 4e8) Number of samples Median number of samples per patient
15 1 (1e2)
TNFa (pg/ml) 1L-6 (pg/ml) IL-10 (pg/ml) IL1-b (pg/ml)
6.8 (4e7) 3. (1.5e5.9) 1.8 (0.9e3.1) 0.2 (0.1e0.4)
>1year
Early samples (Day 2e3) Number of samples Median number of samples per patient
67 1 (1e1)
TNFa (pg/ml) 1L-6 (pg/ml) IL-10 (pg/ml) IL1-b (pg/ml)
3.2 (1.8e6.1) 5.9 (1.7e20.2) 2.2 (0.9e7) 0.2 (0.2 0.21)
Late samples (Day 4e8) Number of samples Median number of samples per patient
24 1 (1e2)
TNFa (pg/ml) 1L-6 (pg/ml) IL-10 (pg/ml) IL1-b (pg/ml)
3.1 (2.2e4.3) 3.6 (0.8e10.9) 1.1 (0.7e2.3) 0.2 (0.1e0.2)
Data presented as median (IQR).
Table 6
Factors affecting IL-6 during early admission period.
Model R R2 Adjusted R2 R P value
IL-6a (all children) 0.457 0.209 0.189
PIM2 scoreb 0.346 0.001*
%of enteral protein receivedb "0.295 0.007*
% of enteral Energy receivedc "0.053 0.638
% of enteral CHO receivedc 0.104 0.351
% of enteral Fat receivedc 0.077 0.490
Agec 0.213 0.055
IL-6a (children < 1 year) 0.544 0.296 0.249
%of enteral protein receivedb "0.544 0.024*
% of enteral Energy receivedc "0.203 0.450
% of enteral CHO receivedc 0.459 0.074
% of enteral Fat receivedc 0.229 0.394
PIM2 score c "0.074 0.0784
Age c 0.034 0.90
IL-6a (children > 1 year) 0.505 0.255 0.232
PIM2 scoreb 0.429 0.00*
Ageb 0.300 0.014*
%of enteral protein receivedc "0.221 0.077
% of enteral Energy receivedc "0.203 0.105
% of enteral CHO receivedc "0.156 0.216
% of enteral Fat receivedc "0.124 0.326
* A p-value of <0.05.
a Dependent variable.
b Predictors: (constant).
c Excluded variables.
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The recent ASPEN guidelines targets delivery of at least two
thirds of the prescribed daily energy requirement by the end of the
ﬁrst week in the PICU to avoid undesired clinical outcomes asso-
ciated with cumulative nutrition deprivation [10]. The majority of
our children achieved this energy goal by day 3, which was likely to
occur as EN was generally commenced within a few hours of
admission (median of 8 h) in accordance with our unit enteral
feeding protocol. However, over the ﬁrst 3 days protein intake on
average achieved only 35% of requirements and reached 46% by day
3. In addition, our results showed that children >20 kg were at the
most risk of not achieving their requirements, with only achieving
an average of 21% of the requirements over 3 days. Insufﬁcient
delivery of protein is common, particularly in the early stages of
admission. Our ﬁndings are similar to previously published data
where under-delivery of protein was also reported [31,33e35]. On
the contrary, on day 3 the median fat intake was 85% and exceeded
the calculated requirements in almost 40% of children among two
weight groups (0e10 kg) and (10e20 kg). This discrepancy of
achieving energy requirements, under delivery of protein and
exceeding fat requirements is related to two aspects: the use of
standardised, ready to feed energy dense formulae, in our unit and
the aim requirements for macronutrients in critically ill children.
The only guidelines available for enteral nutritional support in this
population is for energy and protein [7,10]. However, none have
been set for fat and CHO. The ESPGHAN guidelines for healthy
children were used as a guide to estimate fat requirements in our
critically ill population, as we believe that younger children
particularly breast-fed infants might have higher fat requirements.
RNI for healthy children was used as a guide for establishing CHO
requirements. In our study almost 80% of patients were fed energy
dense formulae to help meet their energy needs. These formulae
have a higher energy density and provide on average 50% of energy
from CHO, 10% from protein and 40% from fat. The macronutrient
composition of all medical formulae in European is guided by the
European Commission of Food for Special Medical Purposes (FSMP)
guidelines [36]. Many factors need to be taken into account with
the development of these enteral feeds, including macronutrient
composition, osmolality, volume of feed for nutritional adequacy,
safety ranges for macro and micro nutrients for children with a
wide range of diagnoses. As energy requirements are lower and
protein requirements are higher in critically ill children [7,10,22,23],
the distribution of macronutrients in standardised feeds do not
match the speciﬁc requirements of critically ill children.
We assessed factors that had an impact on cumulative energy
intake and found that age and weight for age z-score were the
strongest predictor of the cumulative energy intake among our
children. Our ﬁndings regarding the age are similar to Mehta et al.
(2011) but contradictory to the work done by Hulst et al. (2004),
where they found that younger children accumulated the highest
energy deﬁcits. This controversy could be explained by the fact that
younger children had the highest percentage of malnutrition (30%)
as assessed by weight for age Z-score. Due to the well-documented
impact of early malnutrition [39,40], it is likely that the nutrition
support team focussed more on providing full nutritional re-
quirements particularly for smaller (lower weight for age Z scores)
children to avoid further deterioration of their nutritional status
during PICU stay.
Table 8
Factors affecting IL-10.
Model R R2 Adjusted R2 R P value
IL-10a (all children) 0.679 0.461 0.415
% of enteral Energy received b 0.575 0.00*
PIM2 score b 0.437 0.004*
%of enteral protein received b 0.163 0.018*
% of enteral CHO received c 0.082 0.636
% of enteral Fat received c !0.082 0.636
Age c !0.188 0.271
IL-10a (children < 1 year) 0.758 0.575 0.504
% of enteral Energy received b 0.698 0.006*
PIM2 score b 0.540 0.046*
% of enteral protein received c !0.357 0.231
% of enteral CHO received c 0.257 0.397
% of enteral Fat received c !0.185 0.546
Age c !0.143 0.642
IL-10a (children > 1 year) 0.510 0.260 0.227
PIM2 score b 0.510 0.011*
% of enteral Fat received c 0.183 0.403
% of enteral energy received c 0.207 0.344
%of enteral protein received c 0.146 0.507
% of enteral CHO received c 0.177 0.420
Age c !0.198 0.365
* A p-value of <0.05.
a Dependent variable.
b Predictors: (constant).
c Excluded variables.
Table 9
Regression model to determine the effect of feeding on clinical outcomes.
Model R R2 Adjusted R2 R P value
VFHa
PIM2 scoreb 0.132 0.114
Ageb !0.091 0.319
Average energy received (3 days)b !0.160 0.072
Average CHO received (3 days)b !0.186 0.044
Average protein received (3 days)b !0.089 0.208
Average fat received (3 days)b !0.184 0.046
PICU free hours at 30 days
PIM2 scoreb !0.198 0.034
Ageb 0.45 0.203
Average energy received (3 days)b 0.028 0.397
Average CHO received (3 days)b !0.002 0.493
Average protein received (3 days)b !0.090 0.206
Average fat received (3 days)b !0.009 0.466
VFH at 30 days: ventilation free hours at 30 days.
PICU free days at 30 days: days free of Paediatric intensive care at 30 days.
a Dependent variable.
b Excluded variables.
Table 7
Factors affecting TNF-a.
Model R R2 Adjusted R2 R P value
TNF-aa (all children) 0.561 0.315 0.277
% of enteral Fat received b 0.534 0.001*
% of enteral protein received b !0.347 0.033*
% of enteral Energy received c !0.004 0.983
% of enteral CHO received c 0.008 0.963
PIM2 score c 0.187 0.269
Age c !0.191 0.257
TNF-aa (children < 1 year)
% of enteral Fat received c 0.387 0.077
% of enteral protein received c 0.0.119 0.377
% of enteral Energy received c 0.212 0.224
% of enteral CHO received c 0.229 0.206
PIM2 score c 0.037 0.448
Age c !0.202 0.337
TNF-aa (children > 1 year) 0.440 0.193 0.157
% of enteral Fat received b 0.440 0.032*
% of enteral protein received c 0.094 0.669
% of enteral Energy received c !0.094 0.669
% of enteral CHO received c !0.009 0.969
PIM2 score c 0.322 0.134
Age c !0.010 0.963
* A p-value of <0.05.
a Dependent variable.
b Predictors: (constant).
c Excluded variables.
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In this study we also assessed the association between macro-
nutrient intake and inﬂammatory mediators. We found that both
protein deﬁcit and higher delivery of fat were associated with
elevation in the levels of inﬂammatory cytokines; in particular
under-delivery of protein was associated with an increase in serum
IL-6 and TNF-a. The association between dietary protein and in-
ﬂammatory markers has not previously investigated in critically ill
population. However, increased levels of inﬂammatory markers
have been recorded in malnutrition studies where presumably
energy and protein intake is compromised [40,41]. Low protein
intake has been shown to be associated with increased serum IL-6
in a murine model, in addition, IL-6 and TNF-a have been proposed
as a possible biomarker of nutritional deﬁcits [16,42].
Despite the current knowledge about the contribution of di-
etary fatty acids in modulating the production of lipid mediators
and signalling molecules in cells that are involve in immune
regulation and inﬂammation [42], to our knowledge no previous
data has been published linking fat intake with elevated levels of
circulatory cytokines in critical illness. The current study recorded
an association between enteral fat delivery and elevation in TNF-
a, particularly in children >1 year of age. Although the younger
group received higher doses of enteral fat and their median TNF-a
was higher, but surprisingly we did not record such a statistical
association. This could be attributed to variation in fat re-
quirements, particularly in young children who have a higher fat
requirement [25,26]. There are limited data describing the
changes in lipid metabolism in relation to inﬂammation during
critical illness. In septic patients the changes in plasma fatty acids
proﬁles appear to be related to the intensity of the inﬂammatory
response, besides interleukins have shown to be inversely related
to low-LDL/low-HDL [43,44]. In septic children increased
expression of Neutrophil CD64 was associated with low HDL and
LDL levels [45]. None of the above mentioned studies recorded the
EN intake or investigated the dietary factors. Studies linking
inﬂammation to dietary factors do exist in other populations
including obesity, heart disease and inﬂammatory bowel disease.
In patients with heart failure TNF-a levels were elevated with
higher intake of saturated fat [46]. In an obese rat model, use of a
high fat diet induced expression of TNF-a, IL1b and IL-6 in skeletal
muscle, visceral fat and blood [47e50]. Studies also suggest that
the high fat western diet might induce systemic low-level
inﬂammation as a result of changes in gut microbiota [17,18]. In
a study conducted on 15 overweight men, a low-fat diet resulted
in statistically signiﬁcant reduction in TNF-a [19]. However, it is
important to point out that the type of fat delivered might also
impact the inﬂammatory response. In an experimental induced
colitis rat model, medium-chain triglycerides (MCT) rich diet
reduced IL-6, IL-8 levels, indicating that MCT rich formulae exert
an anti-inﬂammatory effect in colitis [51].
Although the exact mechanism that links dietary fat to inﬂam-
mation is not fully understood, but several mechanisms have been
proposed. It is generally accepted that pro-inﬂammatory fatty acids
may act directly and activate receptors that signals inﬂammatory
response [52]. It has also been suggested inﬁltration of macro-
phages associated with adiposity accounts for the increased adi-
pose expression of TNF-a [47]. However, one of the recently
proposed mechanisms that links dietary fat to inﬂammation, is
related to it's effect on promoting the translocation of microbial
products from the gut into the bloodstream [53]. Given the well-
documented evidence of intestinal dysbiosis during critical illness
makes this explanation plausible and of clinical justiﬁcation.
In the current study association between energy intake and IL-
10 could be related to stimulation of insulin secretion. IL-10 sig-
nalling has been proposed as a potential mechanism to increase
energy expenditure and improve insulin sensitivity [54,55].
This study suggests that the energy and macronutrient delivery
in the later phase are associated with alterations in the inﬂam-
matory response when data was analysed in a single cohort.
However, we recorded in consistency in the ﬁndings with further
stratiﬁcation to different age groups, which could be related to
reduction in the sample size. This could also be attributed to vari-
ation in macronutrient requirements between infants and older
children. It is worth mentioning that the changes in clinical con-
dition could be contributory or indeed driving this association to a
large extent and this needs to be explored in further studies.
In the absence of guidelines regarding enteral macronutrient
requirements, it is not surprising that there have been no trials of
enteral macronutrient targets in critically ill children. In a landmark
study of parenteral nutrition in this patient group (the Paediatric
Early versus Late Parenteral Nutrition In Critical Illness (PEPaNIC)
trial [56], the dose of amino acids delivered was associated with an
increased rate of infection and a longer ventilation time. The au-
thors postulate this to be due to repression of autophagy by amino
acids in critical illness. Another potential mechanism is the early
induction of Resistin leading to repression innate immunity and
changes in amino acids kinetics, including increase levels of
phenylalanine and serine and reduce glutamine concentrations
[57e59]. The PEPaNIC trial indicated that parenteral delivery of
glucose and lipids were associated with fewer infections and earlier
PICU discharge respectively. We did not observe such an association
between enteral nutritional intake and the duration of ventilation
or the length of PICU stay. It is important to note that the route of
delivering nutrition was different from our study; also a distinctive
statistical plan was carried out. Unlike the PEPaNIC study, we
monitored the intake for 3 days which may be insufﬁcient to detect
a statistical effect of nutritional intake on clinical outcomes.
Importantly, our cohort had signiﬁcantly lower protein intake
compared to requirements than patients enrolled into the PEPaNIC
trial (36% vs 80%) [56]. although we only measured intake to 3 days
compared to 7 in the PEPANIC trial, making a comparison between
data from the two studies challenging.
There is a lack of published guidelines regarding enteral fat and
CHO requirements for critically ill children. Although the PePANIC
study contributes signiﬁcantly to our knowledge for PN nutrient
delivery in critically ill children, the requirements used for PN are
not applicable for enteral nutrition. There are key differences in the
metabolisms of enteral versus parenteral carbohydrates, lipids and
protein are related to intestinal absorption of nutritional substrates,
insulin and inﬂammatory stimulation and visceral protein syn-
thesis [59]. We therefore used guidelines from ESPGHAN for fat and
RNI for CHO for healthy children, whilst utilising published guid-
ance for recommended protein and energy intake in paediatric
critical illness [7,10,22,23].
Our study has several limitations including the relatively small
sample size and heterogeneity of the patient cohort. Ideally we
would divide the children into more than two age groups and
investigate the relationship between macronutrient and cytokines
more deeply. As this study suggests that fat intake may drive a pro-
inﬂammatory response, it seems prudent to investigate the rela-
tionship between omega3:omega6 in this study. In our smaller
patient cohort, where formula delivery was protocolised and most
children received a similar type of formula, this type of analysis was
not feasible. Within the linear regression model, there were some
variables that had a relatively low r-value that limit how well the
changes in inﬂammatory cytokines can be attributed to them.
However the results of our analysis appear to be in agreement with
reported associations between macronutrient intake and inﬂam-
mation in other disease state [19,41,42,44,50e53].It is clear that
further work is needed to establish appropriate enteral CHO and fat
requirements in critically ill children, and also to examine the effect
S. Zaher et al. / Clinical Nutrition xxx (2018) 1e108
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of speciﬁc fat sources such MCT and omega-3 on inﬂammatory
response and other clinical outcomes. Imminent studies must also
include data from children discharged after a PICU admission in
order to consider long-term effects of enteral macronutrient de-
livery compared to requirements.
Conclusion
The inﬂammatory response in critically ill children is complex
and mediated by many factors. Our study suggests that the enteral
fat and protein intake is associated with changes in the inﬂam-
matory response. This wider signiﬁcance of our ﬁndings need to be
examined in a larger study based on clinical endpoints. Our data
suggests that within the feed delivered, fat intake is often above
requirements compared to protein and CHO delivery. This imbal-
ance of nutrient provision may result from using the standard
paediatric feeds that may not necessarily match the macronutrient
requirements of critically ill children. Therefore it is crucial to take
into account the proportion of macronutrients required and not
only aim to achieve the energy goal. These ﬁndings are based on
generalised guidelines for macronutrient requirements in healthy
children and future work should examine whether critically ill
children have speciﬁc macronutrient needs.
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Abstract	
	
Background	 and	 aims:	Critical	 illness	 is	associated	with	derangement	 in	 the	metabolic	
and	inflammatory	response.	The	persistent	state	of	inflammation	may	derive	a	range	of	
metabolic	abnormalities	in	critically	ill	children.	Previous	work	highlighted	the	cross-link	
between	feeding,	inflammation	and	gut	homeostasis.	The	aim	of	this	study	was	to	assess	
the	 relationship	 between	 inflammatory	 activation	 and	metabolic	 regulation	 of	 energy	
expenditure	by	assessing	cytokine	release,	levels	of	gut-derived	hormone	[Glucagon	like	
peptide-1	(GLP-1)]	and	energy	expenditure	in	a	cohort	of	critically	ill	children.		
Method:	Two	serum	samples	were	collected	from	each	child	between	day	1-5	of	PICU	
admission,	for	the	analysis	of	 inflammatory	cytokines	(TNF-α,	 IL-10,	 IL-6	and	IL-1β)	and	
GLP-1.	 Indirect	 Calorimetry	 (IC)	 measurements	 were	 performed	 concurrently.	 The	
metabolic	index	was	determined	using	the	ratio	of	Measured	Energy	Expenditure	(MEE)	
/	Predicted	Basal	Metabolic	Rate	(PBMR)	based	on	the	Schofield	equation.		
Results:	A	 total	of	42	children	 (0-14	years)	were	 included	 in	 this	study.	The	regression	
analysis	 showed	 a	 statistical	 association	 between	 TNF-α	 and	 the	 GLP-1	 (r=0.453,	
p=0.003).	Where	 IC	measurements	were	performed	 (N=21)	GLP-1	 showed	a	 statistical	
association	 with	 the	 metabolic	 index	 (r=0.632,	 p=0.002).	 No	 evidence	 of	 statistical	
assocaition	was	recorded	between	TNF-α	and	the	metabolic	index.		
Conclusion:	 Circulating	 GLP-1	 appears	 to	 be	 increased	 in	 response	 to	 inflammatory	
stimuli	by	TNF-α	in	critically	ill	children.	Our	findings	suggest	that	GLP-1	could	provide	a	
novel	 link	 between	 the	 inflammatory	 response	 and	 the	 gut	with	 strong	 relevance	 for	
metabolic	dysregulation	in	critically	ill	children.	
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1.	Introduction		
	
Critical	 illness	 is	 associated	 with	 derangement	 in	 the	 metabolic	 and	 inflammatory	
response	 (1).	 The	 persistent	 state	 of	 inflammation	 may	 derive	 a	 range	 of	 metabolic	
abnormalities	 in	 critically	 ill	 children.	 Inflammatory	 cytokines	 have	 the	 capacity	 to	
regulate	energy	metabolism	through	suppression	of	appetite	and	by	inducing	lipolysis	in	
fat	tissue	and	protein	breakdown	in	muscles	 (2).	It	 is	still	not	clear	 if	 the	 inflammatory	
cytokines	 affect	 stress	 mediators	 such	 as	 energy	 expenditure	 directly	 or	 through	
intermediaries	that	influence	the	metabolic	pattern	and	other	nutritional	markers.	
GLP-1	 is	 a	 gut	hormone	 that	plays	 an	 important	 role	 in	 the	 regulation	of	metabolism.	
GLP-1	 induces	 a	 state	 of	 negative	 energy	 balance	 through	 controlling	 the	 appetite,	
gastric	motility	and	to	a	lesser	extent	energy	expenditure.	(3),	(4),	(Parekh	et	al.	2014).	
The	 levels	of	GLP1	appears	to	be	 increased	 in	critically	 ill	adults	 (5),	 (6)	which,	may	be	
related	to	the	inflammatory	stimuli	by	pro-inflammatory	cytokines	(7).	
Critically	 ill	 children	 generally	 have	 reduced	 energy	 expenditure	 (8),	 however	 the	
hypermetabolic	 pattern	 has	 also	 been	 reported	 (9).	 Therefore	 it	 is	 critical	 to	 identify	
factors,	 which	 contribute	 to	 increase	 resting	 energy	 expenditure	 (REE)	 in	 order	 to	
provide	sufficient	nutritional	requirements.	
Previously	 published	 studies	 have	 highlighted	 the	 cross-link	 between	 feeding,	
inflammation	and	gut	homeostasis.	The	aim	of	this	study	was	to	assess	the	relationship	
between	 inflammatory	 activation	 and	 metabolic	 regulation	 of	 energy	 expenditure	 by	
assessing	cytokine	release,	levels	of	gut-derived	hormones	and	energy	expenditure	in	a	
cohort	of	critically	ill	children.		
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2.	Methods	
This	 prospective	 pilot	 study	 was	 conducted	 in	 critically	 ill	 children	 at	 Addenbrookes	
Hospital,	 Cambridge,	 UK.	 Written	 informed	 consent	 was	 obtained	 from	 patients’	
guardians	before	inclusion	in	this	study.		
2.1	Biological	samples	
	
Two	serum	samples	were	collected	from	each	child	between	day	1-5	for	the	analysis	of	
inflammatory	 mediators	 and	 GLP-1.	 Cytokines	 were	 measured	 using	 Electrochemical	
luminescence	immunoassay	from	MSD,	Rockville,	Maryland,	and	USA.	The	lower	limit	of	
detection	 for	 TNF-α	was	 0.01-0.13	 pg/ml,	 IL-10	 0.01-0.15	 pg/ml,	 IL-6	 0.01-0.11	 pg/ml	
and	 for	 IL-1β	was	 0.01-0.27	 pg/ml.	 GLP-1	was	 collected	 in	 a	 special	 tube	with	 added	
inhibitor	 cocktail	 (DPPIV	 inhibitor,	 serine	 protease	 inhibitor)	 and	 measured	 using	 a	
singleplex	multi	array	assay	system	(MSD,	Rockville,	Maryland,	USA).	The	lower	limit	of	
detection	was	0.98	pg/ml.	
	
2.2	Patient’s	clinical	and	nutritional	data	
	
Patient’s	 data	 were	 obtained	 from	 the	 hospital	 electronic	 system	 (EPIC,	 Madison,	
Wisconsin,	 United	 States).	 Information	 including	 gender,	 age,	weight,	 and	Height	was	
collected	for	each	child.	Weight/height	for	age	z-	scores	were	calculated	based	on	WHO	
growth	charts	using	the	WHO	Anthro	and	Anthro	Plus	software	(version	3.2.2,	 January	
2011)	 (10).	Patients’	primary	diagnosis	necessitating	PICU	admission	was	recorded	and	
then	categorized	into	multi-organ	system	failure	(MOF)	or	single	organ	failure	categories	
(11).	 In	 addition	 to	 patient	 demographics,	 the	 Paediatrics	 Index	 of	Mortality	 2	 (PIM2)	
scores	 (12),	 Paediatric	 multiple	 organ	 dysfunction	 score	 (PMODS)	 (13)	 and	 inotrope	
scores	 (14)	 were	 calculated.	 	 Clinical	 outcomes	 such	 as	 hours	 free	 of	 mechanical	
ventilation	(ventilator	free	hours,	VFH)	at	30	days	and	days	free	of	intensive	care	at	30	
days	were	also	recorded.	
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The	 actual	 energy	 intake	 was	 recorded	 for	 each	 child	 from	 the	 hospital	 electronic	
system.	 The	 type	 of	 enteral	 feed,	 total	 volume	 delivered,	 energy	 and	 macronutrient	
delivered	 was	 calculated	 for	 each	 patient	 based	 on	 the	 nutrition	 data	 card	 of	 each	
formula	 (in	 the	 Supplementary	Appendix).	 Calculation	 of	 breast	milk	 composition	was	
based	on	data	from	previous	published	study	on	breast	milk	composition	(15).	
	
2.3	Measuring	Energy	expenditure	
	
Resting	 Energy	 Expenditure	 (REE)	 measurements	 were	 performed	 for	 mechanically	
ventilated	 children	 Weighing	 more	 than	 10	 kg.	 	 For	 those	 who	 had	 chest	 drain,	
peritoneal	 dialysis,	 Fraction	 of	 inspired	 oxygen	 (FiO2	)>60%	 or	 endotracheal	 tube	 leak	
>10%	,	the	measurements	of	REE	was	not	feasible.	
The	metabolic	index	was	determined	using	the	ratio	of	MEE	/	PBMR	based	on	Schofield	
equation.	To	assess	the	association	between	REE,	 inflammatory	cytokines	and	GLP-1,	a	
serum	sample	was	obtained	concurrently	with	IC	measurement.		
Standard	measurement	protocol	for	indirect	calorimetry	(IC)	
	
REE	was	measured	 using	Ultima	 CCM™®	 indirect	 calorimeter.	 	 The	measurement	was	
undertaken	when	the	child	was	in	resting	state.	No	nursing	care	or	physical	therapy	had	
been	provided	for	at	least	1	hour	before	the	test	to	ensure	the	volume	of	oxygen		(VO2)	
and	 volume	of	 Carbone	dioxide	 (VCO2)	was	 as	 stable	 as	 possible.	 IC	was	 calibrated	 to	
reference	gases	prior	to	each	participant	according	to	the	Manufacturers	Manual.	 	The	
IC	was	then	attached	to	mechanical	ventilator	for	at	least	10	minutes	before	starting	the	
test	to	ensure	patient	and	ventilator	stability	prior	to	measuring	REE.	The	test	lasted	for	
40	minutes	in	resting	state,	where	intra	variation	between	VO2	and	VCO2	was	less	than	
10%	 (16).	During	 the	 test	 if	 any	medical	 intervention	had	 to	be	provided	 the	 test	was	
stopped	and	the	measurement	was	repeated	to	ensure	the	continuity	of	a	resting	state.		
IC	measured	VO2	 consumption	and	VCO2	production	and	 calculated	REE	automatically	
according	to	weir	equation:	REE	=	[3.9	(VO2)	+	1.1	(VCO2)]	1.44	(17).		
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2.4	Statistical	analysis:	
	
The	 statistical	 analysis	was	 conducted	using	 IBM	SPSS	v25	USA.	The	Shapiro-Wilk	Test	
was	 used	 to	 assess	 the	 normality	 of	 the	 data	 distribution.	Quantitative	 variables	with	
non-normal	 distribution	 were	 expressed	 as	 a	 median	 with	 interquartile	 ranges	 (IQR).	
Spearman	 correlation	 coefficient	 was	 used	 to	 establish	 the	 correlation	 between	
variables,	which	was	followed	by	a	stepwise	linear	regression	analysis	to	assess	factors	
affecting	GLP-1	and	REE.	A	p-value	of	≤	0.05	was	considered	statistically	significant	and	
log	transformation	was	performed	on	cytokines	prior	to	regression	analysis.		
	
	
3.	Results	
	
Inflammatory	 cytokines	 and	 GLP-1	 were	measured	 in	 42	 children	 enrolled	 in	 this	 (24	
males).	Of	those,	21	children	fulfilled	the	criteria	for	energy	expenditure	study	and	REE	
was	measured	within	5	days	of	Paediatric	 Intensive	Care	Unit	 	 (PICU)	admission	(Table	
1).	 Anthropometric	 and	 clinical	 characteristics	 of	 the	 children	 are	 shown	 in	 (Table	 2).	
None	of	the	study	participants	died	within	the	study	period.		
	
Table	1:	Number	of	IC	measurement	taken	on	each	day	of	PICU	admission	
	
Day	 Day1	 Day2	 Day3	 Day	4	 Day5	
Number	of	children	 2	 5	 9	 2	 3	
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Table	2:		Anthropometric	and	clinical	characteristics	of	children	enrolled	to	the	study	
	
Patients	characteristics					(N	=	42)	 Median		
Age	(years)	 3.7						(					1			–			8.3		)	
Weight		(kg)	 16.8				(	9.8		–			25.2		)	
Height	(cm)	 103					(		79		–	123					)	
Weight	age	Z	score	 -0.1					(	-1.4		–		0.8			)	
Height	age	Z	score	 -0.08			(		-1.9		–	1.1			)	
Weight	for	height	Z	score	 0.3							(	-0.9	–	0.8					)	
TNF-α		(pg/ml)	 3.7							(				2.7	–		5.4		)	
IL-1β				(pg/ml)	 0.2							(				0.1	–		0.3			)	
IL-6						(pg/ml)	 9.8							(				2.2	–		25.7	)	
IL-10				(pg/ml)	 1.8							(				1				–			6.5		)	
GLP1				(pg/ml)	 11.3					(				8.1	–	19				)	
Maximum	glucose	(mmol/l)	 6.5							(				5.2	–	7.9				)	
Disease	severity	variables	 Median	
PMOD	score	 6									(				5				–			7							)	
PIM2	score	 3.1						(			0.9	–			6.1				)	
Inotrope	score		 3									(				0			–					27				)			
VFH	of	mechanical	ventilation	at	30	days	 619					(		535	–			645			)	
Hours	free	of	inotrope	treatment	at	30	days	 714					(		675	–			720			)	
PICU	free	days	at	30	days	 23							(					18			–		24				)	
Primary	admission	diagnosis	 N	
MOF	 14	(33%)	
Respiratory	Failure	 17	(41%)	
CNS	Disorders	 9			(21%)	
Surgical	Disorders	 2			(	5%	)	
																																																						
																																																					Data	are	presented	as	median	(IQR).	
• VFH	at	30	days:	ventilation	free	hours	at	30	days	
• PICU	free	days	at	30	days:	days	free	of	paediatric	intensive	care	at	30	days	
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3.1	GLP-1	and	the	inflammatory	response	in	critically	ill	children	
	
Prior	 to	 performing	 the	 regression	 analysis,	 a	 correlation	 analysis	 was	 performed	 to	
establish	 the	 association	 between	 the	 inflammatory	mediators	 and	 GLP1.	 The	 results	
showed	a	strong	positive	correlation	between	GLP-1	with	TNF-α	(r=0.453,	p=0.003)	and	
IL-10	 (r=0.433,	 p=0.004).	 A	 weak	 correlation	 was	 recorded	 between	 GLP-1	 and	 IL-1β			
(r=0.314,	p=0.043).		
	
To	further	 investigate	this	association	a	stepwise	regression	analysis	was	performed	to	
determine	 if	 TNF-α,	 IL-10	 and	 IL-1β	 independently	 influenced	 plasma	 GLP-1	
concentrations.	 The	 regression	 analysis	 indicated	 that	 TNF-α	 and	 IL-6	 statistically	
influenced	GLP-1	 concentrations	 (p	 <	 0.01)	 (Table	 3).	 Although	 the	 univariate	 analysis	
showed	a	correlation	between	GLP-1	and	IL-10	but	this	correlation	was	confounded	by	
other	factors	in	the	regression	analysis	(Table	3).	
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Table	3:	Factors	affecting	GLP-1	level	in	critically	ill	children		
	
Model	(N=42)	 R		 R	2		 Adjusted	R	2		 R	 P	value	
GLP-1	a		 0.433	 0.187	 0.166	 	
TNF-α	b	 	 0.433	 0.003*	
Maximum	glucose	c		 -0.021	 0.45	
Age	c	 0.078	 0.315	
PIM2	score	c	 0.077	 0.319	
Total	energy	received	(%)	c	 0.218	 0.088	
EN	at	the	time	of	sampling	(Yes/No)	 0.182	 0.131	
GLP-1	a	 0.493	 0.243	 0.202	 	
IL-6	b	 	 0.348	 0.014*	
Total	energy	received	(%)b	 0.218	 0.019*	
Maximum	glucose	c		 -0.021	 0.45	
Age	c	 0.078	 0.315	
PIM2	score	c	 0.077	 0.319	
EN	at	the	time	of	sampling	(Yes/No)	 0.182	 0.131	
GLP-1	a	 0.376	 0.141	 0.119	 	
IL-1β	b	 	 0.376	 0.008*	
Maximum	glucose	c		 -0.021	 0.45	
Age	c	 0.078	 0.315	
PIM2	score	c	 0.077	 0.319	
Total	energy	received	(%)	c	 0.218	 0.088	
EN	at	the	time	of	sampling	(Yes/No)	 0.182	 0.131	
GLP-1	a	 	 	 	
IL-10	c	 	 0.309	 0.026	
Maximum	glucose		 	 -0.021	 0.45	
Age	c	 0.078	 0.315	
PIM2	score	c	 0.077	 0.319	
Total	energy	received	(%)	c	 0.218	 0.088	
EN	at	the	time	of	sampling	(Yes/No)	 0.182	 0.131	
	
a. Dependent	variable	
b. Predictors:	(constant)		
c. Excluded	variables	
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r=	0.632*	
P=0.002	
3.2	GLP-1	and	the	metabolic	response		
	
Where	 energy	 expenditure	 measurements	 were	 performed	 (N=21)	 GLP-1	 showed	 a	
strong	 positive	 correlation	 with	 the	 metabolic	 index	 (r=0.632,	 p=0.002),	 (Figure	 1).	
However,	 no	 evidence	 of	 statistical	 correlation	 was	 recorded	 between	 inflammatory	
cytokines	 and	 the	 metabolic	 index.	 Regression	 analysis	 	 	 was	 then	 performed	 to	
determine	whether	GLP1	and	pro-inflammatory	markers	contributed	to	a	change	in	EE	
independently	from	the	severity	of	disease	and	age.	The	results	indicated	that	only	GLP1	
was	statistically	related	to	the	pattern	of	EE	(p	<	0.01).	This	regression	model	accounted	
for	39%	of	the	variation	in	EE	(Table	4).	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	1.	Association	between	REE	and	serum	GLP1	concentration	
Figure	1	shows	a	positive	correlation	between	GLP-1	and	the	metabolic	index.	
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Table	4:	Association	between	energy	expenditure	
	
Model	(N=21)	 R		 R	2		 Adjusted	R	2		 R	 P	value	
Metabolic	index	a		 0.649	 0.421	 0.388	 	
GLP1	b	 	 0.649	 0.001*	
TNF-α	c	 0.031	 0.448	
Age	c	 -0.311	 0.091	
PIM2	score	c	 -0.23	 0.165	
Total	energy	received	(%)	c	 0.263	 0.132	
Metabolic	index	a		 0.649	 0.421	 0.388	 	
GLP1	b	 	
	
0.649	 0.001*	
IL-6	c	 -0.063	 0.396	
Age	c	 -0.23	 0.165	
PIM2	score	c	 -0.311	 0.091	
Total	energy	received	(%)	c	 0.261	 0.133	
Metabolic	index	a		 0.433	 0.187	 0.166	 	
GLP1	b	 	
	
0.649	 0.001*	
IL-1β	c	 -0.117	 0.312	
Age	c	 -0.23	 0.165	
PIM2	score	c	 -0.311	 0.091	
Total	energy	received	(%)	c	 0.261	 0.133	
	
a. Dependent	variable	
b. Predictors:	(constant)		
c. Excluded	variables	
	
3.3	 The	 GLP-1	 as	 a	 predictor	 of	 clinical	 outcomes	 and	 disease	 severity	 in	
critically	ill	children		
To	establish	 the	association	between	GLP-1	and	disease	 severity	a	 correlation	analysis	
was	 performed	 between	 GLP-1	 and	 a	 range	 of	 disease	 severity	 and	 clinical	 outcome	
variables.	The	results	showed	a	positive	correlation	between	GLP-1	and	inotrope	score	
(r=	0.485,	p=0.001),	and	a	negative	correlation	was	recorded	with	hours	free	of	inotrope	
treatment	(r=	-0.312,	p=0.047).	However,	the	regression	analysis	showed	that	GLP-1	did	
not	predict	the	duration	of	inotrope	treatment	and	mechanical	ventilation	or	length	of	
PICU	stay.		
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4.	Discussion	
The	findings	of	this	study	suggest	that	the	inflammatory	response	to	stress	may	induce	
metabolic	 abnormalities,	 and	 hence	 affect	 energy	 expenditure.	 Although	 no	 direct	
associated	 was	 recorded	 between	 TNF-α	 and	 REE,	 we	 hypothesized	 that	 GLP1-1	
mediates	a	crosstalk	between	the	inflammatory	stimuli	and	REE.	
The	association	between	inflammation	and	REE	has	been	established	in	both	critically	ill	
adults	and	children	(18),	(19).	Numerous	studies	also	have	shown	a	connection	between	
inflammatory	markers	and	REE	 in	other	disease	states	such	as	obesity	 (2),	 (20),	kidney	
disease	(21)	and	cancer	(22).	 In	critically	 ill	adults	energy	expenditure	was	increased	in	
septic	patients	with	systemic	 inflammatory	response	syndrome	(SIRS)	 (Moriyama	et	al.	
1999).	 In	 contrast,	 Briassoulis	 et	 al.	 (2010)	 reported	 reduced	 energy	 expenditure	 and	
increased	 inflammatory	 markers	 in	 children	 with	 sepsis	 and	 	 SIRS.	 In	 patients	 with	
chronic	 kidney	 disease	 inflammation	 assessed	 by	 C-Reactive	 Protein	 (CRP)	 was	
associated	with	 increased	REE	(21).	While	 in	cancer	patients,	an	 increase	 in	TNF-α	was	
associated	 with	 hypermetabolism	 (22).	 Inflammatory	 cytokines	 such	 as	 IL6,	 IL-1β	 and	
TNFα	may	directly	regulate	REE	by	acting	through	cell	membrane	receptors	in	the	brain	
or	 peripheral	 tissues	 to	 induce	 energy	 expenditure	 (2),	 (23).	 These	 pathways	 involve	
induction	of	GLP-1	and	Leptin	expression	by	the	inflammatory	stimuli	(2),	(20).			
The	 inflammatory	 mediators	 are	 thought	 to	 contribute	 to	 the	 induction	 of	 GLP-1	
secretion	through	stimulation	of	intestinal	L	cells	(24).	Mechanistically,	the	activation	of	
STAT-3	transcription	factor	by	cytokines	appears	to	enhance	the	expression	of	GLP1	(24).	
In	critically	 ill	adults	plasma	GLP-1	 levels	were	strongly	 influenced	by	 inflammation	(6),	
(7).	 Furthermore,	 GLP-1	 secretion	 has	 shown	 to	 be	 increased	 in	 diabetic	 patients	 in	
response	 to	 inflammatory	 stimuli	 (25).	 In	 a	 study	 by	 Kahles	 et	 al.	 (2014)	 they	 also	
indicated	that	septic	patients	had	statistically	higher	levels	of	GLP-1	compared	to	none-
septic	patients,	implying	an	association	between	GLP1	with	inflammatory	response	and	
immune	system	activation.	 	GLP-1	secretion	also	appeared	to	be	increased	in	response	
to	 endotoxin	 stimulation	 (26).	 In	 critically	 adults	 the	 levels	 of	 GLP1	 was	 positively	
correlated	with	the	severity	of	disease	(7),	(6).		
New	emerging	researches	recorded	increased	levels	of	GLP1	in	critically	ill	children	and	
adults	(6),	(5),	(7)	which	could	be	implicated	in	the	abnormalities	seen	in	REE	among	this	
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population.	Higher	fasting	plasma	GLP-1	levels	were	associated	with	higher	rates	of	REE	
in	 adults	with	 glucose	 intolerance	 (27).	 In	 addition,	 an	 increase	 in	 energy	expenditure	
was	recorded	after	peripheral	infusion	of	GLP1	in	human	studies	(28).	In	a	murine	model	
the	administration	of	GLP1	was	associated	with	an	upsurge	in	oxygen	consumption	and	
REE	(29),	(30).	Contradictory	to	the	finding	of	the	current	study,	Poggiogalle	et	al.	(2018)	
indicated	that	fasting	plasma	GLP-1	was	not	associated	with	changes	in	REE	in	adults	
The	 available	 data	 on	 how	 GLP-1	 affects	 energy	 expenditure	 is	 still	 not	 conclusive.	
However,	the	effect	of	GLP1	on	insulin	stimulation	was	suggested	as	a	factor	accounting	
for	 the	 increase	 in	REE	 (28).	 In	addition,	GLP-1	appears	 to	promote	browning	of	white	
adipose	tissues	and	stimulates	brown	adipose	tissues	thermogenesis	through	a	process	
involving	 uncoupling	 of	 the	 mitochondrial	 respiration	 by	 uncoupling	 protein-1	 to	
generate	heat	(32).	(Figure	3)	
It	is	also	important	to	note	that	there	might	be	other	factors	contributing	to	the	increase	
of	GLP-1	 concentration	 in	our	 cohort.	 These	 factors	might	be	 related	 to	 the	nature	of	
medications	given	and	the	pathological	state.	For	example,	increased	GLP1	levels	could	
also	 be	 related	 to	 decreased	 renal	 clearance	 (6).	 It	 has	 also	 been	 suggested	 that	
endotoxins	associated	with	gut	injury	might	stimulate	the	secretion	of	GLP-1	(33).	Since	
GLP-1	secretion	is	stimulated	by	nutrient	intake	(34),	it	is	possible	that	the	feeding	status	
of	 the	patients	 contribute	 to	 the	variation	 in	 circulating	GLP1,	although	 in	 the	 current	
study	 no	 such	 association	 was	 recorded	 between	 GLP1	 and	 the	 amount	 of	 energy	
delivered.	
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Figure	2.	Potential	mechanisms	for	the	association	between	inflammation	and	REE	
mediated	by	GLP-1	
Figure	2	shows	the	potential	mechanistic	association	between	pro-inflammatory	cytokines,	GLP1	and	REE.	
TNF-α/IL-6	levels	are	increased	in	response	to	initial	systemic	or	intestinal	insult.	Inflammatory	cytokines	
or	 and	 endotoxins	 acutely	 enhance	 the	 secretion	 of	 GLP1	 through	 intestinal	 L	 cell.	 	 GLP1	 increase	 REE	
though	3	mechanisms:		
1.	Stimulation	of	insulin	secretion.		
2.	Promote	browning	of	white	adipose	tissues.		
3.	Stimulation	of	brown	adipose	tissues	thermogenesis.		
Brown	adipose	tissues	regulate	REE	through	the	adaptive	thermogenesis	process	that	involves	uncoupling	
of	the	mitochondrial	respiration	by	uncoupling	protein	1	to	generate	heat.	(33),	(32).	
	
5.	Conclusion	
	
Circulating	GLP-1	appears	to	be	increased	in	response	to	inflammatory	stimuli	by	TNF-α	
in	critically	ill	children.	These	findings	suggest	that	GLP-1	could	be	a	potential	marker	of	
the	severity	of	the	immune	system	activation.	This	study	also	revealed	that	elevation	in	
GLP-1	 is	 associated	with	 increase	 in	 REE	 in	 this	 population.	 In	 summary,	 GLP-1	 could	
provide	 a	 novel	 link	 between	 the	 inflammatory	 response	 and	 the	 gut	 with	 strong	
relevance	for	metabolic	dysregulation	in	critically	ill	children.	
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Figure	and	Table	Legends:		
Table	1:	Number	of	IC	measurement	taken	on	each	day	of	PICU	admission	
Table	2:	Anthropometric	and	clinical	characteristics	of	children	enrolled	to	the	study	
	Data	are	presented	as	median	(IQR).	
• VFH	at	30	days:	ventilation	free	hours	at	30	days	
• PICU	free	days	at	30	days:	days	free	of	Paediatric	intensive	care	at	30	days	
Table	3:	Factors	affecting	GLP-1	level	in	critically	ill	children		
d. Dependent	variable	
e. Predictors:	(constant)		
f. Excluded	variables	
Table	4:	Association	between	energy	expenditure		
a. Dependent	variable	
b. Predictors:	(constant)		
c. Excluded	variables	
Figure	1.		Association	between	REE	and	serum	GLP1	concentration	
Figure	1	shows	a	positive	correlation	between	GLP-1	and	the	metabolic		
Figure	2.	Potential	mechanisms	for	the	association	between	inflammation	and	REE	
mediated	by	GLP-1	
Figure	 2	 shows	 the	 potential	 mechanistic	 association	 between	 pro-inflammatory	
cytokines,	GLP1	and	REE.	TNF-α/IL-6	levels	are	increased	in	response	to	initial	systemic	
or	 intestinal	 insult.	 Inflammatory	 cytokines	 or	 and	 endotoxins	 acutely	 enhance	 the	
secretion	of	GLP1	through	intestinal	L	cell.		GLP1	increase	REE	though	3	mechanisms:		
1.	Stimulation	of	insulin	secretion.		
2.	Promote	browning	of	white	adipose	tissues.		
3.	Stimulation	of	brown	adipose	tissues	thermogenesis.		
Brown	 adipose	 tissues	 regulate	 REE	 through	 the	 adaptive	 thermogenesis	 process	 that	
involves	 uncoupling	 of	 the	 mitochondrial	 respiration	 by	 uncoupling	 protein	 1	 to	
generate	heat.	
